Biostructural studies on PPAR nuclear receptors by Capelli, Davide
 
DOTTORATO DI RICERCA IN BIOCHIMICA 
CICLO XXIX (A.A. 2013-2016) 
 
Biostructural studies on PPAR  
nuclear receptors 
 
Dottorando 
Davide Capelli 	  
	  	  	  	  	  	  	  	  	  	  Docente guida                                         Coordinatore 
Prof.ssa Roberta Chiaraluce                    Prof. Francesco Malatesta 
 
           Correlatore 
   Dott. Giorgio Pochetti 
 
Gennaio 2017 
 1 
 
 
DOTTORATO DI RICE A IN BIOCHIMICA 
XVII CICLO 
 
 
SNPs and pathological processes: study of 
the stability of human proteins involved in 
signal transduction 
 
 
Dottoranda 
Clorinda Lori 
 
Docente guida                                                           Coordinatore 
Prof. Roberta Chiaraluce                         Prof. Francesco Malatesta 
 
 
Dicembre 2015 
 
 
Ringraziamenti 
La ricerca delle parole più adatte per ringraziare tutti coloro che mi 
hanno accompagnato lungo questo percorso è emozionante e richiede grande 
impegno, segno che molte sono le persone che hanno contribuito al 
raggiungimento di questo obiettivo.  
Innanzitutto, ringrazio la Prof.ssa Roberta Chiaraluce dell'Università 
degli Studi di Roma "La Sapienza" per avermi offerto l'opportunità di 
svolgere il dottorato sotto la sua esperta guida, nonché tutte le persone del 
suo staff, in particolare il Prof. Valerio Consalvi e la Dott.ssa Clorinda Lori 
per la competenza, la gentilezza e la disponibilità che hanno sempre 
dimostrato nei miei confronti. 
Ringrazio il Prof. Francesco Malatesta, coordinatore del Dottorato di 
Ricerca in Biochimica, per avermi trasmesso quell'entusiasmo e quella 
curiosità che ogni uomo di scienza dovrebbe possedere e divulgare. 
Un ringraziamento speciale è dedicato al Dott. Giorgio Pochetti, 
correlatore di questa tesi, e alla Dott.ssa Roberta Montanari dell'Istituto di 
Cristallografia del CNR, dove ho svolto gran parte del lavoro raccontato in 
questa tesi e non solo. Senza di loro non avrei mai raggiunto i traguardi 
finora ottenuti e, per questo motivo, il mio obiettivo è di poter ricambiare 
quanto prima la fiducia e la stima che da sempre ripongono nei miei 
confronti, in ogni caso consapevole di rimanere per sempre in debito. 
Un ringraziamento sincero va anche a tutti i colleghi dell'Istituto di 
Cristallografia del CNR, sempre presenti e coinvolti in tutti gli aspetti della 
mia vita professionale e privata. 
Infine ringrazio gli amici più cari, compagni fedeli di tante avventure, 
e la mia famiglia nella sua interezza, esempio massimo di armonia e di 
amore.  
A Marta e a nostro figlio Valerio è dedicato questo lavoro e, più in 
generale, a loro è dedicata tutta la mia vita.  
 
  
 
 
A Marta e Valerio 
 
	  
Table of contents 
Abstract....................................................................................................................................I	  
	  
1	   Introduction	  ...................................................................................................	  1	  1.1	   Nuclear	  receptors	  ...............................................................................................	  1	  1.1.1	   DNA	  Binding	  Domain	  and	  Ligand	  Binding	  Domain	  ....................	  3	  1.1.2	   Co-­‐activators	  and	  co-­‐repressors	  .........................................................	  7	  1.1.3	   The	  role	  of	  NRs	  in	  the	  activation	  and	  repression	  of	  trascription	  ..................................................................................................................	  9	  1.1.4	   Ligand-­‐Receptor	  interaction	  ..............................................................	  11	  1.2	   Peroxisome	  Proliferator-­‐Activated	  Receptors	  (PPARs)	  .................	  13	  1.2.1	   PPARs	  structure	  and	  function	  ...........................................................	  15	  1.2.2	   The	  ligand	  binding	  domain	  .................................................................	  16	  1.2.3	   The	  role	  of	  the	  AF-­‐2	  helix	  H12	  ..........................................................	  20	  1.2.4	   The	  role	  of	  the	  helix	  H3	  and	  the	  β-­‐sheet	  .......................................	  22	  1.2.5	   Binding	  to	  co-­‐regulators	  ......................................................................	  23	  1.2.6	   Heterodimer	  formation	  with	  RXR	  ...................................................	  26	  1.2.7	   Non-­‐genomic	  actions	  ............................................................................	  30	  1.2.8	   Regulation	  by	  post-­‐translational	  modifications	  (PTM)	  .........	  32	  1.2.9	   Drugs	  and	  active	  compounds	  on	  PPARs	  .......................................	  35	  1.2.10	   Novel	  active	  PPAR	  ligands	  ...............................................................	  38	  1.2.11	   Selective	  PPAR	  Modulators	  (SPPARMs)	  ....................................	  42	  1.2.12	   PPAR	  antagonists	  .................................................................................	  43	  1.3	   Stucture-­‐based	  drug	  discovery	  .................................................................	  45	  
2	   Aim	  of	  the	  study	  ..........................................................................................	  51	  
3	   Experimental	  methods	  .............................................................................	  53	  3.1	   Expression	  and	  purification	  of	  PPARs	  LBD	  ..........................................	  53	  
3.2	    Crystallization	  ,	  data	  collection	  and	  structure	  determination	   	  ....	  55	  
3.3	   Isothermal	  titration	  calorimetry	  (ITC)	    	  .................................................	  62	  
3.4	   Surface	  plasmon	  resonance	  (SPR)	    	  ..........................................................	  63	  
4	   Results	  and	  discussion	  .............................................................................	  65	  4.1	   The	  pan	  agonist	  AL29-­‐26	  .............................................................................	  65	  4.1.1	   Crystallization	  and	  structure	  determination	  of	  the	  complexes	  PPARα-­‐LBD/AL29-­‐26	  and	  PPARγ-­‐LBD/AL29-­‐26	  ...................................	  67	  4.1.2	   PPARγ-­‐LBD/AL29-­‐26	  structure:	  new	  position	  of	  the	  carboxylate	  in	  the	  region	  of	  partial	  agonists	  .............................................	  69	  
4.1.3	   PPARα-­‐LBD/AL29-­‐26	  structure:	  ligand	  occupation	  of	  a	  new	  pocket.	  ........................................................................................................................	  72	  4.1.4	   Specificity	  of	  the	  new	  cavity:	  a	  steric	  clash	  with	  S289	  prevents	  AL29-­‐26	  to	  occupy	  the	  diphenyl	  pocket	  of	  PPARγ-­‐LBD	  determining	  its	  partial	  agonist	  properties	  .................................................	  77	  
4.2	   Saponins	  and	  sapogenins	  as	  potential	  PPARγ	  agonists	  ..................	  80	  4.2.1	   Fast	  screening	  of	  saponins	  and	  sapogenins	  from	  Medicago species	  by	  SPR	  .........................................................................................................	  81	  
4.2.2	   Toxicity	  and	  transcriptional	  activity	  on	  the	  most	  affine	  compounds	  ...............................................................................................................	  87	  4.2.3	   Crystal	  structure	  of	  the	  PPARγ-­‐LBD/caulophyllogenin	  complex	  ......................................................................................................................	  90	  4.2.4	   Isothermal	  titration	  calorimetry	  (ITC)	  assay:	  comparison	  between	  caulophyllogenin	  and	  the	  fatty	  acid	  13-­‐(S)-­‐HODE	  ...............	  93	  4.3	   The	  metabolically	  active	  form	  of	  Metaglidasen	  .................................	  95	  
4.3.1	   PPAR	  activity	    	  ...........................................................................................	  96	  
4.3.2	   Crystal	  structure	  of	  (R)-­‐	  and	  (S)-­‐halofenic	  acid	  in	  the	  PPARγ-­‐	    LBD......	  .....................................................................................................................	  100	  
4.4	   Transactivation	  deficiency	  of	  the	  PPARγ	  F360L	  mutant	  associated	  with	  familial	  partial	  lipodystrophy	  ............................................	  107	  4.4.1	   Overall	  structure	  of	  PPARγ-­‐LBD	  F360L	  and	  conformational	  changes	  induced	  by	  the	  mutation	  .................................................................	  108	  4.4.2	   Ligand	  interactions	  ..............................................................................	  114	  4.4.3	   Crystal	  structure	  of	  the	  complex	  between	  PPARγ-­‐LBD	  R357A	  and	  rosiglitazone	  .................................................................................................	  117	  
4.4.4	   The	  co-­‐activator	  SRC-­‐1	  has	  a	  lower	  binding	  affinity	  for	  the	  mutants	  ....................................................................................................................	  120	  4.5	   Resveratrol	  and	  its	  metabolites	  ..............................................................	  122	  
4.5.1	   Binding	  affinity	  of	  resveratrol	  towards	  PPARs	  LBD  	  .............	  123	  
4.5.2	   Crystal	  structure	  of	  PPARγ-­‐LBD/resveratrol	  complex	    	  .......	  126	  
4.5.3	    Antagonistic	  activity	  of	  resveratrol	    	  .............................................	  129	  4.6	   Betulinic	  acid:	  a	  PPARγ	  antagonist	  ........................................................	  133	  4.6.1	   Crystal	  structure	  of	  PPARγ-­‐LBD	  in	  complex	  with	  betulinic	  acid:	  two	  molecules	  of	  the	  ligand	  bind	  the	  LBD	  simultaneously	  ....	  134	  4.6.2	    Sub-­‐optimal	  stabilization	  of	  helices	  11	  and	  12	  ........................	  136	  4.6.3	   Comparison	  with	  the	  antagonist	  SR1664	  and	  the	  agonist	  SR1663:	  the	  F282/F363	  switch	  mechanism	  ...........................................	  139	  
5	   Summary	  and	  conclusions	    	  ..................................................................	  144	  
References	    	  .......................................................................................................	  149	  
Appendix	   	  ..........................................................................................................	  181	  
 	  	  	  	  
	  
	   I	  
Abstract 
The peroxisome proliferator-activated receptors (PPARs) represent a 
family of nuclear receptors that function as ligand-activated transcription 
factors, regulating genes involved in cell differentiation and various 
metabolic processes, especially lipid and glucose homeostasis. The PPAR 
family comprises three isoforms: PPARα, PPARβ/δ and PPARγ, with 
different tissue distribution, ligand specificitiy and physiological role. 
Because of their wide range of actions on glucose homeostasis, lipid 
metabolism and vascular inflammation, PPARs represent promising targets 
for the development of new drugs for the treatment of metabolic disorders 
such as type 2 diabetes mellitus (T2DM), dyslipidemia and atherosclerosis.  
Among all the subtypes, despite the undesiderable side effects associated to 
the drug treatment, PPARγ is still the most widely studied for its crucial role 
in the complex cross-talk between metabolically active tissues essential for 
energy balance. Then, new combination strategies using dual or pan agonists, 
as well as selective modulators, are currently in development.  
 This study is aimed to understand in deep the dynamic personality of 
the nuclear receptors PPAR in complex with both natural and synthetic 
ligands that, interacting with different regions of the LBD, confer a 
differentiated biological response in cellular and animal models. PPARs 
could be then described as a ‘functionally pluripotent’ proteins being their 
activity mediated by ligands that, causing the functional site to adopt an 
active/inactive conformations, activate different structural and biological 
pathways depending on the co-activator/co-repressor recruited. 
 Through a structural approach we propose to get more insights on 
how the biological response is variably affected by ligands depending on 
their binding mode and even the mutation of a single residue responsible for 
	   II	  
a structural destabilization of the LBD could be associated to rare genetic 
disorder.  
The understanding of such a mechanism required the use of more than 
one biophysical technology. X-ray diffraction was used as the main approach 
to investigate the binding mode of the selected ligands. In addition, the 
binding has been also characterized using other biophysical techniques such 
as Isotermal Titration Calorimetry (ITC) and Surface Plasmon Resonance 
(SPR) to obtain thermodynamic and kinetic parameters of the binding. 	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1. Introduction 
1.1 Nuclear receptors 
Nuclear receptors (NRs) are a large superfamily of transcription 
factors involved in important physiological functions such as control of 
embryonic development, organ physiology, cell differentiation and 
homeostasis [1–3]. Apart from the normal physiology, nuclear receptors have 
been identified to play a role in many pathological processes, such as cancer, 
diabetes, rheumatoid arthritis, asthma or hormone-resistance syndromes [4, 
5]. Therefore, despite their already long history, these transcriptional 
regulators are still of great interest in modern biomedical research and drug 
discovery.  
 Nuclear receptors are soluble proteins that can bind to specific DNA-
regulatory elements and act as cell-type and promoter-specific regulators of 
transcription [6]. In contrast to other transcription factors, the activity of 
nuclear receptors can be modulated by binding to the corresponding ligands – 
small lipophilic molecules that easily penetrate biological membranes. 
Natural ligands already known include steroid and thyroid hormones, retinoic 
acid, oxysterols, vitamines and eicosanoids. 
 The receptors are commonly categorized into seven subfamilies based 
on sequence homology [7], but they can also be classified into three 
subgroups based on characteristics of ligand binding. These subgroups 
include classic hormone receptors, sensor or metabolic receptors and orphan 
receptors. The classic hormone receptors include the glucocorticoid, 
estrogen, thyroid, retinoic acid and vitamin D receptors. In general, these 
receptors bind specific, endogenous ligands with high affinity. Peroxisome 
proliferator-activated receptors (PPARs), liver X receptor (LXR), farnesol X 
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receptor (FXR), liver receptor homolog-1 (LRH-1) and retinoid X receptor 
(RXR) belong to the subgroup known as the sensor receptors. As a result of 
their role in maintaining glucose and lipid homeostasis, these receptors are 
also known as ‘metabolic’ nuclear receptors. In contrast to the classic and 
orphan receptors, the sensor/metabolic receptors bind with lower affinity to a 
broad range of physiological ligands encompassing compounds from dietary 
origin. Ligands have not been identified to date for some receptors, thus they 
are referred to as orphans. 
 Nuclear receptors share a common structure composed of five 
conserved regions or domains (A/B – F): the N-terminal A/B domain, a 
medial DNA-binding domain (DBD), a hinge region (D), the ligand-binding 
domain (LDB) and the C-terminal domain (F) as shown in Figure 1 [8]. The 
N-terminal A/B domain is the least conserved among members of the 
superfamily, with the length of this region varying significantly between 
receptors. The A/B region contains a weak ligand-independent transcriptional 
activation function-1 (AF-1) and is often a site for post-translational 
modification that can dramatically affect receptor activity. In contrast, the C 
region is the most highly conserved and contains the DBD with its two zinc 
finger motifs, the hallmark characteristic of nuclear receptors. The D region 
functions as a hinge, allowing the more conserved and structured C and E 
domains to swivel slightly to accommodate multiple conformations. Region 
E contains the LBD. The ligand-dependent activation function-2 (AF-2) and 
the receptor dimerization interface are embedded within this region. Binding 
of ligands to the receptor induces a conformational change within the LBD 
that initiates a series of events within the receptor resulting in transcriptional 
activation of specific target genes.  
 The functions of nuclear receptors can also be modulated by post-
translational modifications that include phosphorylation, ubiquitylation, and 
	   3	  
sumoylation. Phosphorylation can activate some nuclear receptors 
independently of ligand binding and function as the major mechanism 
regulating activities of orphan receptors. Receptor ubiquitylation can occur in 
response to ligand binding and may contribute to termination of hormonal 
signaling. sumoylation typically reduces the activation function of nuclear 
receptors and/or promotes repressor activity [9]. 
 
 
 
 
 
 
 
 
1.1.1 DNA Binding Domain and Ligand Binding Domain 
 The C region containing the DBD is the most well conserved region; 
through this domain, nuclear receptors bind to specific DNA sequences, 
called hormone response elements (HREs), within the regulatory region(s) of 
target genes. DBD consists of a highly conserved 66-residue core made up of 
two typical cysteine-rich zinc finger motifs, two α helices, and a COOH 
extension. It includes several sequence elements, referred to as P, D, T, and A 
boxes, that have been shown to define or contribute to the response element 
specificity, to a dimerization interface within the DBDs, and to contacts with 
the DNA backbone and residues flanking the DNA core recognition sequence 
[10] (Figure 2). The DBD is also the target of post-translational 
Figure 1. The five conserved domains (A/B – F) that compose the protein structure for 
nearly all members of the nuclear hormone receptor superfamily. 
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modifications. Furthermore, it is involved in nuclear localization and 
functions in interactions with transcription factors and co-activators. 
 
                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 Several in vitro studies have shown that the LBD, which is less 
conserved than the DBD, is functionally complex as it mediates ligand 
binding and dimerization and contains a ligand-dependent transactivation 
function. The LBD consists of 250 residues and contains four structurally 
distinct but functionally linked surfaces: 1) a dimerization surface, which 
mediates interaction with partner LBDs, 2) the ligand-binding pocket (LBP), 
which interacts with diverse lipophilic small molecules in the case of 
liganded NRs, 3) a co-regulator binding surface, which binds to regulatory 
protein complexes that modulate positively or negatively transcriptional 
activity, and 4) an activation function helix, termed AF-2, which mediates 
ligand-dependent transactivation. Within the AF-2, the integrity of a 
conserved amphipathic α-helix called AF-2 activation domain has been 
Figure 2. Heterodimer of thyroid receptor (TR) and RXR DBDs (PDB ID: 2NLL). 
Zinc ions are depicted in yellow, DNA in red. 
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shown to be required for ligand-dependent transactivation and co-activator 
recruitment. Moreover, some NRs can also interact with transcriptional co-
repressors through their LBD [11]. 
 The first resolution of a NR LBD crystal structure, the unliganded 
RXRα, revealed that this domain is highly structured [12]. This crystal 
structure, together with the elucidation of the 3D structures of multiple other 
NR LBDs, showed a common fold comprising 12 α helices (H) and a short β-
turn (Figure 3A), arranged in three layers to form an antiparallel 'α-helical 
sandwich'. Note that some varibility exists; for example, no helix H2 was 
found in RARγ [13], while an additional short helix H2' is present in PPARγ 
[14]. Helices 1 through 3 constitute one face of the LBD. H4, H5, β-turn, H8, 
and H9 correspond to the central layer of the domain and H6, H7, and H10 
form the second face. The superposition of all available LBD structures 
reveals a clear overall similarity, particularly in the top half of the LBD, that 
includes H1, H4, H5, and H7 through H10 and corresponds to a structurally 
rather invariable region. The lower part of the LBD harbors a variable region, 
which contains the LBP. 
 Structural and functional studies of the LBD of NRs revealed that the 
dynamics of their C-terminal helix (H12, also termed AF-2) is fundamental 
for NR activity. Together the various apo- and holo-LBD structures suggest a 
common mousetrap-like mechanism by which AF-2 becomes competent to 
activate transcription: upon ligand binding, H11 is repositioned in the 
continuity of H10, and the concomitant swinging of H12 unleashes the Ω-
loop (between H2 and H3) which flips over underneath H6, carrying along 
the amino-terminal part of H3 (Figure 3B). In its final position, H12 seals as 
a 'lid' the ligand-binding cavity and further stabilizes ligand binding (in some 
but not all NRs) by contributing to additional ligand-protein interactions. The 
transconformation of H12, together with additional structural changes (such 
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as bending of helix H3), brings it into a distinct receptor environment, thus 
creating the surface(s) which allow binding of co-activators and thereby 
generates the transcriptional activity of the AF-2 domain. In the absence of 
ligand some NRs recruit a complex of opposite functionality, composed of 
co-repressors or silencing mediator, which is responsible for the gene 
silencing ability of some NRs [15]. Furthermore, many receptors are able to 
promote transciption even in the absence of ligand, suggesting that the 
structures of LBDs mediating each functional response persist in a dynamic 
equilibrium, which exists independently but is affected by ligand binding 
[16]. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. A) apo-RXRα structure with helix 12 in the inactive conformation. B) holo-
RXRα structure showing the helix 12 in the active conformation, according to the 
mousetrap model. 
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1.1.2 Co-activators and co-repressors 
 The first step of nuclear receptor activation is initiated by ligand 
binding, and thus the ligand binding pocket is an important structural feature 
of nuclear receptors. The second step of nuclear receptor activation is ligand-
induced recruitment of co-activator complexes, which contain chromatin-
modifying enzymes required for transcription. 
 Nuclear co-activators such as steroid receptor co-activator 1 (SRC-1, 
also known as NCoA1) contain multiple LXXLL motifs (where X is any 
amino acid and L is leucine in single-letter code for amino acids) that interact 
with LBDs. X-ray structures of various LBDs bound to agonists and peptides 
with LXXLL motifs reveal a conserved mode of co-activator binding [15]. 
The LXXLL co-activator motif adopts a two-turn α helix with its three-
leucine side chains fitting into the hydrophobic pocket between two charged 
residues - the so-called charge clamp - which further stabilize the co-activator 
helix by capping both helical ends. The high degree of amino acid sequence 
conservation in the co-activator binding pocket (Figure 4) suggests that this 
mode of co-activator binding represents a general mechanism for the 
activation of nuclear receptors. In addition, nuclear receptors can achieve 
specific recognition of co-activators by interacting with the variable residues 
within or flanking the LXXLL motifs. 
 On the other hand, the position of the AF-2 helix also plays a key role 
in recruiting co-repressors such as nuclear receptor co-repressor 1 (NCoR1) 
and silencing mediator for retinoid and thyroid hormone receptors (SMRT, 
also konw as NCoR2). These nuclear co-repressors bind to LBDs via a 
conserved LXXXIXXXL/I motif, which is similar to the LXXLL co-activator 
motif but has an N-terminal extension. In comparison to co-activators, the 
longer co-repressor motif adopts a three-turn α helix instead of two turns for 
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the co-activator motif, and binds to the same overlapped site as for the 
LXXLL helix. The additional turn of the co-repressor helix extends into 
space that would normally be occupied by the AF-2 helix when it is in the 
active conformation. Thus the binding of co-repressors and the active AF-2 
conformation is mutually exclusive: the AF-2 helix must shift to some 
alternative position to accommodate the larger co-repressor helix. The 
binding mode of co-repressors, similar to that of co-activators, is also highly 
conserved among nuclear receptors. It seems clear that binding of co-
activators and co-repressors is tightly modulated by the position of the AF-2 
helix. The conformational flexibility of this helix allows it to sense the 
presence of the bound ligand, either an agonist or an antagonist, and to recruit 
the co-activators or co-repressors that ultimately determine the transcriptional 
output of nuclear receptors [17, 18]. 
  
 
 
Figure 4. Conservation of the Charge Clamp Pocket. Sequence alignment of co-factor binding 
pockets in nuclear receptors reveals the conserved nature of the charge clamp pocket and the AF-2 
helix. Positively charged residues are labeled in blue, negatively charged residues are in red, polar 
residues are in green, and the hydrophobic residues are in black. The arrows indicate the positions 
of the charged clamp residues.  
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1.1.3 The role of NRs in the activation and repression of 
trascription 
 NRs repress or activate transcription by participating in the 
constitution of large, multimeric protein complexes on the promoter of their 
target genes [19]. The functional state of NRs is changed upon the binding of 
ligand such that co-repressors are released and co-activators are recruited. In 
the unliganded state, NRs are associated to co-repressor complexes. These 
complexes are composed of a subunit (SMRT/NCoR2 or NCoR1) directly 
interacting with the receptor through a degenerated LXXLL motif, also called 
the CoRNR box, which interact with amino acids from the LBD hydrophobic 
groove [20, 21]. Co-repressor complexes are built around the SMRT or 
NCoR subunits, which harbor a conserved repression domain on which the 
core repressive machinery (including HDAC3, GPS2 and TBL1 or TBLR1) 
is assembled. HDAC3 negatively affects transcription factor access to DNA 
condensing the nucleosome. Upon ligand binding the co-repressor complex is 
released and the co-activator complex is recruited, allowing the transciptional 
complex to access the gene. In Eukaryotes a group of trascriptional factors, 
the so-called General Trascriptional Factors (GTF), bind to RNA 
Polymerase II at the promoter of the DNA sequence (e.g., TATA box) to 
form a large transcription Preinitiation Complex (PIC) and activate 
transcription (Figure 5).  
 In 1995, SRC-1 was cloned as the first authentic NR co-activator. 
SRC-1 was found to interact with steroid receptors in a hormone-dependent 
manner and robustly increase the transcriptional activities of steroid 
receptors. Soon after, two other homologous proteins, SRC-2 (also known as 
TIF2, GRIP1 and NCoA2) and SRC-3 (also known as p/CIP, RAC3, AIB1, 
ACTR, TRAM1 and NCoA3), were characterized as NR co-activators. These 
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three homologous proteins comprise the p160 SRC family. SRCs contain 
three structural domains. The amino-terminal domain is the most conserved 
region and is required for protein–protein interactions. The central region of 
the SRC proteins contains three LXXLL motifs, which form amphipathic α-
helices and are responsible for interacting with NRs. The carboxyl terminus 
contains two transcriptional activation domains (AD1 and AD2). AD1 binds 
CREB-binding protein (CBP) and the histone acetyltransferase p300 (also 
known as EP300), and the recruitment of CBP or p300 by SRCs to the 
chromatin is essential for SRC-mediated transcriptional activation. AD2 
interacts with co-activator-associated arginine methyltransferase 1 (CARM1) 
and protein arginine N-methyltransferase 1 (PRMT1), which are histone 
methyltransferases. The C-terminal end of SRC-1 and SRC-3 contain HAT 
activity domains, although their cellular substrates are incompletely 
identified. These molecular features provide SRCs with a suitable structural 
base for recruiting additional co-regulators and general transcription factors, 
which in turn results in chromatin remodelling, assembly of general 
transcription factors and recruitment of RNA polymerase II for 
transcriptional activation [22]. 
 
Figure 5. Ligand-dependent NR switching of co-regulators. In the absence of a ligand, co-repressor 
complexes maintain repressive states of NR-mediated transcription. Transactivation is triggered by 
binding of the cognate ligand to the LBD, which induces co-activators binding while co-repressors 
dissociate from the LBD. 
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1.1.4 Ligand-Receptor interaction 
 Occupation of a receptor by a ligand may or may not result in 
activation of the receptor. By activation, it means that the receptor is affected 
by the bound molecule in such a way as to elicit a tissue response. Binding 
and activation represent two distinct steps in the generation of the receptor-
mediated response by an agonist (Figure 6). If a ligand binds to the receptor 
without causing activation and thereby prevents the agonist from binding, it 
is termed a receptor antagonist. The tendency of a ligand to bind to the 
receptors is governed by its affinity, whereas the tendency for it, once bound, 
to activate the receptor is denoted by its efficacy. Ligands of high potency 
generally have a high affinity for the receptors and thus occupy a significant 
proportion of the receptors even at low concentrations. Agonists also possess 
significant efficacy, whereas antagonists, in the simplest case, have zero 
efficacy. Ligands with intermediate levels of efficacy, such that even when 
100% of the receptors are occupied the tissue response is submaximal, are 
known as partial agonists, to distinguish them from full agonists, the efficacy 
of which is sufficient that they can elicit a maximal tissue response [23].  
 One of the most exciting messages for nuclear receptor-based drug 
development arises from the observation that chemistry can provide us not 
only with receptor-selective and various types of full/partial agonists and 
antagonists, but also with compounds that activate only a subset of the 
functions induced by the cognate ligand or with ligands that act in a cell-
type-selective manner [selective nuclear receptor modulators (SNuRMs)]. 
Importantly, recent studies have shed light on the molecular mechanisms 
underlying SNuRM action, which has made it possible to design screening 
and target validation. Moreover, recent data indicate that several other factors 
and mechanisms have to be considered for a full understanding of nuclear 
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receptor pharmacology. For example, we have just begun to recognize the 
importance of the so-called non-genomic action of nuclear receptor ligands 
and the impact of factors that re-direct nuclear receptor signalling. In all of 
these cases, molecular biology has provided us with a variety of concepts by 
which nuclear receptors and/or their ligands can induce or modulate 
important physiological programs. The challenge now is to generate chemical 
compounds that address one or only some of these functions to achieve the 
pharmacologically desired effect [24].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The distinction between ligand binding and activation. Ligand A is an 
agonist, because when it is bound, the receptor (R) tends to become activated, whereas 
ligand B is an antagonist, because binding does not lead to activation. The rate 
constants for the binding and activation steps vary between ligands. For an antagonist, 
which does not activate the receptor, β = 0. 
2
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activate the receptor is denoted by its efficacy. These terms 
are defined more precisely below (p. 13). Drugs of high 
potency generally have a high affinity for the receptors and 
thus occupy a significant proportion of the receptors even 
at low concentrations. Agonists also possess significant 
efficacy, whereas antagonists, in the simplest case, have 
zero efficacy. Drugs with intermediate levels of efficacy, 
such that even when 100% of the receptors are occupied 
the tissue response is submaximal, are known as partial 
agonists, to distinguish them from full agonists, the efficacy 
of which is sufficient that they can elicit a maximal tissue 
response. These concepts, though clearly an oversimplified 
description of events at the molecular level (see Ch. 3), 
provide a useful basis for characterising drug effects.
We now discuss certain aspects in more detail, namely 
drug binding, agonist concentration–effect curves, com-
petitive antagonism, partial agonists and the nature of effi-
cacy. Understanding these concepts at a qualitative level is 
sufficient for many purposes, but for more detailed analy-
sis a quantitative formulation is needed (see p. 16).
THE BINDING OF DRUGS TO RECEPTORS
! The binding of drugs to receptors can often be measured directly 
by the use of drug molecules (agonists or antagonists) labelled with 
one or more radioactive atoms (usually 3H, 14C or 125I). The usual 
procedure is to incubate samples of the tissue (or membrane frag-
ments) with various concentrations of radioactive drug until equilib-
rium is reached. The bound radioactivity is measured after removal 
of the supernatant.
In such experiments, there is invariably a certain amount of ‘non-
specific binding’ (i.e. drug taken up by structures other than recep-
tors), which obscures the specific component and needs to be kept to 
a minimum. The amount of non-specific binding is estimated by 
measuring the radioactivity taken up in the presence of a saturating 
concentration of a (non-radioactive) ligand that inhibits completely 
the binding of the radioactive drug to the receptors, leaving behind 
the non-specific component. This is then subtracted from the total 
binding to give an estimate of specific binding (Fig. 2.2). The binding 
curve (Fig. 2.2B) defines the relationship between concentration and 
the amount of drug bound (B), and in most cases it fits well to the 
relationship predicted theoretically (see Fig. 2.11, below), allowing 
the affinity of the drug for the receptors to be estimated, as well as 
the binding capacity (Bmax), representing the density of receptors in the 
whose actions had been described in exhaustive detail for 
many years, are now known to target well-defined recep-
tors, which have been fully characterised by gene-cloning 
techniques (see Ch. 3).
RECEPTOR CLASSIFICATION
! Where the action of a drug can be associated with a particular 
receptor, this provides a valuable means for classification and refine-
ment in drug design. For example, pharmacological analysis of the 
actions of histamine (see Ch. 17) showed that some of its effects (the 
H1 effects, such as smooth muscle contraction) were strongly antago-
nised by the competitive histamine antagonists then known. Black 
and his colleagues suggested in 1970 that the remaining actions of 
histamine, which included its stimulant effect on gastric secretion, 
might represent a second class of histamine receptor (H2). Testing a 
number of histamine analogues, they found that some were selective 
in producing H2 effects, with little H1 activity. By analysing which 
parts of the histamine molecule conferred this type of specificity, they 
were able to develop selective H2 antagonists, which proved to be 
potent in blocking gastric acid secretion, a development of major 
therapeutic significance (Ch. 29). Two further types of histamine 
receptor (H3 and H4) were recognised later.
Receptor classification based on pharmacological responses contin-
ues to be a valuable and widely used approach. Newer experimental 
approaches have produced other criteria on which to base receptor 
classification. The direct measurement of ligand binding to receptors 
(see below) has allowed many new receptor subtypes to be defined 
that could not easily be distinguished by studies of drug effects. 
Molecular cloning (see Ch. 3) provided a completely new basis for 
classification at a much finer level of detail than can be reached 
through pharmacological analysis. Finally, analysis of the biochemi-
cal pathways that are linked to receptor activation (see Ch. 3) pro-
vides yet another basis for classification.
The result of this data explosion was that receptor classification sud-
denly became much more detailed, with a proliferation of receptor 
subtypes for all the main types of ligand. As alternative molecular 
and biochemical classifications began to spring up that were incom-
patible with the accepted pharmacologically defined receptor classes, 
the International Union of Pharmacological Sciences (IUPHAR) con-
vened expert working groups to produce agreed receptor classifica-
tions for the major types, taking into account the pharmacological, 
molecular and biochemical information available. These wise people 
have a hard task; their conclusions will be neither perfect nor final 
but are essential to ensure a consistent terminology. To the student, 
this may seem an arcane exercise in taxonomy, generating much 
detail but little illumination. There is a danger that the tedious lists 
of drug names, actions and side effects that used to burden the subject 
will be replaced by exhaustive tables of receptors, ligands and trans-
duction pathways. In this book, we have tried to avoid detail for its 
own sake and include only such information on receptor classifica-
tion as seems interesting in its own right or is helpful in explaining 
the actions of important drugs. A comprehensive IUPHAR database 
of known receptor classes is available (see http://www.iuphar-db.org), 
as well as a regularly updated summary (Alexander et al., 2009).
DRUG–RECEPTOR INTERACTIONS
Occupation of a receptor by a drug molecule may or may 
not result in activation of the receptor. By activation, we 
mean that the receptor is affected by the bound molecule 
in such a way as to elicit a tissue response. The molecular 
mechanisms associated with receptor activation are dis-
cussed in Chapter 3. Binding and activation represent two 
distinct steps in the generation of the receptor-mediated 
response by an agonist (Fig. 2.1). If a drug binds to the 
receptor without causing activation and thereby prevents 
the agonist from binding, it is termed a receptor antagonist. 
The tendency of a drug to bind to the receptors is governed 
by its affinity, whereas the tendency for it, once bound, to 
Fig. 2.1 The distinction between drug binding and receptor 
activation. Ligand A is an agonist, because when it is bound, 
the receptor (R) tends to become activated, whereas ligand B is 
an antagonist, because binding does not lead to activation. The 
rate constants k+1, k−1, α and β for the binding and activation 
steps vary between drugs. For an antagonist, which does not 
activate the receptor, β = 0.
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1.2 Peroxisome Proliferator-Activated Receptors 
(PPARs)  
 Peroxisome proliferator-activated receptors (PPARs) are ligand-
activated transcription factors that regulate genes involved in cell 
differentiation and various metabolic processes, especially lipid and glucose 
homeostasis. In molecular terms, PPARs represent a family of ligand-
activated nuclear hormone receptors belonging to the steroid receptor 
superfamily. The family of PPARs comprises three isoforms: PPARα, 
PPARβ/δ and PPARγ. These three isotypes differ from each other in terms of 
tissue distributions, ligand specificities and physiological roles. Each of them 
either activates or suppresses different genes with only partial overlap in 
activity. All isoforms participate in lipid homeostasis and glucose regulation 
(energy balance) and, until recently, their actions were thought to be limited 
to specific tissue types (Figure 7).  
 PPARα is highly expressed in metabolically active tissues, such as 
liver, heart, skeletal muscle, intestinal mucosa and brown adipose tissue. This 
receptor is implicated in fatty acid (FA) metabolism and its activation 
reduces lipid levels. Synthetic PPARα ligands such as fibrates are 
recommended in clinical practice in the dyslipemic state 
(hypertriglyceridemia) (Figure 8). The two PPARγ  isoforms γ1 and γ2 (the 
latter having an extra 28 amino acids at the N-terminus) act in the white and 
brown adipose tissues to promote adipocyte differentiation and lipid storage 
and biosynthesis, while only the expression of PPARγ1 extends to other 
tissues such as the gut or immune cells. This receptor also participates in 
lipoprotein metabolism and insulin sensitivity. Thiazolidinediones are PPARγ 
synthetic agonists used in the treatment of diabetes mellitus. The least known 
isoform is PPARβ/δ, which has not been so intensely studied as PPARα and 
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PPARγ. PPARβ/δ is expressed ubiquitously in virtually all tissues; however, 
it is particularly abundant in the liver, intestine, kidney, abdominal adipose 
tissue, and skeletal muscle, all of which are involved in lipid metabolism. It 
participates in fatty acid oxidation, mainly in skeletal and cardiac muscles, 
regulates blood cholesterol concentrations and glucose levels [25]. A recent 
report that the synthetic molecule GW501516 can suppress insulin level in a 
primate model implies that ligands specific to PPARβ/δ might have 
therapeutic potential by themselves or in combination with PPARγ agonists 
[26].  
 In conclusion, PPARα and PPARβ/δ mainly facilitate energy 
combustion, whereas PPARγ contributes to energy storage by enhancing 
adipogenesis. 
 
 
 
      
homeostasis [12,22,24]. They include docosahexaenoic
acid and eicosapentaenoic acid used in the prevention
and treatment of cardiovascular and metabolic diseases
[25]. Not only EFA but also eicosanoids are natural li-
gands of PPARs – e.g. leukotriene B4 stimulates PPARα,
and prostaglandin PGJ2 activates PPARγ [22]. However,
both EFA and eicosanoids are required in relatively high
concentrations (approximately 100 μM) for PPAR activa-
tion [24]. Also, synthetic ligands are widely used in clin-
ical practice – for example, fibrates (PPARα ligands) are
recommended in the dyslipidemic state (hypertriglyc-
eridemia) and thiazolidinediones (PPARγ agonists) are
used in the treatment of diabetes mellitus [26-29].
Functional role of PPARα
As mentioned above, PPARα is expressed mainly in tis-
sues with a high capacity for fatty acid oxidation, e.g. the
liver, heart, and skeletal muscle. It also plays a role in
glucose homeostasis and insulin resistance development
(Figure 6) [29]. Natural or pharmacological ligands (fatty
acids and fibrates, respectively) primarily control the ex-
pression of genes in olved in lipid metabolism. If the
concentration of fatty acids increases, PPARα is activated
and uptakes oxidized forms of these acids [30,31]. Oxi-
dation of fatty acids is mainly present in the liver and it
prevents steatosis in the case of starvation/fasting. Dur-
ing the influx of fatty acids, transcription of PPARα-
regulated genes is stimulated and the oxidation systems
(microsomal omega-oxidation system, and mitochondrial
and peroxisomal beta-oxidation) are activated (Figure 7)
[21,32]. This activation and increased PPARα sensing in
the liver result in increased energy burning and reduced
fat storage. Conversely, ineffective PPARα sensing or de-
creased fatty acid oxidation causes a reduction in energy
burning that results in hepatic steatosis and steatohepa-
titis (especially during overnight or prolonged fasting)
• -oxidation pathway 
(acyl-CoA oxidase, 
thiolase)  
• Sterol 12-hydoxylase 
(CYP8B1)  
• Fatty acid transport 
protein (FATP)  
• Fatty acid translocase 
(FAT/CD36)  
• Lipoprotein lipase  
• Apolipoprotein A-I and 
A-II
• Genes involved in lipid 
uptake, metabolism and 
efflux (repressed by PPARs) 
• Fatty acid-binding protein 
(aP2)  
• Fatty acid transport protein 
(FATP)  
• Fatty acid translocase 
(FAT/CD36)
β
Figure 3 PPARs and their gene targets.
Main tissue expression:
tissues exhibiting high 
carbolic rates of fatty acids 
(mainly liver and skeletal 
muscle) 
Other tissues:
cardiomyocytes, kidney, 
intestinal mucosa, and 
brown adipose tissue  
Tissue expression: 
ubiquitous, however the 
biggest expression is in 
gastrointestinal tract 
(esophageaous, liver, 
intestines) kidneys and 
skeletal muscle
Main tissue expression:
adipose tissue (white and 
brown) 
Other tissues: intestines, 
liver, kidneys, retina, 
immunologic system (bone 
marrow, lymphocytes, 
monocytes and 
macrophages), trace 
amounts in muscles  
Figure 4 Expression of PPARs in specific tissues.
Grygiel-Górniak Nutrition Journal 2014, 13:17 Page 3 of 10
http://www.nutritionj.com/content/13/1/17
Figure 7. Expression of PPARs in specific tissues. 
	   15	  
 
 
 
1.2.1 PPARs structure and function  
 The PPARs have a domain structure common to other members of the 
nuclear receptor gene family (Figure 9). Sequence comparison of their DNA-
binding domains (DBD) shows that they are highly conserved, while the 
ligand-binding domains (LBD) have a slightly lower level of conservation 
across the subtypes [27]. After interaction with agonists, PPARs are 
translocated to the nucleus and heterodimerize with another nuclear receptor - 
the retinoid X receptor (RXR) - which forms a heterodimer with a number of 
other receptors (e.g., vitamin D or thyroid hormones). The specific DNA 
regions of target genes that bind with PPARs are termed peroxisome 
proliferator hormone response elements (PPREs; Figure 10). The PPREs are 
found in the promoters of PPAR responsive genes, such as the fatty acid-
binding protein (aP2). In most cases, this process activates transcription of 
various genes involved in diverse physiological and pathophysiological 
[32,33]. The diminished effectiveness of oxidation sys-
tems is caused by genetic or toxic factors (including
drug related ones), and metabolic disturbances. In ani-
mal models, inefficient PPARα sensing (characteristic for
PPARα_/_ mice) enables the oxidation of the influxed
fatty acids and leads to severe hepatic steatosis develop-
ment. Administration of PPARα agonists prevents these
processes and even reverses hepatic fibrosis (in animal
models) [34]. Thus, PPARα functions as a lipid sensor
and it controls energy combustion. It also plays also a
prominent role in the pathogenesis of fatty liver disease
(FLD) and ligands of this receptor might be effective in
the reduction of hepatic staetosis by increasing energy
utilization [32,33].
Natural agonists of PPARα
The natural ligands of PPARα are omega-3 fatty acids.
These acids contain three essential elements for optimal
Natural ligands: 
• Unsaturated  fatty acids 
• Leukotriene B4 
• 8-hydroxy-
eicosatetraenoic acid 
Synthetic ligands:
• Fenofibrate 
• Clofibrate 
• Gemfibrozil
Natural ligands: 
• Unsaturated fatty acids  
• Carbaprostacyclin 
• Components of VLDL 
Synthetic ligands: 
• GW501516
Natural ligands: 
• Unsaturated fatty acids  
• 15- hydroxy-
eicosatetraenoic acid  
• 9- and 13- hydroxy-
octadecadienoic acid  
• 15-deoxy 12,14-
prostaglandin J2 
• prostaglandin PGJ2
Synthetic ligands:
• rosiglitazone 
• pioglitizone 
• troglitazone 
• ciglitazone 
• farglitazar 
• S26948 
• INT131
Figure 5 Natural and synthetic ligands of PPAR.
Figure 6 The role of PPARs (↑ - increase, ↓ - decrease).
Grygiel-Górniak Nutrition Journal 2014, 13:17 Page 4 of 10
http://www.nutritionj.com/content/13/1/17
Figure 8. Natural and synthetic ligands of PPARs. 
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processes. The function of PPARs is modified by a number of co-activators 
and co-repressors, the presence of which can either stimulate or inhibit 
receptor function, respectively. Ligands that activate PPARγ-RXR cause an 
exchange of co-repressors for co-activators. Human cells are characterized by 
a different availability of co-factors that depends on the type of cell and the 
association of specific co-factors to other genes [25].  
 
                              
 
     
                                                  
 
 
 
 
 
 
 
 
1.2.2 The ligand binding domain  
 In addition to ligand binding, the LBD is required for 
heterodimerization and interaction with transcriptional co-factors. Due to 
their importance as pharmaceutical targets for regulating the fatty acid 
metabolism and antidiabetic drugs, and since they provide an interesting 
protein (aP2) [5]. In most cases, this process activates
transcription of various genes involved in diverse physio-
logical and pathophysiological processes.
The function of PPARs is modified by a number of co-
activators and corepressors, the presence of which can
either stimulate or inhibit receptor function, respectively
[6]. Ligands that activate PPARγ-RXR cause an exchange
of co-repressors for co-activators [7,8]. Human cells are
characterized by a different availability of cofactors that
depends on the type of cell and the association of spe-
cific cofactors to other genes [7,9,10].
Types of PPARs and their tissue expression
The family of peroxisome proliferation-activated recep-
tors comprises three isoforms: PPARα, PPARβ/δ and
PPARγ [1]. These three isotypes differ from each ther
in terms of their tissue distributions, ligand specificities
and physiological roles. Each of them either activates or
suppresses different genes with only partial overlap in
activity (Figure 3) [5]. All isoforms participate in lipid
homeostasis and glucose regulation (energy balance),
and, until recently, their actions were thought to be lim-
ited to specific tissue types (Figure 4) [5,11]. PPARα is
highly expressed in metabolically active tissues, such as
liver, heart, skeletal muscle, intestinal mucosa and brown
adipose tissue. This receptor is implicated in fatty acid
metabolism and its activation lowers lipid levels [12-15].
PPARγ is expressed in white and brown adipose tissue,
the large intestine and spleen. However, its expression is
highest in adipocytes and it plays a key role in the
regulation of adipogenesis, energy balance, and lipid
biosynthesis [14,16-18]. This receptor also participates in
lipoprotein metabolism and insulin sensitivity.
The least known isoform is PPARβ/δ, which has not
been so intensely studied as PPARα and PPARγ. PPARβ/δ
is expressed ubiquitously in virtually all tissues; however, it
is particularly abundant in the liver, intestine, kidney, ab-
dominal adipose tissue, and skeletal muscle, all of which
are involved in lipid metabolism. It participates in fatty
acid oxidation, mainly in skeletal and cardiac muscles, reg-
ulates blood cholesterol concentrations and glucose levels
[1,13,19,20].
In conclusion, PPARα and PPARβ/δ mainly facilitate
energy comb stion, whereas PPARγ contributes to en-
ergy storage by enhancing adipogenesis [21].
PPAR ligands
Many natural and synthetic agonists of PPARs are used in
the treatment of glucose and lipid disorders. PPARs per-
form different activities, mainly via endogenous ligands
produced in the metabolic pathways of fatty acids; and
therefore, they are called lipid sensors. PPAR agonists have
different properties and specificities for individual PPAR
receptors, different absorption/distribution profiles, and
distinctive gene expression profiles, which ultimately lead
to different clinical outcomes [1,5,17,22,23].
The characteristic feature of the PPAR ligand binding
cavity is its size, which is 3–4 times larger than that of
the other nuclear receptors. Thus, PPARs have the cap-
ability to accommodate and bind a variety of natural and
synthetic lipophilic acids, such as essential fatty acids
(EFA) (Figure 5). These acids act as PPAR agonists that
transcript the genes involved in glucose and lipid
Superfamily of nuclear 
hormone receptors 
Steroid 
hormones 
receptors 
retinoid acid 
receptor - 
RAR 
peroxisome 
proliferator-
activated 
receptor  - 
PPAR
vitamin D3 
receptor - 
VDR 
Thyroid 
hormone 
receptor - THR 
Figure 1 Superfamily of nuclear hormone receptors.
PPRE DNA 
Ligand 
mRNA transcription 
PPAR 
RXR 
 coactivator/coinhibitor 
Figure 2 Mechanism of gene transcription by PPARs.
Grygiel-Górniak Nutrition Journal 2014, 13:17 Page 2 of 10
http://www.nutritionj.com/content/13/1/17
Figure 10. Mechanism of gene transcription by PPARs. 
Figure 9. Functional domains of the PPARs: DBD, DNA-binding domain; LBD, ligand-
binding domain. Numbers represent the percent (%) identity between the human subtypes. 
	   17	  
example of receptors interacting with other molecular partners in a ligand-
dependent manner, the PPARs LBD structure has been intensively studied at 
the atomic level in the past decade. Numerous structures have been 
determined for PPARα, PPARγ and PPARβ/δ, in both liganded and apo 
forms, with or without a co-activator or a co-repressor, and in presence or 
absence of RXR.  
 The overall structure is common to all three isotypes of PPAR LBD 
and resembles the LBDs of other nuclear receptors, like RXR and the retinoic 
acid receptor (RAR). In terms of secondary structure, the molecules fold into 
a single domain that contains a bundle of 13 helices and a small four-stranded 
β-sheet (Figure 11). On the contrary to other NRs LBD, the PPARs LBD 
contains an extra helix, called H2′, between the first β-strand and H3. Also, 
helices H10 and H11 are in fact one continuous helix in PPAR. Helices H4, 
H5, H8, and H9 are sandwiched between helices H1, H3, H7, and H10/H11. 
The ligand binding site - the so-called ligand binding pocket (LBP) - is a very 
large cavity within the protein with a total volume of 1300 to 1400 Å3, which 
is substantially larger than those found in other NRs. It is enclosed by helices 
H2’, H3, H4, H5, H7, H10/H11, H12, and β-strands S3 and S4. The cavity is 
Y-shaped (Figure 12) and consists of an entrance extending from the surface 
of the protein then branching off to two pockets, arm I and arm II (Figure 
13), which are both approximately 12 Å in length: arm I extends toward the 
AF-2 helix H12 and consists of polar residues, while arm II is situated 
between helix H3 and the β-sheet, showing hydrophobic features, which are 
not surprising given the hydrophobic nature of the natural ligands. The 
solvent accessible part of the entrance is essentially composed of polar 
residues, e.g. Pro227, Arg288, Glu295 and Glu343 for PPARγ (Figure 14). 
The loop between helices H2′ and H3, situated at the entrance of the binding 
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site, is very flexible in all PPAR structures and is even disordered in some 
structures. This suggests that the binding site entrance can potentially adapt, 
allowing large ligands to enter the binding pocket without significantly 
changing the overall structure of the LBD [28]. Thirty four residues define 
the wall of the binding cavity, 80% of which are conserved across the three 
isotypes.  
 However, the differences can be linked to ligand specificity. A 
comparison of the experimental 3D structures of the three PPAR LBDs 
indicates that, although the overall size of the cavity is similar, there are 
marked differences in the detailed topology [29]. It is interesting to note the 
conservation of four polar residues in arm I of each PPAR isotype. These 
residues are part of a hydrogen-bonds network involving the carboxylate 
group of FAs and eicosanoic acids, with Ser280 (H3), Tyr314 (H5), His440 
(H11) and Tyr464 (H12) of PPARα (respectively Thr289, His323, His449 
and Tyr473 of PPARβ/δ, and Ser289, His323, His449 and Tyr473 of 
PPARγ).  
Figure 11. secondary structure elements of 
PPARγ LBD. 
Figure 12. PPARγ Ligand Binding Pocket. 
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 A similar hydrogen-bonds network, that involves the Tyr473 residue 
of H12, may exist in PPAR complexes with synthetic ligands and helps 
holding the AF-2 helix in the active conformation, thus promoting the 
binding of co-activator proteins (Figure 15) [28]. 
 
  
 
                                                   
 
 
  
 
 
Figure 13. Arm I (blue), arm II (green) and 
entrance (red) of PPARγ LBP are shown. 
 
Figure 14. PPARγ surface, showing binding site 
entrance. 
	  
Figure 15. Hydrogen-bonds network between a ligand of PPARα 
and residues Ser280, Tyr314, His440 and Tyr464. Hydrogen-bonds 
are shown in green lines. 
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 A structure–activity relationship between the ligand/PPAR interaction 
and the partial or full agonism character of the ligand seems to be provided 
by the hydrogen-bonds network taking place in arm I, involving one residue 
of the AF-2 helix H12. Indeed, a series of experimental 3D structures seem to 
show that partial agonists do not form this hydrogen-bonds network, on the 
contrary to most of the full agonists [30-33]. However, a recent X-ray 
structure shows that a partial PPARγ agonist does make this hydrogen-bonds 
network [34]. Thus, the origin of partial agonism might be more complex and 
a direct interaction with helix H12 does not seem sufficient to have a full 
agonism.  
1.2.3 The role of the AF-2 helix H12  
 In line with the 'mousetrap' model proposed by D. Moras et al. [15], 
several studies performed on the PPAR LBD proved that not only the LBD 
shows conformational changes upon ligand binding, but it also changes 
dynamically. NMR studies on the apo- and holo-PPARα/γ showed an overall 
stabilization of the LBD upon ligand binding [35, 36], resulting in a more 
compact and rigid structure. This stabilization is more relevant for full 
agonists than for partial agonists and was confirmed by Hydrogen/Deuterium 
exchange (HDX) experiments, showing that full agonists stabilize helices 
H11 and H12 through a hydrogen-bonding network, which is lacking in 
partial agonists and antagonists [37]. Moreover, fluorescence anisotropy 
measurements on PPARγ [38] showed that helix 12 is very dynamic in the 
absence of ligand, with movements on the nanosecond timescale, suggesting 
that its mobility is independent of the rest of the LBD. Upon ligand binding, 
it becomes immobilized on the surface of the receptor. Furthermore, the 
structures of apo-PPARγ and β/δ LBDs suggest that the receptors can adopt 
the active conformation even in tha abscence of agonists [39, 40], in 
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accordance with the existence of a basal activity in absence of ligand [41, 
42]. All these data indicate that PPAR LBD does not adopt a well-defined 
structure in the absence of ligand, but rather shows an equilibrium of 
conformations [36]. Ligand binding would shift this equilibrium to a state 
that favors co-activator recruitment, through direct contacts between the 
ligand and the helix 12 and a global stabilization of the LBD. In this model, 
co-activators with high affinity for the receptor could bind to LDB in the 
abscence on any agonist. The high constitutive activity of PPARs [41, 42] 
seems closely related to a ligand-independent stabilization of the active 
position of the AF-2 helix H12, allowing recruitment of co-activators. It has 
been found by comparing several PPAR experimental structures [43] and by 
Molecular Dynamics (MD) simulations [44] that residues Glu324 (H4/H5 
junction) Arg397 (loop between H8 and H9) and Arg443 (H11) are involved, 
together with Tyr477 (H12), in a hydrogen-bonds network that stabilizes the 
AF-2 helix H12 in the active conformation in a ligand-independent manner 
(Figure 16A). MD simulations, together with experimental mutagenesis, 
showed that residues Leu469, Tyr473, Leu476 and Tyr477 significantly 
stabilize the AF-2 helix H12 in the active conformation through interactions 
with the ligand and some adjacent residues of the PPAR LBD [44] (Figure 
16B). Most of these interactions are actually ligand independent. All these 
residues are highly conserved in the PPAR isotypes.  
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1.2.4 The role of the helix H3 and the β-sheet  
 X-ray structures of the PPARγ LBD in complex with full agonists 
indicate the critical of helix 12 in transcriptional regulation of these nuclear 
receptors. The structures of PPARγ bound to partial agonists show that these 
ligands occupy the region between H3 to the β-sheet, forming hydrogen-
bonds with the first strand of the β-sheet (e.g. -NH of S342) and no direct 
interactions with H12. This observation demonstrates the importance of other 
regions such as H3 and β-sheet in the transcriptional response suggesting a 
distinct co-activator binding surface, consistant with the finding that 
stabilization of regions outside the LXXLL motifs contribute to receptor 
binding [45-50]. Moreover, the recently solved structure of full-lenght 
PPARγ-RXR heterodimer demonstrated that the β-sheet region of PPARγ 
binds directly to the RXR DBD [51]. Thus, differential binding of ligands in 
the region between β-sheet and H3 of PPARγ may also affect transcriptional 
ligand, but rather shows an equilibrium of conformations
[28,36]. Ligand binding would shift this conformational equili-
brium to a state that favors co-activator recruitment, through
direct contacts between the ligand and the AF-2 domain and a
global stabilization of the LBD. In this model, co-activator
peptides with high affinity for the receptor could bind to LBD in
the absence of any agonist. It is important to note that a recent
re-analysis of the diffraction data relative to the apo-PPARδ
structure [16] showed that the ligand binding site was in fact
occupied by vaccenic acid, a natural ligand that was not seen in
the first analysis [18,37]. This study also raises doubts about
other structures of apo-PPARs. It would be of great importance
to re-analyze these X-ray structures since the presence of
naturally occurring ligands, even of low affinity, could play a
significant role in the “basal” activity of PPARs.
The high constitutive activity of PPARs [32–35] seems
closely related to a ligand-independent stabilization of the
active position of the AF2 helix H12, allowing recruitment of
co-activator [38,39]. It has been found by comparing several
PPAR experimental structures [38] and by Molecular
Dynamics (MD) simulations [39] that residues Glu324 (H4/
H5 junction) Arg397 (loop between H8 and H9) and Arg443
(H11) are involved, together with Tyr477 (H12), in a
hydrogen-bonds network that stabilizes the AF-2 helix in the
active conformation in a ligand-independent manner (see Fig.
6A). MD simulations, together with experimental mutagenesis,
showed that residues Leu469, Tyr473, Leu476 and Tyr477
significantly stabilize the AF2 helix H12 in the active
conformation through interactions with the ligand and some
adjacent residues of the PPAR LBD [39] (see Fig. 6B). Most
of these interactions are actually ligand independent. All these
residues are highly conserved in the PPAR isotypes.
5. Co-activator binding
It is known that the transcriptional activity of nuclear
receptors is regulated by their interactions with co-activators
such as SRC-1 (steroid receptor co-activator-1) or CBP (CREB-
binding protein), or with co-repressors, such as SMRT
(silencing mediator for retinoid and thyroid hormone receptors).
See Feige et al. [9] for a recent review about PPARs co-
activation and co-repression.
Recruitment of co-activator proteins depends on allosteric
alterations in the AF-2 helical domain. The NR interaction
domain of these activators contains an LXXLL motif that forms
two turns of α-helix and binds into a hydrophobic cleft on the
surface of the receptor. The latter is formed upon stabilization of
the active conformation of the AF-2 helix H12. Several crystal
structures of PPARs complexed with co-activator peptides have
been obtained that allow a detailed analysis of the binding
[1,2,22,23,25,40].
In the 3D structure of PPARγ/rosiglitazone/SRC-1 complex
[1], the hydrophobic face of the LXXLL helix of SRC-1 packs
into a hydrophobic surface formed by some residues situated
between Glu471 and Lys301 of PPARγ. This surface is
formed upon the packing of H12 on H3 and H4, and contains
amino acids Thr297 and Lys301 of H3, Leu311, Gln314,
Val315 and Leu318 of H4, and Leu468 and Glu471 of H12.
The buried hydrophobic core of the LXXLL motif interacts
mainly with L468 and L318 of the PPARγ LBD (see Fig. 7).
This interaction scheme is similar in other PPAR/co-activator
complexes [2,22,23,25,40]. The total surface area of the region
of interaction between LXXLL and PPARγ is 800 Å [1].
In addition to the hydrophobic contacts described above,
hydrogen-bonds are formed between the Glu471 and Lys301
side chains and the co-activator backbone. This important and
conserved set of interactions, the so-called charge clamp, helps
stabilizing the binding of the co-activator to the PPAR LBD
(see Fig. 7). Similar charge clamps are also found in the
complexes of co-activators with other NRs [36], such as the
Fig. 6. (A) PPARγ residues involved in a hydrogen-bonds network stabilizing
the AF-2 domain in a ligand-independent manner (2PRG [1]). Hydrogen-
bonds are shown in green thin lines. AF-2 helix H12 is colored in orange. (B)
Interactions between residues Leu469, Tyr473, Leu476 and Tyr477 (in dark
ball and stick) and some neighboring residues of PPAR (in clear neons) that
stabilize the active conformation of AF-2 helix H1. Rosiglitazone is shown
(magenta).
921V. Zoete et al. / Biochimica et Biophysica Acta 1771 (2007) 915–925
ligand, but rather shows an equilibrium of conformations
[28,36]. Ligand binding would shift this conformational equili-
brium to a state that favors co-activator recruitment, through
direct contacts between the ligand and the AF-2 domain and a
global stabilization of the LBD. In this model, co-activator
peptides with high affinity for the receptor could bind to LBD in
the absence of any agonist. It is important to note that a recent
re-analysis of the diffraction data relative to the apo-PPARδ
structure [16] showed that the ligand binding site was in fact
occupied by vaccenic acid, a natural ligand that was not seen in
the first analysis [18,37]. This study also raises doubts about
other structures of apo-PPARs. It would be of great importance
to re-analyze these X-ray structures since the presence of
naturally occurring ligands, even of low affinity, could play a
significant role in the “basal” activity of PPARs.
The high constitutive activity of PPARs [32–35] seems
closely related to a ligand-independent stabilization of the
active position of the AF2 helix H12, allowing recruitment of
co-activator [38,39]. It has been found by comparing several
PPAR experimental structures [38] and by Molecular
Dynamics (MD) simulations [39] that residues Glu324 (H4/
H5 junction) Arg397 (loop between H8 and H9) and Arg443
(H11) are involved, together with Tyr477 (H12), in a
hydrogen-bonds network that stabilizes the AF-2 helix in the
active conformation in a ligand-independent manner (see Fig.
6A). MD simulations, together with experimental mutagenesis,
showed that residues Leu469, Tyr473, Leu476 and Tyr477
significantly stabilize the AF2 helix H12 in the active
conformation through interactions with the ligand and some
adjacent residues of the PPAR LBD [39] (see Fig. 6B). Most
of these interactions are actually ligand independent. All these
residues are highly conserved in the PPAR isotypes.
5. Co-activator binding
It is known that the transcriptional activity of nuclear
receptors is regulated by their interactions with co-activators
such as SRC-1 (steroid receptor co-activator-1) or CBP (CREB-
binding protein), or with co-repressors, such as SMRT
(silencing mediator for retinoid and thyroid hormone receptors).
See Feige et al. [9] for a recent review about PPARs co-
activation and co-repression.
Recruitment of co-activator proteins depends on allosteric
alterations in the AF-2 helical domain. The NR interaction
domain of these activators contains an LXXLL motif that forms
two turns of α-helix and binds into a hydrophobic cleft on the
surface of the receptor. The latter is formed upon stabilization of
the active conformation of the AF-2 helix H12. Several crystal
structures of PPARs complexed with co-activator peptides have
been obtained that allow a detailed an lysis of the binding
[1,2,22,23,25,40].
In the 3D structure of PPARγ/rosiglitazone/SRC-1 complex
[1], the hydrophobic face of the LXXLL helix of SRC-1 packs
into a hydrophobic surface formed by some residues situated
between Glu471 and Lys301 of PPARγ. This surface is
formed upon the packing of H12 on H3 and H4, and contains
amino acids Thr297 and Lys301 of H3, Leu311, Gln314,
Val315 and Leu318 of H4, and Leu468 and Glu471 of H12.
The buried hydrophobic core of the LXXLL motif interacts
mainly with L468 and L318 of the PPARγ LBD (see Fig. 7).
This interaction scheme is similar in other PPAR/co-activator
complexes [2,22,23,25,40]. The total surface area of the region
of interaction between LXXLL and PPARγ is 800 Å [1].
In addition to the hydrophobic contacts described above,
hydrogen-bonds are formed between the Glu471 and Lys301
side chains and the co-activator backbone. This important and
conserved set of interactions, the so-called charge clamp, helps
stabilizing the binding of the co-activator to the PPAR LBD
(see Fig. 7). Similar charge clamps are also found in the
complexes of co-activators with other NRs [36], such as the
Fig. 6. (A) PPARγ residues involved in a hydrogen-bonds network stabilizing
the AF-2 domain in a ligand-independent manner (2PRG [1]). Hydrogen-
bonds are shown in green thin lines. AF-2 helix H12 is colored in orange. (B)
Interactions between residues Leu469, Tyr473, Leu476 and Tyr477 (in dark
ball and stick) and some neighboring residues of PPAR (in clear neons) that
stabilize the active conformation of AF-2 helix H1. Rosiglitazone is shown
(magenta).
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Figure 16. A) PPARγ residues involved in a hydrogen-bonds n twork stabilizing the AF-2 domain in a 
ligand-independent manner (2PRG [39]). Hydrogen-bonds are shown in green lines, AF-2 helix H12 is 
coloured in orange. B) Interactions between residues Leu469, Tyr473, Leu476 and Tyr477 and some 
neighboring residues of PPAR that stabilize the active conformation of AF-2 helix H1. Rosiglitazone is 
shown in magenta. 
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activity through modulation of its interaction with RXR. 
 Another X-ray and molecular dynamics work explained at molecular 
level the different pharmacological profile of the enantiomers of a novel 
PPARα/γ dual agonist [52], confirming that a differential stabilization of H3 
plays an important role in determining the partial agonist character of a 
ligand. In particular, partial agonism seems to be ascribed to closer contacts 
with the residue Q286 belonging to H3, whereas full agonism could be 
related to stronger interactions with H11, H12 and the loop 11/12. 
 Also, H/D exchange kinetics and X-ray experiments have been 
performed for six complexes of PPARγ with full and partial agonists [45]. On 
the basis of the structures of these complexes, ligands were broadly grouped 
into those that occupy the portion of LBD spanning from H11 and H12 
beyond H3 to those that occupy the region between H3 and the β-sheet only. 
Among both classes of compounds, the partial agonists showed differential 
stabilization of H3 when compared to full agonists. With the first class of 
compounds, stronger transactivation was achieved with a corresponding 
decrease in stabilization of H3; this can perhaps be explained by the ability of 
the compounds in this area to achieve increase in transactivation by directly 
stabilizing H12. In contrast, compounds unable to directly contact H12 
showed increased stabilization of H3 in proportion with transactivation 
efficacy. 
1.2.5 Binding to co-regulators  
 It is well established that the transcriptional activity of nuclear 
receptors is regulated by their interactions with co-factors that positively 
regulate target gene expression, such as the co-activators SRC-1 or CBP, or 
with negative regulatory proteins that inhibit target gene transcription, such 
as the co-repressors SMRT or N-CoR. 
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 Recruitment of co-activator proteins depends on allosteric changes in 
the AF-2 helical domain. The NR interaction domain of these activators 
contains a LXXLL motif that forms two turns of α-helix and binds into a 
hydrophobic cleft on the surface of the receptor, which is formed upon 
stabilization of the active conformation of the FA-2 helix H12. Many crystal 
structures of PPARs complexed with co-activators have been obtained that 
allow a detailed analysis of the binding [29, 31, 32, 39, 53]. In the 3D 
structure of PPARγ in complex with rosiglitazone and SCR-1 [39], the 
hydrophobic face of the LXXLL helix of the co-activator packs into a 
hydrophobic surface formed by some residues situated between Glu471 and 
Lys301 of PPARγ, interacting mainly with L468 and L318 of the PPARγ 
LBD (Figure 17). In addition to the hydrophobic contacs described above, an 
important and conserved set of hydrogen-bond interactions, the so-called 
charge clamp, is formed between the Glu471 and Lys301 side chains and the 
co-activator backbone. It is interesting to note that the residues involved in 
the charge clamp or defining the hydrophobic pocket where the LXXLL 
binds are highly conserved among other members of the NR family. 
 To understand the molecular basis of co-repressor recruitment, the 
crystal structure of a ternary complex containing the PPARα LBD bound to 
the antagonist GW6471 and a peptide derived from the C-terminal receptor-
interacting motif of SMRT (LXXXIXXXL) has been studied [54]. In this 
structure the co-repressor peptide adopts a three-turn α-helix and docks into a 
hydrophobic groove formed by helices H3, H3', H4 and H5. Superposition of 
the agonist- and antagonist-bound PPARα (Figure 18A) reveals that the co-
repressor binding site partially overlaps with the co-activator binding site. 
The additional helical turn in the SMRT motif extends into the space usually 
occupied by AF-2 helix H12 and prevents this helix from folding back into 
its active conformation. 
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 Also, the ligand GW6471 was obtained by replacing the carboxylate 
head of the GW409544 agonist by a larger ethylamide group that prevents 
any hydrogen-bond with the side chain of Tyr464 of AF-2 helix H12 and 
pushes it out of the agonist bound position. In this way, the integrity of the 
charge clamp is also destroyed. 
 This study also suggests two main differences between the binding 
modes of the co-activator and co-repressor [54]. First, the additional helical 
turn in the co-repressor motif result in a larger interaction surface with 
PPARα than the two helical turns of the co-activator motif and could partially 
explain the preference for co-repressor instead of co-activator binding to 
PPAR in presence of an antagonist. Moreover, superposition of the 
PPARα/GW409544/SRC-1 [29] and the PPARα/GW6471/SMRT [54]    
complexes indicates that the +5 and +8 positions of the LXXXIXXXL co- 
repressor motif, respectively occupied by Ile and Ala residues, correspond to 
oestrogen receptor [41], the thyroid receptor [42] and RXR [2].
By comparing several PPAR structures in complex with
agonist/co-activator and antagonist/co-repressor, Molnar et al.
[38] found that the distance between the Cα atoms of Glu471
and Lys301 res dues ra ge between 18 and 20 Å in presence
of a co-activator and an agonist ligand, while it is much larger
in presence of an antagonist ligand and a co-repressor as a
consequence of the H12 reorientation (26.3 Å in the PPARα/
GW6471/SMRT complex [43]). MD simulations of active and
inactive xenopus PPARα mutants were able to reproduce this
finding [39]. This could help the rational design of engineered
PPARs, or the a priori estimation of the a onist or antag ist
character of a putative ligand.
It is interesting to note that the residues involved in the
charge clamp or defining the hydrophobic pocket where the
LXXLL binds are highly conserved among other members of
the NR family.
6. Co-repressor binding
The interaction between a co-repressor peptide and PPAR
complexed with an antagonist has been studied by X-ray
crystallography [43]. In this study, the author complexed
PPARα with the GW6471 antagonist. This ligand was obtained
by replacing the carboxylate head of the GW409544 agonist by
a larger ethylamide group that prevents any hydrogen-bond with
Tyr464, and pushes the AF-2 helix out of the agonist bound
position [43]. Unlike the antagonist-bound oestrogen-receptor
structures [41], the AF-2 helix does not occupy the co-activator-
binding groove, but is loosely packed against helix 3 (see Fig.
8A). This 3D structure reveals that removing H12 from its
active position destroys the charge clamp but leaves sufficient
space to accommodate the additional helical turn of the co-
repressor motif, i.e. LXXXIXXXL. The latter extends into the
space that is left by the repositioning of the AF-2 helix, and
prevents it from going back to its active position [43].
The study also suggests two main differences between the
binding modes of the co-activator and co-repressor [43]. First,
the three helical turns in the co-repressor motif result in a larger
interaction interface with PPARα than the two helical turns of
the co-activator motif, and could explain in part the preference
for co-repressor instead of co-activator binding to PPAR in
presence of an antagonist. Also, superposition of the PPARα/
Fig. 7. Interactions between the SRC-1 peptide co-activator and PPARγ (2PRG
[1]). Helices H3 and H12 are labeled in yellow. The co-activator and the
important residues of PPAR are shown in dark neon and clear ball and stick
representations, respectively. The LXXLL motif of the co-activator is shown in
green. The hydrogen-bonds of the charge clamp are shown in green thin lines.
Fig. 8. Structural superposition of PPARα/GW409544/SRC-1 [23] (white) and
PPARα/GW6471/SMRT [43] (magenta). In the PPARα/GW409544/SRC-1
structure, the AF-2 helix H12 and the SRC-1 co-activator are orange and green,
respectively. In the PPARα/GW6471/SMRT structure, the AF-2 helix H12 and
the SMRT co-repressor are yellow and blue, respectively. (A) The co-repressor
occupies partly the position of the active conformation of AF-2. (B) The Ile (+5)
and Ala (+8) residues of the LXXXIXXXL co-repressor motif correspond to the
Leu (+1) and Leu (+4) residues of the LXXLL co-activator motif. The larger
size of the Leu residues prevents the co-activator to bind tightly to the LBD
surface in the inactive conformation, on the contrary to the co-repressor.
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Figure 17. interactions between the SRC-1 peptide and PPARγ (2PRG [39]). 
The LXXLL motif of the co-activ tor is shown in gre n. The hydrogen-bonds 
of the charge clamp are shown in green thin lines. 
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the first and second Leu residues in the LXXLL co-activator motifs (Figure 
18B). The presence of the two larger Leu residues in the co-activator 
prevents it from binding tightly to the LBD surface when AF-2 helix H12 is 
in its inactive conformation, so they become strong contributors to the 
interaction in the context of the active conformation due to interactions with 
H12. Second, as already described, the charge clamp between PPAR and the 
co-activator is destroyed in the complex with co-repressor due to the 
repositioning of Glu462 (H12). However, Lys301 still makes hydrogen-
bonds with the co-repressor backbone [54].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.6 Heterodimer formation with RXR  
 Although some evidence suggests that the PPARs can form 
homodimers and bind to DNA response elements such as the Pal3 motif [55], 
it is widely accepted that the PPARs must heterodimerize with RXR to carry 
oestrogen receptor [41], the thyroid receptor [42] and RXR [2].
By comparing several PPAR structures in complex with
agonist/co-activator and antagonist/co-repressor, Molnar et al.
[38] found that the distance between the Cα atoms of Glu471
and Lys301 residues range between 18 and 20 Å in presence
of a co-activator and an agonist ligand, while it is much larger
in presence of an antagonist ligand and a co-repressor as a
consequence of the H12 reorientation (26.3 Å in the PPARα/
GW6471/SMRT complex [43]). MD simulations of active and
inactive xenopus PPARα mutants were able to reproduce this
finding [39]. This could help the rational design of engineered
PPARs, or the a priori estimation of the agonist or antagonist
character of a putative ligand.
It is interesting to note that the residues involved in the
charge clamp or defining the hydrophobic pocket where the
LXXLL binds are highly conserved among other members of
the NR family.
6. Co-repressor binding
The interaction between a co-repressor peptide and PPAR
complexed with an antagonist has been studied by X-ray
crystallography [43]. In this study, the author complexed
PPARα with the GW6471 antagonist. This ligand was obtained
by replacing the carboxylate head of the GW409544 agonist by
a larger ethylamide group that prevents any hydrogen-bond with
Tyr464, and pushes the AF-2 helix out of the agonist bound
position [43]. Unlike the antagonist-bound oestrogen-receptor
structures [41], the AF-2 helix does not occupy the co-activator-
binding groove, but is loosely packed against helix 3 (see Fig.
8A). This 3D structure reveals that removing H12 from its
active position destroys the charge clamp but leaves sufficient
space to accommodate the additional helical turn of the co-
repressor motif, i.e. LXXXIXXXL. The latter extends into the
space that is left by the repositioning of the AF-2 helix, and
prevents it from going back to its active position [43].
The study also suggests two main differences between the
binding modes of the co-activator and co-repressor [43]. First,
the three helic l turns in the co-repressor motif result in a larger
interaction interface with PPARα than the two helical turns of
the co-activat r motif, and could explain in part the preferenc
for co-repressor instead of co-activator binding to PPAR in
presence of an antagonist. Also, superposition of the PPARα/
Fig. 7. Interactions between the SRC-1 peptide co-activator and PPARγ (2PRG
[1]). Helices H3 and H12 are labeled in yellow. The co-activator and the
important residues of PPAR are shown in dark neon and clear ball and stick
representations, respectively. The LXXLL motif of the co-activator is shown in
green. The hydrogen-bonds of the charge clamp are shown in green thin lines.
Fig. 8. Structural superposition of PPARα/GW409544/SRC-1 [23] (white) and
PPARα/GW6471/SMRT [43] (magenta). In the PPARα/GW409544/SRC-1
structure, the AF-2 helix H12 and the SRC-1 co-activator are orange and green,
respectively. In th PPARα/GW6471/SMRT structure, the AF-2 helix H12 and
the SMRT co-repressor are yellow and blue, respectively. (A) The co-repressor
occupies partly the position of the active conformation of AF-2. (B) The Ile (+5)
and Ala (+8) residues of the LXXXIXXXL co-repressor motif correspond to the
Leu (+1) and Leu (+4) residues of the LXXLL co-activator motif. The larger
size of the Leu residues prevents the co-activator to bind tightly to the LBD
surface in the inactive conformation, on the contrary to the co-repressor.
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oestrogen receptor [41], the thyroid receptor [42] and RXR [2].
By comparing several PPAR structures in complex with
agonist/co-activator and antagonist/co-repressor, Molnar et al.
[38] found that the distance between the Cα atoms of Glu471
and Lys301 residues range between 18 and 20 Å in presence
of a co-activator and an agonist ligand, while it is much larger
in presence of an antagonist ligand and a co-repressor as a
consequence of the H12 reorientation (26.3 Å in the PPARα/
GW6471/SMRT complex [43]). MD simulations of active and
inactive xenopus PPARα mutants were able to reproduce this
finding [39]. This could help the rational design of engineered
PPARs, or the a priori estimation of the agonist or antagonist
character of a putative ligand.
It is interesting to note that the residues involved in the
charge clamp or defining the hydrophobic pocket where the
LXXLL binds are highly conserved among other members of
the NR family.
6. Co-repressor binding
The interaction between a co-repressor peptide and PPAR
complexed with an antagonist has been studied by X-ray
crystallography [43]. In this study, the author complexed
PPARα with the GW6471 antagonist. This ligand was obtained
by replacing the carboxylate head of the GW409544 agonist by
a larger ethylamide group that prevents any hydrogen-bond with
Tyr464, and pushes the AF-2 helix out of the agonist bound
position [43]. Unlike the antagonist-bound oestrogen-receptor
structures [41], the AF-2 helix does not occupy the co-activator-
binding groove, but is loosely packed against helix 3 (see Fig.
8A). This 3D structure reveals that removing H12 from its
active position destroys the charge clamp but leaves sufficient
space to accommodate the additional helical turn of the co-
repressor motif, i.e. LXXXIXXXL. The latter extends into the
space that is left by the repositioning of the AF-2 helix, and
prevents it from going back to its active position [43].
The study also suggests two main differences between the
binding modes of the co-activator and co-repressor [43]. First,
the three helical turns in the co-repressor motif result in a larger
interaction interface with PPARα than the two helical turns of
the co-activator motif, and could explain in part the preference
for co-repressor instead of co-activator binding to PPAR in
presence of an antagonist. Also, superposition of the PPARα/
Fig. 7. Interactions between the SRC-1 peptide co-activator and PPARγ (2PRG
[1]). Helices H3 and H12 are labeled in yellow. The co-activator and the
important residues of PPAR are shown i dark neon a d clear ball and stick
representations, respectively. The LXXLL motif of the co-activator is shown in
green. The hydrogen-bonds of the charge clamp are shown in green thin lines.
Fig. 8. Structural superposition of PPARα/GW409544/SRC-1 [23] (white) and
PPARα/GW6471/SMRT [43] (magenta). In the PPARα/GW409544/SRC-1
structure, the AF-2 helix H12 and the SRC-1 co-activator are orange and green,
respectively. In the PPARα/GW6471/SMRT structure, the AF-2 helix H12 and
the SMRT co-repressor are yellow and blue, respectively. (A) The co-repressor
occupies partly the position of the active conformation of AF-2. (B) The Ile (+5)
and Ala (+8) residues of the LXXXIXXXL co-repressor motif correspond to the
Leu (+1) and Leu (+4) residues of the LXXLL co-activator motif. The larger
size of the Leu residues prevents the co-activator to bind tightly to the LBD
surface in the inactive conformation, on the contrary to the co-repressor.
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Figure 18. Structural superposition of PPARα-LBD/GW409544/SRC-1 [29] (white) and the PPARα-
LBD/GW6471/SMRT [54] (magenta). In the PPARα-LBD/GW409544/SRC-1 structure, the AF-2 
helix H12 and the SRC-1 co-activator are orange and green, respectively. In the PPARα-
LBD/GW6471/SMRT structure, the AF-2 helix H12 and the SMRT co-repressor ar  yellow and blue, 
respectively. (A) The co-repressor occupies partly the position of the a tive conformation of AF-2. 
(B) The Ile (+ 5) and Ala (+ 8) residues of the LXXXIXXXL co-repressor motif correspond to the 
Leu (+1) and Leu (+4) residues of the LXXLL co-activator motif. The larger size of the Leu residues 
prevents the co-activator to bind tightly to the LBD surface in the inactive conformation, on the 
contrary to the co-repressor. 
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out most of their functions. Therefore, like other RXR’s partners, the PPARs 
are integral parts of the RXR-dependent signaling network. The crystal 
structure of the PPARγ and RXRα LBDs complexed to the RXR ligand 9-cis-
retinoic acid (9cRA), the PPARγ agonist rosiglitazone and the co-activator 
peptides has been described [53]. The structural analysis of domains E 
present principles of heterodimerization in comparison to homodimerization. 
Homodimers of domain E of RXRs and PPARs are symmetric around a 
twofold rotation axis parallel to the core of the dimerization interface formed 
by helix 10. Further, residues are located in helices 7, 9, and 11 as well as in 
loops 7/8 and 9/10. These structural elements contribute to the dimerization 
in the same manner from both molecules in homodimers. This symmetry is 
not maintained in the interface of the heterodimers of RXRs with PPARs. 
The PPARγ/RXRα interface is asymmetric where the PPARγ LBD is rotated 
about 10° from the C2 symmetry axis of the RXR LBD. The interface is 
comprised of a complex network of hydrophobic and polar interactions 
mediated by H7, H9, and H10 and the loop between H8 and H9 of both 
receptors (Table 1). The majority of the heterodimerization interactions are 
mediated through H10 of both receptors (Table 1 and Figure 19a). 
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Figure 1. Ov rall Structure of the PPARg/RXRa Heterodim r Complex
The front and top views of the PPARg/RXRa heterodimer complex are presented in solid rendering (a helices in cylinders, and b strands in
arrows). RXR is colored in yellow, PPARg in blue, and the two SRC-1 peptides in purple. The two compounds (9cRA and GI262570) are shown
in space-filling representation with carbon, oxygen, and nitrogen atoms depicted in green, red, and blue, respectively.
and theglutamate residues, as seen in thePPARg homo- of the hydrophobic and charged residues in the hetero-
dimer interface is evident from examination of the elec-dimer structure with SRC-1 (Nolte et al., 1998).
trostatic surface of each receptor (Figure 2). The core
hydrophobic interactions between the two receptors areThe H terodimer Interface further stabilized by basic and acidic surfaces, whichThe PPARg/RXRa interface is asymmetric where the lie on alternate sides of the C2 symmetry axis for PPARgPPARg LBD is rotated z108 from the C2 symmetry axis and RXRa and effectively eutralize each other in theof the RXR LBD. The interface is comprised of an intri- heterodimer. The majority of the heterodimerization in-cate network of hydrophobic and polar interactions me- teractions are mediated through H10 of both receptorsdiated by H7, H9, and H10 and the loop between H8 (Table 2; Figure 3a). The N-terminal halves of H10 formandH9 of both receptors (Table 2). The complementarity a parallel coiled-coil structure, which contributes 10 of
the 18 residues that are involved in heterodimerization
(Figure 3a). This dimerization interface, which involves
Table 2. Interactions in the RXRa/PPARg Dimer Interface residues 432–447 in PPARg and residues 415–434 from
Non polar interactions Polar Interactions RXRa, is composed of complimentary hydrophobic
RXRa PPARg RXRa PPARg amino acids. In addition to H10, residues L414 of PPARg
and Y397 of RXR on H9 contribute to the heterodimer(H9) Y397 – A433 (H10) (H7) K356 – E407 (H9)
(H10) F415 – A433 (H10) (H7) K356 –G395 (L8) interface. Finally, residues from H7, H9, and the loop
(H10) A416 – L414 (H9) (H7) D379 – K438 (H10) between H8 and H9 are involved in the formation of
(H10) A416 – F432 (H10) (H7) D379 –D441 (H10) hydrogen bonds that further increase the specificity and
(H10) A416 – L436 (H10) (H9) E390 – K434 (H10) stability of the dimer interface.(H10) L419 – L436 (H10) (H9) E394 – K434 (H10) Members of the nuclear receptor subfamily 2, which(H10) L420 – L414 (H10) (H9) E401 –Q430 (H9)
includes RXR, COUP-TF, and HNF4 (Nuclear Receptors(H10) L420 – L436 (H10) (H9) R393 –D441 (H10)
Nomenclature Committee, 1999), are unique in having(H10) L420 –Q437 (H10) (H9) Y397 –Q437 (H10)
(H10) L420 –M439 (H10) (H10) K417 – E407 (H9) a glutamic acid residue (E352 in RXRa) in the middle of
(H10) L422 – T440 (H10) (H10) R421 – E407 (H9) H7 that we designate the “E insert.” Close examination
(H10) P423 – T440 (H10) (H10) R421 –D396 (L8) of the 9cRA-RXRa portion of the heterodimer structure
(H10) P423 –M439 (H10) (H10) R426 –Q444 (H10) reveals an unwinding of H7 that is absent in the pub-(H10) S427 –Q444 (H10) (H10) S427 – R443 (H10)
lished apo-RXRa structure (Bourguet et al., 1995). The(H10) L430 –Q444 (H10) (H10) K431 – Y477 (AF2)
unwinding of H7 by the E insert initiates an intricate(H10) L430 – T447 (H10)
(H7) E352 – P398 (L8) series of charge-driven interactions along the hetero-
(H7) R348 – Y477 (AF2) dimer interface. The E insert rotates K356 one residue
around H7 of RXR, which places it close to a negativelyResidues involved in dimerization are listed along with the second-
charged region at E407 on the surface of PPARg (Figureary structures. The intermolecular interactions are grouped into po-
lar and nonpolar interactions. The nonpolar interactions include Van 3b). E352 also makes a salt bridge with R348 on H7,
der Waals contacts and hydrophobic interactions with a distance holding this residue in close proximity to K431 on H10
cutoff of 4.5 A˚, and the polar interactions include charged interac- of RXRa. An unexpected consequence of these interac-
tions (5.5 A˚ cutoff) and hydrogen bonds (4.0 A˚ cutoff). tions is the formation of a salt bridge between K431 of
Table 1. Interactions in the 
RXRα/PPARγ dimer interface. 
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 Members of the nuclear receptor subfamily 2, which includes RXR, 
are unique in having a glutamic acid residue (E352 in RXRα) in the middle 
of H7. Close examination of the 9cRA-RXRα portion of the heterodimer 
structure reveals an unwinding of H7 that is absent in the published apo-
RXRα structure [12]. The unwinding of H7 by the E352 give rise to a 
complex series of charge-driven interactions along the heterodimer interface. 
The E352 rotates K356 one residue around H7 of RXR, which places it close 
to a negatively charged region at E407 on the surface of PPARγ (Figure 19b). 
E352 also makes a salt bridge with R348 on H7, holding this residue in close 
proximity to K431 on H10 of RXRα. An unexpected consequence of these 
interactions is the formation of a salt bridge between K431 of RXRα and the 
free carboxylate of Y477 in PPARγ (Figure 19b). This salt bridge is further 
reinforced by a packing interaction between the side chains of Y477 and 
R348. Thus, E352 of RXRα forms an intradimer salt bridge with R348, 
which facilitates an interdimer salt bridge between K431 of RXRα and the C-
terminal residue of the PPARγ. These salt bridges stabilize the PPARγ AF-2 
helix in a position that facilitates the recruitment of co-activators. Notably, 
the corresponding interaction between the RXRα AF-2 helix and H10 of 
PPARγ was not observed. These charge-driven interactions, which are 
asymmetric with respect to the heterodimer, suggest a structural basis for the 
permissiveness of the PPARγ/RXRα complex. Indeed the existence of two 
types of nuclear receptor heterodimers, nonpermissive and permissive, has 
been already described. No response of RXRs to agonists is detected in 
nonpermissive heterodimers formed with RARs, TRs, VDR. Agonists will 
induce a signal via RXRs in heterodimers formed with RARs if a ligand of 
RARs is present. 
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Figure 19. Interactions between RXRα and PPARγ. (a) Intermolecular interactions mediated by helices 
10 of RXRα and PPARγ. Key residues that form the core hydrophobic interface of the parallel coiled 
coil are labeled, along with the C2 axis of symmetry. (b) Interactions between the PPARγ AF-2 helix 
and RXRα. Helices 7 and 10 of RXRα are shown in yellow, with residues that form key charge 
interactions with PPARγ indicated, including the E insert, E352. The surface of PPARγ is shown in 
gray, with the AF-2 helix of PPARγ indicated in cyan. PPARγ residues Y477, the C-terminal residue 
that interacts with K431 and R348 of RXRα; K319, which caps the C-terminal carbonyls of the AF-2 
helix; and Y473, which interacts with the PPARγ ligands, are indicated. The LxxLL motif of SRC-1 is 
shown in magenta. 
 However, RXRs can be activated by agonists in permissive 
heterodimers formed with PPARs, LXR and FXR independently of the 
presence of a ligand in the heterodimeric partner. Addition of an agonist of 
PPARs results in an additive effect on transcriptional activation in the case of 
RXR/PPAR heterodimers. The crystal structure of the heterodimer of RXRα 
and PPARγ in complex with 9cRA, rosiglitazone and peptides derived from 
SRC-1 suggests some features of the structural basis for permissiveness of 
RXR heterodimers. The interconnection of hydrogen-bonds and salt bridges 
stabilizes the formation of a salt bridge between the ε-amino group of K431 
in helix 10 of RXRα and the carboxylate group of Y477, which is the C-
terminus of domain E of PPARγ. Thus, this salt bridge may permit the 
stabilization of helix 12 in transcriptionally active form of PPARγ, even in 
the absence of a PPAR agonist [53]. 
Molecular Cell
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Figure 2. The PPARg/RXRa Heterodimer Interface
Molecular surface representations of RXRa and PPARg are colored according to electronic potentials ranging from 26 to 16 kcal/mol/e. The
color spectrum includes red for negative charge, white for neutral, and blue for positive charge. The approximate C2 symmetry axis between
the two LBDs is indicated, and the regions of charge complementarity are labeled as “A” and “B” in RXR and “A9” and “B9” in PPARg.
RXRa and the free carboxylate of Y477 in PPARg (Figure position that facilitates the recruitment of coactivators.
Notably, the corresponding interaction between the3b). This salt bridge is further reinforced by a packing
interaction between the side chains of Y477 and R348. RXRa AF-2 helix and H10 of PPARg was not observed.
These charge-driven interactions, which are asymmetricThus, E352 of RXRa forms an intradimer salt bridge with
R348,which facilitates an interdimer salt bridge between with respect to the heterodimer, suggest a structural
basis for the permissiveness of the PPARg/RXRaK431 of RXRa and the C-terminal residue of the PPARg.
These salt bridges stabilize the PPARg AF-2 helix in a complex.
Figure 3. Interactions between RXRa and PPARg
(a) Intermolecular interactions mediated by helices 10 of RXRa and PPARg. Key residues that form the core hydrophobic interface of the
parallel coiled coil are labeled, along with the C2 axis of symmetry.
(b) Interactions between the PPARg AF-2 helix and RXRa. Helices 7 and 10 of RXRa are shown in yellow, with residues that form key charge
interactions with PPARg indicated, including the E insert, E352. The surface of PPARg is shown in gray, with the AF-2 helix of PPARg indicated
in cyan. PPARg residues Y477, the C-terminal residue that interacts with K431 and R348 of RXRa; K319, which caps the C-terminal carbonyls
of the AF-2 helix; and Y473, which interacts with the PPARg ligands, ar indicated. The LxxLL motif of SRC-1 is shown in magenta.
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1.2.7 Non-genomic actions 
 Studies on the role of PPARs in integrating and modulating 
inflammatory stimuli have highlighted many unknown mechanisms of action 
of the receptors at the non-genomic level. Indeed, PPARs can mediate 
indirect repressive effects termed transrepression by inhibiting the activity of 
key transcription factors. As shown in Figure 20, transrepression can occur 
either by inhibiting the binding of transcription factors to DNA through direct 
protein-protein interactions (tethering) or by sequestring co-factors necessary 
to their activity (squelching). 
 
                                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Tethering of transcriptional factors is illustrated by the inhibition of 
interleukin-2 (IL-2) expression in response to PPARγ. The ligand-dependent 
binding of PPARγ to nuclear factor of activated T cells (NFAT) correlates 
Figura 20. General mechanisms of transrepression by PPAR/RXR heterodimers. Tethering (interaction 
with transcriptional factors that inhibit their DNA binding), squelching (titration of a co-activator in the 
presence of a ligand) and inverse squelching (titration of a co-repressor in the absence of a ligand) are 
schematically described. 
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with the dissociation of NFAT from the IL-2 promoter [58]. Another example 
is the repression of the α1-acid glycoprotein (AGP) promoter by PPARα 
which inhibits the binding of the CCAAT/enhancer binding protein β 
(C/EBPβ) to the promoter through a direct interaction [59]. Tethering of the 
p65/RelA subunit of NFkB and of the c-jun subunit of the activator protein 1 
(AP-1) by PPARα is also plausible since both of these factors interact with 
PPARα and are necessary to the fibrate-dependent inhibition of the IL-6 
promoter [60, 61]. Finally, in enterocytes, the nuclear export of the p65/RelA 
and the consequent anti-inflammatory effect induced by exposure to a 
specific commensal bacterium is caused by the translocation of PPARγ from 
the nucleus to the cytoplasm [62]. This example suggests that under some 
circumstances, tethering seems to involve direct interactions which promote 
the nuclear export of the transcription factor tethered. 
Recently, a model explaining the ligand-dependent squelching of NcoR and 
the subsequent repression of the iNOS promoter has been proposed [63]. In 
response to rosiglitazone, PPARγ is sumoylated and indirectly recruited to 
the iNOS promoter through ligand-dependent association with the nuclear 
receptor co-repressor (NcoR). This association prevents NcoR dissociation 
and therefore repress transcription of iNOS (Figure 21). Another example of 
co-factor squelching is the repression of the cyclin D1 promoter by PPARγ 
ligands which promote PPARγ/p300 versus AP-1/p300 interactions [64]. 
PPARα also competes with C/EBPβ for binding to their common co-activator 
GRIP1/TIF-2/SRC-2 and thereby represses the action of C/EBPβ on the 
fibrinogen promoter [65]. Finally, inverse squelching has also been 
obsverved between PPARγ and STAT3. Troglitazone inhibits the interaction 
between PPARγ and the co-repressor SMRT, thereby inducing the 
redistribution of SMRT to activated STAT3 and repressing STAT3 signaling 
[66]. 
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1.2.8 Regulation by post-translational modifications (PTM) 
 PPARs function, as well as that of other nuclear receptors, is 
regulated by post-translational modifications (PTM) including 
phosphorylation, ubiquitylation and sumoylation.  
Several phosphorylation sites spanning all across the receptor have been 
characterized using in vitro or cellular assays. At the molecular level, the 
effects of PPAR phosphorylation are mediated by different mechanism 
including changes in the affinity for ligands, RXR, co-factors and target 
genes, which often result from long-range conformational changes across the 
Figure 21. On the iNOS promoter, LPS relieves the repression by NCoR in the absence of 
PPARγ ligands. However, rosiglitazone-induced PPARγ lysine 365 sumoylation induces the 
binding of sumoylated PPARγ to the repressive complex and thereby stabilizes tha association 
of NCoR with the promoter to maintain the gene in an inactive state [63]. 
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entire receptor. For instance, phosphorylation of PPARγ2 serine112 by MAP 
kinase induces conformational changes which are transmitted to the LBD and 
result in a weakened affinity for ligands [67], causing a lower transcriptional 
activity [68]. The interaction between PPAR and RXR also seems to be 
modulated by phosphorylation in the hinge region as mutation of the PKC 
phosphorylation sites T129 and S179 of PPARα reduces heterodimerization 
[69]. The effects of phosphorylation on the interactions with co-factors are 
illustrated by the MAP kinase-mediated phosphorylation of the AF-1 which 
activates PPARα in response to insulin, probably by relieving inhibition by 
co-repressors [41]. Since PPARα interact with NCoR through its C terminus 
[70], this co-repressor release would be mediated by interdomain 
communication. Phosphorylation may also regulate binding to response 
elements as observed upon phosphorylation of the PPARα DBD by PKA 
[42]. Moreover, phosphorylation of serine245 (PPARγ2 residue S273) by 
Cdk5 could be responsible of the dysregulation of a large number of genes, 
whose expression is altered in obesity, including a reduction in the expression 
of the insulin-sensitizing adipokine and adiponectine [71]. Finally, besides 
these direct effects of phosphorylation, PPAR activity can also be modulated 
by changing the expression level of the receptor. 
 Ubiquitin is an 8 kDa protein which covalently binds to proteins to 
target them for degradation by the 26S proteasome. Ubiquitylation of 
proteins occurs on lysine residues and requires the action of a sequential 
activation cascade composed of an activating enzymne (E1), a conjugating 
enzyme (E2) and finally an ubiquitin ligase (E3). Ubiquitylation and 
proteasome-mediated degradation are linked to the transcriptional activity of 
nuclear receptors through the regulation of cellular levels of the receptor but 
also through the intrinsic crosstalk between proteasome activity and 
transcription [72]. Both PPARα and PPARγ can be targeted for degradation 
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by ubiquitylation. The degradation of PPARγ is enhanced by ligand binding 
through a mechanism that requires an intact AF-2 structure and probably an 
active conformation of the receptor as the association of the RIP140 co-
repressor reverses the effect of the ligand on degradation [73]. In contrast, 
PPARα agonists stabilize the receptor [74, 75]. Finally, it should be noted 
that PPARβ/δ can affect ubiquitylation by regulating the expression of 
ubiquitin C, possibly through direct transcriptional control [76]. 
 Small ubiquitin-like modifiers (SUMO) compose a family of three 11 
kDa proteins homologous to ubiquitin which can be reversibly conjugated to 
proteins through covalent binding to regulate various cellular mechanism 
including transcriptional repression [77]. Sumoylation is catalyzed by the 
coordinated action of specific E1, E2 and E3 enzymes and occurs on lysine 
residues located in ΨKXE/D motifs (where Ψ is a large hydrophobic residue 
and X is any residue). K77 sumoylation occurs in a ligand-independent and 
exerts inhibitory effects on the activity of the receptor [63, 78, 79]. Indeed, 
both the basal and the ligand-dependent activity of the PPARγ K107R mutant 
are increased and this mutant can enhance physiological effects such as 
apoptosis in response to TZDs [78] or adipogenesis [79]. In contrast, 
sumoylation at lysine 365 is ligand-dependent and leads to complex 
transrepressive effects on the iNOS promoter by promoting the interaction 
with NCoR [63]. The mechanism controlling this sumoylation event involves 
a direct ligand-independent interaction between PPARγ and the protein 
inhibitor of activated STAT 1 (PIAS1), an E3 SUMO ligase. In this model, 
rosiglitazone binding induces a conformational change which guides K365 
towards the surface of the LBD and thereby allows PIAS to exert its sumo 
ligase activity on this residue (Figure 21) [63]. However, PIAS proteins can 
also be recruited in a ligand-dependent manner and coactivate nuclear 
receptors including PPARγ [78, 80]. Thus, PIAS proteins could exert a dual 
	   35	  
action on PPARγ signaling by promoting transpression through sumoylation 
of PPARγ K365 and by acting as a co-activator of PPARγ on direct target 
genes, possibly through sumoylation of other co-factors or histones. Finally, 
since transcriptional repression by SUMO is generally mediated by the 
recruitment of co-repressors and histone deacetylases (HDACs) [81] and 
since sumoylation of PPARγ K365 promotes the association of PPARγ and 
NCoR, studying the influence of K77 sumoylation on the recruitment of co-
repressors to target gene promoters could allow to better understand the 
mechanisms of PPAR target gene silencing.  
1.2.9 Drugs and active compounds on PPARs 
 The broad roles of PPARs in regulating metabolism, inflammation, 
differentiation and cellular growth, have made them a central focus of 
pharmacological and genetic research for more than a decade [82, 83]. 
 Agonists of PPARα and PPARγ are currently approved for use in 
treating, respectively, dyslipidemia and type 2 diabetes. Agonists of PPARβ/δ 
are currently in development by many pharmaceutical companies. Despite 
their therapeutic importance, there are dose limiting side effects associated 
with PPAR drug treatment, thus a new generation of safer PPAR drugs are 
being actively sought after [83, 84]. Initial strategies aimed to develop new 
highly potent PPAR agonists specific for only one isotype. Therefore, pure 
PPARγ agonists have been or are in development while, surprisingly, only 
few pure PPARα ligands are in the pipeline. However, combination therapy 
with drugs acting on different PPAR isotypes may have synergistic and wider 
therapeutic effects improving both glucose and lipid metabolism of patiens 
suffering from metabolic syndrome and/or type 2 diabetes. Based on this 
hypothesis, new dual and pan agonists are currently developed aiming to 
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obtain synergism on lipid and glucose homeostasis from simultaneous 
activations of the three PPAR isotypes (Figure 23). 
• Fibrates 
 All marketed PPARα agonists belong to the fibrate class (clofibrate, 
ciprofibrate, fenofibrate, bezafibrate, gemfibrozil; Figure 22). these 
compounds have been used therapeutically for more than 30 years, and are 
well established effective agents for managing dyslipidemia, in particular 
elevated concentrations of triglyceride-rich lipoproteins (VLDL) and low 
levels of HDL-C that are typically associated with the mixed dyslipidemia 
characteristic of type 2 diabetes and the metabolic syndrome. They are 
generally considered as safe drugs with only few side effects, although some 
Figure 22. Chemical structures of some PPAR ligands. 
unrelated effect. Therefore, the risk evaluation of each adverse
effect should be viewed on a case by case basis considering
both the PPAR profile of the drug, its absorption/distribution
profile, the nature of the side effect and the putative PPAR-
related mechanism of action. In this review, we will mainly
focus on the preclinical and clinical outcomes of developed or
marketed PPAR agonists that can be of concern with respect
to the long-term use of PPAR agonist in the treatment of
chronic diseases.
3. Distinct PPAR activation profiles
As shown in Table 2, the selectivity ratio of the various
PPAR agonists varies depending on the report and the in vitro
test that has been used. However, it is noteworthy that none of
the failed PPAR agonists were pure PPARα or PPARα-
preferential dual agonists when tested on the human PPAR
isoforms. Indeed, for most of the failed PPAR agonists, the
apparent affinity for PPARγ is higher than the affinity for
PPARα (see Table 2). Furthermore, these compounds should be
viewed as full PPARγ agonists since they induce 100% of the
transcriptional activity of the PPAR when compared to the
reference compound rosiglitazone, while they behave as partial
agonists on PPARα, inducing about 50% of the maximal
activity seen with fenofibrate. Thus, all failed PPAR agonists to
date are apparently pure PPARγ or PPARγ-preferential dual
agonists. Consequently, although one cannot exclude cross-talk
and synergistic toxic effects resulting from simultaneous actions
on PPARα and PPARγ, most safety issues that led to
development discontinuations are rather associated to over-
activation of PPARγ than to action on the alpha isotype.
As extensively reviewed in the same issue of BBA, recent
drug discovery studies have focused on identifying new non-
TZD selective PPARγ modulators trying to minimize the side
effects associated with the use of glitazones. These include
metaglidasen (Metabolex), FMOC-Leu [26], nTZDpa [27],
SPPARM12 [28], and the T131 molecule (Amgen (Tularik)). As
exemplified in Fig. 2 for metaglidasen (the most advanced
SPPARM presently in phase II/III), such ligands typically
behave as partial agonists of the human form of PPARγ inducing
about half of the maximal activity provoked by a saturating dose
of rosiglitazone. Furthermore, SPPARγMs have a reduced
ability to recruit specific cofactors and competitively block some
rosiglitazone-mediated cofactor recruitment and transcriptional
activity [26,28,29]. In agreement with the SPPARM concept,
some of these compounds have already demonstrated pharma-
cological activity in various animal models of type 2 diabetes,
without some of the side effects generally observed with full
agonists ([27,28,30], metabolex). Therefore, in type 2 diabetic
patients, metaglidasen is expected to have demonstrated anti-
Fig. 1. Chemical structures of some PPAR ligands.
1067A. Rubenstrunk et al. / Biochimica et Biophysica Acta 1771 (2007) 1065–1081
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adverse effects might be related to PPARα activation in humans including 
rare cases of myopathy, increase in creatinine and homocysteine, 
lithogenicity and gastro intestinal disorders. To date, no fibrate has been 
withdrawn from the market or interrupted at late stage of development due to 
any of these side effects. However, such safety issues may become relevant 
when developing more potent PPARα agonists. Recently, the development of 
the dual PPARα/γ agonist tesaglitazar was suspended due to an unexpected 
increase in plasma creatinine levels [84].                                                                            
• Thiazolidinediones (TZDs) 
 This class of compounds includes rosiglitazone, pioglitazone (which 
are currently approved for the treatment of type 2 diabetes) and troglitazone 
(Figure 22). Although they are efficacious in ameliorating hyperglycemia, 
their administration is associated with several adverse effects which have 
been categorized as either unique to individual TZDs or common to the class 
of drug. Of the unique effects, the best characterized is hepatotoxicity, which 
has been associated to date specifically with troglitazone [85]. Studies with 
other glitazones indicate that hepatotoxicity is not a class effect [86]. Class 
side effects include body weight gain, decrease in hematocrit and hemoglobin 
and peripheral edema, mild anemia and possible increased risk for congestive 
heart failure, which limit their clinical use [84]. 
• PPARβ/δ agonists 
 While several studies have been performed to investigate the effects 
of PPARα and PPARγ activation by specific ligands, the role of the third 
member of the PPAR family, PPARβ/δ, has not been extensively studied 
until recently. As a consequence, less is known about the potential safety 
issues that could be associated to the use of PPARβ/δ-specific ligands. 
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Contradictory results have been published regarding the role of PPARβ/δ in 
carcinogenesis. Intestinal tumorigenesis, but not colon carcinogenesis, is 
reported to increase in response to GW501516 in a genetically modified 
animal model [87]. However, other reports suggest that ligand activation of 
PPARβ/δ will inhibit colon carcinogenesis [88, 89]. 
 
1.2.10 Novel active PPAR ligands 
 The development of new PPAR drugs that reduce the reported 
adverse side effects is a major area of research in the pharmaceutical 
industry. The ability of each PPAR subtype to regulate distinct metabolic 
pathways has led to the investigation of combination approaches. The final 
purpose of the combination agonist strategy is to activate each receptor 
subtype to provide maximal efficacy on appropriate target genes associated 
with specific pharmacological pathways while minimizing undesired adverse 
side effects. Initial efforts have focused on developing PPARα/γ dual 
agonists, but other subtype combinations such as PPARγ/β(δ) dual agonists 
and PPARα/γ/β(δ) pan agonists are emerging. Given that PPAR subtype 
selective compounds each have specific documented side effect issues, it 
remains to be seen whether or not combination agonists will have increased 
risk of safety liabilities compared to selective agonists. One of the key 
challenges facing the development of a dual agonist in a single molecule is 
identifying the optimal receptor subtype specific functional activity ratio as 
the intrinsic potencies at each receptor subtype will ultimately determine the 
overall efficacy with respect to metabolic effects and minimized side effects.  
• PPARα/γ dual agonists 
 PPARα/γ dual agonists have been hypothesized as a combination 
strategy to achieve a broad spectrum of metabolic effects and reduce 
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mortality rates associated with type 2 diabetes by improving insulin 
resistance, hyperglycemia and reducing atherogenic dyslipidemia. Moreover, 
PPARα agonists stimulate lipid oxidation and decrease adiposity in rodent 
obesity models. Thus, the propensity of PPARγ activation to induce weight 
gain through its adipogenic affects may be offset by the ability of PPARα 
activation to stimulate lipid catabolism thereby providing a compound with 
reduced propensity for inducing undesired weight gain [86]. In recent years, a 
number of structurally diverse PPARα/γ dual agonists have been reported. 
Many of these have been evaluated in the clinic and some have advanced into 
late stage development. The clinical efficacy of the initially discovered dual 
PPARα/γ agonists has been encouraging. However, the discontinuation of the 
development of the most promising PPARα/γ dual agonists, including 
muraglitazar, tesaglitazar, ragaglitazar, TAK559 and KRP297 [91–94] 
(Figure 23) due to various safety liability issues has been disconcerting. 
Other dual agonists are advancing through different stages of development.  
• PPARγ/β(δ) dual agonists 
 Based on the central roles that both PPARγ and PPARβ/δ play in lipid 
metabolism, PPARγ/β(δ) dual agonists have been postulated as a beneficial 
combination therapy for type 2 diabetes. Such a combination is predicted to 
effectively lower glucose and improve insulin sensitivity while 
simultaneously improving the dyslipidemia common in diabetic patients [95, 
96]. The beneficial effects on lipid homeostasis and ability to stimulate 
reverse cholesterol transport are expected to significantly prevent the 
progression of atherosclerosis which should contribute to reducing the 
mortality rates of type 2 diabetic patients. Furthermore, the propensity of 
PPARβ/δ activation to improve insulin sensitivity and increase fatty acid 
oxidation suggests that a dual PPARγ/β(δ) agonist could attenuate the 
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undesired weight gain realized with selective PPARγ agonists. Reports of 
PPARγ/β(δ) dual agonists have been limited. The design and characterization 
of a ligand with predominately dual PPARγ/β(δ) activity has been described 
by GlaxoSmithKline [97] and more recently by Eli Lilly and Co. [98] 
(compound 23 and compound 20, respectively; Figure 23). The pre-clinical 
studies provide evidence supporting the hypothesis that a dual PPARγ/β(δ) 
agonist can attenuate the undesired weight gain side effect prevalent with 
marketed TZDs. It remains to identify tha appropriate γ/β(δ) ratios that will 
deliver optimal glucose control with minimized adverse side effects. 
• PPAR pan agonists 
 The development of dual PPARα/γ and PPARγ/β(δ) agonists has 
highlighted the potential therapeutic benefits gained from targeting multiple 
PPAR receptors in a single molecule. Combining the agonist activity of all 
three PPAR subtypes - the so called PPAR pan agonist - into a single 
chemical entity could potentially deliver a drug that treats a broad spectrum 
of metabolic diseases by improving insulin sensitization, obesity, 
dyslipidemia and hypertension as well as providing beneficial effects on 
inflammatory markers. Improved management of overall adverse safety 
events may be realized through the synergistic effects of PPARα and 
PPARβ/δ on fatty acids oxidation to sequester the undesired weight gain 
induced through PPARγ activation as well as improved cardiovascular health 
through the beneficial anti-atherogenic effects of PPARβ/δ. This strategy has 
led several pharmaceutical companies to pursue the design and development 
of PPAR pan agonists for the treatment of type 2 diabetes and metabolic 
syndrome [83]. The development of PPAR pan agonists is in its early stages 
and only a few compounds have progressed into clinical trials. 
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 GlaxoSmithKline's PPAR pan agonist GW677954 (Figure 23) is 
currently being investigated in Phase II trials for the treatment of insulin 
resistance, hyperglycemia and dyslipidemia associated with type 2 diabetes 
and metabolic syndrome [98]. LY465608 (Figure 23) was originally reported 
as a dual PPARα/γ agonist by researchers at Eli Lilly Pharmaceuticals [99].  
 
 
 
functional activity ratio as the intrinsic potencies at each receptor
subtype will ultimately determine the overall efficacy with
respect to metabolic effects and minimized side effects. One
possible route to identifying lead molecules with different ratios
of PPAR activity in target tissues would be to identify PPAR
subtype response genes in primary muscle, hepatocyte and
adipose cell cultures and employ these to categorize the ligands.
Testing in animal models will ultimately be required to validate
the approach, but if successful, subsequent rounds of optimiza-
tion would be greatly facilitated.
4.1. PPARα/γ dual agonists
PPARα/γ dual agonists have been postulated as a com-
bination strategy to achieve a broad spectrum of metabolic
effects and reduce mortality rates associated with type 2 diabetes
by improving insulin resistance, hyperglycemia and alleviating
atherogenic dyslipidemia. In addition, PPARα agonists sti-
mulate lipid oxidation and decrease adiposity in rodent obesity
models. Thus, the propensity of PPARγ activation to induce
weight gain through its adipogenic affects may be offset by the
ability of PPARα activation to stimulate lipid catabolism thereby
providing a compound with reduced propensity for inducing
undesired weight gain [32,33]. In recent years, a number of
structurally diverse PPARα/γ dual agonists have been reported.
Many of these have been evaluated in the clinic and some have
advanced into late stage development. The clinical efficacy of
the initially discovered dual PPARα/γ agonists has been
encouraging. However, the discontinuation of the development
of the most promising PPARα/γ dual agonists, including
muragl tazar, tesaglitazar, ragagl taza , TAK559 and KRP297
[34–37] (Fig. 1) due to various safety liability issues has been
disconcerting. Other dual agonists are advancing through
different stages of development. However, growing concerns
regarding toxicities, as well as the recent requirement by the
FDA to include 2-year rodent carcinogenicity studies prior to
advancing any PPAR compound into any clinical study of
greater than 6 months in duration, has tempered enthusiasm.
Fig. 1. Dual PPAR and PPARpan agonist compounds.
1086 B.G. Shearer, A.N. Billin / Biochimica et Biophysica Acta 1771 (2007) 1082–1093
Figure 23. PPARs dual and pan agonist compounds. 
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 Further detailed studies demonstrated that this compound also 
possesses significant PPARβ/δ activity and now LY465608 is classified as a 
PPAR pan agonist. The prospect of PPAR pan agonists to combat multiple 
aspects of the diabetic phenotype has high expectations. The key issue for the 
development of PPAR pan agonists, as well as PPAR dual agonist 
combinations, is whether they can deliver an improved therapeutic index 
compared to the existing PPAR subtype selective agonists. More clinical 
information on these PPAR pan agonists is anxiously anticipated and will be 
closely examined as the first generation of these compounds advance through 
development.  
1.2.11 Selective PPAR Modulators (SPPARMs)  
 Another potential approach to minimize side effects is to identify new 
selective PPAR modulating drugs that can deliver improved therapeutic 
indexes. The design of selective modulators requires consideration of the 
many factors that control the functional properties of a ligand. For example, 
the level of agonism induced by a ligand is regulated in part by the ability to 
recruit co-activators as well as the relative abundance of specific co-
activators present in a given tissue. The functional profile of a ligand is thus 
dependent upon the context of tissue, available concentrations of co-factor 
proteins and target gene [100, 101]. A ligand, therefore, can function as a full 
agonist in one tissue where sufficient concentrations of co-activators are 
present and as a partial agonist or antagonist in selective tissues with 
insufficient levels of co-activator proteins. The kinetics of co-factor 
recruitment plays a defining role in the assembly of transcriptional complexes 
and can also influence the level of agonism. Finally, the unique structural 
receptor conformations induced by a ligand plays a key role in determining 
differential co-activator recruitment. Hence, ligands that modulate the 
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activity of PPARs in a tissue and pharmacological specific manner would 
offer opportunities to regulate desired biological pathways while reducing 
undesired side effects pathways. Based on this concept, selective estrogen 
receptor modulator (SERMs) drugs with improved therapeutic benefits 
compared to the natural estrogen receptor ligand estradiol have been 
successfully developed [102]. The success of the SERMs has inspired the 
development of selective PPAR modulators (SPPARMs), in particular 
selective PPARγ modulators able to uncouple insulin sensitizing and 
adipogenesis properties [103]. Microarray studies investigating the gene 
expression profile of TZDs in a variety of organs has shown that some genes 
are universally regulated by TZDs while the regulation of other genes is 
ligand specific [104]. These results provide hope that the rational design of 
novel PPARγ ligands which activate target genes that mediate glucose 
disposal but are neutral toward genes involved in undesired side effects such 
as weight gain, fluid retention or edema can be developed. In recent years, 
several unique PPARγ modulators with differential potency and selectivity 
have been described. The limited characterization of these ligands, however, 
has not definitively demonstrated that these compounds possess efficacy with 
improved safety profiles compared to existing PPARγ antidiabetic agents. 
Nevertheless, a collection of exciting results observed with various PPARs 
modulators has encouraged several pharmaceutical companies to increase 
their research efforts to identify novel SPPARMs with pharmacological 
efficacy and minimized adverse effects.  
1.2.12 PPAR antagonists  
 Genetic studies in humans and mice paradoxically suggest that a 
moderate reduction of PPARγ activity may confer a reduced risk for the 
development of type 2 diabetes. New research efforts have begun to explore 
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the potential utility of PPAR antagonists to deliver therapeutic benefit with 
reduced side effect profiles [83]. Therefore, a number of pure PPARγ 
antagonists and a series of triazolone based PPARα antagonists useful as tool 
compounds have been reported. 
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1.3 Stucture-based drug discovery  
 Discovering new drugs is crucial in providing novel treatments to 
improve the health of the developed world's increasingly aging population as 
well as in combating the threats posed by emerging new diseases. The fast 
pace of development and increased prosperity of large areas of the world will 
lead to increases in incidence of various chronic conditions (such as diabetes, 
cancer and cardiovascular problems), but also the expectation of improved 
healthcare, life exprectancy and quality of life. These necessities continue to 
challenge and inspire the huge scientific and financial resources of the 
pharmacological industry [105].  
 The potential of detailed structural knowledge to provide a molecular 
basis of disease was first demonstrated by Max Perutz in his studies relating 
mutations to the structure of haemoglobin in the 1960s. By the mid-1970s, 
structural insight were being used not only to rationalise structure-activity 
relationship but also to provide guidance in the design of compounds with 
improved properties against such targets as dihydrofolate reductase and 
angiotensin converting enzyme. These early decriptions of structure-based 
design illustrate the two long-standing applications of structural methods in 
drug discovery. The first is to provide detailed understading of the 
mechanism of action of the protein and how this relates to its biological 
function. Such understanding can be significant in designing the most 
appropriate strategy for modulating the activity of the target and the design of 
the in vitro and in vivo assays on which drug discovery depends. The second 
conventional use of structural methods is to employ the structure of a lead 
molecule bound to the target to guide the design of modifications to improve 
compound affinity, selectivity or drug-like properties. 
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 These protein crystal structures were an important driver in moving 
drug discovery to be more rational and target oriented. As more structural 
information has become available, an increasing number of drug-discovery 
projects use rational, target-oriented approaches that rely on either explicit or 
model structures of the target. 
 Nowadays, an appreciation of the 3D structure of both the compounds 
and their target are a part of just about every drug-discovery project. This 
target structure can be experimentally determined, a model constructed on the 
basis of homology or a virtual model of the receptor created on the basis of 
the chemical structure of the known active compounds. In addition, 
computational methods such as virtual screening and experimental methods 
such as fragment screening can generate many new ideas for compound 
templates and possible interactions with the active site. The major advantage 
of experimentally determining the structure of these different compounds 
bound to the target is to increase the confidence in the hypotheses and 
increase the scope of subsequent design. This encourages the medicinal 
chemists to embark on novel and often challenging syntheses in the search 
for novel, distinctive and drug-like lead compounds. Our ability to predict 
conformational changes in proteins and the binding energy of protein-ligand 
complexes remains relatively poor, so there is still plenty of scope for 
experience, inspiration and guess work in the details of design. 
 The determination of the structure of a protein target, perhaps 
complexed to a substrate or a ligand, can provide a clear insight into its 
mechanism of action, which can often be related to the biological or 
therapeutic role. Modern structural biology, particularly protein 
crystallography, is generating the structure of an increasing number of 
therapeutically important targets. The two main issues limiting the number of 
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structures are the ability to produce sufficient quantities of pure, soluble, 
functional, homogenous protein for crystallography trials and the ability of 
the protein to form regular crystals suitable for diffraction experiments. This 
combination of limitations often means that a structure is not available for the 
whole therapeutic target. However, even the structure of individual domains 
can be sufficient to make a real impact on a discovery project and provide 
conditions to understand the overall function of the protein. The members of 
PPAR family provide one example. Although each receptor consists of a 
number of domains, the detailed structure of just the ligand-binding domain 
is sufficient to successfully design selective ligands. However, the 
complexities of the function of the receptor in the cell can only be understood 
in terms of the interaction between the different domains that have an 
influence on receptor activity. 
 The crystal structure of a ligand bound to a protein provides a detailed 
insight into the interactions made between the two molecules. Such 
understanding can be used to design changes to the ligand introducing new 
interactions to modify the affinity and specificity of the ligand for a particular 
protein. In addition, the structure can be used to identify where the ligand can 
be changed to modulate the physicochemical and ADME (absorption, 
distribution, metabolism, and excretion) properties of the compound, by 
showing which parts of the compound are important for affinity and which 
parts can be altered without affecting binding. 
 As the availability of crystal structures increased in the early 1990s, a 
number of experimental and computational methods were developed to use 
the structure of the protein target as a route to discover novel hit compounds. 
The methods include de novo design, virtual screening and fragment-based 
discovery. Virtual screening use computational docking methods to assess 
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which of the large database of compounds will fit into the unliganded 
structure of the target protein. Current protocols and methods can, with up to 
80% success, predict the binding position and orientation of ligands that are 
known to bind a protein. However, identifying which ligands bind into a 
particular binding site is much less successfull, with many more false positive 
hits being identified. De novo design attempts to use the unliganded structure 
of the protein to generate novel chemical structures that can bind. There are 
varying algorithms, most of which depend on identifying initial hot spots of 
interactions that are then grown into complete ligands. Fragment-based drug 
discovery is founded on the premise that most ligands that bind strongly to a 
protein active site can be considered as a number of smaller fragments or 
functionalities, which can be identified by screening a small library of 
molecules by X-ray crystallography, NMR spectroscopy or functional assay. 
The structures of the fragments binding to the protein can be used to design 
new ligands by adding functionality to the fragment, by merging together or 
linking various fragments or by grafting features of the fragments onto 
existing ligands. 
 Selection of promising, well characterized hits and leads is essential 
for success in the drug discovery process. Furthermore, information on the 
interaction of potential drug candidates with the targeted biomolecule is 
important as a basis for the understanding of more complex schemes. Binding 
assays are the type of assays that provide such information on affinity, 
kinetics and thermodynamics [106]. Until recently, obtaining reliable data 
was often difficult and time consuming, because most of the methods 
available used labeled compounds that had to be specially synthesized. Many 
of the methods were not able to follow a binding event in real time. Stop flow 
technilogies have for a long time been the only possibility to get kinetic 
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information on an interacting system, but this technology is time and material 
consuming. 
 High-throughput screening (HTS) set-ups are preferentially used to 
perform functional and binding assays in order to be able to test a large 
number of compounds in a short time. It is well known that often a very large 
portion of false positive [107] hits are identified for many reasons: 
interference with the labeling method, interaction with substrate or other 
auxiliary reagents, general and/or promiscuous protein binding. 
 Biophysical binding assays are alternative tools in generating label 
free, high quality data on the interaction between a target and a potential drug 
candidate. Label free screening methods include mass spectroscopy [108], 
analytical ultracentrifugation (AUC) [109], nuclear magnetic resonance 
spectroscopy [110], isothermal titration calorimetry (ITC) [111] and 
biosensor [112, 113]. 
 Biosensors based on optical detection principles are the type of 
sensors most often used. They offer a rapid way to determine relevant 
binding data without the need for labeling of the interacting molecules. These 
biosensors measure in real time the quantity of complex formed between a 
molecule immobilized on the sensor surface and a molecule in solution. The 
optical biosensor type most often used in such experiments is based on 
determining small changes in refractive index induced at the interface upon 
binding. A huge number of different optical techniques to monitor such 
refractive index changes have already been introduced in the past and this 
number is still increasing [114, 115]. Surface plasmon resonance (SPR) is 
currently the most widely used. When first launched, the technology was 
most frequently applied in the characterization of diagnostic antibodies used 
in immunological testing. With the growing interest in biomolecular drugs, 
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the technique was more and more applied in the drug discovery. A real 
challenge, however, was to apply the technique for the discovery of low 
molecular weight drugs. It is only more recently that interactions of small 
synthetic molecules with biomolecules were described. This type of 
application became possible due to increased sensitivity through 
improvements in hardware, software and data evaluation [116]. 
 Of all the techniques that are currently available to measure binding, 
ITC is the only one capable of measuring not only the magnitude of the 
binding affinity but also the magnitude of the two thermodynamic terms that 
define the binding affinity: the enthalpy (ΔH) and entropy (ΔS) changes. 
Several reports examine issues concerning drug design and the correlation of 
thermodynamic and X-ray structural data. New instruments allow volumetric 
effects in biochemical systems to be evaluated calorimetrically and to 
substantially expand the throughput of differential scanning calorimetry 
measurements in drug discovery and other high-throughput applications 
[117]. 
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2. Aim of the study 
 The aim of this study has been the biostructural characterization of the 
ligand binding domain (LBD) of the three PPAR isotypes complexed with 
both natural (resveratrol, betulinic acid, saponins and sapogenins) and 
synthetic (halofenic acid and AL29-26) ligands, indeed a better 
understanding of the ligand binding mode and its relation to the activity 
could suggest novel basis for ligand design and enable the development of 
safer drugs with minimized unwanted side-effects. The development of more 
balanced drugs interacting with PPARs, devoid of the side effects showed by 
the currently marketed PPARγ full agonists, is considered the major 
challange for the pharmaceutical companies. Therefore, alternative strategies 
have been used to develop ligands with a modulated and selective 
pharmacological profile among PPARs in order to reduce the undesired 
effects and obtain more beneficial responses (e.g. dual or pan agonists with 
an optimal receptor subtype selectivity ratio: partial agonists towards PPARγ 
and full agonists towards PPARα and/or PPARβ/δ). 
 This study arises from the participation to several research projects, 
supported from both private and public organizations, concerning the 
screening of a compounds collection for the identification of novel ligands 
for PPAR nuclear receptors, which also made it possible financing my PhD. 
 To this purpose, X-ray crystallography represents one of the most 
powerful approaches providing information for structure-based ligand design. 
Indeed, knowledge of the 3D structures of protein targets is now playing a 
major role in all stages of drug discovery.  Therefore, the complex of PPARs 
with several ligands has been solved in order to investigate the binding mode 
in the LBD of these nuclear receptors.  
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 In addition to these structural studies, the binding between PPARs and 
some of the examined ligands has been further characterized by Isothermal 
Titration Calorimetry (ITC) and Surface Plasmon Resonance (SPR). ITC is a 
powerful technique that allows to obtain all the thermodinamic parameters 
associated to the protein/ligand interaction at equilibrium, such as the affinity 
constant Ka, ΔH and ΔG. SPR technology has been used to measure the 
kinetic parameters of the binding, including the rate constants (Kon and Koff), 
and to reveal the antagonist character of some ligands. Compared to ITC, 
SPR allows to consume less sample and to perform high-troughput 
experiments, as in the case of the screening of a large number of 
saponins/sapogenins in a single experiment. 
 Moreover, structural studies on PPARγ mutant F360L, which is 
associated with familial partial lipodystrophy, have been also performed in 
complex with the partial agonist LT175 to provide insights into the structural 
basis of the transactivation deficiency of this pathological mutant.  
 For all these experiments, the ligand binding domain of the three 
PPAR isoforms has been expressed as soluble fusion protein using E.coli as 
heterologous host and then purified through many steps of liquid 
chromatography. 
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3. Experimental methods 
3.1 Expression and purification of PPARs LBD 
 The recombinant ligand binding domain (LBD) of human PPARγ 
(gene ID 5468, amino acids 174–477, expected molecular mass 34.5 kDa), 
PPARα (gene ID 5465, amino acids 180-468, expected molecular mass 33.3 
kDa) and PPARβ/δ (gene ID 5467, amino acids 185-477, expected molecular 
mass 33.27 kDa) was expressed as N-terminal His-tagged protein using the 
pET28a vector (Novagen) and then purified as follows. Freshly transformed 
E.coli BL21 (DE3) were grown in LB medium with 30 µg/ml of kanamycin 
at 310 K to an OD600 of 0.6. The culture was then induced with 0.2 mM 
isopropyl-β-D-thio-galactopyranoside (IPTG) and further incubated at 291 K 
for 20 hours (overnight). Cells were harvested with centrifugation and 
resuspended in a 20 ml/liter culture of Buffer A [20 mM Tris, pH 8.0, 150 
mM NaCl, 10% (v/v) glycerol, 1 mM Tris 2-carboxyethylphosphine HCl 
(TCEP)] in the presence of protease inhibitors (Complete Mini EDTA-free; 
Roche Applied Science). Cells were sonicated in an ice bath and the soluble 
fraction was isolated by centrifugation (35000 rpm for 45 minutes). The 
supernatant was loaded onto an Ni2+-nitrilotriacetic acid column following 
the procedure recommended by the manufacturer (GE Healthcare, UK) and 
eluted stepwise with a gradient of imidazole 10–500 mM in Buffer A (batch 
method). The fractions containing the pure protein were analyzed by SDS gel 
electrophoresis with Coomassie blue staining. The protein was then dialyzed 
over Buffer A to remove imidazole and cleaved with 10 units/mg of thrombin 
protease (GE Healthcare, UK) at room temperature for 2,5 hours. The 
cleavage was monitored by SDS-PAGE and the identity of the native and 
digested protein was determined on the basis of the molecular weight. The 
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digested mixture was reloaded onto a Ni2+-nitrilotriacetic acid column to 
remove the His-tags and the undigested protein. The flow-through was 
dialyzed with Buffer B [20 mM Tris, pH 8.0, 10% (v/v) glycerol, 1 mM Tris 
2-carboxyethylphosphine HCl (TCEP)] to remove NaCl and then loaded onto 
a HiTrap™ Q HP anion-exchange column (GE Healthcare, UK) and eluted 
with a linear gradient of 0.01-500 mM sodium chloride in Buffer B using a 
BioLogic DuoFlowTM FPLC system (BioRad Laboratories, USA). The 
pooled fractions were analyzed by SDS gel electrophoresis and those 
containing PPARs were concentrated using Amicon® Ultra centrifugal filter 
with a 10 kDa cutoff membrane (EMD Millipore, USA). Finally, the protein 
was purified by gel-filtration chromatography on a Superdex™ 75 10/300 GL 
column (GE Healthcare, UK) eluted with Buffer C [20 mM Tris, pH 8.0, 0,5 
mM EDTA, 1 mM Tris 2-carboxyethylphosphine HCl (TCEP)]. In the case 
of the PPARβ/δ LBD, the cell-lysis supernatant was treated and partially 
purified as for the PPARγ/α LBD and the protein was further purified by two 
steps of column chromatography. After the addition of thrombin protease to 
cleave the N-terminal His-tag, the pooled fraction from the nickel-chelate 
column was dialyzed against buffer D (20 mM MES, 10 mM DTT, 100 mM 
ammonium acetate, pH 6.0) and loaded onto a HiTrap™ SP HP cation-
exchange column (GE Healthcare, UK). The protein was eluted with a linear 
gradient of 0.01–1.0 M Ammonium acetate. Finally, the protein was purified 
by gel-filtration chromatography on a Superdex™ 75 10/300 GL column (GE 
Healthcare, UK) eluted with buffer E (20 mM HEPES, 10 mM DTT, 500 
mM Ammonium acetate, pH 7.5).  
 For crystallization, PPARγ, PPARα and PPARβ/δ LBDs were then 
concentrated at 8-10 mg mL-1 using Microcon® centrifugal filter with a 10 
kDa cutoff membrane (EMD Millipore, USA) and the concentration was 
estimated by Bradford Assay (BioRad Laboratories, USA) with calibration 
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against a set of Bovine Serum Albumine (BSA) standards of known 
concentration. The purity of the proteins was determined to be greater than 
95% using SDS gel electrophoresis with Coomassie blue staining. 
The QuickChange Site-Directed Mutagenesis Kit (Stratagene) was used to 
introduce the point mutations F360L and R357A into the bacterial expression 
vectors. 
3.2 Crystallization, data collection and structure 
determination 
• Soaking experiment of PPARγ-LBD and co-crystallization of 
PPARα-LBD with AL29-26 
 Crystals of apo-PPARγ-LBD (0.3 x 0.3 x 0.2 mm) were obtained by 
vapour diffusion at 291 K using a sitting drop made by mixing 2 µl of protein 
solution [8 mg mL-1, in 20 mM Tris, pH 8.0, 0.5 mM EDTA, 1 mM Tris 2-
carboxyethylphosphine HCl (TCEP)] with 2 µl of reservoir solution (0.8 M 
Sodium citrate and 0.15 M Tris, pH 8.0). The crystals were soaked for seveal 
days in a storage solution (1.2 M Sodium citrate and 0.15 M Tris, pH 8.0) 
containing the ligand (0.25 mM) and then flash-cooled in liquid nitrogen. The 
ligand dissolved in DMSO was diluted in the storage solution so that the final 
concentration of DMSO was 0.5% (v/v). The storage solution with 20% (v/v) 
glycerol was used as cryoprotectant. Preliminary PPARα-LBD co-
crystallization were performed by using a Phoenix liquid-handling robot (Art 
Robbins Instruments, USA) with the ligand AL29-26 in a threefold excess 
with respect to the protein. Crystals (0.7 x 0.2 x 0.2 mm), obtained at the 
condition A12 of the Qiagen JCSG Core I Suite [PEG 3350 20% (w/v) , 0.2 
M Magnesium acetate], were freezed using the mother solution with 35% 
(w/v) PEG 3350 as cryoprotectant and used for data collection. Co-
crystallization trials were also performed for PPARβ/δ-LBD/AL29-26 and 
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small crystals were obtained at the conditions G5 [PEG 6000 10% (w/v), 
citric acid 0.1 M, pH 5.0], G6 [PEG 6000 5% (w/v), citric acid 0.1M, pH 5.0] 
and H5 [PEG 3000 10% (w/v), Sodium chloride 0.2 M, Phosfate/citrate 0.1 
M, pH4.2] of the Qiagen JCSG Core I Suite. X-ray data set were collected at 
100 K under a nitrogen stream by using sinchrotron radiation (beamline ID 
23-2 at ESRF, Grenoble, France). The collected data were processed with the 
programs MOSFLM and SCALA [118]. Structure solution was performed 
with AMoRe [119] using the coordinates of PPARγ-LBD/LT175(R) (PDB 
ID: 3D6D) [52] and PPARα-LBD/APHM13 [125] complexes as the starting 
models for PPARγ-LBD and PPARα-LBD, respectively. The coordinates 
were then refined with CNS [120]. All data between 50.0 and 2.0 Å were 
included for PPARγ-LBD/AL29-26 complex belonging to C2 space group, 
whereas all data between 50.0 and 1.83 Å were used for PPARα-LBD/AL29-
26 complex appertaining to the space group P41212. A final step of 
refinement was performed with the software PHENIX [121]. The coordinates 
of PPARγ-LBD/AL29-26 and PPARα-LBD/AL29-26 complexes have been 
deposited in the Protein Data Bank (PDB) with the code 5HZC and 5HYK, 
respectively. Diffraction data were also collected for PPARβ/δ-LBD/AL29-
26 at low resolution (4-5 Å), but no interpretable electron density maps could 
be obtained. 
• Soaking experiments of PPARγ-LBD with Caulophyllogenin 
(SAP19) 
 Crystals of apo-PPARγ-LBD (0.2 x 0.2 x 0.2 mm) were obtained by 
vapour diffusion at 291 K using a sitting drop made by mixing 2 µL of 
protein solution [8 mg mL-1, in 20 mM Tris, pH 8.0, 0.5 mM EDTA, 1 mM 
Tris 2-carboxyethylphosphine HCl (TCEP)] with 2 µL of reservoir solution 
(0.8 M Sodium citrate and 0.15 M Tris, pH 8.0) and equilibrating against 500 
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µl reservoir solution. The crystals were soaked for eight days in storage 
solution (1.2 M Sodium citrate and 0.15 M Tris, pH 8.0) containing the 
ligand (0.25 mM) and then flash-cooled in liquid nitrogen. The ligand 
dissolved in DMSO was diluted in the storage solution so that the final 
concentration of DMSO was 0.5% (v/v). The storage solution with 20% (v/v) 
glycerol was used as cryoprotectant. X-ray data set were collected at 100 K 
under a nitrogen stream by using sinchrotron radiation (beamline ID 23-2 at 
ESRF, Grenoble, France). The collected data were processed with the 
programs MOSFLM and SCALA. Structure solution was performed with 
AMoRe, using the coordinates of PPARγ-LBD/LT175(S) (PDB ID: 3B3K) 
[52] as the starting model. The coordinates were then refined with CNS. All 
data between 50.00 and 2.25 Å were included for PPARγ-LBD/SAP19 
complex belonging to C2 space group. A final step of refinement was 
performed with the software PHENIX. The coordinates of PPARγ-
LBD/SAP19 complex have been deposited in the Protein Data Bank (PDB) 
with the code 5F9B. 
• Soaking experiments of PPARγ-LBD with metaglidasen's 
metabolically active form halofenic acid (R) and (S) 
 Crystals of apo-PPARγ-LBD (0.3 x 0.2 x 0.2 mm) were obtained by 
the vapour diffusion method at 291 K using a sitting drop made by mixing 2 
µL of protein solution [10 mg mL-1, in 20 mM Tris, pH 8.0, 1 mM Tris 2-
carboxyethylphosphine HCl (TCEP)] with 2 µL of reservoir solution (0.8 M 
Sodium citrate and 0.15 M Tris, pH 8.0). Crystals were soaked for two weeks 
in a storage solution (1.2 M Sodium citrate and 0.15 M Tris, pH 8.0) 
containing the ligand (0.25 mM). The ligand was dissolved in DMSO and 
added to the storage solution so that the final concentration of DMSO was 
0.5% (v/v). The storage solution with 20% (v/v) glycerol was used as a 
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cryoprotectant.  
 X-ray crystallographic data were collected at 100 K under a nitrogen 
stream by using synchrotron radiation (beamline ID29 at ESRF, Grenoble, 
France). The diffracted intensities were processed with the programs 
MOSFLM and SCALA. Structure solution was performed with AMoRe, using 
the coordinates of PPARγ–LBD/LT175(S) complex (PDB ID: 3B3K) [52] as 
the starting model. The coordinates were then refined with the software 
PHENIX. All data between 58 and 2.6 Å ︎ were included for both structures. 
The coordinates of PPARγ-LBD/(R)-2 and PPARγ-LBD/(S)-2 complexes 
have been deposited in the Protein Data Bank with access codes 4PVU and 
4PWL, respectively.  
• Co-crystallization of PPARγ-LBD F360L with LT175 and 
PPARγ-LBD R357A with rosiglitazone 
 The protein complexes with the ligands were formed by mixing 98 µl 
protein solution (10 mg mL-1) with 2 µl ligand stock solution (50 mM in 
DMSO) so that the ligands were in a threefold excess with respect to the 
protein and the final concentration of DMSO was 2% (v/v). The mutant 
complexes in buffer C [20 mM Tris, pH 8.0, 0,5 mM EDTA, 1 mM Tris 2-
carboxyethylphosphine HCl (TCEP)] were used for crystallization at 291K 
by the vapour-diffusion method in 96-well sitting-drop plates (MRC plates; 
Molecular Dimensions, UK). Preliminary crystallization trials of the mutant 
complexes were performed with a Phoenix liquid-handling robot (Art 
Robbins Instruments, USA) by mixing 200 nl protein solution with an equal 
volume of reservoir solution (Biocrystal Facility at the CNR Institute of 
Biology and Molecular Pathology, Sapienza University of Rome). Crystals of 
PPARγ-LBD F360L with LT175 (referred to in the following as F360L) 
appeared in well No. 18 (0.49 M Sodium dihydrogen phosphate, 0.91 M 
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dipotassium hydrogen phosphate, pH 6.9) and No. 25 (3.5 M Sodium 
formate, pH 7.0) of the Index crystallization screen (Hampton Research). 
More suitable crystals for X-ray analysis were then obtained by the vapour-
diffusion method at 291 K using a sitting drop made by mixing 2 µl protein–
ligand solution (8 mg ml-1 in 20 mM Tris, 1 mM TCEP, pH 8.0) with 2 µl 
reservoir solution (3.5 M Sodium formate, pH 7.0, or 1.4 M 
Sodium/Potassium phosphate, pH 6.9) and equilibrating against 0.5 µl 
reservoir buffer. Crystals appeared after a few days from both tested 
conditions and belonged to space group P21212 or I222, respectively. 
Crystals were flash-cooled in liquid nitrogen after brief soaking in a 
cryoprotectant buffer composed by mother-liquor solution with 20% (v/v) 
glycerol. Crystals of R357A with rosiglitazone (referred to in the following 
as R357A) belonging to space group C2221 appeared in well No. 5 [50% 
(w/v) PEG 500 MME/PEG 20K, 0.06 M MgCl2 and CaCl2, 0.1 M Sodium 
HEPES and MOPS, pH 7.5] of the Morpheus crystallization screen 
(Molecular Dimensions, UK). Suitable crystals for X-ray data collection were 
directly flash-cooled in liquid nitrogen after brief soaking in a cryoprotectant 
buffer composed by mother-liquor solution with 20% (v/v) glycerol. 
 X-ray data were collected at 100 K under a nitrogen stream by using 
synchrotron radiation (beamlines ID23-2 for F360L and ID29 for R357A at 
ESRF, Grenoble, France). The collected data were processed with MOSFLM 
and SCALA for the crystal of F360L belonging to space group I222 and XDS 
and XSCALE [122] for that belonging to space group P21212. Structure 
solution was performed with AMoRe using the coordinates of PPARγ–
LBD/LT175(S) complex (PDB ID: 3B3K) [52] as the starting model. The 
coordinates were then refined with CNS. Finally, both refined models were 
optimized by the PDB_REDO web server using REFMAC 5.8.0049 [123]. 
The coordinates of F360L complexed with LT175 have been deposited in the 
	   60	  
Protein Data Bank (PDB ID: 4L98 for space group P21212 and 4L96 for 
space group I222). MOSFLM and SCALA were used to process the data 
regarding the mutant R357A in complex with rosiglitazone. Structure 
solution was performed with AMoRe using the coordinates of PPARγ–
LBD/rosiglitazone complex (PDB ID: 2PRG) [39]. The coordinates were 
then refined with PHENIX and the quality of the structure was validated 
using MolProbity [124]. The coordinates of this complex have been 
deposited in the Protein Data Bank with access code 4O8F.         
• Soaking experiment of PPARγ-LBD with resveratrol 
 Crystals of apo-PPARγ-LBD (0.2 x 0.3 x 0.2 mm) were obtained by 
vapour diffusion at 291 K using a sitting drop made by mixing 2 µL of 
protein solution [10 mg mL-1, in 20 mM Tris, pH 8.0, 0.5 mM EDTA, 1 mM 
Tris 2-carboxyethylphosphine HCl (TCEP)] with 2 µL of reservoir solution 
(0.8 M Sodium citrate and 0.15 M Tris, pH 8.0) and equilibrating against 500 
µl reservoir solution. The crystals were soaked for three days in storage 
solution (1.2 M Sodium citrate and 0.15 M Tris, pH 8.0) containing the 
ligand (0.25 mM) and then flash-cooled in liquid nitrogen. The ligand 
(Cayman Chemicals, USA) was dissolved in Dimethyl sulfoxide (DMSO) 
and added to the storage solution so that the final concentration of DMSO 
was 0.5% (v/v). The storage solution with 20% (v/v) glycerol was used as 
cryoprotectant.  
 X-ray data were collected at 100 K under a nitrogen stream by using 
synchrotron radiation (beamline XRD1 at Elettra, Trieste, Italy). The 
diffracted intensities were processed with the softwares MOSFLM and 
SCALA. Structure solution was performed with AMoRe using the coordinates 
of PPARγ-LBD complexed with the agonist LT175(S) (PDB ID: 3B3K) as a 
starting model [52]. The coordinates were then refined with CNS. All data 
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between 52.10–2.85 Å ︎ were included. The coordinates of PPARγ-LBD 
complexed with resveratrol have been deposited in the Protein Data Bank 
with access code 4JAZ.  
• Soaking experiment of PPARγ-LBD with betulinic acid 
 Crystals of apo-PPARγ-LBD (0.2 x 0.2 x 0.2 mm) were obtained by 
the vapour diffusion method at 291 K using a sitting drop made by mixing 2 
µL of protein solution [10 mg mL-1, in 20 mM Tris, pH 8.0, 1 mM Tris 2-
carboxyethylphosphine HCl (TCEP)] with 2 µL of reservoir solution (0.8 M 
Sodium citrate and 0.15 M Tris, pH 8.0) and equilibrating against 500 µl 
reservoir solution. The crystals were soaked for one week in storage solution 
(1.2 M Sodium citrate and 0.15 M Tris, pH 8.0) containing the ligand (0.5 
mM) and then flash-cooled in liquid nitrogen. The ligand was dissolved in 
Dimethyl sulfoxide (DMSO) and added to the storage solution so that the 
final concentration of DMSO was 1% (v/v). The storage solution with 20% 
(v/v) glycerol was used as cryoprotectant.  
 X-ray data were collected at 100 K under a nitrogen stream by using 
synchrotron radiation (beamline BM14U at ESRF, Grenoble, France). The 
diffracted intensities were processed with the softwares XDS and XSCALE. 
Structure solution was performed with AMoRe using the coordinates of 
PPARγ-LBD complexed with the agonist LT175(R) (PDB ID: 3D6D) as a 
starting model [52]. The coordinates were then refined with CNS. All data 
between 50.00–2.00 Å were included in the refinement. The coordinates of 
PPARγ-LBD complexed with BA have been deposited in the Protein Data 
Bank with access code 5LSG. 
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3.3 Isothermal titration calorimetry 
 ITC experiments were performed at 298 K by using an ITC200 
microcalorimeter (MicroCal, Inc., USA). The PPARγ and PPARα LBDs 
were extensively dialyzed against a solution of HEPES (20 mm, pH 8.0) and 
Tris 2-carboxyethylphosphine HCl (TCEP, 1 mM) with Amicon® Ultra 
centrifugal filter, and the final exchange buffer was used to dilute the ligand 
stock solution (50 mM in DMSO). DMSO was added to the protein solution 
at the same percentage of the ligand solution (1%, v/v). Sample were 
centrifuged before the experiments to eliminate possible aggregates. Protein 
and ligand solutions were also degassed before use. The protein solution (50 
µM) was placed in the sample cell, and ligand solution (500 µM) was loaded 
into the syringe injector. The titrations involved 19 injections of 2 µL each at 
180 second intervals. The syringe stirring speed was set to 1000 rpm. A 
reference titration of ligand into buffer was used to correct for heats of 
dilution. In the experiments with betulinic acid, a reverse titration was 
performed with the protein solution (500 µM) injected into the cell 
containing the ligand (50 µM), both with 0.1% DMSO (v/v). 
  Thermodynamic data was processed with the software Origin 7.0 
provided by MicroCal. The ΔH values were measured for both titrations, and 
fitting the isotherms with one-site binding model yielded the values of the 
association constant (Ka). From the Gibbs-Helmhotz equation is also 
calculated the change of entrophy (ΔS). The inflection point in the 
calorimetric isotherm gives the stoichiometry value n, indicating the 
ligand:protein ratio of the binding. To correct for any discrepancies in the 
baseline outlined by the software, a manual adjustment was performed. 
In all of the experiments with PPARγ-LBD F360L mutant, the protein 
solution (25–50 µM) was placed in the sample cell and the co-activator SRC-
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1 (500 µM) was loaded into the syringe injector. The experiments with SRC-
1 (purchased from GL Biochem Ltd, Shanghai, People’s Republic of China) 
were performed after equilibrating the protein with LT175 in a twofold 
excess.  
 In the experiment of PPARγ-LBD with 13-(S)-HODE, the ligand 
solution (400 µM) was obtained by dissolving 10 µg of the ligand in 83 µl of 
exchange buffer and titrated against the protein solution (40 µM). 
 In the experiment  of PPARγ-LBD with caulophyllogenin, exchange 
buffer was used to dilute the ligand stock solution (25 mM in DMSO) and the 
same percentage of DMSO (2%, v/v) was added to the protein solution. The 
titrations involved 19 injections of 2 µL each at 150 second intervals.  
3.4 Surface Plasmon Resonance 
 Surface plasmon resonance analyses were performed by using Pioneer 
AE optical biosensor equipped with COOH5 sensor chips (SensiQ 
Technologies, Inc., USA). PPARγ-LBD surfaces were prepared by using 
standard amine-coupling procedures [126] and HBS [Hepes-buffered saline: 
20 mM Hepes, pH 7.4, 150 mM Sodium chloride, 0.005% (v/v) P20] as the 
running buffer. Flow cells were activated for 7 minutes by injecting 140 µL 
of 50 mM N-hydroxysuccinimide (NHS):200 mM ethyl-3(3-dimethylamino) 
propyl carbodiimide (EDC). Fifty µL of a 0.25 mg mL-1 PPARγ-LBD 
solution (in 10 mM Sodium acetate, pH 5.0) were injected for 5 minutes at 10 
µL/min on channels 1 and 3 (channel 2 was used as ref. 3, for a duplicate 
experiment), followed by a 70-µL injection of ethanolamine to block any 
remaining activated groups on the surface. More then 13,500 RU of protein 
were immobilized on both channels. The stability of the PPARγ surface was 
demonstrated by the flat baseline achieved at the beginning (0–60 seconds) of 
each sensorgram. The screening of the analytes (saponins and sapogenins) 
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was performed using HBS without P20, with 1 mM DTT and 2% (v/v) 
DMSO. To collect detailed kinetic data the OneStep [127-129] protocol was 
used, injecting the analytes at a flow rate of 50 µL/min and at the 
concentration of 100 µM (50 µM for SAP14 and SAP15) over the three 
channels at 293 K (association phase of 180 seconds). Five buffer blanks 
were injected for double referencing. The regeneration of the surfaces 
between binding cycles was not necessary because all the analytes dissociate 
quickly in the 120 second dissociation phase. A DMSO calibration plot was 
constructed [buffer sample containing 1–3% (v/v) DMSO] to correct for bulk 
refractive index shifts [130]. Data were collected at a rate of 20 Hz. All 
sensorgrams were processed by using double referencing [131]. First, the 
responses from the reference surface (channel 2) were subtracted from the 
binding responses collected over the reaction surfaces to correct for bulk 
refractive index changes. Second, the response from an average of the blanks 
was subtracted to remove any systematic artifact observed between the 
reaction and the reference flow cells. To obtain kinetic rate constants and 
affinity constants the corrected response data were fit in the QDAT software 
provided by SensiQ Technologies. A kinetic analysis of each ligand/analyte 
interaction was obtained by fitting the response data to a reversible 1:1 
bimolecular interaction model (but for few analytes a 2:1 interaction model 
was used). The equilibrium dissociation constant (Kd) was determined by the 
ratio koff/kon. 
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4. Results and discussion 
 
 
 
 
 
 
 
 
4.1 The pan agonist AL29-26 
In this study a novel PPAR pan agonist (AL29-26; Figure 24) has 
been identified using a structure-based virtual screening (SBVS) approach 
and its crystal structure in the complex with PPARα and PPARγ LBDs has 
been solved. This naphthalenic derivative showed a very attractive PPAR pan 
agonist activity profile in transactivation assay: potent full agonist on PPARα 
and partial agonist on γ and β/δ subtypes (Table 2). The structural 
investigation revealed that this ligand occupies a new pocket of PPARα LBD 
whose filling is allowed by the ligand-induced switching of the F273 side 
chain from a closed to an open conformation. The comparison between this 
pocket and the corresponding cavity in PPARγ provides a rationale for the 
different activation of the ligand towards PPARα and PPARγ, suggesting a 
novel basis for ligand design. To date, indeed, the data show that an 
appropriate dual PPARγ/α activation results in improved metabolic profile.    
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to an open conformation. The comparison between this pocket and the corresponding cavity in PPARγ 
provides a rationale for the different activation of the ligand towards PPARα and PPARγ, suggesting a 
novel basis for ligand design.
The peroxisome proliferator-activated receptors (PPARs) are members of the II class of nuclear receptors (NRs) 
superfamily1 and play a crucial role in the regulation of metabolic homeostasis. They can induce or repress genes 
involved in adipogenesis, lipid and glucose metabolism, energy balance, and inflammation. PPARs dynamically 
shuttle between nucleus and cytoplasm, although they constitutively and predominantly appear in nucleus2. The 
nuclear-cytoplasmic shuttling of PPARs is regulated by respective PPAR ligands2. After ligation with their ago-
nists, PPARs heterodimerize with retinoid X receptor (RXR); this complex recognizes specific DNA sequence 
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and δ . PPARα is expressed in tissues with a high rate of fatty acid catabolism and modulates lipid metabolism 
and inflammation9. PPARγ is predominant in adipose tissue where it induces lipogenesis and fat storage, and in 
skeletal muscle, where it improves insulin sensitivity10, whereas the PPARδ subtype is ubiquitously expressed but 
remains the less understood PPAR subtype and would benefit from further development of pharmacological 
tools11. However, recent studies have identified the role of PPARδ in cholesterol metabolism, adipocyte differ-
entiation, neuronal function and colon cancer12. PPARs, therefore, represent valuable therapeutic targets and 
1Istituto i ristaorafiaǡ onsiio aionae ee icerceǡ ia aaria m. 29ǡ 300ǡ 0001ͻ onterotono 
Stazione, Roma, Italy. 2Dipartimento i 	armaciaǡ niersit ei tui i apoiǡ ia ontesano 49ǡ 80131 apoiǡ 
Italy. 3Dipartimento i 	armaciaǦciene e 	armacoǡ niersit ei tui i ari ǲo oroǳǡ ia .Oraona 4ǡ 
70126 ariǡ Ita. 4Dipartimento i ciene iocimice ǲ. ossi 	aneiǳǡ niersit i oma ǲa apienaǳǡ iaae 
. oro ͻǡ 0018ͻ omaǡ Ita. *ese autors contriute eua to tis wor. orresponence an reuests for 
materias sou e aresse to 
.. ȋemai: iorio.pocetti̻ic.cnr.itȌ or .. ȋemai: antonio.aeccia̻unina.itȌ
Receie: 02 une 2016
accepte: 20 eptemer 2016
uise: 06 Octoer 2016
OPEN
	  	   66	  
 However, an over-activation of PPARγ can lead to serious side effects 
including weight gain and steatosis, for this reason PPARγ partial agonists 
are more advisable. On the other hand, a strong activation of PPARα is also 
beneficial because improves dyslipidemia, lowering plasma tryglicerides and 
increasing HDL cholesterol levels. Therefore, the search for the optimal 
pharmacological profile of a ligand plays an important role and for this 
purpose is required the understanding, at molecular level, of the mechanism 
by which the ligand behaves as full or partial agonist on PPARs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PPARα PPARγ PPARβ/δ 
Compound EC50 (µM) 
Emax a EC50 (µM) 
Emax a EC50 
(µM) 
Emax a 
AL29-26 0.31 ± 0.13 87 ± 8 5.3 ± 1.6 27 ± 3 11 ± 2 54 ± 6 
Wy14,643 1.6 ± 0.3 100 ± 10 i i i i 
rosiglitazone i i 0.04 ± 0.02 100 ± 9 i i  
L165,041 i i i i 1.6 ± 1.3 100 ± 10 
Table 2. Results of transactivation assays performed on the three PPAR isotypes with AL29-26 and the 
reference agonist compounds. a Efficacy values were calculated as the percentage of the maximum 
obtained fold induction with the reference compounds. i = inactive at tested concentrations.  
Figure 24. Chemical structure of AL29-26. 
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4.1.1 Crystallization and structure determination of the 
complexes PPARα-LBD/AL29-26 and PPARγ-LBD/AL29-26 
 Crystals (0.3 x 0.3 x 0.2 mm) of apo-PPARγ-LBD (Figure 25) were 
obtained by vapour diffusion using the sitting drop method and then soaked 
for several days in storage solutions containing the ligand (0.25 mM). As 
regards PPARα-LBD, co-crystallization trials were performed using the 
Phoenix liquid-handling robot with the ligand in three-fold excess with 
respect to the protein. Suitable crystal (0.7 x 0.2 x 0.2 mm) for X-ray data 
collection were obtained at the condition A12 of the Qiagen JCSG Core I 
suite (see Experimental Methods). Preliminary co-crystallization trials were 
also performed for PPARβ/δ-LBD and small crystals were obtained at the 
conditions G5, G6 and H5 (see Experimental Methods) of the same 
crystallization screen. X-ray diffraction data were collected at ESRF of 
Grenoble (France), but only the crystal structures of PPARα-LBD and 
PPARγ-LBD complexes were solved since the ligand could be unambiguosly 
modelled in the electron density maps (Figures 26A-C).   
 The solved structures for PPARα- and PPARγ-LBD have been 
deposited in the PDB with codes 5HYK and 5HZC, respectively, and the 
crystallographic statistics are shown in Table 3. Diffraction data were also 
collected for PPARβ/δ-LBD/AL2926 complex at low resolution (4 - 5 Å), but 
no interpretable electron density maps could be obtained. With the aim to 
obtain more suitable crystal for X-ray analysis of the latter complex, the three 
conditions identified in the trials were reproduced on a larger scale but they 
have not been successful.  
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Figure 25. Crystals of apo-PPARγ-LBD. 
Wy-14,643 1.6 ± 0.3 100 ± 10 i i i i 
Rosiglitazone i i 0.04 ± 0.02 100 ± 9 i i 
L-165,041 i i i i 1.6 ± 0.3 100 ± 10 
a Efficacy values were calculated as the percentage of the maximum obtained fold induction with the 
reference compounds. i = inactive at tested concentrations. 
 
 
 
Structure determination 
X-ray diffraction data were collected for the complexes PPARα/AL29-26, 
PPARγ/AL29-26 and PPARδ/AL29-26 to provide an explanation at the molecular 
level for the different behaviour of AL29-26, as partial or full agonist, towards the 
three PPAR subtypes. The crystal structures of PPARα and PPARγ complexes were 
solved and the ligand could be unambiguously modelled in the electron density maps 
(Figure 3). The crystallographic statistics are shown in Table 2. Diffraction data were 
also collected for PPARδ/AL29-26 at low resolution (4-5 Å) but no interpretable 
electron density maps could be obtained.  
 
Figure 3. Ligand binding to PPARα and PPARγ 
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Wy-14,643 1.6 ± 0.3 100 ± 10 i i i i 
Rosiglitazone i i 0.04 ± 0.02 100 ± 9 i i 
L-165,041 i i i i 1.6 ± 0.3 100 ± 10 
a Efficacy values were calculated as the percentage of the maximum obtained fold induction with the 
reference compounds. i = inactive at tested concentrations. 
 
 
 
Structure determination 
X-ray diffraction data were collected for the complexes PPARα/AL29-26, 
PPARγ/AL29-26 and PARδ/AL29-26 to provide an explanation at the molecular 
level for the different behaviour of AL29-26, as partial or full agonist, towards the 
three PPAR subtypes. The crystal structures of PPARα and PPARγ complexes were 
solved and the ligand could be unambiguously modelled in the electron density maps 
(Figure 3). The crystallographic statistics are shown in Table 2. Diffraction data were 
also collected for PPARδ/AL29-26 at low resolution (4-5 Å) but no interpretable 
electron density maps could be obtained.  
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4.1.2 PPARγ-LBD/AL29-26 structure: new position of the 
carboxylate in the region of partial agonists 
 As known, the apo-form of PPARγ-LBD crystallizes as a dimer, 
where the molecule A of the asymmetric unit has its activation function-2 
helix (H12) in the active conformation and the molecule B in the inactive 
conformation, due to the crystal packing. AL29-26 was very easily modelled 
in the density of the molecule B and its binding mode in the LBD of PPARγ 
is shown in Figure 26A. A second molecule of the ligand could be also fitted 
in molecule A of the dimer with a similar binding mode. The protein-ligand 
interactions observed in chains A and B were essentially the same, therefore 
the two complexes of the asymmetric unit will be described hereafter as a 
generic model. Notably, the ligand occupies the conventional region of 
PPARγ partial agonists, between helix 3 and the β-sheet, even though its 
position is significantly different from that of all the partial agonists known 
in literature (Figure 27).           
 
 
 
 
 
 
 
 
 
 
 
 
 
packing.  AL29-26 was very easily modelled in the density of the molecule B and its 
binding mode in the LBD of PPARγ is shown in Figure 3A. A second molecule of the 
ligand could be also fitted in molecule A of the dimer with a similar binding mode. 
The protein-ligand interactions observed in chains A and B were basically the same, 
consequently, the two complexes of the asymmetric unit will be described hereafter as 
a generic model. 
 
 New position of t e ca oxylate in the region of PPARγ partial agonists 
 Remarkably, t e ligand occupies the canonical region of PPARγ partial agonists, 
between helix 3 and the β-sheet, but its position is significantly different from that of 
all the partial agonists known in literature (Figure 4A).  
 
Figure 4. Comparison of PPARγ complexes 
(A) Superposition of PPARγ complexes (gray) with known partial agonists (pdb codes: 3D6D, 4PVU, 
4PWL, 4JL4, 4JAZ, 4E4K, 2Q5P, 2Q6S, 2Q5S, 4E4Q, 5F9B) onto the PPARγ complex with AL29-26 
(cyan). The carboxylate groups are depicted in red, the residue S342 in blue.  
(B) Superposition of SR2067 (magenta) (pdb code 4R06) onto the PPARγ complex with AL29-26 
(cyan). The red arrow indicates the naphthalene groups of the two ligands.  
 
Usually, all the PPARγ partial agonists form a more or less efficient H-bond 
interaction through their carboxylate group with the NH of S342, belonging to inner 
strand of the β-sheet. On the contrary, the carboxylate of AL29-26 is significantly 
shifted along the axis of H3 towards the helix 5, forming two H-bonds with the side 
chain of R288 through one of its oxygens (2.7 and 2.9 Å) (Figure 3A). The other 
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Figure 27. Superposition of 
PPARγ complexes (grey) with 
known partial agonists (PDB IDs: 
3D6D, 4PVU, 4PWL, 4JL4, 
4JAZ, 4E4K, 2Q5P, 2Q6S, 2Q5S, 
4E4Q, 5F9B) onto the PPARγ 
complexes with AL29-26 (cyan). 
The carboxylate groups are 
depicted in red, the residue S342 
in blue. 
	  	   70	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Conversely from the other PPARγ partial agonists, which form a more 
or less efficient H-bond interaction through the carboxylate group with the 
NH of S342 belonging to inner strand of the β-sheet, the carboxylate of 
AL29-26 is significantly shifted along the axis of H3 toward H5, with one of 
its oxygens forming two H-bonds with the side chain of R288 (2.7 and 2.9 Å; 
Figure 26A). The other carboxylate oxygen makes H-bonds (2.7 Å) with two 
 
 
 
PPARγ-LBD/AL29-26 PPARα-LBD/AL2926 
Data collection   
space group C2 P41212 
cell dimension a, b, c [Å] 93.40, 60.79, 119.00 63.65, 63.65, 126.00 
wavelenght [Å] 0.873 0.873 
resolution range [Å] 50.00 - 2.00 50.00 - 1.83 
last shell [Å] 2.21 - 2.00 2.05 - 1.83 
Rmerge [%] 5.9 (64.6) a 7.1 (51.8) a 
unique reflections 23665 43099  
mean (I)/σ(I) 10.1 (1.2) a 22.7 (5.0) a 
completeness 98.0 (97.0) a 100 (100) a 
No. of molecules in 
asymmetric unit 2 1 
 
Refinement   
resolution range [Å] 50.00 - 2.00 50.00 - 1.83 
Rwork [%] 22.5 21.1 
Rfree [%] 26.8 26.2 
Bond lenghts r.m.s.d. [Å] 0.009 0.007 
Bond angles r.m.s.d. [deg] 1.519 1.108 
Table 3. Summary of crystallographic analysis for crystals of the PPARγ-LBD/AL2916 
and PPARα-LBD/AL29-26 complexes. a The values in parentheses refer to the outer shell.  
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water molecules bridged to CO of L228 on the loop 1/2 (2.8 Å) and to CO of 
M329 on the helix 5 (2.9 Å), respectively. One of the two methyl groups of 
the ligand makes van der Waals (vdW) interactions with the methyls of the 
A292 and M329 side chains (3.8 and 4.3 Å, respectively), the other one with 
those of L330 and L333 (4.2 and 4.1 Å, respectively). The single aromatic 
ring is sandwitched between the R288 and L330 side chains. The naphthalene 
ring is positioned between I341 and C285 side chains, facing the NH of 
S342, usually H-bound to the carboxylte group of canonical partial agonists. 
The naphthalene system of the ligand is almost perpendicular to the plane of 
the single aromatic ring. 
 It would be interesting to determine whether this unusual position of a 
partial agonist could be associated to a different stabilization of the β-sheet 
and, consequently, to a different degree of inhibition of the S245 
phosphoryltion with respect to other partial agonists. In the recent years, 
indeed, a new antidiabetic mechanism depending upon the inhibition of S245 
phosphorylation (PPARγ2 residue S273) by ciclin-dependent kinase 5 (Cdk5) 
has been proposed [71]. This inhibition maintains the transcription of many 
insulin-responsive genes, such as adiponectine and adipsin [71]. 
Interestingly, obesity and other pro-inflammatory signals induce the 
phosphorylation of PPARγ at S245, explaining why obese people also 
develop insulin resistance. Given that the Cdk5 recognition site extends into 
the first β-strand of PPARγ, structural stabilization of the β-sheet region, 
caused by partial agonists, presumably makes the residue S245 less 
accessible to the kinase, protecting the receptor from phosphorylation, an 
event well correlated with glucose-lowering effects. This might explain how 
PPARγ partial agonists can exhibit similar or higher antidiabetic effects than 
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those of TZDs and other full agonists. At this regard, it has been recently 
published the crystal structure of PPARγ-LBD complexed with the ligand 
SR2067 (PDB ID: 4R06), which interacts with the β-sheet exclusively 
through hydrophobic interactions mediated by a naphthalene group, revealing 
a unique kinetic and structural signature for PPARγ partial agonism [132]. 
The superposition of this structure with that of PPARγ-LBD/AL29-26 shows 
an equivalent position of the naphthalene groups of the two ligands in front 
of the β-sheet (Figure 28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.3 PPARα-LBD/AL29-26 structure: ligand occupation of a 
new pocket  
 In the complex with PPARα-LBD, the polar head of AL29-26 is 
engaged in a very efficient H-bonds network with the side chain of Y464 (2.7 
packing.  AL29-26 was very easily modelled in the density of the molecule B and its 
binding mode in the LBD of PPARγ is shown in Figure 3A. A second molecule of the 
ligand could be also fitted in molecule A of the dimer with a similar binding mode. 
The protein-ligand interactions observed in chains A and B were basically the same, 
consequently, the two complexes of the asymmetric unit will be described hereafter as 
a generic model. 
 
 New position of the carboxylate in the region of PP Rγ p rtial agonis s 
 Remarkably, the ligand occupies the canonical region of PPARγ partial agonists, 
between helix 3 and the β-sheet, but its position is significantly different from that of 
all the partial agonists known in literature (Figure 4A).  
 
Figure 4. Comparison of PPARγ complexes 
(A) Superposition of PPARγ complexes (gray) with known partial agonists (pdb codes: 3D6D, 4PVU, 
4PWL, 4JL4, 4JAZ, 4E4K, 2Q5P, 2Q6S, 2Q5S, 4E4Q, 5F9B) onto the PPARγ complex with AL29-26 
(cyan). The carboxylate groups are depicted in red, the residue S342 in blue.  
(B) Superposition of SR2067 (magenta) (pdb code 4R06) onto the PPARγ complex with AL29-26 
(cyan). The red arrow indicates the naphthalene groups of the two ligands.  
 
Usually, all the PPARγ partial agonists form a more or less efficient H-bond 
interaction through their carboxylate group with the NH of S342, belonging to inner 
strand of the β-sheet. On the contrary, the carboxylate of AL29-26 is significantly 
shifted along the axis of H3 towards the helix 5, forming two H-bonds with the side 
chain of R288 through one of its oxygens (2.7 and 2.9 Å) (Figure 3A). The other 
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Figure 28. Superposition of SR2067 (magenta; PDB ID: 4R06) onto PPARγ-LBD/AL2926 
complex (cyan). The red arrow indicates the naphthalene groups of the two ligands.  
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Å) on the helix 12, as well as Y314 (2.7 Å), H440 (2.8 Å) and with OH of 
S280 (2.5 Å) (Figure 26B). All of the PPARα agonists already reported in the 
PDB share the same standard polar interactions. The two methyl groups of 
the ligand form vdW contacts with M355, F318, H440 and C276, in the 
upper portion of the binding pocket. The rigid and bulky aromatic groups of 
the ligand occupy a new region of the hydrophobic pocket within PPARα 
ligand binding domain, between H3 and H11, never occupied by other known 
PPARα agonists (Figure 29), with the only exception of the ligand BMS-
631707 (PDB ID: 2REW) [133]. The opening of this usually unaccessible 
region is allowed by the ligand-induced switching of the F273 from the 
commonly adopted extended conformation to the folded gauche* one (χ1= -
67°). As a consequence, the aromatic moiety of the ligand occupies the 
position usually assumed by the aromatic ring of F273, that operates as a 
gate-keeper for the accomodation of rigid and bulky substituents at the 
carbon atom linked to the carboxylate group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Comparison of PPARα complexes 
(A) Superposition of PPARα complexes (gray) with known partial agonists (pdb codes: 
2REW,4BCR,1K7L, 3SP6, 3FEI, 2GTK, 3G8I, 3ET1, 3KDT, 1I7G) onto the PPARα complex with 
AL29-26 (ligand yellow, protein cyan). The ligand BMS-631707 (PDB code 2REW) is shown in 
green. The “closed” (trans) conformation of F273 side-chain is also shown (gray).  
(B) New conformation of the loop 11-12 in the PPARα/AL29-26 complex: superposition of the loops 
11-12 of known PPARα structures (light-brown) (same pdb codes of Figure 5A) with that of 
PPARα/AL29-26 (ligand yellow, protein cyan). The ligand BMS-631707 (PDB code 2REW) is shown 
in green. Additional vdW interactions realized by AL29-26 are shown as red dashed lines. 
 
The opening of this usually inaccessible region is allowed by the ligand-induced 
switching of the F273 from the generally adopted extended to the folded g* 
conformation (χ1=-67°). As a consequence, the aromatic moiety of the ligand 
occupies the position usually occupied by the aromatic ring of F273, that acts as a 
gate-keeper for the accommodation of rigid and bulky substituents at the carbon atom 
linked to the carboxylate group. The above mentioned ligand BMS-631707, 
containing the conformationally constrained azetidinone ring linked to the 
carboxylate, behaves in the same way replacing the side chain of F273, forced to 
assume a gauche conformation. A similar situation was also observed in the complex 
of PPARγ with LT175 (PDB code 3B3K) where the rigid and straight diphenyl group 
of the ligand induced the flipping-out of the corresponding F282 side chain, towards 
the  “benzophenone pocket”, making available a new region of the LBD, the so-called 
“diphenyl pocket”.44 In that case, it was observed that the diphenyl pocket is L-shaped 
and the diphenyl group of LT175 occupied only the first branch (Figure 6A). In 
PPARα the similar, but more spherical, new region of the LBD is totally filled, by the 
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Figure 29. Superposition of PPARα complexes with known partial agonists 
(gray; PDB IDs: 2REW, 4BCR, 1K7L, 3SP6, 3FEI, 2GTK, 3G8I, 3ET1, 3KDT, 
1I7G) onto the PPARα complex with AL29-26 (ligand yellow, protein cyan). 
The ligand BMS-631707 (PDB ID: 2REW) is shown in green. The “closed” 
(trans) conformation of F273 side-chain is also shown (gray).  
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 The above mentioned ligand BMS-631707, containing the 
conformationally constrained azetidinone ring linked to the carboxylate, 
behaves in the same manner replacing the side chain of F273, forced to 
assume a gauche conformation. A similar situation was also observed in the 
complex of PPARγ-LBD with LT175 (PDB ID: 3B3K) where the rigid and 
straight diphenyl group of the ligand caused the flipping-out of the 
corresponding F282 side chain, toward the 'benzophenone pocket', making 
available a new region of the LBD, the so-called 'dyphenil pocket' [52]. In 
that case, it was observed that the dyphenil group of LT175 occupied only 
the first branch (Figure 30). In PPARα the similar, but more spherical new 
region of the LBD is totally filled by the single aromatic ring of AL29-26, 
that occupies the first branch, whereas the naphthalene rings fill the second 
branch of the cavity (Figure 30). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. New PPARα (left) and PPARγ (right) hydrophobic pockets allowed by the 
ligand-induced switching of the F273 side-chain (F282 in PPARγ). The cavities were 
calculated using the software Molegro [134]. 
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 The positioning of the ligand in this new region induces a significant 
conformational change of the loop 11/12 that forms the edges of the pocket 
with H3 and H11. It is worth noting that in all the known structures of 
PPARα complexes this loop always assumes a different and ordered 
conformation in which the residue A454 would make a steric clash with the 
bulky naphthalene rings of AL29-26. Consequently, the ligand provokes a 
rearrangement of the loop 11/12 whose new conformation, closer to helix 3, 
is strongly stabilized by a vdW interaction between A454 and the two 
methyls of V270, on helix 3 (3.4 and 3.6 Å, respectively) (Figure 31). A 
further  stabilization is achieved through vdW interactions of the methyl 
groups of A454 and L456 with carbon atoms of the naphthalene ring system 
(3.4 and 3.6 Å, respectively). This novel and distinct interaction between H3 
and the loop 11/12, indirectly, also contributes to further stabilize the active 
conformation of H12.  
 The discovery of this new cavity of PPARα-LBD, analogue to the 
PPARγ-LBD diphenyl pocket, whose accessibility is regulated by the side 
chain of the gate-keeper F273, was never observed before and its structural 
characterization provides new opportunities to rational design of more 
balanced PPAR modulators. Moreover, we confirmed in this work the many 
possibilities used by PPARs to modulate the stabilization of the activation 
function 2 (AF-2) region through a subtle mechanism of molecular cross-talk, 
mediated by the ligand, among different regions of the protein. It is known 
the unique mode of binding to PPARα-LBD of the ligand WY14643 (PDB 
ID: 4BCR) [135] that revealed a new pattern of nuclear receptor ligand 
recognition in which a second molecule of ligand is involved in the 
interaction with the protein, providing additional stabilization to the AF-2 
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region. This molecule strongly stabilizes the highly mobile ω-loop by the 
formation of a charge cluster that involves the ligand itself, the helix 3 and 
the loop 11/12, providing in this way a more subtle stabilization of helix 12. 
 At the same way, in this work we showed that the bulky AL29-26, 
occupying a new hydrophobic pocket, perturbs the PPARα standard 
conformation of the loop 11/12 forcing it to a different and stable 
conformation in which A454 of the loop strongly interacts with V270 on 
helix 3. This novel interaction between H3 and the loop 11/12, mediated by 
the ligand, also contributes to further stabilize the active conformation of 
H12. Similar mechanisms have been proposed to explain actions of PPARγ 
partial agonists, that activate H12 to a lesser extent stabilizing H3 and the β-
sheet and/or modifying the dynamics of the flexible ω-loop [135]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
Figure 31. New conformation of the loop 11/12 in the PPARα-LBD/AL29-26 complex: 
superposition of the loops 11/12 of known PPARα structures (light-brown) (same PDB IDs of 
Figure 29) with that of PPARα-LBD/AL29-26 (ligand yellow, protein cyan). The ligand BMS-
631707 (PDB ID: 2REW) is shown  in green. Additional vdW interactions realized by AL29-26 
are shown as red dashed lines. 
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4.1.4 Specificity of the new cavity: a steric clash with S289 
prevents AL29-26 to occupy the diphenyl pocket of PPARγ-
LBD determining its partial agonist properties 
 Within PPARγ-LBD the ligand AL29-26 doesn't occupy the diphenyl 
pocket, preferring to accomodate in the region of partial agonists. In order to 
investigate the reason of this behaviour, the ligand was modelled in the 
PPARγ diphenyl pocket considering the different hydrogen-bond network 
realized by the carboxylate group with respect to PPARα-LBD, for the 
presence of H323 instead of Y314. For this purpose the structure of PPARγ-
LBD/LT175 complex was used as template, given the structural similarity of 
the two ligands. AL29-26 could occupy the diphenyl pocket, completely 
filling the second branch of the cavity even though with very short vdW 
distances with some residues of the protein (2.7 Å with M463, 2.6 Å with 
L453 and 3.0 Å with I456 side chains). In this position, however, one of its 
methyls would make a steric clash with the OH of S289 (2.2 Å), preventing 
H-bonding with the carboxylate group and perturbating in this way the 
efficient H-bond network of the ligand (Figure 32A). 
 On the contrary, in the PPARα LBD the new hydrophobic pocket has 
more space to accomodate the ligand due to the presence of the shorter A454 
in place of M643 of PPARγ-LBD, the shorter V444 instead of L453 and the 
side chain of I447 less close to the ligand compared to the corresponding 
I456. The global volume of the two cavities, calculated by the software 
Molegro [134], seems to be very similar (200.7 vs 198.1 Å3 for PPARα- and 
PPARγ-LBD, respectively) although showing differences concerning the 
shape. Unlike the L-shaped PPARγ-LBD diphenyl pocket, indeed, the 
PPARα cavity shows an almost spherical shape that better allows the 
accomodation of a bulkier ligand (Figure 30). In this situation, the two 
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methyls of the ligand have no clashes with the side chain of S280 (S289 in 
PPARγ-LBD), due to the shifted positioning of the ligand in the pocket 
caused by the presence of the bulkier Y314 on helix 12, with respect to 
PPARγ H323 (Figure 32B). 
 
          
 
 
 At this regard, we noticed that in the molecule A of PPARγ, whose 
helix 12 is in its active conformation, there is weak electron density in 
correspondence of the side chain of F282 in its closed conformation, and 
some residual Fo-Fc electron density is visible in the region corresponding to 
its “flipped-out” conformation; moreover, there is some poor, not easily 
interpretable, additional density in the diphenyl pocket that cannot be merely 
attributed to water molecules and that let hypothesize a small percentage of 
Figure 32. A) Modelled AL29-26 (gray) onto LT175 (green) (PDB ID: 3B3K) in the complex with 
PPARγ-LBD. Residues belonging to the “diphenyl pocket” are shown in red (vdW interactions with 
AL29-26 as red dashed lines). The residues interacting with the carboxylate group are shown in green 
(H-bonds are shown as blue dashed lines).  B) Superposition of PPARγ-modelled AL29-26 (gray) 
onto the PPARα/AL29-26 complex (the ligand is shown in yellow). Two representative residues of 
PPARγ are shown in gray, the corresponding residues of PPARα in cyan. 
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occupation of this region by a second molecule of ligand with lower affinity. 
This could also be a consequence of the soaking method used to bind AL29-
26 in the crystal of apo-PPARγ, whereas the ligand is in large excess with 
respect to the protein. However, this event is not visible in the molecule B of 
PPARγ where H12, in its inactive conformation, cannot interact with the 
ligand. In this case the side chain of F282 assumes unambiguously the 
extended conformation, blocking the entrance of the new pocket. In 
conclusion, AL29-26 in the PPARγ-LBD complex prefers to occupy the 
region facing the β-sheet, behaving as a partial agonist. It could be 
hypothesized that the substitution of one of the two methyl groups of AL29-
26 with a H atom could relieve the steric clash with S289 of PPARγ changing 
the pharmacological character of this ligand and turning it in a more potent 
agonist.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   80	  
 
 
 
 
 
 
 
 
4.2 Saponins and sapogenins as potential PPARγ agonists 
 Some medicinal plants have been traditionally used to treat metabolic 
diseases such as insulin resistance, steatosis and diabetes, because of their 
hypoglycemic and antidiabetic properties. Saponins are a class of chemical 
compounds found in particular abundance in various plant species which 
have been reported to exhibit hypoglycemic potential in diabetic states [136, 
137], and attracted a lot of interest because of their potent, hypolipidemic and 
insulin-like properties [138-141]. Saponins are amphipathic glycosides 
consisting of a sugar moiety linked to a hydrophobic aglycone (sapogenin) 
with a triterpenoid or a steroid structure. The number of saccharide chains 
attached to the sapogenin/aglycone core can vary, giving rise to another 
dimension of nomenclature (monodesmosidic, bidesmosidic, etc.) as can the 
length of each chain. Due to their variety of chemical structures, naturally 
occurring saponins display a broad diversity of polarity, hydrophobicity and 
acidity that determine their various biological and pharmacological features 
[142]. Saponins from Platycodi radix have been shown to improve 
1Scientific RepoRts | 6:27658 | DOI: 10.1038/srep27658
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Screening of saponins and 
sapogenins from Medicago species 
as potential PPARγ agonists and 
X-ray structure of the complex 
PPARγ/caulophyllogenin
Roberta Montanari1, Davide Capelli1, Aldo Tava2, Andrea Galli2, Antonio Laghezza3, 
Paolo Tortorella3, Fulvio Loiodice3 & Giorgio Pochetti1
A series of saponins and sapogenins from Medicago species were tested for their ability to bind and 
activate the nuclear receptor PPARγ by SPR experiments and transactivation assay, respectively. 
The SPR analysis proved to be a very powerful and fast technique for screening a large number of 
compounds for their affinity to PPARγ and selecting the better candidates for further studies. Ba ed on 
the obtained results, the sapogenin caulophyllogenin was proved to be a partial agonist towards PPARγ 
and the X-ray structure of its complex with PPARγ was also solved, in order to investigate the binding 
mode in the ligand binding domain of the nuclear receptor. This is the first known crystal structure of 
a sapogenin directly interacting with PPARγ. Another compound of the series, the echinocistic acid, 
showed antagonist activity towards PPARγ, a property that could be useful to inhibit the adipocyte 
differentiation which is a typical adverse effect of PPARγ agonists. This study confirms the interest on 
saponins and sapogenins as a valuable natural resource exploitable in the medical and food industry for 
ameliorating the metabolic syndrome.
PPARγ is a crucial regulator of glucose and lipid homeostasis and an important pharmacological target for treat-
ing metabolic diseases1–3. PPARγ full agonists are strong insulin-sensitizing agents4. However, over-activation of 
PPARγ can lead to serious side effects including weight gain and steatosis, for this reason PPARγ partial agonists 
are more desirable5,6. On the other hand, PPARγ antagonists are also interesting targets because may inhibit 
lipogenesis and adipocyte differentiation, reduce fat weight and improve insulin resistance in the obesity state7,8. 
Obesity is also associated with a low-grade inflammation in white adipose tissue and liver, which may exacerbate 
insulin resistance, steatosis and diabetes. Control of inflammation seems important in the clinic treatment of the 
metabolic diseases9.
Some medicinal plants have been traditionally used to treat this kind of metabolic diseases because of their 
hypoglycemic and antidiabetic properties. Saponins are a class of chemical compounds found in particular abun-
dance in various plant species which have been reported to exhibit hypoglycemic potential in diabetic states10,11, 
and attracted a lot of interest because of their potent, hypolipidemic and insulin-like properties12–15.
Saponins are biologically active plant-derived glycosides consisting of a sugar moiety linked to a hydrophobic 
aglycone (sapogenin) with a triterpenoid or a steroid structure. They may have one (monodesmosidic) or more 
(bi- and tridesmosidic) linear or branched sugar chains linked to the aglycone mojety through an ether or ester 
bond. Due to their variety of chemical structures, naturally occurring saponins display a broad diversity of polar-
ity, hydrophobicity and acidity that determine their various biological and pharmacological features16.
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homeostasis in type 2 diabetic states, partly by enhancing hepatic and 
adipocyte insulin sensitivity which is achieved by activating PPARγ [143]. 
They also inhibit lipogenesis through AMPKa-PPARγ2 in 3T3-L1 cell and 
modulate fat accumulation in obese mice [144]. Saponins and sapogenins 
were recently studied for their anti-inflammatory effect due to the inhibition 
of NF-kB and for their effect on PPAR transcriptional activity [145, 146]. 
Particularly, several oleanane-type triterpenoid saponins from the roots of 
Pulsatilla koreana inhibited TNFα-stimulated NF-kB activation in a dose-
dependent manner, with IC50 values ranging from 0.75–8.30 µM, repressing 
the expression of the iNOS and ICAM-1 genes, which play important roles in 
the inflammatory response [147, 148]. The same compounds also 
significantly activated the transcriptional activity of PPARs in a dose-
dependent manner, with EC50 values up to 1 µM. Moreover, protopanaxatriol, 
a monoglucoside sapogenin present in the root of Panax ginseng, showed 
antagonist activity towards PPARγ [146]. It specifically inhibited the 
transactivation activity of PPARγ, but not that of PPARα, β/δ and LXR α,β, 
by repressing the adipocyte differentiation and ameliorating obesity, insulin 
resistance, steatosis and hyperlipidemia in diet-induced obesity mice.  
4.2.1 Fast screening of saponins and sapogenins from 
Medicago species by SPR 
 In the present study a series of previously purified and characterized 
saponins and sapogenins from Medicago species were tested by Surface 
Plasmon Resonance (SPR) experiments for their ability to bind and activate 
PPARγ, in order to select the most promising compounds for further activity 
tests and for X-ray analysis. Compounds of this genus have been shown to 
possess a broad spectrum of biological properties such as fungicidal, 
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molluscicidal, insecticidal, nematicidal, allelopathic, antiviral cytotoxic and 
hemolytic activity [149].  
 The affinity (Kd) and rate constants (Kon, Koff) for PPARγ-
LBD/saponin or sapogenin interactions are reported in Table 4 and compared 
with the reference ligand LT175, whose Kd obtained by this analytical 
method (2.34 µM) basically confirmed that previously achieved from 
experiments (3.66 µM) [150]. The compounds used in this study (Figure 33) 
are both saponins (compounds 1–17) and sapogenins (compounds 18–24), all 
having the same pentacyclic triterpene structure with differences in number 
and position of hydroxyl and carboxylic groups on the triterpene skeleton and 
nature and number of the sugars linked at C-3 and C-28 position. For 
saponins, different values of affinity towards PPARγ-LBD were registered: 
higher affinity (Kd less than 100 µM) were found for saponins 1 (that shows 
the lowest equilibrium dissociation constant Kd = 18.33 µM), 3, 4, 6–8, 10, 
and 17; a middle affinity (Kd 125–150 µM) was found for saponins 2, 5 and 
9, while a very low or no affinity (Kd from about 500 to >1000 µM) was 
observed for saponins 11–16 (see Table 4). The first group of saponins, 
including compounds with high and middle PPARγ-LBD affinity, was 
composed by mono- and bidesmosides of oleanolic acid, 2β-hydroxy 
oleanolic acid, echinocystic acid, hederagenin, bayogenin and soyasapogenol 
B, whereas the second group of saponins showing low or no affinity with 
PPARγ-LBD, are all derivatives of medicagenic and zanhic acid. Concerning 
sapogenins, only echinocystic acid (18) and caulophyllogenin (19) showed 
considerable affinities for PPARγ-LBD, with Kd = 9.70 and 54.82 µM, 
respectively, whereas the other tested sapogenins had very low or no affinity 
(Kd > 500, see Table 4).  
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Figure 33. Structure and classification of saponins (1–17) and sapogenins (18–24) used in this study. 
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Interaction Kon (M-1 s-1) a Koff (s-1) a Kd (µM) a 
LT175 b, c 3.5(0.1)e5  9.5(0.2)e2 0.82(0.04)  0.81(0.02) 2.34(0.04)  850(30) 
SAP1 6.12(0.04)e4 1.122(0.002) 18.33(0.09) 
SAP2 1.254(0.003)e4 1.572(0.004) 125.34(0.04) 
SAP3 1.567(0.003)e4 1.264(0.003) 80.67(0.03) 
SAP4 1.333(0.003)e4 0.694(0.002) 52.05(0.05) 
SAP5 1.040(0.002)e3 1.381(0.003) 132.71(0.05) 
SAP6 1.346(0.004)e4 0.913(0.002) 67.85(0.06) 
SAP7 2.928(0.007)e4 1.260(0.003) 43.03(0.03) 
SAP8 3.74(0.01)e4 2.139(0.008) 57.18(0.04) 
SAP9 5.18(0.02)e3 0.769(0.002) 148.25(0.09) 
SAP10 1.626(0.004)e4 1.451(0.004) 89.28(0.04) 
SAP11 1.949(0.006)e3 0.970(0.003) 497.4(0.2) 
SAP12 d - - - 
SAP13 5.64(0.03)e3 4.13(0.03) 731.2(0.2) 
SAP14 - - >1000 
SAP15 - - >1000 
SAP16 - - >1000 
SAP17 c 5.1(0.1)e4 1.68(0.04) 32.5(0.02) 
SAP18 c 144.8(0.2)  1.98(0.01)e4 1.405(0.004)e
-3  
0.715(0.002) 9.70(0.03)  36.1(0.2) 
SAP19 2.053(0.005)e4 1.126(0.002) 54.82(0.03) 
SAP20 - - >1000 
SAP21 d - - - 
SAP22 4.65(0.04)e3 2.47(0.02) 513(7) 
SAP23 4.76(0.08)e3 3.33(0.05) 699.2(0.6) 
SAP24 d - - - 
Table 4. Affinity (Kd) and rate constants (Kon, Koff) for PPARγ receptor/saponin (or sapogenin) 
interactions. a Experimental error is reported in parentheses. b LT175 was chosen as reference 
compound because its Kd is known from ITC experiments (Kd = 3.66 µM).  
c For this compound data 
were fit to a 2:1 molecular interaction model. d For this compound data didn’t fit to models.  
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 Interestingly, echinocistic acid (18) showed a binding profile that 
differed from all the other tested compounds. Indeed, the data obtained from 
kinetic analysis of 18 were more suitable for a 2:1 molecular interaction 
model (Figure 34), suggesting that two molecules of 18 could simultaneously 
bind the receptor LBD. In addition, the high affinity binding site has a very 
small kinetic association rate constant Kon compared to that of the other 
compounds (144.8 M-1s-1 vs values ranging from 1 x 103 to 7.6 x 104 M-1s-1) 
and a lower dissociation rate constant Koff (1.4 x 10
-3 vs 0.3 – 64 s-1), 
therefore a slow kinetics of association and dissociation can be hypothesized. 
A similar behavior has been observed for other nuclear receptor antagonists 
[151]. By contrast, caulophyllogenin (19) showed a kinetic behavior 
characterized by a rapid association and dissociation time (Figure 34).  
 
 The SPR experiment showed that, among saponins, the compounds 
with higher affinity were, in general, short sugar chains mono- and 
bidesmoside saponins characterized by the presence of a methyl or alcoholic 
group at C-23 position on the triterpenic nucleus. On the contrary, a 
carboxylic group in the same position, as in the derivatives of medicagenic 
Figure 34. Representative data sets for kinetic analysis of sapogenins 18 (left) and 19 (right) in the 
interaction with PPARγ-LBD. Red lines represent the global fits of the data to a 1:1 bimolecular 
interaction model for SAP19 and a 2:1 model for SAP18. The kinetic parameters obtained from each 
interaction are reported in Table 4. 
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and zanhic acid, significantly reduced the affinity. In addition, the hydroxyl 
group at the 2β position of the aglycone seemed to lower the affinity. 
Saponins of 2β-hydroxy oleanolic acid (2) and bayogenin (compounds 9 and 
10) showed, in general, higher dissociation constants Kd compared to 
saponins of oleanolic acid (1) and hederagenin (compounds 4, 6 and 7) in 
which the 2β-hydroxy group was not present. The glycosidic portion of the 
molecule seemed to be an additional important feature for the interaction 
with PPARγ-LBD. As reported in Table 4, most saponins with higher affinity 
were glycosides of hederagenin (compounds 4, 6, 7 and 8), bayogenin 
(compounds 9 and 10) and soyasapogenol B (17) even though their aglycone 
portion, hederagenin (20), bayogenin (21) and soyasapogenol B (24), didn’t 
show affinity to the nuclear receptor. This allows to suggest that sugars, in 
particular when linked at the C-3 position, are of relevance for the interaction 
mechanisms with the binding site of PPARγ. Sugar chains could either allow 
a correct positioning of the aglycone moiety in the affinity site of the nuclear 
receptor or favor its accommodation into an alternative binding site. Also the 
sugar chain length, in particular at C-28 position, seems to be of importance 
to improve affinity. The most active saponins are both monodesmosidic or 
monosaccaride C-28 substituted compounds.  
 As regards sapogenins, the SPR experiment showed that only 
echinocystic acid (18) and caulophyllogenin (19) possessed a good affinity 
for the PPARγ-LBD (for 19 this was also confirmed by ITC analysis). Both 
compounds are characterized by the presence of a 16α-hydroxyl group in the 
molecule that probably is another important feature in conferring affinity to 
PPARγ. The same 16α-hydroxy substituent is also present in zanhic acid but 
this character is probably not sufficient to contrast the strong binding 
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inhibition performed by the carboxylic group at C-23 position.  
 In conclusion, some chemical characteristics of substrates were of 
relevance in conferring binding affinity to PPARγ. The presence of a methyl 
or hydroxyl at C-23 position of the triterpenic nucleus strongly increased 
affinity, which was inhibited from the presence of a carboxylic group at the 
same position. The 2β-hydroxy substitution seemed to lower the affinity, 
while the 16α-hydroxy substitution had some positive effects on affinity only 
if no carboxylic group was present at C-23 position. Moreover, the 
glycosylation at C-3 seemed to increase the activity, although it should be 
taken into account the possibility that oral administrations of saponins might 
lead to hydrolysis of glycosides from terpenoid. Finally, the SPR analysis has 
been proved to be a very powerful and fast method for screening a large 
number of compounds with the aim to select the better candidates as agonists 
and also antagonists of nuclear receptors. 
4.2.2 Toxicity and transcriptional activity on the most affine 
compounds 
 
 MTT assay was performed by Loiodice and collaborators in order to 
evaluate the toxicity on HepG2 cells of saponins/sapogenins showing higher 
affinity, such as compounds 3, 6, 7, 8, 17, 18 and 19. As shown in Table 5, 
only caulophyllogenin (19) and soyasaponin I (17) did not show cytotoxicity 
at concentrations up to 100 µM, whereas the other tested compounds showed 
cytotoxic activities at values ranging from 3 to 20 µM. 
 Concerning PPARγ activity, the same compounds were tested at 
doses lower than that at which they showed cytotoxicity (100 µM for 
soyasaponin I 17 and caulophyllogenin 19, 50 µM for saponin 8, 12.5 µM for 
saponins 3 and 7, 6.25 µM for saponin 6 and echinocystic acid (18), as 
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reported in Figure 35A. Only caulophyllogenin (19) behaved as a partial 
agonist with EC50 = 12.6 ± 2.7 µM and efficacy = 9.4 ± 0.6% (Figure 35B). 
Its low potency and efficacy should not be undrestimated because very 
similar to those of the well-known selective modulator metaglidasen [152, 
153], a compound already investigated as a useful agent for the treatment of 
type 2 diabetes and hyperglycemia, showing reduced adverse side effects. 
Echinocystic acid (18) displayed similar activity only at concentrations up to 
6.25 µM. 
 The antagonist behaviour of the above compounds was also evaluated 
in displacement experiments against rosiglitazone, indicating that only 
echinocystic acid (18) shows moderate activity reducing the effects of the 
reference compound by 40% at 5 µM. This property could be useful to inhibit 
the adipocyte differentiation which is a typical adverse effect of PPARγ 
agonists. The cytotoxic activity in vitro of compound 18 against human 
cancer cell lines (HepG2) deserves to be deepened to establish a possible role 
of this sapogenin as potential anti-cancer in combination with other anti-
tumorigenic drugs, as already evidenced in previous papers [154, 155]. 
Echinocystic acid (18) and caulophyllogenin (19) used in this investigation 
were extracted from M. polimorpha (Leguminose family), but they are also 
components of Crysantellum americanum, a plant of the Asteraceae family 
which contains several triterpen saponins, whose therapeutic properties as 
hypolipidemic and hepatoprotective agents are known [156]. Further studies 
should be also performed to evaluate the anti-inflammatory activity of these 
sapogenins as possible inhibitors of NF-kB. 
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Table 5. Cytoxicity values (MTT assay) on HepG2 from saponins/sapogenins showing higher 
affinities. IC50 represents the concentration that reduces the cell viability by 50%. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. A) PPARγ activity from saponins/sapogenins showing higher affinities (Rosi corresponds to 
the reference compound rosiglitazone); B) Dose-response curve on PPARγ from rosiglitazone and 
sapogenin 19. 
 
 
Compound IC50 (µM) 
3 7.8 ± 0.3 
6 3.5 ± 0.1 
7 12.3 ± 0.2 
8 20.2 ± 1.8 
17 > 100 
18 4.1 ± 0.4 
19 > 100 
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PPARγ -LBD with a Kd not far from that obtained by SPR techniques (6.5 vs 54.8 µ M, respectively). Moreover, 
the comparison of the thermodynamic parameters between the two compounds showed that although the two 
compounds have similar Kd (6.5 and 9.4 µ M for 19 and 13-(S)-HODE, respectively), the binding of 13-(S)-HODE, 
whose higher flexibility allows better interactions with the protein, shows a more favorable enthalpic contribution 
(∆ H = − 2.21 versus − 1.55 kcal/mol, respectively), instead the binding of 19 is associated to a more favorable 
entropic term (− T∆ S = − 5.46 versus − 4.56 kcal/mol, respectively), also due to the minor loss of translational 
and rotational degrees of freedom of this more rigid ligand upon binding. Anyway, both binding interactions 
seem to be entropy-driven and more hydrophobic in character.
Discussion
A selected series of previously purified saponins and sapogenins was screened by SPR techniques to test their 
affinity to PPARγ in order to select the most promising compounds for the activity test and for X-ray analysis. 
All the tested compounds had the same pentacyclic triterpene structure with differences in number and position 
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Figure 4. Binding of Sapogenin 19 in the LBD of PPARγ with 2Fo-Fc electron density map calculated 
around the ligand. 
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4.2.3 Crystal structure of the PPARγ-LBD/caulophyllogenin 
complex 
 In order to provide an explanation at molecular level for the different 
behavior of echinocystic acid (18) and caulopyllogenin (19) as antagonist and 
partial agonist, respectively, crystals (0.2 x 0.2 x 0.2 mm) of apo-PPARγ-
LBD were obtained by vapour diffusion using the sitting drop method and 
then soaked for eight days in a storage solution containing the ligand (0.25 
mM). X-ray data collection for the PPARγ complexes with the two 
sapogenins was performed at ESRF of Grenoble (France). Unfortunately, for 
the PPARγ-LBD/echinocystic acid complex the electron density in the region 
of the ligand could not be clearly interpretated, so that only the structure of 
the PPARγ-LBD/caulophyllogenin complex was solved and deposited in the 
PDB with the code 5F9B. The summary of the crystallographic analysis is 
shown in Table 6. 
 The final omit map in Figure 36 showed clear electron density in the 
LBD of PPARγ where one molecule of caulophyllogenin (19) can be easely 
fitted. The ligand was accommodated between the helix 3 and the β-sheet, 
where its carboxylic oxygens formed a hydrogen bond (2.1 Å) with the NH 
group of S342, belonging to the β-sheet, and the CO of L340 (3.3 Å), 
respectively. The 16α-hydroxy group is H-bound to the CO of G284 on helix 
3 (2.7 Å). The 3β-hydroxy group made a H-bond with the hydroxyl group of 
the Y327 side-chain (2.9 Å). Moreover, there were extensive van der Waals 
interactions between the sulphur atom of C285, on the helix 3, and the carbon 
atoms of the rings C and E of the ligand. The ring E was also engaged in van 
der Waals interactions with the aromatic ring of F363, on helix 7. 
Hypothetically, in this orientation of the ligand it could be very easy to 
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accommodate glycoside moietes linked to the carbon atom 3 that protrude 
towards the helix 12, in the region occupied by full agonists. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
PPARγ-LBD/caulophyllogenin 
Data collection  
space group C2 
cell dimension a, b, c [Å] 93.21, 61.66, 118.9 
monoclinica angle β [deg] 102.8 
wavelenght [Å] 0.8726 
resolution range [Å]        50.00 - 2.25 
last shell [Å] 2.30 - 2.25 
Rmerge [%] 6.0 (34.9) a 
unique reflections 31203 (2012) a 
mean (I)/σ(I) 9.2 (2.8)  a 
completeness 99.3 (99.5)  a 
multiplicity 3.6 (3.4)  a 
Refinement  
Rwork [%] 23.2 
Rfree [%] 28.1 
Bond lenghts r.m.s.d. [Å] 0.010 
Bond angles r.m.s.d. [deg] 1.389 
Table 6. Summary of crystallographic analysis for the PPARγ-LBD/caulophyllogenin 
complex; a  The values in parenthesis refer to the outer shell. 
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 As demonstrated by the superposition of the crystal structures, the 
position of caulophyllogenin (19) in the LBD of PPARγ was very similar to 
that of the partial agonist (R) enantiomer of LT175 (PDB ID: 3D6D) [52] 
(Figure 37A) and also to that of the fatty acid 13-(S)-HODE (PDB ID: 2VST) 
[157], a natural agonist of PPARγ (Figure 37B). 
 
 
 
 
 
 
 
 
 
 
Figure 36. Binding of caulophyllogenin in the LBD of PPARγ with 2Fo-Fc electron density map 
calculated around the ligand. 	  	  
     
 
 
 
 
 
 
Figure 37. Superposition of (A) SAP19 (green) and LT175R (cyan) (PDB ID: 3D6D) and (B) SAP19 
(green) and 13-(S)-HODE (yellow) (PDB ID: 2VST), in the LBD of PPARγ.  
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 4.2.4 Isothermal titration calorimetry (ITC) assay: 
comparison between caulophyllogenin and the fatty acid 13-
(S)-HODE 
 To further confirm the interaction of caulophyllogenin 19 with 
PPARγ-LBD, ITC experiments were performed comparing the 
thermodynamic parameters (ΔH, ΔS and Kd) of this rigid sapogenin with 
those of the more flexible fatty acid 13-(S)-HODE. This technique is one of 
the most powerful method for characterizing protein-ligand interactions, 
which are observed directly from the change in intrinsic heat (binding 
entalphy) of the reaction. The results (Figure 38) indicated that 
caulophyllogenin (19) binds to the PPARγ-LBD with a Kd not far from that 
calculated by SPR techniques (6.5 vs 54.8 µM, respectively). Moreover, the 
comparison of the thermodynamc parameters between the two compounds 
showed that altough they have similar Kd values [6.5 and 9.4 µM for 
caulophyllogenin (19) and 13-(S)-HODE, respectively], the binding of 13-
(S)-HODE, whose higher flexibility allows better interactions with the 
protein, shows a more favorable enthalpic contribution (ΔH = -2.21 vs -1.55 
kcal/mol, respectively), instead the binding of caulophyllogenin (19) is 
associated to a more favorable entropic term (-TΔS = -5.46 vs -4.56 kcal/mol, 
respectively), also due to the minor loss of translational and rotational 
degrees of freedom of this more rigid ligand upon binding. In any case, both 
binding interactions seem to be entropy-driven and more hydrophobic in 
character. 
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Figure 38. Titration of (A) caulophyllogenin (19) (500 µM) and (B) 13-(S)-HODE 
(400 µM) to PPARγ- LBD (50 µM). The upper panel of each figure shows the raw 
data of the ITC experiment. The lower panel shows the corresponding binding 
isotherm fitted according to the “one binding site” model. 
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4.3  The metabolically active form of Metaglidasen 
 Because of the mechanism-based side-effects associated with the use 
of PPARγ full agonists already developed and marketed, such as 
rosiglitazone and pioglitazone, emphasis has shifted in the recent years to the 
development of partial agonists or selective PPARγ modulators 
(SPPARγMs). This approach proposes that diverse PPARγ ligands, 
depending on their structure, would bind in a distinct manner to PPARs, 
inducing various levels of activation and distinct conformational changes of 
the receptors, leading to differential interactions with co-activators and co-
repressors. This may enable uncoupling of the benefits of PPAR activation 
from the adverse effects associated with full agonism. According to this 
concept, a number of these modulators have already demonstrated 
desiderable pharmacological profiles in various rodent models with 
significantly decreased side effects relative to those generally observed with 
existing full agonists [31, 104, 158, 159]. One key representative is 
metaglidasen, a selective PPARγ partial agonist that structurally, 
mechanistically and preclinically differs from the glitazones [160]. 
On the Metabolically Active Form of Metaglidasen:
Improved Synthesis and Investigation of Its Peculiar
Activity on Peroxisome Proliferator-Activated Receptors
and Skeletal Muscles
Antonio Laghezza,[a] Roberta Montanari,[b] Antonio Lavecchia,[c] Luca Piemontese,[a]
Giorgio Pochetti,[b] Vito Iacobazzi,[d, e] Vittoria Infantino,[d, f] Davide Capelli,[b]
Michela De Bellis,[a] Antonella Liantonio,[a] Sabata Pierno,[a] Paolo Tortorella,[a]
Diana Conte Camerino,[a] and Fulvio Loiodice*[a]
Introduction
Peroxisome proliferator-activated receptors (PPARs) are ligand-
dependent transcription factors that belong to the nuclear re-
ceptor superfamily. They control the expression of genes in-
volved in fatty acid and glucose metabolism and function as
cellular lipid sensors that activate transcription in response to
the binding of cognate ligands, generally fatty acids and their
eicosanoid metabolites.[1–3] As ligand-dependent receptors,
PPARs form heterodimers with the retinoid X receptor (RXR)
and adopt an active conformation in the presence of a ligand.
Additional co-regulator proteins are recruited to create a com-
plex that binds to peroxisome proliferator response elements
(PPRE) in target genes, thus regulating thei expression.[4–6]
There are three PPAR subtypes, commonly designated as
PPARa, PPARg, and PPARd (b) expressed in different tissues.[7]
Agonists of the g subtype have been extensively studied for
their role in regulating glucose metabolism and insulin sensi-
tivity.[8] Full agonists of PPARg such as rosiglitazone and piogli-
tazone have been developed and marketed for the treatment
of type 2 diabetes.[9] However, mechanism-based side effects
including weight gain, edema, congestive heart failure, and
the recently reported increased risk of bone fracture following
treatment with rosiglitazone or pioglitazone are major unde-
sired effects associated with the use of PPARg full agonists.[10,11]
As a result of th clinical observations m ntione above,
emphasis has shifted to the development of partial agonists or
selective PPARg modulators (SPPARgMs). The SPPARM ap-
proach has recently attracted considerable attention because it
proposes that diverse PPAR ligands, depending on their struc-
tures, would bind in a distinct manner to PPARs, inducing vari-
ous levels of activation and distinct conformational changes of
the receptor, leading to diff rential in eractio s with co-activa-
Metaglidasen is a fibrate-like drug reported as a selective mod-
ulator of peroxisome proliferator-activated receptor g (PPARg),
able to lower plas a glucose levels in the absence of the side
effects typically observed with thiazolidinedione antidiabetic
agents in current use. Herein we report an improved synthesis
of metaglidasen’s metabolically active form halofenic acid (R)-2
and that of its enantiomer (S)-2. The activity of the two stereo-
isomers was carefully examined on PPARa and PPARg sub-
types. As expected, both showed partial agonist activity
toward PPARg ; the investigation of PPARa activity, however,
led to unexpected results. In particular, (S)-2 was found to act
as a partial agonist, whereas (R)-2 behaved as an antagonist. X-
ray crystallographic studies with PPARg were carried out to
gain ore insight on the molecular-level interactions and to
propose a binding mode. Given the adverse effects provoked
by fibrate drugs on skeletal muscle function, we also investi-
gated the capacity of (R)-2 and (S)-2 to block conductance of
the skeletal muscle membrane chloride channel. The results
showed a more beneficial profile for (R)-2, the activity of which
on skeletal muscle function, however, should not be over-
looked in the ongoing clinical trials studying its long-term ef-
fects.
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 Metaglidasen is the (R) enantiomer of halofenate (compound 1; 
Figure 39) and both of them are prodrugs esters that are rapidly and 
completely modified in vivo by non specific esterases to give the 
corresponding free acid form (compound 2; Figure 39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Metaglidasen showed promising therapeutic potential for the 
treatment of type 2 diabetes and hyperglycemia, as demonstrated by some 
recent patents [161, 162]. Metaglidasen and (S)-halofenate also showhed the 
same activity both in vitro and in vivo, suggesting a lack of stereoselectivity 
for PPARγ [158, 160, 163]. The reason of the clinical development of (R)-1 
in place of the most accessible (S)-halofenate seems to be its decreased 
inhibitory activity toward cytochrome P450 2C9 (CYP2C9) relative to the 
corresponding dextro isomer (S)-1 [164].  
 
4.3.1 PPAR activity 
 Two stereoisomers of halofenic acid were evaluated for their agonist 
activity on the human PPARγ-LBD and PPARα-LBD subtypes. To this 
tors and co-repressors. Therefore, structurally diverse modula-
tors or partial agonists are likely to elicit different pharmaco-
logical and toxicological effects depending on the context of
the tissue, i.e. , abundance of cofactor proteins and target
gene. This may enable uncoupling of the benefits of PPAR acti-
vation from the adverse effects associated with full agonism. In
agreement with the SPPARgM concept, a number of these
modulators have already demonstrated desirable pharmaco-
logical profiles in various rodent models with significantly de-
creased side effects relative to those generally observed with
existing full agonists.[12–24] One key representative is metaglida-
sen, a selective PPARg partial agonist that structurally, mecha-
nistically, and preclinically differs from the glitazones.[25] Meta-
glidasen is the R enantiomer of halofenate (1), a drug that was
tested clinically i the 1970s as a hypolipidemic and hypourice-
mic agent.[26,27] Both halofenate and metaglidasen are prodrug
esters that are rapidly and completely modified in vivo by non-
specific serum esterases to give the corresponding free acid
form 2 (Figure 1).
Phase 2a clinical trial d ta indicat that m taglidasen signifi-
cantly lowers plasma glucose levels in the absence of side ef-
fects such as weight gain and edema, which are observed with
pharmacological agents in current use. During this develop-
ment program, researchers at Metabolex discovered that meta-
glidasen is an effective uricosuric agent with unique proper-
ties; they repurposed the drug to treat gout with excellent
safety and tolerability. Nevertheless, metaglidasen is still inves-
tigated as a useful agent for the treatment of type 2 diabetes
and hyperglycemia as demonstrated by some recent pat-
ents.[28, 29] Int stingly, in precl nical rodent mo els, metagl da-
sen also displays pronounced triglyceride lowering, whic is
often considered a hallmark of PPARa activation. However, in
vivo and in vitro studies conducted with (R)-1 and its metabol-
ically active form (R)-2, respectively, indicate that this drug has
no PPARa activity, suggesting that its in vivo lipid-lowering
ability is therefore mediated by an alternative mechanism that
has yet to be determined.[30]
Metaglidasen and halofenate show the same activity both in
vitro and in vivo, suggesting a lack of stereoselectivity for
PPARg.[21,25] The mainspring for the clinical development of (R)-
1 in place of the more easily accessible halofenate seems to be
its decreased inhibitory activity toward cytochrome P450 2C9
(CYP2C9) relative to the corresponding dextro isomer (S)-1.[31]
Given the promising therapeutic potential of metaglidasen,
herein we describe a more convenient synthesis to obtain the
active metabolite of this drug; moreover, we assign with cer-
tainty its absolute configuration, which, in a 2007 patent,[32]
was attributed in a somewhat unclear manner. The transcrip-
tional activity of the free acid form (R)-2 was carefully exam-
ined with PPARa and PPARg ; the same biological evaluation
was also performed on its enantiomer (S)-2, never investigated
before. As expected, both stereoisomers showed partial ago-
nist activity toward PPARg ; however, the investigation of
PPARa activity led to unexpected results. In particular, (S)-2
acted as a partial agonist, whereas its enantiomer behaved as
an antagonist. These results were confirmed by the different
effects on the PPARa-mediated gene expression of mitochon-
drial carnitine palmitoyltransferase 1 (CPT1), which is a molecu-
lar component of the carnitine shuttle system essential for the
mitochondrial oxidation of fatty acids. X-ray crystallography on
the PPARg subtype was performed for both stereoisomers to
gain greater insight into the interactions at a molecular level
and to propose a binding mode that explains the lack of ste-
reoselectivity at this receptor. Finally, because skeletal muscle
is a target for PPAR agonists, the effects of both stereoisomers
on the function of this tissue were evaluated by measuring the
resting chloride conductance (gCl) sustained by the voltage-
gated chloride channel ClC-1. Previous studies have shown
that a decrease in gCl function is one of the mechanisms of
action responsible for myopathies, the most significant of the
complications of lipid-lowering treatment with statins and fi-
brates.[33–36]
Results and Discussion
Chemistry
As described in a 2007 patent, the synthesis of racemic halo-
fenic acid 2, the active metabolite of halofenate, is carried out
in five steps.[37] The corresponding levo isomer, the free acid
form of metaglidasen, is obtained either by the same proce-
dure using a chiral auxiliary[32] or by resolution of the race-
mate.[37] The authors assigned the R configuration to this
isomer, even though the procedure used for this attribution re-
mains unclear. In an attempt to find a rapid and mild method
to prepare (!)-halofenic acid, we applied a modified form of
the procedure reported by Job, Buchwald, and co-workers,[38,39]
which allowed us to obtain the target compound in a single
step as shown in Scheme 1.
Racemic 4-chloromandelic acid was condensed with 1-iodo-
3-trifluoromethylbenzene in the presence of a catalyst system
consisting of copper(I) iodide and cesium carbonate to afford
(!)-halofenic acid in 40% yield. The yield of this reaction is not
remarkable, yet is fairly good considering that this procedure is
Figure 1. Structure of halofenate and its metabolically active form, halofenic
acid.
Scheme 1. Preparation of (!)-halofenic acid. Reagents and conditions :
a) Cs2CO3, CuI, BuCN, 110 8C, argon, 72 h, 40% yield.
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Figure 39. Structure of halofenate and its metabolically active form, halofenic acid. 
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purpose, transactivation assays were performed by Antonio Laghezza and the 
results were compared to corresponding data for rosiglitazone and Wy14,643 
used as reference compounds in the PPARγ and PPARα assays, respectively 
(Figure 40). The maximum induction obtained with the reference agonist was 
defined as 100%. As concerns PPARγ, the results showed this receptors to 
lack any stereoselectivity between (R)- and (S)-halofenic acid, since both 
isomers behaved as partial agonists with similar potency (EC50 : 4.8 and 7.6 
µM, respectively) and efficacy (Emax : ~ 10%) confirming previously reported 
data [160] (Figure 40A). 
 
 
 
 
 
 
 
 
Figure 40. Transactivation assay data for A) human PPARγ and B) human PPARα. Gal4–hPPARγ or 
Gal4–hPPARα ligand binding domain expression plasmid was co-transfected with a luciferase reporter 
plasmid in HepG2 cells. The insert in panel A) is a magnification of the curves that relate only to 
compounds (R)-2 and (S)-2. Data are normalized with respect to control, and values are the mean ︎± 
SEM of n=3 experiments performed in duplicate. 
 
 In addition, isothermal titration calorimetry (ITC) was used to 
calculate the thermodynamic parameters relating to the formation of the 
complexes of both stereoisomers with the PPARγ ligand binding domain 
(LBD). The results obtained for the enantiomers (R) and (S) were 1.36 x 105 
M-1 and 1.72 x 105 M-1, respectively, demonstrating that these ligands bind to 
PPARγ-LBD with similar affinity in according with their functional activity. 
much less expensive and faster than that reported.[37] The only
drawback of this reaction concerns the pH in its workup;
indeed, pH values only slightly outside the range of 5–6 lead
to drastic decreases in yield. The resolution of (!)-2 was car-
ried out by fractional crystallization from ethanol/water of the
diastereomeric salts obtained with (S)- or (R)-1-(2-naphthyl)-
ethylamine.[37] As an alternative to resolution, we tried to pre-
pare (+)-2 and (")-2 by the same procedure used for the race-
mate by starting from optically active 4-chloromandelic acid.
Unfortunately, the reaction occurred with partial racemization;
however, this synthetic method was useful for unambiguously
assigning the absolute configuration to both isomers, given
that the stereogenic center of optically active 4-chloromandelic
acid was not involved in the reaction. So, starting from (R)-4-
chloromandelic acid,[40] we obtained the partially enriched levo
isomer of halofenic acid; this allowed us to confirm that the
absolute configurations of (")-2 and (+)-2 are R and S, respec-
tively.
PPAR activity
(R)-2 and (S)-2 were evaluated for their agonist activity on the
human PPARa (hPPARa) and PPARg (hPPARg) subtypes. For
this purpose, GAL4–PPAR chimeric receptors were expressed in
transiently transfected HepG2 cells according to a previously
reported procedure.[41] The results obtained were compared
with corresponding data for Wy14,643 and rosiglitazone used
as reference compounds in the PPARa and PPARg transactiva-
tion assays, respectively. The maximum induction obtained
with the reference agonist was defined as 100%.
As regards PPARg, the transactivation assay showed this re-
ceptor to lack any stereoselectivity between (R)-2 and (S)-2 ; in
fact, both isomers acted as partial agonists with similar poten-
cy (EC50: 4.8 and 7.6 mm, respectively) and efficacy (Emax : ~10%)
confirming previously reported data[25] (Figure 2A).
We also decided to determine the thermodynamic parame-
ters relating to formation of the complexes of both stereoiso-
mers with the PPARg ligand binding domain (LBD) by isother-
mal titration calorimetry (ITC). ITC is a very useful alternative to
conventional PPAR binding assays, which need specific radioli-
gands for labeling of receptors. This technique, which we have
successfully applied to some PPAR agonists,[42–45] measures the
heat absorbed or released by titrating the protein with
a ligand at constant temperature, allowing one to obtain the
affinity constant. The results obtained for (R)-2 and (S)-2 were
1.36!105m"1 and 1.72!105m"1, respectively, showing that
these ligands bind to PPARg LBD with similar affinity in accord-
ance with their functional activity. Figure 1 of the Supporting
Information shows the calorimetric data (raw and integration
data) obtained in the titration of PPARg with both isomers.
Afterward we evaluated the activity of both stereoisomers
toward PPARa. Previous experiments reported no activity on
this receptor subtype from racemic halofenic acid and its levo
isomer, so it was clear to assume that the dextro isomer was in-
effective as well.[21,30] In spite of this, however, we decided to
investigate the effects on PPARa of (R)-2 and (S)-2 because of
their great similarity with some chiral a-aryloxy-a-arylacetic
acids previously claimed as highly stereoselective PPARa ago-
nists.[46] The investigation of PPARa activity led to unexpected
results for the two stereoisomers. In fact, (S)-2 acted as a partial
agonist (EC50: 11 mm, Emax : 31%), whereas its enantiomer be-
haved as an antagonist (Figure 2B). The antagonist activity of
(R)-2 was confirmed by conducting a competitive binding
assay in which PPARa activity at a fixed concentration of the
reference agonist Wy14,643 was measured in cells treated
with increasing concentrations of (R)-2. As shown in Figure 3,
(R)-2 displayed a dose-dependent inhibition of Wy14,643-
mediated PPARa activity, with a half-maximal inhibitory con-
centration of ~21 mm. These data suggest that (R)-2 is able to
interact with PPARa in such a way to displace Wy14,643 and
inhibit its activity in a cellular context. It is reasonable to
assume that (R)-2 is able to similarly displace (S)-2, thus ex-
plaining why racemic halofenic acid does not display PPARa
activity.
To further corroborate the differing results between (R)-2
and (S)-2 on PPARa activity, we investigated the effects of both
stereoisomers on mitochondrial carnitine/acylcarnitine carrier
(CAC) and carnitine palmitoyltransferase 1 (CPT1) PPARa-medi-
ated gene expression. These two molecular components of the
Figure 2. Gal4 reporter assay data for A) human PPARg and B) human
PPARa. A Gal4–hPPARg or Gal4–hPPARa ligand binding domain expression
plasmid was co-transfected with a luciferase reporter plasmid in HepG2
cells. The insert in panel A) is a magnification of the curves that relate only
to compounds (R)-2 and (S)-2. Data are normalized with respect to control,
and values are the mean!SEM of n=3 experiments performed in duplicate.
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much less expensive and faster than that reported.[37] The only
drawback of this reaction concerns the pH in its workup;
indeed, pH values only slightly outside the range of 5–6 lead
to drastic decreases in yield. The resolution of (!)-2 was car-
ried out by fractional crystallization from ethanol/water of the
diastereomeric salts obtained with (S)- or (R)-1-(2-naphthyl)-
ethylamine.[37] As an alternative to resolution, we tried to pre-
pare (+)-2 and (")-2 by the same procedure used for the race-
mate by starting from optically active 4-chloromandelic acid.
Unfortunately, the reaction occurred with partial racemization;
however, this synthetic method was useful for unambiguously
assigning the absolute configuration to both isom rs, given
that the stereogenic center of optically active 4-chloromandelic
acid was not involved in the reaction. So, starting from (R)-4-
chloromandelic acid,[40] we obtained the partially enriched levo
isomer of halofenic acid; this allowed us to confirm that the
absolute configurations of (")-2 and (+)-2 are R and S, respec-
tively.
PPAR activity
(R)-2 and (S)-2 were evaluated for their agonist activity on the
human PPARa (hPPARa) and PPARg (hPPARg) subtypes. For
this purpose, GAL4–PPAR chimeric receptors were expressed in
transiently transfected HepG2 cells according to a previously
reported procedure.[41] The results obtained were compared
with corresponding data for Wy14,643 and rosiglitazone used
as reference compounds in the PPARa and PPARg transactiva-
tion assays, resp ctively. The maximum induction obtained
with the reference agonist was defined as 100%.
As regards PPARg, the transactivation assay showed this re-
ceptor to lack any stereoselectivity between (R)-2 and (S)-2 ; in
fact, both isomers acted as partial agonists with similar poten-
cy (EC50: 4.8 and 7.6 mm, respectively) and efficacy (Emax : ~10%)
confirming previously reported data[25] (Figure 2A).
We also decided to determine the thermodynamic parame-
ters relating to formation of the complexes of both stereoiso-
mers with the PPARg ligand binding domain (LBD) by isother-
mal titration calorimetry (ITC). ITC is a very useful alternative to
conventional PPAR binding assays, which need specific radioli-
gands for labeling of receptors. This technique, which we have
successfully applied to some PPAR agonists,[42–45] measures the
heat absorbed or released by titrating the protein with
a ligand at constant temperature, allowing one to obtain the
affi ity constant. The results obtained for (R)-2 and (S)-2 were
1.36!105m"1 and 1.72!105m"1, respectively, showing that
these ligands bind to PPARg LBD with similar affinity in accord-
ance with their functional activity. Figure 1 of the Supporting
Information shows the calorimetric data (raw and integration
data) obtained in the titra ion f PPARg with both isomers.
Afterward we evaluated he activity of both stereoisomers
toward PPARa. Previous experi ents report d no activity on
this receptor subtype from racemic halofenic acid and its levo
isomer, so it was clear to assume that the dextro isomer was in-
effective a well.[21,30] In spite of his, however, we decided to
investigate the ffects on PPARa of (R)-2 and (S)-2 becaus of
their grea s milarity with some chiral a-aryloxy-a-arylacetic
acids previously claimed as highly stereoselective PPARa ago-
nists.[46] The investigation of PPARa activity led to unexpected
results for the two stereoisomers. In fact, (S)-2 acted as a partial
agonist (EC50: 11 mm, Emax : 31%), whereas its enantiomer be-
haved as an antagonist (Figure 2B). The antagonist activity of
(R)-2 was confirmed by conducting a competitive binding
assay in which PPARa activity at a fixed concentration of the
reference agonist Wy14,643 was measured in cells treated
with increasing concentrations of (R)-2. As shown in Figure 3,
(R)-2 displayed a dose-dependent inhibition of Wy14,643-
mediated PPARa activity, with a half-maximal inhibitory con-
centration of ~21 mm. These data suggest that (R)-2 is able to
interact with PPARa in such a way to displace Wy14,643 and
inhibit its activity in a cellular context. It is reasonable to
assume that (R)-2 is able to similarly displace (S)-2, thus ex-
pl ining why racemic halofenic acid does not display PPARa
activity.
To further corroborate the differing results between (R)-2
a d (S)-2 on PPARa activity, we investigated the effects of both
stereoisomers on mitochondrial carnitine/acylcarnitine carrier
(CAC) and carnitine palmitoyltransferase 1 (CPT1) PPARa-medi-
ated gene expression. These two molecular components of the
Figure 2. Gal4 reporter assay data for A) human PPARg and B) human
PPARa. A Gal4–hPPARg or Gal4–hPPARa ligand binding domain expression
plasmid was co-transfected with a luciferase reporter plasmid in HepG2
cells. The insert in panel A) is a magnification of the curves that relate only
to compounds (R)-2 and (S)-2. Data are normalized with respect to control,
and values are the mean!SEM of n=3 experiments performed in duplicate.
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Calorimetric data (raw and integration data) for both isomers are shown in 
Figure 41A. 
 Although previous experiments reported no activity on PPARα from 
racemic halofenic acid [152, 158, 161, 162, 163], the effects on PPARα-LBD 
of both (R)- and (S)-halofenic acid were investigated because of their great 
similarity with some chiral α-aryloxy-α-aryacetic acids previously claimed as 
highly stereoselective PPARα agonists [165]. Surprisingly, (S)-halofenic acid 
acted as a partial agonist (EC50: 11µM, Emax: 31%), whereas its enantiomer 
behaved as antagonist (Figure 41B). The antagonist activity was confirmed 
by a competitive binding assay, in which (R)-halofenic acid displayed a dose-
dependent inhibition of Wy14,643-mediated PPARα activity, with a half-
maximal inhibitory concentration of ~ 21 µM (Figure 42). These data suggest 
that (R)-halofenic acid is able to interact with PPARα-LBD in such a way to 
displace the agonist Wy14,643 from the ligand binding domain and inhibit its 
activity in a cellular context. It is reasonable to assume that this compound is 
able to similarly displace its enantiomer, thus explaining why racemic 
halofenic acid does not show PPARα activity. Due to the absence of crystal 
structures of PPARα-LBD complexed with carboxylic antagonists to be used 
as a starting point for docking, crystallization of the complexes with both (R)-
and (S)-halofenic acid will be crucial to confirm the obtained results. These 
study are still in progress for PPARα-LBD, whereas they have already been 
achieved for PPARγ-LBD with the aim to provide a molecular explanation 
for the lack of stereoselectivity of this receptors towards the two enantiomers. 
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Figure 1. Binding of A) (R)-2 and B) (S)-2 to PPARγ-LBD. The upper panel shows the raw data, 
the lower panel shows the corresponding binding isotherm fitted according to the “one binding site” 
model.            
 
Figure 41. Binding of A) (R)-halofenic acid and B) (S)-halofenic acid to PPARγ-LBD. The upper 
panel shows the raw data, the lower panel shows the corresponding binding isotherm fitted according 
to the “one binding site” model. 
carnitine shuttle system are essential for the mitochondrial oxi-
dation of fatty acids, because they catalyze the entry of fatty
acid acyl groups into the mitochondrial matrix, where the en-
zymes of fatty acid b-oxidation are located. Recent studies
demonstrated that transcription of the CAC gene is enhanced
by statins and fibrates, providing a novel contribution to the
understanding of their hypolipidemic action.[42,47,48] Therefore,
we decided to test (S)-2 and (R)-2 with the aim to determine if
these fibrate-like drugs are able to similarly up-regulate mito-
chondrial CAC and CPT1 gene expression. The effects of in
vitro application of these compounds were investigated on
HepG2 cells, which were incubated for 48 h with (S)-2 and (R)-
2 at 50 mm. The PPARa agonist Wy14,643 (50 mm) was used as
a reference compound. After incubation, total mRNA was ex-
tracted and used to determine CAC and CPT1 transcript levels.
As shown in Figures 4A and 5A, (R)-2 did not induce any in-
crease of CAC and CPT1 mRNA, as expected; in contrast, (S)-2
caused a ~1.5-fold increase in CPT1 mRNA, whereas no effect
was detected for CAC mRNA. Consistently, western blotting
analysis showed no effects on CAC and CPT1 protein levels
from (R)-2 (Figure 4B,C and 5B,C) whereas it confirmed a sig-
nificant, albeit weak, increase in CPT1 protein level (Fig-
ure 5B,C) in cells treated with (S)-2. The observed effects of
(S)-2 on CPT1 gene expression level, however, turned out to be
lower than that obtained with Wy14,643 at the same concen-
tration.
Given that no crystal structures of PPARa complexed with
carboxylic antagonists are available as a starting point for
docking, X-ray crystal studies of the complexes PPARa–(S)-2
and PPARa–(R)-2 will be crucial to confirm the obtained results.
These studies are still in progress for PPARa, whereas they
have already been achieved for PPARg with the aim to provide
a molecular explanation for the lack of stereoselectivity of this
receptor toward (R)-2 and (S)-2.
Binding of (R)-2 in the PPARg LBD
The final omit map (Figure 6A) showed clear electron density
where one molecule of (R)-2 can be easily fitted. This isomer
was accommodated between helix 3 and the b-sheet, where
one of its carboxylic oxygen atoms was found to form a hydro-
gen bond (2.7 !) with the NH group of S342 belonging to the
b-sheet (Figure 7A). This interaction has often been observed
in other PPARg complexes with partial agonists. Upon binding,
the ligand forced the side chains of R288 and E291 to assume
different conformations. In this new orientation, the charged
guanidinium group of R288 interacts with the electronegative
trifluoromethyl group of the ligand (3.5 !) and made van der
Waals (vdW) interactions with the residue A292 belonging to
helix 3. The chlorine atom, at the opposite extremity of the
ligand, is directed toward a hydrophobic core of the LBD
formed by the side chains of I281, L353, F363, and M364 (Fig-
ure S2, Supporting Information). The shortest distances of the
chlorine atom were with one methyl group of I281 (3.7 !) and
a carbon atom of the aromatic ring of F363 (3.7 !). A LigPlot
analysis[49] of the vdW interactions of (R)-2 is shown in Fig-
ure S3A in the Supporting Information.
Figure 3. PPARa antagonist effect of (R)-2. PPARa activity was measured in
Gal4–hPPARa LBD transfected cells treated with Wy14,643 at 10 mm and in-
creasing concentrations of (R)-2. Data are normalized with respect to control,
and values are the mean!SEM of n=2 experiments performed in triplicate.
Figure 4. A) Total RNA extracted from HepG2 cells, treated with or without
50 mm (R)-2, 50 mm (S)-2, or 50 mm Wy14,643 for 24 h, was used to quantify
CAC mRNA by real-time PCR; data are the mean!SD of three independent
duplicate experiments. B) CAC and b-actin of HepG2 cells, treated for 48 h as
described for panel A), were immunolabeled with specific antibodies. C) The
intensities of immunolabeled protein bands depicted in panel B) were quan-
tified by densitometric scanning. Quantitation represents fold change of
CAC protein signals relative to control cells ; data are the mean!SD from
three independent experiments (*p<0.05; one-way ANOVA, Bonferroni test).
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Figure 42  PARα antagonist effect of (R)-2. PPARα activity was 
measured in Gal4–hPPARα-LBD transfected cells treated with Wy 14,643 
at 10 µm and incre sing concentrations of (R)-2. Data are normalized with 
respect to control, and values are the mean ± SEM of n=2 experiments 
performed in triplicate. 
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4.3.2 Crystal structure of (R)- and (S)-halofenic acid in the 
PPARγ-LBD 
 Crystals (0.3 x 0.2 x 0.2 mm) of apo-PPARγ-LBD were obtained by 
vapour diffusion using the sitting drop method and then soaked for two 
weeks in storage solutions containing the ligands (0.25 mM). X-ray data 
collection for the PPARγ-LBD in complex with the two enantiomers was 
performed at ESRF of Grenoble (France) and the solved structures have been 
deposited in the PDB with codes 4PVU and 4PWL for the enantiomers (R) 
and (S), respectively . Crystals of the PPARγ-LBD complexes belong to the 
C2 space group, with cell parameters shown in Table 7. 
 As regards (R)-halofenic acid, the final omit map (Figure 43) showed 
clear electron density where one molecule can be easely fitted. This isomer 
was accommodated between H3 and the β-sheet, where one of its carboxylic 
oxygen atoms was found to form a hydrogen bond (2.7 Å) with the NH group 
of S342 belonging to the β-sheet (Figure 44A). This interaction has often 
been observed in other PPARγ complexes with partial agonists. Upon 
binding, the ligand forced the side chains of R288 and E291 to assume 
different conformations. In this new orientation, the charged guanidinium 
group of R288 interacts with the electronegative trifluoromethyl group of the 
ligand (3.5 Å) and made van der Waals interactions with the residue A292 
belonging to helix 3. The chlorine atom, at the opposite extremity of the 
ligand, is directed toward a hydrophobic core of the LBD formed by the side 
chains of I281, L353, F363, and M364. The shortest distances of the chlorine 
atom were with one methyl group of I281 (3.7 Å) and a carbon atom of the 
aromatic ring of F363 (3.7 Å).  
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 PPARγ-LBD/(R) PPARγ-LBD/(S) 
Data collection   
space group C2 C2 
cell dimension a, b, c [Å] 93.4, 60.2, 119.1 93.1, 61.7, 118.7 
monoclinica angle β [deg] 103.4 102.3 
wavelenght [Å] 0.97623 0.97623 
resolution range [Å] 57.91 - 2.60 57.99 - 2.60 
last shell [Å] 2.72 - 2.60 2.72 - 2.60 
Rmerge [%] 4.3 (37.3) a 6.4 (48.9) a 
observation 59572 (6467) a 54799 (5959) a 
unique reflections 19580 (2296) a 19771 (2273) a 
mean (I)/σ(I) 11.8 (2.3) a 7.9 (1.8) a 
completeness 98.0 (95.2) a 96.7 (92.6) a 
multiplicity 3.0 (2.8) a 2.8 (2.6) a 
Refinement   
resolution range [Å] 57.9 - 2.60 58 - 2.60 
Rwork [%] 20.0 21.8 
Rfree [%] 25.1 30.8 
Bond lenghts r.m.s.d. [Å] 0.008 0.027 
Bond angles r.m.s.d. [deg] 1.321 1.594 
Table 7. Summary of crystallographic analysis for the PPARγ-LBD/(R)-halofenic acid and 
PPARγ-LBD/(S)-halofenic acid complexes. a The values in parentheses refer to the outer 
shell.  
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 Enantiomer (S)-halofenic acid also bound to PPARγ assuming the 
typical position of partial agonists, although more shifted toward the entrance 
of the LBD with respect to the (R) isomer. (S)-halofenic acid faced the β-
sheet and both its carboxylic oxygens were found to be engaged in two 
hydrogen bonds with the NH group of S342 and the side chain OH of S342, 
respectively (Figure 44B). The side chain of R288 maintained its typical 
position (t conformation), and its guanidinium group made two hydrogen 
bonds with one of the ligand carboxylic oxygen atoms and the NH group of 
E343, respectively. The ligand electronegative CF3 group interacted with the 
positively charged side chain of R288 through a water molecule also bridged 
with the CO of L340 (Figure 44B). One of the fluorine atoms also contacted 
the residue C285 at distances of ~ 3.0 Å. The (S) enantiomer formed more 
and stronger interactions with H3 and the β-sheet than (R), better stabilizing 
these regions of the LBD as shown by the Ligplot analysis [166] (Figure 45). 
Figure 43. 2FoFc omit map calculated around (R)-halofenic acid (green). 
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 The largest number of hydrogen bonds and vdW interactions 
realized by this ligand, in comparison with (R)-halofenic acid, was in 
accordance with the more favorable enthalpic contribution observed in the 
ITC experiment upon binding to PPARγ-LBD (-6.5 vs -3.8 kcalmol-1, 
respectively). The omit map around (S)-halofenic acid is shown in Figure 46. 
Superimposition of (R)- and (S)-halofenic acid in the PPARγ LBD (Figure 
ulatory proteins. These findings suggest that ligand-induced
decreases in the dynamic nature of helix 3, the b-sheet, and
the CDK5 site, may “freeze” this region into a conformation
less favorable to CDK5-mediated phosphorylation. According
to this hypothesis, it is likely that (R)-2 decreases the dynamics
of helix 3, b-sheet, and CDK5 site, explaining the consequent
decrease of PPARg phosphorylation at S273. This could be the
principal molecular mechanism responsible for its antidiabetic
activity and lack of undesirable side effects typical of classical
PPARg full agonists. A similar behavior could also be suggested
for (S)-2, which binds to the same region of PPARg LBD, al-
though slightly shifted with respect to (R)-2.
Effects of (R)-2 and (S)-2 on skeletal muscle chloride
conductance
Statins and PPAR agonists such as fibrates are widely used in
therapy to treat hyperlipidemia. However, clinical evidence has
shown drug-associated skeletal muscle disorders ranging from
myalgia to severe myopathy.[35] This type of myopathy has
been characterized biochemically and morphologically, and
there are a few mechanistic hypotheses.[35] Our previous stud-
ies allowed us to identify the target of the skeletal muscle
damage; in fact, both statins and fenofibrate are able to
reduce resting chloride conductance (gCl), sustained by the
voltage-gated chloride channel ClC-1, a parameter that con-
trols sarcolemma electrical stability and functional processes
such as excitation and contraction. A reduced gCl causes disor-
ders related to abnormal action potential firing.[36, 51] On this
basis, we decided to test (R)-2 and (S)-2 to assess the possibili-
ty that these fibrate-like drugs were able to interfere with the
chloride ion flux of skeletal muscle membrane, as previously
reported for similar compounds.[36,51,52]
The effects of in vitro application of these compounds were
evaluated on extensor digitorum longus (EDL) muscle in terms
of resting membrane ionic conductances and excitability pa-
rameters. As can be seen in Figure 9, both enantiomers signifi-
cantly decreased gCl in a concentration-dependent manner,
with (S)-2 more potent than (R)-2. In particular, the application
of (S)-2 produced a significant (p<0.001, Student’s t test) 32
and 43% block of gCl at 10 and 100 mm, respectively, relative
to the control value. (R)-2, instead, produced a lower, although
significant (p<0.01, Student’s t test), decrease in gCl by 11 and
30% at 10 and 100 mm, respectively. The resting potassium con-
ductance (gK) was slightly and not significantly increased from
366!61 to 435!35 mScm"2 when a 100 mm dose of the less
potent R enantiomer was applied to the muscle bath solution.
The effects of the two enantiomers were completely reversible,
Figure 7. Hydrogen bond network of A) (R)-2 (green) and B) (S)-2 (yellow) in complex with PPARg.
Figure 8. Superpositions of A) (R)-2 (green) and (S)-2 (yellow); B) (R)-2
(green) and 3 (cyan) ; C) (S)-2 (yellow) and 4 (magenta) into the LBD of
PPARg1. S245 of PPARg1 corresponds to S273 of PPARg2.
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Figure 44. Hydrogen bond network of A) (R)-halofenic acid (green) and B) (S)-halofenic acid (yellow) 
in complex with PPARγ-LBD 
  
 
Figure 3. The Ligplot diagrams illustrate the protein-ligand interactions for the complexes A) 
PPARγ/(R)-2 (PDB code 4pvu) and B) PPARγ/(S)-2 (PDB code 4pwl) 
Figure 45. The Ligplot diagrams illustrate the protein-ligand interactions for A) (R)-halofenic 
acid  and B) (S)-halofenic acid in complex with PPARγ-LBD 
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47A) shows that the two enantiomers, although both interacting with the NH 
group of S342 through their carboxylic oxygen atoms, occupy slightly 
different positions between H3 and the β-sheet, with the (S) enantiomer less 
inserted into the LBD cavity. The superimposition with other known PPARγ 
partial agonists showed that (R)-halofenic acid occupied the same position of 
MRL24 [167] (PDB ID: 2Q5P) and (S)-halofenic acid, that of the partial 
agonist FS214 [168] (PDB ID: 4E4Q) (Figures 47B and 47C). Both 
stereoisomers seem to be able to stabilize, even though in different ways, the 
same region of the receptor (H3 and β-sheet), thus explaining their similar 
affinity and activity toward PPARγ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  Figure 46. 2FoFc omit map calculated around (S)-halofenic acid (yellow). 
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 The binding mode of (R)-halofenic acid would also explain its ability 
to inhibit the Cdk5-mediated phosphorylation of PPARγ. Recently, indeed, 
Choi et al. reported this biochemical effect at the level of S273 of PPARγ2 
(corresponding to S245 of PPARγ1) for rosiglitazone and some PPARγ 
partial agonists including (R)-halofenic acid [71]. This study suggests that 
both thiazolidinediones (TZDs) and partial agonists with antidiabetic effects 
improve insulin sensitivity primarily by this mechanism. Inhibition of S273 
phosphorylation seems to be distinct from classical transcriptional activation, 
ulatory proteins. These findings suggest that ligand-induced
decreases in the dynamic nature of helix 3, the b-sheet, and
the CDK5 site, may “freeze” this region into a conformation
less favorable to CDK5-mediated phosphorylation. According
to this hypothesis, it is likely that (R)-2 decreases the dynamics
of h lix 3, b-sheet, and CDK5 site, explaining the consequent
decrease of PPARg phosphorylation at S273. This could be the
principal molecular mechanism responsible for its antidiabetic
activity and lack of undesirable side effects typical of classical
PPARg full agonists. A similar behavior could also be suggested
for (S)-2, which binds to the same region of PPARg LBD, al-
though slightly shifted with respect to (R)-2.
Effects of (R)-2 and (S)-2 on skeletal muscle chloride
conductance
Statins and PPAR agonists such as fibrates are widely used in
therapy to treat hyperlipidemia. However, clinical evidence has
shown drug-associated skeletal muscle disorders ranging from
myalgia to severe myopathy.[35] This type of myopathy has
been characterized biochemically and morphologically, and
there are a few mechanistic hypotheses.[35] Our previous stud-
ies allowed us to identify the target of the skeletal muscle
damage; in fact, both statins and fenofibrate are able to
reduce resting chloride conductance (gCl), sustained by the
voltage-gated chloride channel ClC-1, a parameter that con-
trols sarcolemma electrical stability and functional processes
such as excitation and contraction. A reduced gCl causes disor-
ders related to abnormal action potential firing.[36, 51] On this
basis, we decided to test (R)-2 and (S)-2 to assess the possibili-
ty that these fibrate-like drugs were able to interfere with the
chloride ion flux of skeletal muscle membrane, as previously
reported for similar compounds.[36,51,52]
The effects of in vitro application of these compounds were
evaluated on extensor digitorum longus (EDL) muscle in terms
of resting membrane ionic conductances and excitability pa-
rameters. As can be seen in Figure 9, both enantiomers signifi-
cantly decreased gCl in a concentration-dependent manner,
with (S)-2 more potent than (R)-2. In particular, the application
of (S)-2 produced a significant (p<0.001, Student’s t test) 32
and 43% block of gCl at 10 and 100 mm, respectively, relative
to the control value. (R)-2, instead, produced a lower, although
significant (p<0.01, Student’s t test), decrease in gCl by 11 and
30% at 10 and 100 mm, respectively. The resting potassium con-
ductance (gK) was slightly and not significantly increased from
366!61 to 435!35 mScm"2 when a 100 mm dose of the less
potent R enantiomer was applied to the muscle bath solution.
The effects of the two enantiomers were completely reversible,
Figure 7. Hydrogen bond network of A) (R)-2 (green) and B) (S)-2 (yellow) in complex with PPARg.
Figure 8. Superpositions of A) (R)-2 (green) and (S)-2 (yellow); B) (R)-2
(green) and 3 (cyan) ; C) (S)-2 (yellow) and 4 (magenta) into the LBD of
PPARg1. S245 of PPARg1 corresponds to S273 of PPARg2.
ChemMedChem 0000, 00, 0 – 0 www.chemmedchem.org ! 0000 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim6&
!! These are not the final page numbers!
Full Papers
Figure 47. Superpositions of A) (R)-halofenic acid (green) and (S)-halofenic acid (yellow); B) 
(R)-halofenic acid (green) and MRL24 (cyan); C) (S)-halofenic acid (yellow) and FS214 
(magenta) into the LBD of PPARγ1. S245 of PPARγ1 corresponds to S273 of PPARγ2. 
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which involves the stabilization of the highly dynamic activation of helix 12 
and appears to mediate at least some of the undesirable side effects of chronic 
PPARγ activation. In this study, using amide hydrogen/deuterium exchange 
kinetics, the authors showed that binding of the PPARγ partial agonist 
MRL24 significantly decreases flexibility of the loop region around S273 and 
that both rosiglitazone and MRL24 decrease the mobility of H3 and the 
adjacent β-sheet, which are sites for potential interaction with co-regulatory 
proteins. These findings suggest that ligand-induced decreases in the 
dynamic nature of H3, the β-sheet, and the Cdk5 site, may “freeze” this 
region into a conformation less favorable to Cdk5-mediated phosphorylation. 
According to this hypothesis, it is likely that (R)-halofenic acid decreases the 
dynamics of H3, β-sheet, and Cdk5 site, explaining the consequent decrease 
of PPARγ phosphorylation at S273. This could be the principal molecular 
mechanism responsible for its antidiabetic activity and lack of undesirable 
side effects typical of classical PPARγ full agonists. A similar behavior could 
also be suggested for (S)-halofenic acid, which binds to the same region of 
PPARγ-LBD, although slightly shifted with respect to the (R) enantiomer. In 
conclusion, it appears that a more careful investigation of the structural 
determinants of the metabolically active form of metaglidasen could allow 
the identification of new analogues with improved pharmacological 
properties, that is a dual PPARα/γ activity. In this perspective, particular 
attention must be paid to the stereochemistry, which, as widely reported for 
PPAR ligands, plays a key role in the biological activity of these compounds. 
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4.4 Transactivation deficiency of the PPARγ F360L 
mutant associated with familial partial lipodystrophy 
 There is evidence that some rare missense mutations in PPARγ have 
serious phenotypic effects, contributing to the risk of insulin resistance, 
dyslipidaemia, type 2 diabetes [169] and colon cancer [170, 171] in affected 
individuals. Some of this mutations can also be associated with familial 
partial lipodystrophy (FPLD) [172, 173], which is an autosomal dominant 
skin condition characterized by adipose-tissue repartitioning associated with 
multiple metabolic deseases such as severe insulin resistance, 
hypertriglyceridaemia and diabetes [174, 175]. In this study the effect of the 
F360L mutation on the structure and thermal stability of human PPARγ-LBD 
has been investigated, in order to gain more insight into the effects of such a 
mutation at a molecular level. To date, indeed, the structurally disruptive 
effect of this missense mutation is unknown. 
 
 
electronic reprint
Acta Crystallographica Section D
Biological
Crystallography
ISSN 1399-0047
Structural basis of the transactivation deficiency of the human
PPARγ F360L mutant associated with familial partial
lipodystrophy
Clorinda Lori, Alessandra Pasquo, Roberta Montanari, Davide Capelli,
Valerio Consalvi, Roberta Chiaraluce, Laura Cervoni, Fulvio Loiodice,
Antonio Laghezza, Massimiliano Aschi, Alessandra Giorgi and Giorgio
Pochetti
Acta Cryst. (2014). D70, 1965–1976
Copyright c⃝ International Union of Crystallography
Author(s) of this paper may load this reprint on their own web site or institutional repository provided that
this cover page is retained. Republication of this article or its storage in electronic databases other than as
specified above is not permitted ithout prior permission in writing from the IUCr.
For further information see http://journals.iucr.org/services/authorrights.html
Acta Crystallographica Section D: Biological Crystallography welcomes the submission of
papers covering any aspect of structural biology, with a particular emphasis on the struc-
tures of biological macromolecules and the methods used to determine them. Reports
on new protein structures are particularly encouraged, as are structure–function papers
that could include crystallographic binding studies, or structural analysis of mutants or
other modified forms of a known protein structure. The key criterion is that such papers
should present new insights into biology, chemistry or structure. Papers on crystallo-
graphic methods should be oriented towards biological crystallography, and may include
new approaches to any aspect of structure determination or analysis. Papers on the crys-
tallization of biological molecules will be accepted providing that these focus on new
methods or other features that are of general importance or applicability.
Crystallography Journals Online is available from journals.iucr.org
Acta Cryst. (2014). D70, 1965–1976 Lori et al. · Human PPARγ F360L mutant
	  	   108	  
4.4.1 Overall structure of PPARγ-LBD F360L and 
conformational changes induced by the mutation 
 Initially we unsuccessfully tried to crystallize the apo form of the 
mutant in the same conditions of wild-type (WT) PPARγ-LBD [39], so we 
decided to find the right conditions performing co-crystallization trials with 
the partial agonist LT175 with the aim of making the LBD more stable and 
favouring its crystallization. This ligand was selected because it occupies the 
diphenyl pocket [52], a region of the LBD which is also formed by the loop 
containing the mutated Phe360 residue. A comparison of this structure with 
the previously solved complex structure [52] of the WT receptor with the 
same ligand (PDB ID: 3B3K) would have allowed us to verify the 
consequences of the mutation for ligand binding. 
 Co-crystallization trials has been performed at Biocrystal Facility of 
the CNR Institute of Biology and Molecular Pathology (Sapienza University 
of Rome) using a Phoenix liquid-handling robot (Art Robbins Instruments, 
USA), which allows to rapidly screen a large number of different conditions 
with a small sample consumption. Small crystals of the complex with LT175 
appeared in well Nos. 18 and 25 of the Index crystallization kit (see 
Experimental Methods), which have been reproduced on a larger scale to 
obtain more suitable crystals for X-ray analysis. Crystals appeared after a few 
days from both tested conditions and X-ray data were collected at ESRF of 
Grenoble (France). The solved structures have been deposited in the PDB 
with codes 4L98 and 4L96 and the summary of crystallization analysis for 
crystals of both conditions, belonging to space group P21212 or I222, 
respectively, is shown in Table 8. Crystallization trials were also performed 
with the full agonist rosiglitazone, but they did not produce crystals suitable 
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for X-ray analysis. Accurate observation of both of the structures revealed 
that the crystal packing is almost the same with an identical arrangement of 
the single monomers (r.m.s.d. of 0.53 and 0.63 Å , respectively, for the two 
monomers in P21212 superimposed onto the monomer of I222) and of the 
homodimer. Comparing the PPARγ-LBD F360L/LT175 crystal structure 
(space group P21212) with that of the WT receptor also complexed with 
LT175 (PDB ID: 3B3K) [52], it can be noticed that the interface between the 
two monomers of the homodimer in PPARγ-LBD F360L/LT175 is different 
from that of PPARγ-LBD/LT175 and of all the known crystal structures of 
the wild type receptor complexed with other ligands. The WT interface is 
formed by helices 11 and 10 of the two monomers, which face each other 
(Fig. 48A), while the PPARγ F360L interface is formed by H3, H12 and loop 
11/12 of each molecule (Fig. 48B). An analysis of the dimerization interface 
of F360L with the program PSAP (Protein Structure Analysis Package) [176] 
revealed that this new arrangement of the dimer in PPARγ F360L is very 
stable, with five salt bridges and 21 hydrogen bonds and a more extended 
surface of interaction between the two monomers with respect to the WT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48. Homodimer of the A) wild type and B) the F360L mutant. The interface between the 
monomers is drawn in red, orange and cyan. 
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 The superposition of a single monomer of WT and F360L mutant 
shows that the two molecules have comparable conformations, except for the 
terminal end of H11, loop 11/12 and H12 (Figure 49). The strong van der 
Waals interaction made by the side chain of Phe360 in the WT with those of 
Ile279 in helix 3 and Ile456 in helix 11 (3.2 and 3.7 Å, respectively) are lost 
in the mutant (6.2 and 5.4 Å, respectively), suggesting a key role of Phe360 
in stabilizing the diphenyl pocket of the LBD (Figure 50A). Destabilization 
of the terminal end of H11 caused by the mutation and the resulting 
rearrangement of the following loop 11/12 permits a different stabilization of 
this region, with the side chain of Leu465 in loop 11/12 which forms vdW 
interaction with Leu360 and Ile279 (3.8 and 3.2 Å, respectively; Figure 50B). 
Moreover, the very strong salt bridge formed in the WT between Arg357 
(loop 6/7) and Glu460 (loop 11/12) is partially lost in the mutant, with an 
increase of the shortest distance from 2.6 to 5.2 Å, respectively (Figure 51). 
Another salt bridge between Arg357 and Glu276 in helix 3 is also weakened 
(the shortest distance increases from 2.8 to 4.1 Å, respectively). This could be 
also due to the loss of interaction between the positively charged Arg357 and 
the polarizable π-electron cloud of the aromatic ring of Phe360 (the shortest 
distance between the two residues is 3.4 Å). This is a common interaction in 
proteins that provides conformational tethering of the arginine side chain 
while leaving its hydrogen-bond capacity intact for use in the binding of 
acidic residues [177]. The shorter leucine is not able, using only van der 
Waals interactions, to stabilize the side chain of Arg357, which loses the salt 
bridge with Glu460, in this way destabilizing loop 11/12 in which Glu460 is 
located. In addition, as shown in Figure 52, the side chain of His466 also 
plays a critical role in the different stabilization of this loop and of helix 12.  
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 PPARγ-LBD F360L/LT175 
Data collection   
space group P21212 I222 
cell dimension a, b, c [Å] 64.41, 112.46, 117.74 67.17, 112.00, 116.8 
wavelenght [Å] 0.973 0.973 
resolution range [Å] 50.00 - 2.28 41.00 - 2.38 
last shell [Å] 2.50 - 2.28 2.47 - 2.38 
Rmerge [%] 8.8 (42.4) a 11.0 (60.1) a 
unique reflections 39713 17959  
mean (I)/σ(I) 18.9 (4.8) a 11.3 (2.9) a 
completeness 99.9 (99.9) a 100 (99.3) a 
No. of molecules in 
asymmetric unit 2 1 
 
Refinement   
resolution range [Å] 50.00 - 2.28 41.00 - 2.38 
Rwork [%] 21.4 18.9 
Rfree [%] 25.6 22.7 
Bond lenghts r.m.s.d. [Å] 0.011 0.011 
Bond angles r.m.s.d. [deg] 1.506 1.435 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Summary of crystallographic analysis for crystals of the PPARγ-LBD F360L/LT175 
complex obtained with conditions Nos. 18 and 25 of Index crystallization screen. a The values in 
parentheses refer to the outer shell    
(Hess et al., 1997) were used in conjunction with the Particle
Mesh Ewald method (Darden et al., 1993) with 34 wavevectors
in each dimension and a fourth-order cubic interpolation for
the long-range electrostatics. Much of the collective analysis
used in this work is based on essential dynamics (ED; Amadei
et al., 1993). On purpose, the covariance matrix of the atomic
positional fluctuations (either all atoms or backbone; see x3)
was built from the MD trajectory and then diagonalized,
producing an orthonormal set of eigenvectors defining a new
set of generalized coordinates along which the protein fluc-
tuations occur. The trace of the covariance matrix provides us
with a direct measure of the extent of the overall fluctuations
of the WT and mutant receptor.
3. Results
3.1. Overall structure of PPARc F360L
Crystals of PPAR! F360L–LT175 were obtained from two
different conditions (sodium/potassium phosphate and sodium
formate) and they belonged to different space groups (I222
and P21212), with one and two molecules in the asymmetric
unit, respectively (Table 1). Accurate observation of both of
the structures revealed that the crystal packing is almost the
same ith an identical arrangement of the single monomers
(r.m.s.d. of 0.53 and 0.63 A˚, respectively, for the two mono-
mers in P21212 superimposed onto the monomer of I222) and
of the homodimer. Comparing the PPAR! F360L–LT175
crystal structure (space group P21212) with that of the WT
receptor also complexed with LT175, it can be noticed that the
interface between the two monomers of the homodimer in
PPAR! F360L–LT175 is different from that of PPAR! WT–
LT175 and of all the known crystal structures of the WT
complexed with other ligands. The WT interface is formed by
helices 11 and 10 of the two monomers, which face each other
(Fig. 1a), while the PPAR! F360L interface is formed by
helices 3, 12 and loop 11/12 of each molecule (Fig. 1b). An
analy is of the dimerization interface of F360L with the
research papers
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Figure 1
Homodimer of the WT (a) and the F360L mutant (b). The interface
between the monomers is drawn in red, orange and cyan.
Figure 2
(a) Superposition of the crystal structures of the WT (green) and the
F360L mutant (cyan) complexed with the ligand LT175. The regions with
the main conformational differences are included in the ellipse. (b) An
enlargement of helices H11, H12 and loop 11/12 is shown.
electronic reprint
Figure 49. Superposition of the crystal 
structures of the WT (green) and the 
F360L mutant (cyan) complexed with 
the ligand LT175. The regions with the 
main conformational differences are 
included in the ellipse.   
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Figure 50. Superposition of the crystal structures of the WT (grey) and the F360L mutant (cyan) 
complexed with the ligand LT175. A) Van der Waals interactions between residues of H3, H11 and 
loop 6/7; B) van der Waals interactions of loop 6/7 with loop 11/12 and helix 3 in the F360L mutant. 
research papers
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program PSAP (Protein Structure Analysis Package; Bala-
murugam et al., 2007) revealed that this new arrangement of
the dimer in PPAR! F360L is very stable, with five salt bridges
and 21 hydrogen bonds and a more extended surface of
interaction between the two monomers with respect to the
WT.
3.2. Conformational changes in the monomer induced by the
F360L mutation
The superposition of a single monomer of WT and F360L
PPAR! shows that the two molecules have similar confor-
mations, with the exception of the terminal end of helix 11,
loop 11/12 and helix 12 (Figs. 2a and 2b). A more careful
observation of the structures shows that the strong van der
Waals interactions made by the side chain of Phe360 in the
WTwith the side chains of Ile279 in helix 3 and Ile456 in helix
11 (3.2 and 3.7 A˚, respectively) are lost in the mutant (6.2 and
5.4 A˚, respectively), denoting a key role of Phe360 in stabi-
lizing this region of the LBD (the diphenyl pocket; Fig. 3a).
Destabilization of the terminal end of helix 11 owing to the
F360L mutation and the consequent rearrangement of the
following loop 11/12 allows a different stabilization of this
region, whereas a pivotal role is played by the side chain of
Leu465 in loop 11/12, which forms van der Waals contacts with
Leu360 and Ile279 (3.8 and 3.2 A˚, respectively; Fig. 3b).
Moreover, the very strong salt bridge present in the WT
between Arg357, belonging to loop 6/7, and Glu460, in loop
11/12, is partially lost in the mutant (the shortest distance
increases from 2.6 to 5.2 A˚, respectively; Fig. 3c). Another salt
bridge between Arg357 and Glu276 in helix 3 is also weakened
(the shortest distance increases from 2.8 to 4.1 A˚, respec-
tively). This could be also owing to the loss of interaction
between the positively charged Arg357 and the polarizable
"-electron cloud of the aromatic ring of Phe360 (the shortest
distance between the two residues is 3.4 A˚). This is a common
interaction in proteins that provides conformational tethering
of the arginine side chain while leaving its hydrogen-bond
capacity intact for use in the binding of acidic residues (Flocco
& Mowbray, 1994). The shorter leucine is not able, using only
van der Waals interactions, to stabilize the side chain of
Arg357, which loses the salt bridge with Glu460, in this way
destabilizing loop 11/12 in which Glu460 is located.
As mentioned above, the changed van der Waals interaction
network in the region of the diphenyl pocket and the weak-
ening of the salt bridges Arg357–Glu460 and Arg35–Glu276
provoke a dramatic rearrangement of the mutant loop 11/12,
which assumes a different conformation with respect to the
WT (Fig. 4a), with the side chain of His466 playing a critical
role in the different stabilization of this loop and of helix 12
Figure 3
Superposition of the crystal structures of the WT (white) and the F360L mutant (cyan) complexed with the ligand LT175. (a) Van der Waals interactions
between residues of H3, H11 and loop 6/7; (b) van der Waals interactions of loop 6/7 with loop 11/12 and helix 3 in the F360L mutant; (c) electrostatic
interactions of Arg357 with Glu460 and Glu276. Hydrogen bonds are depicted as red dashed lines.
electronic reprint
Figure 51. Superposition of the crystal structures of the WT (grey) and the F360L mutant 
(cyan) complexed with the ligand LT175, showing the electrostatic interactions of 
Arg357 with Glu460 and Glu276. Hydrogen bonds are represented as red dashed lines.   
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 Figure 53 shows the different networks of van der Waals interaction 
at the bottom of diphenyl pocket for the WT and the mutant. It can be noticed 
that the mutated Leu360 makes van der Waals contacts with Phe282 and 
Ala278 in helix 3 (3.1 and 3.4 Å, respectively) and Leu465 in loop 11/12 (3.8 
Å), whereas in the WT the shortest van der Waals contacts of Phe360 are 
with the side chain of Phe282 and Ile279 belonging to H3 (3.5 and 3.3 Å, 
respectively) and Ile456 in helix 11 (3.6 Å). Phe360 and Phe282 are also 
involved in a typical 'edge-to-ring face' interaction between the two aromatic 
rings. Furtermore, the important role played by Met463 of the WT in the 
interaction with the terminal end of the ligand (Figure 53A) is assumed by 
Pro467 (Figure 53B) in the mutant. The final result of all of these 
conformational changes induced by the F360L mutation is that the 
transactivation helix 12 assumes a different and inactive conformation 
(Figures 49 and 53B). 
 
Figure 52. Conformation of loop 11/12 in A) the WT and B) the F360L mutant. Hydrogen 
bonds are drawn as black dashed lines; the black arrow indicates the different position of the 
His466 side chain in the WT. 
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4.4.2 Ligand interactions 
 Figure 53 shows that LT175 maintains the same position in the F360L 
LBD (the OMIT maps calculated around the ligand are shown in Figure 54), 
although inserted more deeply in the pocket, with similar van der Waals 
contacts; the only exception is provided by the already discussed interaction 
with Pro467 at the bottom of the diphenyl pocket. Conversely, many 
differences can be found in the hydrogen-bond network made by its 
carboxylate O atoms. In addition to the canonical interaction with His449 and 
His323, the two O atoms make H-bonds with Tyr473 and Tyr447 in helix 12, 
both belonging to the facing molecule of the homodimer (Figure 55). 
 
Figure 53. Van der Waals interactions in the diphenyl pocket of A) the WT and B) the F360L mutant. 
The mutated residue Leu360 is represented in red and the ligand LT175 in yellow. 
Acta Cryst. D (2014). 70,  doi:10.1107/S1399004714009638        Supporting information, sup-1 
 
 
Table S1 List of oligonucleotides used for site-directed mutagenesis. 
F360L Fw-CGAAAGCCTCTGGGTGACTTTA 
F360L Rev-TAAAGTCACCCAGAGGCTTTCG 
R357A Fw-GGAGTTTCTAAAGAGCCTGGCAAAGCCTTTTGGTGACTTTAT 
R357A Rev-ATAAAGTCACCAAAAGGCTTTGCCAGGCTCTTTAGAAACTCC 
 
 
Figure S1. Omit 2Fo-Fc electron-density maps calculated around (a) molecule A and (b) molecule B 
of the ligand LT175 (P21212), and (c) molecule A of LT175 (I222). All the maps are contoured at the 
1 level. 
 
 
Figure S2. Regions of the PPAR  LBD complexed with rosiglitazone with markedly (red 
color) and less markedly (pink color) higher B-factors with respect to the corresponding WT crystal 
structure with the same ligand. The variation of B-factors regarding helix 8 is less relevant because in 
the WT structure this helix is affected by crystal packing interactions. 
Figure 54. 2FO-FC omit maps calculated around (a) molecule A and (b) molecule B of the ligand 
LT175 (P21212), and (c) molecule A of LT175 (I222). All the maps are contoured at the 1 σ level. 
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 Therefore, there is an additional tyrosine, Tyr477, that is engaged in 
hydrogen bonds to the carboxylate group besides the canonical Tyr473, 
which, however, in the WT homodimer belongs to the same monomer where 
the ligand is bound. This very stable arrangement, as denoted by well defined 
electron densities of all the residues of H12, is made possible by the new 
interface between the two monomers, in which H12 of one molecule 
protrudes towards the ligand inserted into the LBD of the facing molecule. 
This is probably an artifact of the crystal packing: the destabilization of H12 
caused by the mutation allows this helix to find a new conformation that 
favours a new stable interface between two monomers in the crystal.  
 It is worth noting that despite several trials it was not possible to 
crystallize the apo form of the mutant in the conditions generally used to 
crystallize the WT apo form, suggesting that the mutation destabilizes the 
LBD of PPARγ and the active conformation of H12 and only the presence of 
suggesting that the mutation destabilizes the LBD of PPAR!
and the active conformation of H12 and only the presence of
the ligand allows the complex to crystallize, albeit through a
new dimer interface.
3.4. MD simulations
In order to check the results of the X-ray analysis, MD
simulations were also performed on the apo form of F360L
and the WT. Table 2 contains the basic data concerning the
simulated systems. The backbone root-mean-square deviation
(r.m.s.d.) evaluated for both the WTand F360L with respect to
the initial structure of the WT (PDB entry 1prg; Nolte et al.,
1998), characterized by a relatively low value, indicates that
the average structure of both of the macromolecules in solu-
tion is not dramatically different from that found in the
crystalline state. Also, the close values of the radius of gyra-
tion reported in Table 2 suggest a strong average morpholo-
gical similarity of the WTand the F360L mutant. On the other
hand, the high difference in the trace of the backbone covar-
iance matrix, which concisely provides us with the whole
internal fluctuation of the macromolecules, clearly shows that
the point mutation produces a sharp mechanical destabiliza-
tion of the whole system accompanied by a very large increase
in the whole fluctuation. This is further confirmed by analysis
of the root-mean-square fluctuation (r.m.s.f.) per residue, as
reported in Fig. 7(a), where it is possible to appreciate the
increase of the fluctuation of the F360L mutant in the marked
regions which specifically correspond to H12 and residues
280–287 of H3. The H12 destabilization induced by the F360L
mutation is also revealed through analysis of the inter-
fragment distances, as reported in Fig. 7(b). In fact, a sharp
strengthening and lengthening of the mutual interaction
between H12 and the subportion 280–287 of H3 in the WTand
the F360L mutant, respectively, can be observed. Moreover, in
the simulation, residue 360, in both the WTand the mutant, is
found to be surrounded at relatively close distances (less than
4 A˚) by the following four residues: Ala278, Ile279, Phe282
and Ile456. Fig. 7(c) reports the mobility (r.m.s.f.) of these
residues. The result indicates that the change from Phe to Leu
at position 360 produces a sharp increase in the r.m.s.f., i.e. a
weakening of the nonbonding interaction, for residues Ile279
and Ile456.
3.5. Crystal structure of the complex between R357A and
rosiglitazone
In order to check the importance of the residue Arg357 in
the stabilization of the LBD, we solved the structure of the
PPAR! R357A mutant complexed with the potent agonist
rosiglitazone. The PPAR! R357A–rosiglitazone complex
crystallized in space group C2221 with two molecules in the
asymmetric unit (Table 1). A comparison with the crystal
structure of the WT with the same ligand (PDB entry 2prg;
Nolte et al., 1998) showed that the complex of the mutant
maintains the same dimer interface and the same monomer
conformation with H12 in the active form. However, an
accurate examination of the B factors of the mutant reveals a
general increase in the thermal parameters with respect to the
WT, particularly for the atoms in loop 6/7 containing the
mutation, in the region 276–282 in helix 3 and in the region
453–475 including the terminal part of H11 and loop 11/12
(Supplementary Fig. S2), as found in the MD simulation of
apo F360L and in the crystal structure of F360L–LT175. In
particular, the electron density around the side chains of
Ile279 and Ile456, contacting Phe360, is very weak. Super-
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Table 2
Results of MD simulations for PPAR! WT and the F360L mutant.
The standard deviations are reported in parentheses.
WT F360L
Backbone r.m.s.d. (nm) 2.59 " 10#1
(1.57 " 10#2)
2.75 " 10#1
(2.44 " 10#2)
Radius of gyration (nm) 1.95 (1.0 " 10#2) 1.95 (1.1 " 10#2)
Trace of the covariance
matrix (nm2)
10.9 (0.5) 13.2 (0.6)
Figure 6
(a) PPAR! homodimer of the F360L mutant (monomer A in yellow and
monomer B in green); (b) hydrogen bonds made by residues of monomer
A (yellow) and monomer B (green) of the homodimer with the
carboxylate group of the ligand LT175 (yellow).
electronic r print
Figure 55. Hydrogen-bonds made by residues of monomer A (yellow) and monomer B 
(green) of the homodimer with the carboxylate group of the ligand LT175 (yellow). 
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the ligand allows the complex to crystallize, although in consequence of a 
new dimer interface. However, in order to check the results obteined by X-
ray analysis , molecular dynamics (MD) simulations were also performed by 
Aschi and collaborators on the apo form of the mutant and the WT. Table 9 
contains the basic data concerning the simulated system. The backbone root-
mean-square deviation (r.m.s.d.) evaluated for both the WT and F360L with 
respect to the initial structure of the WT (PDB ID: 1PRG) [39], characterized 
by a relatively low value, indicates that the average structure of both the 
macromolecules in solution is not dramatically different from that found in 
the crystalline state. Also, the close values of the radius of gyration reported 
in Table 9 suggest a strong average morphological similarity of the WT and 
the F360L mutant. On the other hand, the high difference in the trace of the 
backbone covariance matrix, which concisely provides us with the whole 
internal fluctuation of the macromolecules, clearly shows that the point 
mutation produces a sharp mechanical destabilization of the whole system 
accompanied by a very large increase in the whole fluctuation. This is further 
confirmed by analysis of the root mean square fluctuation (r.m.s.f.) per 
residue, which highlighted the increase of fluctuation of the F360L mutant in 
the marked regions which specifically correspond to H12 and residues 280 - 
287 of H3. 
 WT F360L 
Backbon r.m.s.d. (nm) 2.59 x 10-1 (1.57 x 10-2) 2.75 x 10-1 (2.44 x 10-2) 
Radius of gyration (nm) 1.95 (1.0 x 10-2) 1.95 (1.1 x 10-2) 
Trace of the covariance matrix (nm2) 10.9 (0.5) 13.2 (0.6) 
Table 9. Results of MD simulations for PPARγ WT and the F360L mutant. The standard deviations are 
reported  
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4.4.3 Crystal structure of the complex between PPARγ-LBD 
R357A and rosiglitazone 
 In order to evaluate the importance of the residue Arg357 in the 
stabilization of the diphenyl pocket  whitin the LBD, the PPARγ mutant 
R357A was also expressed and co-crystallization trials with the full agonist 
rosiglitazone has been performed using the Phoenix liquid-handling robot. 
Suitable crystals for X-ray data collection appeared in well No. 5 of the 
Morpheus crystallization screen (see Experimental Methods) and the 
summary of the crystallographic analysis performed at ESRF is shown in 
Table 10. The solved structure has been deposited in the PDB with code 
4O8F. On the contrary, co-crystallization trials of the R357A mutant with the 
ligand LT175 was not successful. 
 The complex crystallized in space group C2221, with two molecules 
in the asymmetric unit. OMIT maps calculated around the two molecules of 
the ligand are shown in Figure 56. A comparison with the crystal structure of 
the WT with the same ligand (PDB ID: 2PRG) [39] showed that the complex 
of the mutant maintains the same dimer interface and the same monomer 
conformation with helix 12 in the active form. However, an accurate 
examination of the B factors of the mutant reveals a general increase in the 
thermal parameters with respect to the WT, particularly for the atoms in loop 
6/7 containing the mutation, in the region 276–282 of H3 and in the region 
453–475 including the terminal part of H11 and loop 11/12 (Figure 57), as 
found in the MD simulation of apo F360L and in the crystal structure of 
F360L/LT175. In particular, the electron density around the side chains of 
Ile279 and Ile456, contacting Phe360, is very weak. Superposition of the 
crystal structures of R357A and the WT shows that the ligands occupy the 
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same position in the LBD, making identical interactions with H12; however, 
the N-methyl group of R357A assumes a different conformation (C14— 
C15—N16—C17 torsion angle of -86° vs 70°, respectively), with its methyl 
group pointing towards the Leu353 side chain (Figure 58). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PPARγ-LBD R357A/rosiglitazone 
Data collection  
space group C2221 
cell dimension a, b, c [Å] 85.70, 87.10, 163.80 
wavelenght [Å] 0.976 
resolution range [Å] 82.00 - 2.56 
last shell [Å] 2.72 - 2.60 
Rmerge [%] 6.1 (43.5) a 
unique reflections 18994  
mean (I)/σ(I) 9.3 (1.3) a 
completeness 98.8 (97.5) a 
No. of molecules in asymmetric 
unit 2 
 
Refinement  
resolution range [Å] 82.00 - 2.56 
Rwork [%] 23.8 
Rfree [%] 29.6 
Bond lenghts r.m.s.d. [Å] 0.011 
Bond angles r.m.s.d. [deg] 1.602 
Table 10. Summary of crystallographic analysis for crystals of the PPARγ-LBD R357A/rosiglitazone 
complex obtained with conditions No. 5 of Morpheus crystallization screen. a The values in 
parentheses refer to the outer shell  
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Acta Cryst. D (2014). 70,  doi:10.1107/S1399004714009638        Supporting information, sup-1 
 
 
Table S1 List of oligonucleotides used for site-directed mutagenesis. 
F360L Fw-CGAAAGCCTCTGGGTGACTTTA 
F360L Rev-TAAAGTCACCCAGAGGCTTTCG 
R357A Fw-GGAGTTTCTAAAGAGCCTGGCAAAGCCTTTTGGTGACTTTAT 
R357A Rev-ATAAAGTCACCAAAAGGCTTTGCCAGGCTCTTTAGAAACTCC 
 
 
Figure S1. Omit 2Fo-Fc electron-density maps calculated around (a) molecule A and (b) molecule B 
of the ligand LT175 (P21212), and (c) molecule A of LT175 (I222). All the maps are contoured at the 
1 level. 
 
 
Figure S2. Regions of the PPAR  LBD complexed with rosiglitazone with markedly (red 
color) and less markedly (pink color) higher B-factors with respect to the corresponding WT crystal 
structure with the same ligand. The variation of B-factors regarding helix 8 is less relevant because in 
the WT structure this helix is affected by crystal packing interactions. 
Figure 57. Regions of the PPARγ-LBD 
R357A complexed with rosiglitazone with 
markedly (red color) and less markedly 
(pink color) higher B-factors with respect to 
the corresponding WT crystal structure with 
the same ligand. The variation of B-factors 
regarding H8 is less relevant because in the 
WT structure this helix is affected by crystal 
packing interactions. 
Acta Cryst. D (2014). 70,  doi:10.1107/S1399004714009638        Supporting information, sup-2 
 
 
Figure S3. Superposition of molecules A of rosiglitazone in R357A (green color) and WT (cyan 
color), respectively.  
 
 
Figure S4. Omit 2Fo-Fc electron-density maps calculated around (a) molecule A and (b) molecule B 
of the ligand rosiglitazone. All the maps are contoured at the 1 level. 
 
 
Figure 58. Superposition of molecules A of 
rosiglitazone in R357A (green color) and WT 
(cyan color), respectively. 
Figure 56. 2FO-FC omit maps calculated ar und (a) molecule  and (b) molecule B f the ligand 
rosiglitazone. All the maps are contoured at the 1 σ level. 
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4.4.4 The co-activator SRC-1 has a lower binding affinity for 
the mutants 
 As previously discussed, the inactive conformation of helix 12 
observed in the crystal structure of the complex with F360L mutant is clearly 
an artefact of the crystal packing, since the new dimer interface allows helix 
12 of one monomer to protrude towards the ligand bound to the other 
monomer forming an hydrogen bond with it. However, such a marked 
deviation of H12 from its active conformation would not be possible without 
the F360L mutation, which strongly destabilizes the region of the diphenyl 
pocket allowing the formation of a new dimer interface. In the abscence of 
ligands with agonistic activity an increase in the H12 dynamics and a 
stronger fluctuation of some regions of the LBD is probable, as indicated for 
instance by the MD simulation. A more disordered conformation of H12 in 
the classic heterodimer interface with RXRα would impair efficient 
recruitment of the co-activator, because, as is known, this helix forms part of 
the hydrophobic cleft used to bind the co-activator [39]. As shown in Figure 
59, ITC experiments reveal a less efficient recruitment of co-activator SRC-1 
for the F360L and R357A mutants. The co-activator SRC-1 was injected into 
a cell containing the ligand binding domain of the WT and the mutants pre-
equilibrated with the ligand LT175. The results showed that the WT is able to 
recruit the co-activator with higher affinity with respect to the mutants F360L 
and R357A (Ka = 7.64 ± 1.17 x 105 M-1 vs Ka = 3.01 ± 0.54 x 105 M-1 and Ka 
= 1.79 ± 0.28 x 105 M-1, respectively), thus explaining the lower 
transacativation activity of the mutated receptors. 
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Figure 59. ITC experiments: binding of SRC-1 to A) WT, B) F360L and C) R357A after equilibration 
with LT175. 
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4.5 Resveratrol and its metabolites 
 Resveratrol (3,5,4′-trihydroxystilbene, Figure 60) is a type of natural 
phenol which can be found in the skin and seeds of grapes and is the active 
component of red wine that has led to the "French paradox" [178], according 
to which French people have a relatively low incidence of coronary heart 
disease (CHD), while having a diet relatively rich in saturated fats. It is a 
known activator of the NAD+-dependent deacetylase SIRT1 and, for this 
reason, has been the subject of intense studies for its potential role in diabetes 
and aging [179]. In addition, the SIRT1-dependent repression of visceral 
white adipocyte genes involves deacetylation of PPARγ [180]. This dietary 
polyphenol also inhibits platelets aggregation [181], promotes vasodilatation 
[182, 183] and shows anti-inflammatory activity [184]. However, recent data 
have revealed that resveratrol can affect PPAR activity and modulate many 
biological actions of PPAR agonists [185]. Resveratrol also has inhibitory 
effect on adipogenesis [186], that is believed to occur through down-
regulation of PPARγ mRNA expression in human visceral adipocytes [187]. 
To date, there is no evidence about the direct interaction between resveratrol 
and/or its metabolites with PPARs. 
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Introduction
Peroxisome proliferator-activat d receptors (PPARs) are mem-
bers of the nuclear receptor family of ligand-dependent tran-
scription factors.[1] PPARs form heterodimers with the 9-cis reti-
noic acid receptor (RXR) and subsequently interact with a
ligand to bind to specific peroxisome proliferator responsive
elements (PPREs) in the promoter regions of specific target
genes. Three isoforms of PPAR have been identified: PPARg,
PPARd, and PPARa, of which PPARg is the most extensively
studied subtype.[2] PPARa agonists, which include fibrates, nor-
malize dyslipidaemia, whereas PPARg agonists (e.g. , thiazoli-
dinediones) improve insulin resistance and diabetes control.
PPARa and PPARg have been implicated in the increase of in-
sulin sensitivity through the control of lipid and glucose me-
tabolism as well as in conferring anti-inflammatory protection
in liver, adipose, and vascular tissues.[3, 4] PPARg is adipogenic,[5]
and ligand-mediated activation of PPARg exhibits antitumori-
genic effects in many types of cancer.[6, 7]
Resveratrol (3,5,4’-trihydroxystilbene) is found in the skin
and seeds of grapes and is the active component of red wine
that has led to the “French paradox”.[8] It is a known activator
of the NAD+-dependent deacetylase SIRT1 and, for this reason,
has been the subject of intense studies for its potential role in
diabetes and aging.[9] Although there is no consensus on the
mechanism by which resveratrol modulates SIRT1 activity, re-
sveratrol treatment results in an eightfold increase in SIRT1 de-
acetylation.[9,10] This dietary polyphenol inhibits platelet aggre-
gation,[11] promotes vasodilation,[12,13] and exerts anti-inflamma-
tory activity.[14] Resveratrol also inhibits differentiation of 3T3-
L1 adipocytes by the activation of the AMP kinase/SIRT1 axis[15]
and offers potential cancer chemopreventive effects.[16] Howev-
er, recent data have reveal d that resveratrol can affect PPAR
activity and modulate many biological actions of PPAR ago-
nists.[17, 18] The inhibitory effect of resveratrol on adipogenesis[19]
is believed to occur through down-regulation of PPARg mRNA
expression in human visceral adipocytes.[20] Moreover, the
SIRT1-dependent repression of visceral white adipocyte genes
involves deacetylation of PPARg.[21] Whether resveratrol and/or
its metabolites can interact directly with PPAR proteins to influ-
ence their function remains unclear.
Resveratrol, a modulator of several signaling proteins, can
exert off-target effects involving the peroxisome proliferator-
activated receptor (PPAR) transcription factors. However, evi-
dence for the direct interaction between this polyphenol and
PPARs is lacking. Here, we addressed the hypothesis that res-
veratrol and its metabolites control aspects of PPAR transcrip-
tional activity through direct interaction with PPARs. Bioaffinity
chromatographic studies with the immobilized ligand-binding
domains (LBDs) of PPARg and PPARa and isothermal titration
calorimetry allowed the binding affinities of resveratrol, resver-
atrol 3-O-glucuronide, resveratrol 4-O-glucuronide, and resvera-
trol 3-O-sulfate to both PPAR-LBDs to be determined. Interac-
tion of resveratrol, resveratrol 3-O-glucuronide, and resveratrol
4-O-glucuronide with PPARg-LBD occurred with binding affini-
ties of 1.4, 1.1, and 0.8 mm, respectively, although only resvera-
trol bound to the PPARa-LBD with a binding affinity of 2.7 mm.
Subsequently, X-ray crystallographic studies were carried out
to characterize resveratrol binding to the PPARg-LBD at the
molecular level. The electron density map from the crystal
structure of the complex between PPARg-LBD and resveratrol
revealed the presence of one molecule of resveratrol bound to
the LBD of PPARg, with the ligand occupying a position close
to that of other known PPARg ligands. Transactivation assays
were also performed in HepG2 cells, with the results showing
that resveratrol was not a PPAR agonist but instead was able
to displace rosiglitazone from PPARg and Wy-14643 from
PPARa with IC50 values of (27.4!1.8) mm and (31.7!2.5) mm,
r spectively. We propose that resveratrol acts as PPAR antag-
onist through its direct interaction with PPARg and PPARa.
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4.5.1 Binding affinity of resveratrol towards PPARs LBD 
 Frontal affinity chromatographic (FAC) [188] studies were carried out 
by Calleri and collaborators in order to determine whether resveratrol and its 
metabolites bind to the LBD of PPARγ and PPARα. Resveratrol, the high-
affinity full agonist of PPARγ GW1929 (Ka value of ~ 40 nM) [189] and the 
dual agonist R-1 (Ka values of ~ 270 nM) [188, 190] have been used as 
marker ligands on the PPARγ/α-open tubular (OT) silica capillary stationary 
phase. As shown in Table 11, resveratrol and its metabolite 4-O-glucoronide 
had similar binding affinities towards PPARγ-LBD when resveratrol and 
GW1929 were used as marker ligands, suggesting that the binding site of 
resveratrol overlaps with GW1929. Conversely, a significant decrease in the 
affinity of resveratrol 3-O-glucoronide to PPARγ-LBD was observed when 
GW1929 was used as marker ligand. Moreover, resveratrol 3-O-sulfate did 
not displace resveratrol although it displaced GW1929, indicating that the 
sulfated analogue does not compete with resveratrol for binding.  
 
 
Figura 60. Chemical structure of resveratrol. 
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 Ki [µM] 
Compound Resveratrol GW1929 R-1 
resveratrol 1.37 ± 0.57 1.80 ± 0.43 no displacement 
resveratrol-3-O-glucoronide 1.07 ± 0.22 16.6 ± 5.81 no displacement 
resveratrol-4-O-glucoronide 0.77 ± 0.23 1.75 ± 0.71 no displacement 
resveratrol-3-O-sulfate no displacement 3.80 ± 1.29 no displacement 
 
 As shown in Table 12, only resveratrol showed affinity for PPARα-
LBD, indicating that the metabolites do not bind PPARα-LBD at the same 
site as resveratrol. Neither resveratrol nor its metabolites (concentrations up 
to 10 µM) were able to dose-dependently displace compound R-1 from both 
PPARγ-OT and PPARα-OT columns, suggesting a lack of overlap between 
the  binding sites for R-1 and resveratrol. 
 Isothermal titration calorimetry experiments were used to confirm the 
interaction of resveratrol with PPARγ-LBD. The association constants (Ka 
values) of the binding and the thermodynamic parameters, such as ΔG, ΔH, 
ΔS and n, were determined from the thermograms (Figure 61) using the 
Table 11. Binding affinity of resveratrol, resveratrol-3-O-glucuronide, resveratrol-4-O-glucuronide, 
and resveratrol-3-O-sulfate was determined by frontal displacement affinity chromatography by 
using the PPARγ-OT column. Resveratrol, GW1929, and R-1 were used as markers.   
 Ki [µM] 
Compound Resveratrol R-1 
resveratrol 2.69 ± 0.18 no displacement 
resveratrol-3-O-glucoronide no displacement no displacement 
resveratrol-4-O-glucoronide no displacement no displacement 
resveratrol-3-O-sulfate no displacement no displacement 
Table 12. Binding affinity of resveratrol, resveratrol-3-O-glucuronide, resveratrol-4-O-glucuronide, 
and resveratrol-3-O-sulfate was determined by frontal displacement affinity chromatography by using 
the PPARα-OT column. Resveratrol and R-1 were used as markers. 
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software Origin 7.0 provided by the manufacturer. The results indicated that 
resveratrol bound to the PPARγ-LBD with an affinity constant similar to that 
calculated by frontal affinity chromatography (1.09 ± 0.08 µM vs 1.37 ± 0.57 
µM, respectively; Tables 11, 12 and 13). 
 Ka x 105 [M-1] n[a] ΔH [Kcal M-1] -TΔS [Kcal M-1] 
PPARγ-LBD/resveratrol 1.09 ± 0.08 0.91 -3.40[b] ± 0 -3.49 
 
Table 13. Thermodynamic parameters of the formation of the PPARγ-LBD/resveratrol complex 
determined by isothermal titration calorimetry. [a] Molar binding ratio of the ligand–protein interaction 
(observed stoichiometry). [b] This value was kept fixed during the fitting by Origin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the reaction. The association constants (Ka values) of the bind-
ing of resveratrol to PPARg and the thermodynamic parame-
ters, including DG, DH, DS, and n, were determined from the
thermograms (Figure 2). The results indicated that resveratrol
bound to the PPARg-LBD with an affinity constant similar to
that obtained by frontal affinity chromatography ((1.09!
0.08) mm vs. (1.37!0.57) mm, respectively; Tables 1, 2, and 3).
To gain more insight into the interaction of PPARg with re-
sveratrol, X-ray studies were performed. The crystal structure
of the complex between PPARg-LBD and resveratrol was
solved (PDB ID: 4JAZ) at 2.85 ! resolution. The electron density
map (Figure S1 in the Supporting Information) clearly reveals
the presence of one molecule of resveratrol bound to the LBD
of PPARg. The ligand occupies a region close to the b-sheet in
a position close to that of other known PPARg partial ago-
nists,[27–29] in which a strong hydrogen bond was formed be-
tween the Ser342 amide and one of the hydroxy groups of re-
sveratrol (Figure 3A). The side chain of Arg288 was displaced
by the ligand from its usual position and, consequently, the
side chain of Glu291 was also forced to assume a new orienta-
tion. Van der Waals interactions were present between resvera-
trol and the side chains of Phe264, His266, and Arg288, with
electrostatic forces between the charged side chains of Arg288
and Arg280 and the negative dipoles of the ligand hydroxy
groups. Unlike other known partial agonists of PPARg, the ter-
minal end of resveratrol occupied a small pocket close to the
entrance of the LBD to form a hydrogen bond with the side
chain of Arg280. This new pattern of receptor–ligand recogni-
tion could be exploited for ligand design. The crystal structure
of PPARg, complexed with amorfrutin 1, a ligand structurally re-
lated to resveratrol, was recently published.[30] The superposi-
tion of the two crystal structures illustrates that both ligands
occupied the same position and formed similar interactions
with the PPARg-LBD (Figure 3B).
The crystal structure of the PPARg-LBD in complex with re-
sveratrol was further examined in order to explain the results
obtained from frontal displacement chromatography. Superpo-
sition of the PPARg-LBD with resveratrol and farglitazar, a high-
affinity PPARg ligand that is structurally very similar to
GW1929,[31] showed that the latter compound partially occu-
pies the same region as resveratrol, which could explain the
displacement of GW1929 by resveratrol (Figure 3C). In contrast,
compound R-1, a full PPARg agonist,[32] occupied a different po-
sition within the PPARg-LBD when compared to resveratrol
(Figure 3D). Superposition of the two molecules demonstrated
Figure 1. Frontal chromatographic study of the displacement of A) 100 nm
of compound R-1 by B) 10 mm resveratrol, C) resveratrol 3-O-sulfate, D) res-
veratrol 3-O-glucuronide, and resveratrol 4-O-glucuronide on the PPARg-OT
column. Figure 2. Titration of PPARg (50 mm) with resveratrol (500 mm). The upper
panels show the raw data; the lower panels show the corresponding bind-
ing isotherm, fitted according to the “one binding site” model. The thermo-
dynamic parameters (Kd, DH, and DS) are indicated in the boxes.
Table 3. Thermodynamic parameters of the formation of the PPARg-LBD/
resveratrol complex determined by isothermal titration calorimetry.
Ka"10
5 [m"1] n[a] DH [kcalm"1] "TDS [kcalm"1]
PPARg/resveratrol 1.09!0.08 0.91 "3.40[b]!0 "3.49
[a] Molar binding ratio of the ligand–protein interaction (observed stoichi-
ometry). [b] This value was kept fixed during the fitting by Origin.
# 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2014, 15, 1154 – 1160 1156
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Figure 61. Titration of PPARγ (50 µM) with resveratrol (500 µM). The upper panels 
show the raw data; the lower panels sh w the corresponding binding isotherm, fitted 
accordi g to the “one binding site” model. The thermodynamic parameters (Kd, ΔH, 
and ΔS) are indicated in the boxes. 
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4.5.2 Crystal structure of PPARγ-LBD/resveratrol complex 
 To gain more insights into the interaction of PPARγ-LBD with 
resveratrol, X-ray studies were performed. Crystals (0.2 x 0.3 x 0.2 mm) of 
apo-PPARγ-LDB were obtained by vapor diffusion using the sitting drop 
method and then soaked for three days in a storage solution containing the 
ligand (0.25 mM). X-ray data were collected at Elettra Sinchrotron of Trieste 
(Italy). Crystals of the PPARγ-LBD/resveratrol complex belong to the C2 
space group, with cell parameters shown in Table 14. The crystal structure of 
the complex between PPARγ-LBD and resveratrol was solved (PDB ID: 
4JAZ) with a resolution of 2.85 Å. The electron density map (Figure 62) 
clearly reveals the presence of one molecule of the ligand bound to the LBD 
of PPARγ. The ligand occupies a region close to the β-sheet in a position 
similar to that of other known PPARγ partial agonists [45, 52, 168], in which 
a strong hydrogen bond was formed between the Ser342 amide and one of 
the hydroxy groups of resveratrol (Figure 63A). The side chain of Arg288 
was displaced by the ligand from its usual position and, consequently, the 
side chain of Glu291 was also forced to assume a new orientation. Van der 
Waals interactions were present between resveratrol and the side chains of 
Phe264, His266, and Arg288, with electrostatic forces between the charged 
side chains of Arg288 and Arg280 and the negative dipoles of the ligand 
hydroxy groups. Unlike other known partial agonists of PPARγ, the terminal 
end of resveratrol occupied a small pocket close to the entrance of the LBD 
to form a hydrogen bond with the side chain of Arg280. This new pattern of 
receptor–ligand recognition could be exploited for ligand design. The crystal 
structure of PPARγ, complexed with amorfrutin 1, a ligand structurally 
related to resveratrol, was recently published [191]. The superposition of the 
	  	   127	  
two crystal structures illustrates that both ligands occupied the same position 
and formed similar interactions with the PPARγ-LBD (Figure 63B). The 
crystal structure of the PPARγ-LBD in complex with resveratrol was further 
examined in order to explain the results obtained from frontal displacement 
chromatography. Superposition of the PPARγ-LBD with resveratrol and 
farglitazar, a high-affinity PPARγ ligand that is structurally very similar to 
GW1929 [53], showed that the latter compound partially occupies the same 
region as resveratrol, which could explain the displacement of GW1929 by 
resveratrol (Figure 63C). In contrast, compound R-1, a full PPARγ agonist 
[192], occupied a different position within the PPARγ-LBD when compared 
to resveratrol (Figure 63D). Superposition of the two molecules demonstrated 
that, although the fused ring moiety of compound R-1 was very close to the 
terminal part of resveratrol, the two did not occupy the same region. This 
result supports the notion that resveratrol is unable to displace compound R-1 
from the PPARγ-LBD, as evidenced by frontal displacement 
chromatography.  
 
 
 
 
 
 
 
 
 
 
 Figure 62. Fo-Fc omit map calculated around the ligand and contoured at 2.5 σ. 
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 PPARγ-LBD/Resveratrol 
Data collection  
space group C2 
cell dimension a, b, c [Å] 93.72, 63.38, 119.8 
monoclinica angle β [deg] 102.9 
wavelenght [Å] 1 
resolution range [Å]       52.10 - 2.85 
last shell [Å] 3.00 - 2.85 
Rmerge [%] 7.2 (42.2) a 
observation 32406 (4415) a 
unique reflections 13805 (2012) a 
mean (I)/σ(I) 7.2 (1.8) a 
completeness 86.2 (86.3) a 
multiplicity 2.3 (2.2) a 
Refinement  
resolution range [Å] 10 - 2.85 
Rwork [%] 23.7 
Rfree [%] 26.3 
Bond lenghts r.m.s.d. [Å] 0.012 
Bond angles r.m.s.d. [deg] null 
Table 14. Summary of crystallographic analysis for the PPARγ-LBD/resveratrol 
complex; a The values in parenthesis refer to the outer shell. 
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4.5.3 Antagonistic activity of resveratrol  
 Inoue et al. initially reported PPARα/γ dual agonism of resveratrol, 
excluding any activity toward the PPARβ/δ isoform and other nuclear 
receptors [185], and subsequently updated their work and reported the pan-
agonism of resveratrol for PPARs [193]. Surprisingly, there was no PPAR 
transactivation observed in response to resveratrol treatment at concentrations 
up to 100 µM (Figure 64A and 64B) in luciferase-based transactivation 
assays performed on HepG2 cells by Loiodice and collaborators. Similarly, 
that, although the fused ring moiety of compound R-1 was
very close to the terminal part of resveratrol, the two did not
occupy the same region. This result supports the notion that
resveratrol is unable to displace compound R-1 from the
PPARg-LBD, as evidenced by frontal chromatography.
Previous studies have demonstrated that 10 mm resveratrol
activates PPARa and PPARg in a number of cell-based r porter
assays.[18] In order to confirm whether a similar result would be
observed with HepG2 cells, resveratrol was first evaluated for
its agonistic activity toward the human PPARg and PPARa sub-
types by using luciferase-based transactivation assays. HepG2
cells were transiently transfected either with the GAL4-PPARa
or GAL4-PPARg chimeric construct, together with the luciferase
reporter vector containing the pGal5TkpGL3 construct, and
then treated with increasing concentrations of resveratrol. Ro-
siglitazone and Wy-14643 were used as positive controls for
PPARg and PPARa transactivation potential, respectively. Of
significance, there was no PPAR transactivation observed in
response to resveratrol treatment at concentrations up to
100 mm (Figure 4A and B). The agonistic activity of resveratrol
was compared with that of its metabolites at two fixed con-
centrations (10 and 25 mm), and no apparent effect was seen
on the transactivation potential of PPARa and PPARg (Fig-
ure S2).
The lack of PPAR activity from resveratrol was surprising, as
Inoue et al. initially reported PPARa/g dual agonism of resvera-
trol, excluding any activity toward the PPARd isoform and
other nuclear receptors,[18] and subsequently updated their
work and reported the pan-agonism of resveratrol for PPARs.[33]
The difference between the previously reported data and our
own could result from the type of cell line used. Specifically,
different cell lines might provide different results depending
on the presence of recruitable cofactors (coactivators
or corepressors) and/or metabolic processes, such as
cellular metabolism of resveratrol during the experi-
ment. In fact, these in vitro assays might not be the
most suitable for studying the effects of resveratrol
on PPARs, and might require a more careful investi-
gation in vivo.
Nevertheless, the demonstration of direct binding
of resveratrol to PPAR (results from frontal affinity
chromatography, ITC, and X-ray experiments) led us
to investigate whether resveratrol exhibited PPAR an-
tagonistic activity. For this purpose, transiently trans-
fected HepG2 cells were coincubated with or without
resveratrol in the presence of either rosiglitazone or
Wy-14643 for 20 h. Data from the luciferase reporter
assay indicated that resveratrol was able to displace
rosiglitazone from PPARg and Wy-14643 from PPARa
with IC50 values of (27.4!1.8) mm and (31.7!2.5) mm,
respectively (Figure 5). Taken together, these results
demonstrate that resveratrol acts on both PPARg and
PPARa as an antagonist.
A comparison of the structure of resveratrol with
structures of the ligands used as positive controls in
the cell-based reporter assays was also carried out
(Figure S3). Rosiglitazone is a PPARg full agonist
whose crystal structure in complex with the PPARg-LBD
showed a standard agonist position with direct interaction
with helix 12 through a hydrogen bond with Tyr473.[34] More-
over, the X-ray crystal structure of the PPARa/Wy-14643 com-
plex showed one molecule of the ligand directly interacting
with H12, similar to rosiglitazone and many other PPAR full ag-
onists, and, more interestingly, a second molecule that inter-
acted with a secondary site between H2’ and H3, called the W-
Figure 3. A) Hydrogen-bond network of resveratrol in the PPARg-LBD. B) Superposition of
the complexes of PPARg with resveratrol (yellow) and amorfrutin 1 (white). For the sake
of clarity, the cartoon of PPARg-LBD complexed with resveratrol is shown (green). C) Su-
perposition of the complexes of PPARg with resveratrol (yellow) and farglitazar (purple).
D) Superposition of the complexes of PPARg with resveratrol (yellow) and compound R-
1 (pink).
Figure 4. Transactivation assay on PPARa and PPARg of resveratrol in HepG2
cells. Fold induction by resveratrol (RV) over vehicle (EtOH, 0.1%) on
A) PPARa and B) PPARg as determined by luciferase-based transactivation
assays. Reference compounds: Wy-14643 (10 mm) and rosiglitazone (2 mm).
! 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2014, 15, 1154 – 1160 1157
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Figure 63. A) Hydrogen-bond network of resveratrol in the PPARγ-LBD. B) Superposition of the 
complexes of PPARγ with resveratrol (yellow) and amorfrutin 1 (white). For the sake of clarity, the 
cartoon of PPARγ-LBD complexed with resveratrol is shown (green). C) Superposition of the 
complexes of PPARγ-LBD with resveratrol (yellow) and farglitazar (purple). D) Superposition of the 
complexes of PPARγ-LBD with resveratrol (yellow) and compound R-1 (pink). 	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no apparent effect was seen on the transactivation potential of PPARα and 
PPARγ treated with two fixed concentration (10 and 25 µM) of its 
metabolites. However, the incongruity of these data and the previously 
reported could result from the type of cell line used. Specifically, different 
cell lines might provide different results depending on the presence of 
recruitable co-factors (co-activators or co-repressors) and/or metabolic 
processes, such as cellular metabolism of resveratrol during the experiment. 
Actually, these in vitro assays might not be the most suitable for studying the 
effects of resveratrol on PPARs, and might require a more careful 
investigation in vivo.  
 Nevertheless, the demonstration of direct binding of resveratrol to 
PPAR resulting from frontal affinity chromatography, ITC and X-ray 
experiments, led us to investigate whether resveratrol exhibited PPAR 
antagonistic activity. For this purpose, transiently transfected HepG2 cells 
were coincubated with or without resveratrol in the presence of either 
rosiglitazone or Wy-14643 for 20 h. Data from the luciferase reporter assay 
indicated that resveratrol was able to displace rosiglitazone from PPARγ and 
Wy-14643 from PPARα with IC50 values of 27.4 ± 1.8 µM and 31.7 ± 2.5 
µM, respectively (Figure 65A and 65B). Taken together, these results suggest 
that resveratrol acts on both PPARγ and PPARα as an antagonist.  
 A comparison of the structure of resveratrol with structures of the 
ligands used as positive controls in the cell-based reporter assays was also 
carried out (Figures 66A and 66B). Rosiglitazone is a PPARγ full agonist 
whose crystal structure in complex with the PPARγ-LBD showed a standard 
agonist position with direct interaction with H12 through a hydrogen bond 
with Tyr473 [135]. 
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Figure 64. Transactivation assay on PPARα and PPARγ of resveratrol in HepG2 cells. Fold induction 
by resveratrol (RV) over vehicle (EtOH, 0.1%) on  A) PPARα and B) PPARγ as determined by 
luciferase-based transactivation assays. Reference compounds: Wy-14643 (10 µM) and rosiglitazone (2 
µM). 	  
 
                      
 
 
 
 
 
Figure 65. Inhibition of agonist-induced transactivation of PPARα and PPARγ by resveratrol in 
HepG2 cells. Transiently transfected HepG2 cells were incubated with increasing concentrations of 
resveratrol (1–100 µM) in the presence of either A) 10 µM Wy-14643 or B) 2 µM rosiglitazone. 
Luciferase reporter activity was measured in cell lysates 20 h later. Data represent mean ± SEM from 
two independent experiments, each performed in triplicate wells. 
 
 However rosiglitazone and resveratrol partially occupy the same 
region (Figure 66A), so that the latter compound is able to displace 
rosiglitazone from its position as demonstrated by luciferase reporter assay. 
Moreover, the X-ray crystal structure of the PPARα-LBD/Wy-14643 
complex showed one molecule of the ligand directly interacting with H12, 
similar to rosiglitazone and many other PPAR full agonists, and, more 
interestingly, a second molecule that interacted with a secondary site between 
that, although the fused ring moiety of compound R-1 was
very close to the terminal part of resveratrol, the two did not
occupy the same region. This result supports the notion that
resveratrol is unable to displace compound R-1 from the
PPARg-LBD, as evidenced by frontal chromatography.
Previous studies have demonstrated that 10 mm resveratrol
activates PPARa and PPARg in a number of cell-based reporter
assays.[18] In order to confirm whether a similar result would be
observed with HepG2 cells, resveratrol was first evaluated for
its agonistic activity toward the human PPARg and PPARa sub-
types by using luciferase-based transactivation assays. HepG2
cells were transiently transfected either with the GAL4-PPARa
or GAL4-PPARg chimeric construct, together with the luciferase
reporter vector containing the pGal5TkpGL3 construct, and
then treated with increasing concentrations of resveratrol. Ro-
siglitazone and Wy-14643 were used as positive controls for
PPARg and PPARa transactivation potential, respectively. Of
significance, there was no PPAR transactivation observed in
response to resveratrol treatment at concentrations up to
100 mm (Figure 4A and B). The agonistic activity of resveratrol
was compared with that of its metabolites at two fixed con-
centrations (10 and 25 mm), and no apparent effect was seen
on the transactivation potential of PPARa and PPARg (Fig-
ure S2).
The lack of PPAR activity from resveratrol was surprising, as
Inoue et al. initially reported PPARa/g dual agonism of resvera-
trol, excluding any activity toward the PPARd isoform and
other nuclear receptors,[18] and subsequently updated their
work and reported the pan-agonism of resveratrol for PPARs.[33]
The difference between the previously reported data and our
own could result from the type of cell line used. Specifically,
different cell lines might provide different results depending
on the presence of recruitable cofactors (coactivators
or corepressors) and/or metabolic processes, such as
cellular metabolism of resveratrol during the experi-
ment. In fact, these in vitro assays might not be the
most suitable for studying the effects of resveratrol
on PPARs, and might require a more careful investi-
gation in vivo.
Nevertheless, the demonstration of direct binding
of resveratrol to PPAR (results from frontal affinity
chromatography, ITC, and X-ray experiments) led us
to investigate whether resveratrol exhibited PPAR an-
tagonistic activity. For this purpose, transiently trans-
fected HepG2 cells were coincubated with or without
resveratrol in the presence of either rosiglitazone or
Wy-14643 for 20 h. Data from the luciferase reporter
assay indicated that resveratrol was able to displace
rosiglitazone from PPARg and Wy-14643 from PPARa
with IC50 values of (27.4!1.8) mm and (31.7!2.5) mm,
respectively (Figure 5). Taken together, these results
demonstrate that resveratrol acts on both PPARg and
PPARa as an antagonist.
A comparison of the structure of resveratrol with
structures of the ligands used as positive controls in
the cell-based reporter assays was also carried out
(Figure S3). Rosiglitazone is a PPARg full agonist
whose crystal structure in complex with the PPARg-LBD
showed a standard agonist position with direct interaction
with helix 12 through a hydrogen bond with Tyr473.[34] More-
over, the X-ray crystal structure of the PPARa/Wy-14643 com-
plex showed one molecule of the ligand directly interacting
with H12, similar to rosiglitazone and many other PPAR full ag-
onists, and, more interestingly, a second molecule that inter-
acted with a secondary site between H2’ and H3, called the W-
Figure 3. A) Hydrogen-bond network of resveratrol in the PPARg-LBD. B) Superposition of
the complexes of PPARg with resveratrol (yellow) and amorfrutin 1 (white). For the sake
of clarity, the cartoon of PPARg-LBD complexed with resveratrol is shown (green). C) Su-
perposition of the complexes of PPARg with resveratrol (yellow) and farglitazar (purple).
D) Superposition of the complexes of PPARg with resveratrol (yellow) and compound R-
1 (pink).
Figure 4. Transactivation assay on PPARa and PPARg of resveratrol in HepG2
cells. Fold induction by resveratrol (RV) over vehicle (EtOH, 0.1%) on
A) PPARa and B) PPARg as determined by luciferase-based transactivation
assays. Reference compounds: Wy-14643 (10 mm) and rosiglitazone (2 mm).
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that, although the fused ring moiety of compound R-1 was
very close to the terminal part of resveratrol, the two did not
occupy the same region. This result supports the notion that
resveratrol is unable to displace compound R-1 from the
PPARg-LBD, as evidenced by frontal chromatography.
Previous studies have demonstrated that 10 mm resveratrol
activates PPARa and PPARg in a number of cell-based reporter
assays.[18] In order to confirm whether a similar result would be
observed with HepG2 cells, resveratrol was first evaluated for
its agonistic activity toward the human PPARg and PPARa sub-
types by using luciferase-based transactivation assays. HepG2
cells were transiently transfected either with the GAL4-PPARa
or GAL4-PPARg chimeric construct, together with the luciferase
reporter vector containing the pGal5TkpGL3 construct, and
then treated with increasing concentrations of resveratrol. Ro-
siglitazone and Wy-14643 were used as positive controls for
PPARg and PPARa transactivation potential, respectively. Of
significance, there was no PPAR transactivation observed in
response to resveratrol treatment at concentrations up to
100 mm (Figure 4A and B). The agonistic activity of resveratrol
was compared with that of its metabolites at two fixed con-
centrations (10 and 25 mm), and no apparent effect was se n
on the transactivation potential of PPARa and PPARg (Fig-
ure S2).
The lack of PPAR activity from resveratrol was surprising, as
Inoue et al. initially reported PPARa/g dual agonism of resvera-
trol, excluding any activity toward the PPARd isoform and
other nuclear receptors,[18] and subsequently updated their
work and reported the pan-agonism of resveratrol for PPARs.[33]
The difference between the previously reported data and our
own could result from the type of cell line used. Specifically,
different cell lines might provide different results depending
on the presence of recruitable cofactors (coactivators
or corepressors) and/or metabolic processes, such as
cellular metabolism of resveratrol during the experi-
ment. In fact, these in vitro assays might not be the
most suitable for studying the effects of resveratrol
on PPARs, and might require a more careful investi-
gation in vivo.
Nevertheless, the demonstration of direct binding
of resveratrol to PPAR (results from frontal affinity
chromatography, ITC, and X-ray experiments) led us
to investigate whether resveratrol exhibited PPAR an-
tagonistic activity. For this purpose, transiently trans-
fected HepG2 cells were coincubated with or without
r sveratrol in th p esenc of eithe rosiglitazone or
Wy-14643 for 20 h. Data from the luciferase reporter
assay indicated that resveratrol was able to displace
rosiglitazone from PPARg and Wy-14643 from PPARa
with IC50 values of (27.4!1.8) mm and (31.7!2.5) mm,
respectively (Figure 5). Taken together, these results
demonstrate that resveratrol acts on both PPARg and
PPARa as an antagonist.
A comparison of the structure of resveratrol with
structures of the ligands used as positive controls in
the cell-based reporter assays was also carried out
(Figure S3). Rosiglitazone is a PPARg full agonist
whose crystal structure in complex with the PPARg-LBD
showed a standard agonist position with direct interaction
with helix 12 through a hydrogen bond with Tyr473.[34] More-
over, t e X-ray crystal structure of the PPARa/Wy-14643 com-
plex showed one molecule of the ligand directly interacting
with H12, similar to rosiglit z e and many ther PPAR full ag-
onists, and, more interestingly, a second molecule that inter-
acted with a secondary site between H2’ and H3, called the W-
Figure 3. A) Hydrogen-bond network of resveratrol in the PPARg-LBD. B) S erposition of
the complexes of PPARg with resveratrol (yellow) and amorfrutin 1 (white). For the sake
of clarity, the cartoon of PPARg-LBD complexed with resveratrol is shown (green). C) Su-
perposition of the complexes of PPARg with resveratrol (yellow) and farglitazar (purple).
D) Superposition of the complexes of PPARg with resveratrol (yellow) and compound R-
1 (pink).
Figure 4. Transactivation assay on PPARa and PPARg of resveratrol in HepG2
cells. Fold induction by resveratrol (RV) over vehicle (EtOH, 0.1%) on
A) PPARa and B) PPARg as determined by luciferase-based transactivation
assays. Reference compounds: Wy-14643 (10 mm) and rosiglitazone (2 mm).
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loop. It seems that the occupation of this second site can
better activate PPARa by stabilizing H12 in the active confor-
mation without any direct contact with the helix but only
through interactions connecting the W-loop, H3, and loop 11/
12, w ich precedes H12. I teresti ly, superposition of the
PPARg/resveratrol and PPARa/Wy-14643 crystal structures (Fig-
ure S3) showed that one aromatic ring of resveratrol occupied
almost th s m position as an aromatic ring of Wy-14643.
Conclusions
Evidence that resveratrol interacts directly with PPARs is lack-
ing, and very little effort has been placed on determining
whether resveratrol metabolites contribute to the biological
activities of resveratrol. In the study herein, results from chro-
matographic and ITC experiments have indicated that resvera-
trol and its metabolites bind directly with PPARg, and that only
resveratrol interacts with PPARa. In addition, we report the X-
ray crystal structure of the PPARg-LBD complexed with resvera-
trol, solved at 2.5 ! resolution. The binding mode of resveratrol
reveals a new pattern of receptor–ligand recognition and sug-
gests a novel basis for ligand design. The fact that resveratrol
binds to PPARg and conveys antagonistic activity on both
PPARg and PPARa highlights the need for better understand-
ing the role of cellular metabolism in resveratrol signaling.
Experimental Section
Chemicals: The reagents for target immobilization on silica capilla-
ries, including NaOH (Carlo Erba Reagenti, Rodano, Milan, Italy),
3-aminopropyltriethoxysilane, glutaraldehyde, KH2PO4, NaBH3CN,
monoethanolamine, CH3OH, DMSO, and CH3COONH4 were pur-
chased from Sigma–Aldrich, as was GW1929 (N-(2-benzoylphenyl)-
O-[2-(methyl-2-pyridinylamino)ethyl]-l-tyrosine hydrate). High-qual-
ity water was obtained by using a Milli-Q water purification system
(Millipore). The open tubular silica capillaries (100 mm i.d."
0.375 mm"40 cm) were from Thermo Fisher Scientific. Compound
R-1 (2-(4-{2-[1,3-benzoxazol-2-yl(heptyl)amino]ethyl}phenoxy)-2-
methyl-butanoic acid), used for displacement chromatography, is
a ureidofibrate-like derivative that was prepared as previously
described.[26] Reference compounds (Wy-14643 and rosiglitazone)
used for the transactivation assay were purchased from Sigma–Al-
drich. Resveratrol, resveratrol-3’-O-d-glucuronide, and resveratrol-3-
O-sulfate were purchased from Cayman Chemical (Ann Arbor, MI,
USA). Resveratrol-4-O-d-glucuronide was provided by SPI-Bio Bertin
Pharma (Montigny le Bretonneux, France). Minimum essential
medium (MEM) and other cell culture reagents were purchased
from Sigma–Aldrich.
Immobilization of the PPAR LBDs on open tubular capillary col-
umns: The human PPARg and PPARa LBDs were expressed as N-
terminal His-tagged proteins by using a pET28 vector and purified
onto a Ni2+-nitriloacetic acid column (GE Healthcare, Milan,
Italy).[31] LBDs were immobilized by using open tubular silica capil-
laries (100 mm i.d."0.375 mm"40 cm) following previously report-
ed procedures.[22, 23] Briefly, after activation of the capillary with
2 mL of 0.5n NaOH solution flushed at 100 mLmin!1, 1 mL of a so-
lution of 3-aminopropyltriethoxysilane (10%, v/v, in water) was run
through the column and incubated at 95 8C for 30 min. This step
was repeated twice and the capillary stored overnight at room
temperature. A glutaraldehyde solution (1%, v/v, in water) was
pumped through the capillary at 50 mLmin!1 followed by the infu-
sion of the PPAR-LBD solution (0.5 mgmL!1, 1 mL) at 50 mLmin!1.
After a washing step, the residual reactive sites on the column
were blocked by pumping a 5 mgmL!1 solution of NaBH3CN in
phosphate buffer, supplemented with 0.1m monoethanolamine for
1 h at 5 mLmin!1. The amount of immobilized LBD proteins was
measured from the PPAR solutions collected before and after the
immobilization step by using a Lambda 25 spectrophotometer
(PerkinElmer). The percentage of covalently attached LBD was ap-
proximately 86% and 50% for PPARg and PPARa, respectively.
Frontal displacement chromatographic studies
PPARg : Frontal analysis was carried out on a chromatographic
system composed of a syringe pump delivering the mobile phase
(90% 10 mm ammonium acetate, pH 7.4, 10% MeOH) through the
capillary at a flow rate of 2.5 mLmin!1, with post column mixing
with MeOH pumped at 5 mLmin!1 with an HPLC pump (Surveyor,
Thermo Finnigan). Ligands were detected by using either a Linear
Trap Quadrupole (LTQ) mass spectrometer with electrospray ioniza-
tion (ESI) as the ion source (Thermo Finnigan) for GW-1929 and R-
1 as marker ligands or a Series 1100 Liquid Chromatography/Mass
Selective Detector (Agilent Technologies) equipped with a vacuum
degasser (G1322A), a binary pump (1312A), an autosampler
(G1313A) with a 20 mL injection loop, a mass selective detector
(G1946B) supplied with atmospheric pressure ionization electro-
spray, and an on-line nitrogen generation system (Whatman, Ha-
verhill, MA, USA) for resveratrol. The former system was controlled
by Xcalibur software 1.4 (Thermo Finnigan). The conditions of the
instrument were held constant: source voltage 5.0 kV, sheath gas
flow 2.0 (arbitrary units), auxiliary gas flow 16.0 (arbitrary units), ca-
pillary voltage 14.95 V, capillary temperature 250 8C, and tube lens
voltage 90 V. For the latter system, the capillary voltage was set at
3200 V, the nebulizer pressure at 60 psi, and the drying gas flow at
Figure 5. Inhibition of agonist-induced transactivation of PPARa and PPARg
by resveratrol in HepG2 cells. Transiently transfected HepG2 cells were incu-
bated with increasing concentrations of resveratrol (1–100 mm) in the pres-
ence of either A) 10 mm Wy-14643 or B) 2 mm rosiglitazone. Luciferase report-
er activity was measured in cell lysates 20 h later. Data represent mean"
SEM from two independent experiments, each performed in triplicate wells.
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loop. It seems that the occupation of this second site can
better activate PPARa by stabilizing H12 in the active confor-
mation without any direct contact with the helix but only
through interactions connecting the W-loop, H3, and loop 11/
12, which precedes H12. Interestingly, superposition of the
PPARg/resveratrol and PPARa/Wy-14643 crystal structures (Fig-
ure S3) showed that one aromatic ring of resveratrol occupied
almost the same position as an aromatic ring of Wy-14643.
Conclusions
Evidence that resveratrol interacts directly with PPARs is lack-
ing, and very little effort has been placed on determining
whether resveratrol metabolites contribute to the biological
activities of resveratrol. In the study herein, results from chro-
matographic and ITC experiments have indicated that resvera-
trol and its metabolites bind directly with PPARg, and that only
resveratrol interacts with PPARa. In addition, we report the X-
ray crystal structure of the PPARg-LBD complexed with resvera-
trol, solved at 2.5 ! resolution. The binding mode of resveratrol
reveals a new pattern of receptor–ligand recognition and sug-
gests a novel basis for ligand design. The fact that resveratrol
binds to PPARg and conveys antagonistic activity on both
PPARg and PPARa highlights the need for better understand-
ing the role of cellular metabolism in resveratrol signaling.
Experimental Section
Chemicals: The reagents for target immobilization on silica capilla-
ries, including NaOH (Carlo Erba Reagenti, Rodano, Milan, Italy),
3-aminopropyltriethoxysilane, glutaraldehyde, KH2PO4, NaBH3CN,
monoethanolamine, CH3OH, DMSO, and CH3COONH4 were pur-
chased from Sigma–Aldrich, as was GW1929 (N-(2-benzoylphenyl)-
O-[2-(methyl-2-pyridinylamino)ethyl]-l-tyrosine hydrate). High-qual-
ity water was obtained by using a Milli-Q water purification system
(Millipore). The open tubular silica capillaries (100 mm i.d."
0.375 mm"40 cm) were from Thermo Fisher Scientific. Compound
R-1 (2-(4-{2-[1,3-benzoxazol-2-yl(heptyl)amino]ethyl}phenoxy)-2-
methyl-butanoic acid), used for displacement chromatography, is
a ureidofibrate-like derivative that was prepared as previously
described.[26] Reference compounds (Wy-14643 and rosiglitazone)
used for the transactivation assay were purchased from Sigma–Al-
drich. Resveratrol, resveratrol-3’-O-d-glucuronide, and resveratrol-3-
O-sulfate were purchased from Cayman Chemical (Ann Arbor, MI,
USA). Resveratrol-4-O-d-glucuronide was provided by SPI-Bio Bertin
Pharma (Montigny le Bretonneux, France). Minimum essential
medium (MEM) and other cell culture reagents were purchased
from Sigma–Aldrich.
Immobilization of the PPAR LBDs on open tubular capillary col-
umns: The human PPARg and PPARa LBDs were expressed as N-
terminal His-tagged proteins by using a pET28 vector and purified
onto a Ni2+-nitriloacetic acid column (GE Healthcare, Milan,
Italy).[31] LBDs were immobilized by using open tubular silica capil-
laries (100 mm i.d."0.375 mm"40 cm) following previously report-
ed procedures.[22, 23] Briefly, after activation of the capillary with
2 mL of 0.5n NaOH solution flushed at 100 mLmin!1, 1 mL of a so-
lution of 3-a inopropyltriethoxysilane (10%, v/v, in water) was run
through the column and incubated at 95 8C for 30 min. This step
was repeated twice and the capillary stored overnight at room
temperature. A glutaraldehyde solution (1%, v/v, in water) was
pumped through the capillary at 50 mLmin!1 followed by the infu-
sion of the PPAR-LBD solution (0.5 mgmL!1, 1 mL) at 50 mLmin!1.
After a washing step, the residual reactive sites on the column
were blocked by pumping a 5 mgmL!1 solution of NaBH3CN in
phosphate buffer, supplemented with 0.1m monoethanolamine for
1 h at 5 mLmin!1. The amount of immobilized LBD proteins was
measured from the PPAR solutions collected before and after the
immobilization step by using a Lambda 25 spectrophotometer
(PerkinElmer). The percentage of covalently attached LBD was ap-
proximately 86% a d 50% for PPARg and PPARa, respectively.
Frontal displacement chromatographic studies
PPARg : Frontal analysis was carried out on a chromatographic
system composed of a syringe pump delivering the mobile phase
(90% 10 mm ammonium acetate, pH 7.4, 10% MeOH) through the
capillary at a flow rate of 2.5 mLmin!1, with post column mixing
with MeOH pumped at 5 mLmin!1 with an HPLC pump (Surveyor,
Thermo Finnigan). Ligands were detected by using either a Linear
Trap Quadrupole (LTQ) mass spectrometer with electrospray ioniza-
tion (ESI) as the ion source (Thermo Finnigan) for GW-1929 and R-
1 as marker ligands or a Series 1100 Liquid Chromatography/Mass
Selective Detector (Agilent Technologies) equipped with a vacuum
degasser (G1322A), a binary pump (1312A), an autosampler
(G1313A) with a 20 mL injection loop, a mass selective detector
(G1946B) supplied with atmospheric pressure ionization electro-
spray, and an on-line nitrogen generation system (Whatman, Ha-
verhill, MA, USA) for resveratrol. The former system was controlled
by Xcalibur software 1.4 (Thermo Finnigan). The conditions of the
instrument were held constant: source voltage 5.0 kV, sheath gas
flow 2.0 (arbitrary units), auxiliary gas flow 16.0 (arbitrary units), ca-
pillary voltage 14.95 V, capillary temperature 250 8C, and tube lens
voltage 90 V. For the latter system, the capillary voltage was set at
3200 V, the nebulizer pressure at 60 psi, and the drying gas flow at
Figure 5. Inhibition of agonist-induced transactivation of PPARa and PPARg
by resveratrol in HepG2 cells. Transiently transfected HepG2 cells were incu-
bated with increasing concentrations of resveratrol (1–100 mm) in the pres-
ence of either A) 10 mm Wy-14643 or B) 2 mm rosiglitazone. Luciferase report-
er activity was measured in cell lysates 20 h later. Data represent mean"
SEM from two independent experiments, each performed in triplicate wells.
# 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2014, 15, 1154 – 1160 1158
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H2’ and H3, called the ω-loop. It seems that the occupation of this second 
site can better activate PPARα by stabilizing H12 in the active conformation 
without any direct contact with the helix but only through interactions 
connecting the ω-loop, H3, and loop 11/12, which precedes H12. 
Interestingly, superposition of the PPARγ-LBD/resveratrol and PPARα-
LBD/Wy-14643 crystal structures (Figure 66B) showed that one aromatic 
ring of resveratrol occupied almost the same position as an aromatic ring of 
Wy-14643.  
 In conclusion, the binding mode of resveratrol reveals a new pattern 
of receptor-ligand recognition and suggests a novel basis for ligand design. 
Moreover, the fact that resveratrol binds to PPARγ-LBD and conveys 
antagonistic activity on both PPARγ and PPARα highlights the need for 
better understanding the role of cellular metabolism in resveratrol signalling. 
 
                             
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66. The superposition of A) 
resveratrol (yellow) and rosiglitazone 
(purple) within LBD of PPARγ and B) 
PPARγ/resveratrol and PPARα/Wy-14,643 
(cyan) crystal structures. 
	  	   133	  
4.6 Betulinic acid: a PPARγ antagonist 
 In this study to be published some medicinal plants commonly used 
by the pygmies Baka, a community living in the south of Cameroon and 
possessing a consolidate tradition in the use of medicinal natural compounds, 
were selected as candidates to be PPARs ligands. Among them, Diospyros 
bipidensis has been identified as the most interesting plant for PPARs 
receptors considering that some plants of the same family are kown to have 
anti-inflammatory, anti-diabetic and hypoglicemic properties [194 - 197]. All 
the active components have been tested using affinity-based assay and further 
analyzed for their in vitro activity (agonist and/or antagonist assay) toward 
PPARα and PPARγ receptors by employing GAL4-PPAR transactivation 
assay. Plumbagin was the only ligand showing PPARγ partial agonism, while 
no transactivation activity was observed in response to all other ligands. With 
the aim to investigate whether they exhibited PPAR antagonistic activity, 
competitive displacement experiments were performed. The results showed 
that betulinic acid (BA; Figure 67) was able to displace rosiglitazone from 
PPARγ-LBD and Wy-14643 from PPARα-LBD with micromolar IC50 values 
of 3.1 ± 1.2 µM and 7.4 ± 1.8 µM, respectively. Betulinic acid, which has 
been proved to have a variety of pharmacological and biochemical effects 
including anti-inflammatory and anti-cancer activities [198], as well as anti-
adipogenic action in high-fat diet-fed mice [196], was also the ligand with 
higher affinity. Subsequently, X-ray-studies were performed on the complex 
between PPARγ-LBD and betulinic acid and a possible structural mechanism 
by which BA antagonizes PPARγ was proposed. 
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4.6.1 Crystal structure of PPARγ-LBD in complex with 
betulinic acid: two molecules of the ligand bind the LBD 
simultaneously 
 Crystals (0.2 x 0.2 x 0.2 mm) of apo-PPARγ-LBD were obtained by 
vapour diffusion using the sitting drop method and then soaked for one week 
in storage solutions containing the ligand (0.5 mM). X-ray data were 
collected at ESRF of Grenoble (France). Crystals of the PPARγ-LBD/BA 
complex belong to the C2 space group, with cell parameters shown in Table 
15. The solved structure has been deposited in the PDB with code 5LSG. 
 In the molecule A of the asymmetric unit the electron density map 
clearly revealed the presence of one molecule of BA in the region usually 
occupied by full agonists (Figure 68). Additional less evident electron density 
was also observed in the region occupied by partial agonists, between H3 and 
the β-sheet, where a second molecule of the ligand could be accomodated and 
refined. The presence of a second potential BA binding site was also 
suggested by docking studies (data not shown), which predicted an 
Figure 67. Chemical structure of betulinic acid. 
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energetically favourable pose in this second cleft. The first BA molecule has 
all its methyl groups engaged in vdW interactions with the protein 
environment (L453, F282, M364, C285, L330 and V339). The carboxylate 
group makes H-bonds bridging the OH of Y327 and that of S289. One of the 
two oxygen atoms is also involved in a H-bond with the carboxylate group of 
the second BA molecule, which is also H-bound to the CO of I281. The 3-
OH group of the second BA molecule makes a H-bond with the side-chain of 
E343, while the methyl groups interact at short distance with R280, G284, 
I341, F287, E291 and one carbon atom of the first BA molecule (3.3 Å). 
Unlikely most of the partial agonists, this second molecule of BA doesn't 
form H-bonds with residues belonging to the backbone of the β-sheet. H-
bonds interaction of both molecules of the ligand in the LBD of PPARγ are 
shown in Figure 69. 
 
 
 
 
Figura 68. 2Fo-Fc omit map around molecule 1 of BA (yellow) is shown in mesh and 
contoured at 0.7 σ 
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4.6.2 Sub-optimal stabilization of helices 11 and 12 
 Unlike the strong agonist rosiglitazone (PDB ID: 2PRG) the ligand 
BA doesn’t interact directly with Y473 by H-bonds with its carboxylate 
group, which instead is engaged in H-bonds with Y327, H323 and the side-
chain of S289. On the contrary, BA contacts the Y473 OH by vdW 
interactions through a carbon atoms of its 5-membered ring (shortest C-O 
distance: 3.1 Å). The H-bond network realized by the triad Y473, H323 and 
H449 is less stable than that of complexes with full agonists such as 
rosiglitazone, as denoted by the slightly shifted position of the activation 
function-2 helix (AF-2 or H12) from its active conformation with the 
consequent loss of the H-bond between the H449 ring and the Y473 OH 
(distance of 3.6 Å). From the crystal structure it can be noticed a steric clash 
between carbon atoms of the ligand and the ring of H449 (shortest distance 
2.9 Å). Moreover, the environment around H449 is different compared to the  
 
$
Figure,1.$(A)$2Fo-Fc omit map around molecule 1 of BA (yellow) is shown in mesh and contoured at 
0.7 σ; (B) H-bonds interactions (red dashed lines) of molecule 1 (yellow) and 2 (green) of BA, bound 
simultaneously to the LBD of PPARγ. 
 
 
Figura 69. H-bonds interactions (red dashed lines) of molecule 1 (yellow) and 2 (green) of 
BA, bound simultaneously to the LBD of PPARγ.  
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 PPARγ-LBD/BA 
Data collection  
space group C2 
cell dimension a, b, c [Å] 92.86, 60.85, 118.30 
monoclinica angle β [deg] 102.482 
wavelenght [Å] 0.9537 
resolution range [Å] 50.00 - 2.00 
last shell [Å] 2.20 - 2.00 
Rmerge [%] 2.7 (41.3) a 
unique reflections 84071  
mean (I)/σ(I) 20.33 (2.63) a 
completeness 98.6 (97.6) a 
Refinement  
resolution range [Å] 50.00 - 2.00 
Rwork [%] 22.9 
Rfree [%] 27.0 
Bond lenghts r.m.s.d. [Å] 0.009 
Bond angles r.m.s.d. [deg] 1.367 
Table 15. Summary of crystallographic analysis for PPARγ-LBD/BA complex. 
a The values in parentheses refer to the outer shell 
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structure of the complex with rosiglitazone, because the side-chain of F363 
has changed its conformation, due to a steric clash with one methyl of BA 
(3.0 Å), and now approaches H449 (3.3 Å), L453 (3.6 Å), L452 (3.7 Å), and 
the methyl group of I456 (3.5 Å) which is slightly displaced from its original 
position (Figure 70). Therefore, the dynamics of the helix 11 around H449 is 
changed, a helix which is part of the AF-2 surface and directly affects H12. A 
loss of stabilization of the region including H11, near H449, has been also 
observed in HDX experiments for the complex of PPARγ with the antagonist 
SR1664 [199]. We suggest that the antagonist character of BA is due to the 
loss of direct H-bonds with Y473 and the consequent destabilization, or sub-
optimal stabilization, of helices 11 and 12. In any case, the micromolar 
affinity (Kd = 4 µM) of BA for the LBD of PPARγ, as determined by ITC 
(Figure 71), was sufficient to displace rosiglitazone as observed in the 
competitive test performed by Loiodice and collaborators (IC50 value of 3.0 ± 
1.7 µM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$
Figure,1.$(A)$2Fo-Fc omit map around molecule 1 of BA (yellow) is shown in mesh and contoured at 
0.7 σ; (B) H-bonds interactions (red dashed lines) of molecule 1 (yellow) and 2 (green) of BA, bound 
simultaneously to the LBD of PPARγ. 
 
 Figure 70. Superpose of the crystal structures of the complexes PPARγ-
LBD/BA (yellow) and PPARγ-LBD/rosiglitazone (PDB ID: 2PRG) 
(cyan). The F363 side-chain in gauche conformation (cyan) would make 
a steric clash (black dashed lines) with a methyl group of BA. The 
gouche* conformation of F363 allows vdW interactions (ranging from 
3.3 to 3.7 Å) with hydrophobic residues on H11 (red dashed lines). 
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4.6.3 Comparison with the antagonist SR1664 and the agonist 
SR1663: the F282/F363 switch mechanism.  
 
 It is interesting to compare the crystal structure of PPARγ/BA with 
that of the complex with another PPARγ antagonist available in the PDB. 
Figure 72 shows the superposition of the structures of BA and SR1664 [199, 
200] in the complex with PPARγ. The two compounds occupy a similar 
position in the LBD, both contacting Y473 only through vdW interactions, 
and forming instead a H-bond with Y327. In the case of the bulkier SR1664 
the authors observed steric clashes, not present in the (R) enantiomer 
SR1663, with the F282 aromatic ring and the hydrophobic side chains of 
Figure 71. Reverse titration of PPARγ-LBD to BA. The upper panel of the figure shows the 
raw data of the ITC experiment. The lower panel shows the corresponding binding isotherm 
fitted according to the “one binding site” model. 
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H11, such as that of Leu 453 as well as that of Leu 465 of the loop 11/12. 
Therefore, the authors suggested that SR1664 actively antagonizes PPARγ 
through a stereo-specific AF2-mediated, F282-dependent clash. Moreover, 
they confirmed the role of F282 in the antagonism of SR1664, showing that 
this ligand turns into an agonist upon mutation F282A. Anyway, the shortest 
distance of SR1664 with F282 is 3.0 Å (NO2-C) that is consistent with a 
strong vdW interaction rather than a steric clash. As discussed hereafter, the 
F282A mutation may result in a different position of the ligand into the 
pocket, explaining its agonism towards the mutant. The corresponding (R) 
enantiomer SR1663 shows agonist properties (80% efficacy compared to 
rosiglitazone). Observing the interaction of the ligand with the the protein 
molecule A in the complex with PPARγ, the molecule whose H12 is in the 
active conformation (H12 of the molecule B of the dimer is in a inactive 
conformation and it should not be considered to discuss its interaction with 
an agonist), it can be seen a deeper protruding of the NO2 group towards 
F282, due to the different stereochemistry, that would give a strong clash 
with F282 if this residue would assume its usual conformation. Actually, 
there is poor electron density in the position of F282 and the authors could 
assign only the position of the Cβ atom of the F282 side-chain.  
 A more accurate observation of the electron density maps reveals a 
possible different conformation of the F282 side-chain, switching from trans 
to gauche* (Figure 73). A similar situation was already observed in the 
structure with the ligand LT175 (PDB ID: 3B3K) where the bulky and rigid 
diphenyl group of the ligand displaced the side-chain of F282, shifting in turn 
those of F363 and I456 and opening a new hydrophobic pocket in the LBD 
between H11 and H3 (Figure 74).  
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 This is also confirmed in the PPARγ/SR1663 structure by the shifted 
conformation of F363, with respect to that observed in the apo-PPARγ, and 
the alternate conformation of C285, that in this new conformation can 
interact with the side-chain of F282. This role of gate-keeper of F282 was 
recently observed also in the PPARα complex with the ligand AL29-26 (in 
this case the PPARα corresponding residue is F273; see chapter 4.1). The 
accomodation of the nitro-substituted ring of SR1663 in the new pocket, as 
well as the diphenyl moiety of LT175, can determine the agonist character of 
the ligand with an additional stabilization of H11 and H3. It is possible that 
SR1664 in the F282A mutant could assume a similar deeper position in the 
pocket, becoming an agonist, but only its crystal structure in the complex 
with the mutant could unveil it. Looking at the structures of the the two 
compounds BA and SR1664, both lacking the H-bond interaction with Y473 
on H12, it would seem that this feature could be responsible of their 
antagonist character. In any case, also SR1663 showed no direct interactions, 
other than vdW contacts, with Y473. This would suggest that a direct 
hydrogen bond with Y473 is not necessarily required for some agonist 
 
Figure,2.$Superpose$of$the$crystal$structures$of$the$complexes$PPARγ/BA$(yellow)$and$PPARγ/rosiglitazone$(pdb$code$2PRG)$(cyan).$The$F363$side1chain$in$gauche$conformation$(cyan)$would$make$a$steric$clash$(black$dashed$lines)$with$a$methyl$group$of$BA.$The$gouche*$conformation$of$F363$allows$vdW$interactions$(ranging$from$3.3$to$3.7$Å)$with$hydrophobic$residues$on$H11$(red$dashed$lines). 
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Figure,3.$Reverse,titration,of,,PPARγJLBD,to,BA$The$upper$panel$of$the$figure$shows$the$raw$data$of$the$ITC$experiment.$The$lower$panel$shows$the$corresponding$binding$isotherm$fitted$according$to$the$“one$binding$site”$model.$$$
Figure,4.$Activity$test$and$displacement$of$rosiglitazone$(da$inserire:$Loiodice/Laghezza)$$
$
Figure 72. Stereoview of the superposed crystal structures of PPARγ/BA (cartoon gray, BA yellow) 
and PPARγ/SR1664 complexes (cartoon wheat, SR1664 cyan). 
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activity, but rather stabilizing H12 in its active conformation seems more 
important, as well as keeping the proper conformations of the other helices 
composing tha AF-2 surface together with H12, for the co-activator 
recruitment. In the case of the antagonist BA, the loosening of the interaction 
with H12, associated with a different stabilization of H449 on the helix 11, 
could be responsible for different dynamics of the helices forming the co-
activator binding site, determining the antagonist character of the ligand. In 
conclusion, it can be noted that the PPARγ LBD is formed by closely related 
domains whose dynamics, upon ligand binding into different regions of the 
LBD (between H3, H12, H11 and the loop 11/12, as in the case of full 
agonists, or between H3, the β-sheet and the ω loop, as in the case of partial 
agonists), can produce long range allosteric effects affecting the recruitment 
of co-activators or the phosphorylation of S245 (S273 in PPARγ2) and other 
post-translational modifications, modulating in this way the biological 
response. 
 
Figure 73. 2Fo-Fc electron 
density map of SR1663 after a 
new refinement by Phenix with 
the side-chain of F282 in g* 
conformation (χ1
 
= -87°).  
The conformation of F363 side-
chain is also changed, with respect 
to the structure of apo-PPARγ or 
of the complex with rosiglitazone, 
after the shift of F282. 
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Figure,5.,Stereoview$of$the$superposed$crystal$structures$of$$PPARγ/BA$(cartoon$gray,$BA$yellow)$and$PPARγ/SR1664$complexes$(cartoon$wheat,$SR1664$cyan).$
$
Figure,6.,F282/F363,switch,mechanism,In$the$PPARγ/LT175$X1ray$structure$(cyan)$the$ligand$LT175$(green)$forces$the$F282$side1chain$to$switch$from$the$trans$to$the$gauche*$conformation,$and$in$turn$the$F363$side1chain$also$changes$its$conformation$by$180°,$contacting$H449.$In$the$new$conformation$the$F282$aromatic$ring$makes$favorable$pi1stacking$interactions$with$the$rings$of$F360$and$F363.$$
 
 
Figure S1 of Supplementary Info: 2Fo-Fc electron density map of SR1664 after a 
Figure 74. F282/F363 switch 
mechanism: in the structure of 
the complex between PPARγ-
LBD (cyan) and LT175, the 
ligand (green) forces the F282 
side-chain to switch from the 
trans to the gauche* 
conformation, and in turn the 
F363 side-chain also changes its 
conformation by 180°, 
contacting H449. In the new 
conformation the F282 aromatic 
ring makes favorable pi-
stacking interactions with the 
rings of F360 and F363. 
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5. Summary and conclusions 
In this thesis the PPARs LBD in complex with both natural and 
synthetic ligands have been investigated using X-ray crystallography, with 
the aim to determine a structure-activity relationship between the 
ligand/receptor interaction and the partial/full agonism or antagonism 
character of the ligands, thus providing information for the design of novel 
compounds with a better pharmacological profile. In addition, the interaction 
with the receptors for some of these ligands has been further characterized 
through SPR and ITC techniques, which provided information on binding 
affinity, kinetics and thermodynamics. In particular, SPR has proved to be a 
potent and fast tool for high-throughput screening of a large number of 
compounds, as in the case of saponins and sapogenins, also being able to 
reveal the antagonistic character of some  ligands (e.g. echinocistic acid).  
 PPARs represent a central point of pharmacological and medical 
research, due to the broad roles of the three isotypes in regulating 
metabolism, inflammation, differentiation and cellular growth. In particular, 
all isoforms are involved in lipid homeostasis and glucose regulation (energy 
balance), with PPARα and PPARβ/δ facilitating energy combustion and 
PPARγ contributing to energy storage by enhancing adipogenesis. For this 
reason PPARγ ligands, in particular full agonists for the receptor such as 
TZDs, were used in the clinic for treatment of type 2 diabetes mellitus 
(T2DM). However, they showed serious life-threatening side effects so that 
in the recent years the research have been focused on partial agonists and 
selective modulators with a weaker effect in specific tissues.  
 In the strategy for searching safer therapeutic agonists of PPARγ, 
devoided of the side effects of the full agonists, new drug candidates called 
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selective PPARγ modulators (SPPARMs), able to differentially induce 
specific effects, have been developed and clinically tested. Ideal SPPARMs 
would be potent and highly efficacious inducers of insulin sensitivity (e.g. 
up-regulation of adiponectin or adipsin target genes) with low potency and/or 
low maximal activity (partial agonists) on adipogenesis (e.g. down-regulation 
of aP2 and LPL target genes). 
 It has been observed that specific binding of a ligand to the PPARγ 
LBD can be associated to a different recruitment of co-activators and to 
different gene expression profiles. A preliminar NMR structural dynamics 
study performed on the apo-PPARγ LBD [36] indicated that the LBD is in 
very high molecular motion when not bound to the ligand. The converse was 
shown upon addition of rosiglitazone, indicating that full agonists are able to 
greatly stabilize the mobility of the receptor. Further HDX studies showed 
that full agonists strongly and selectively stabilize H3 and H12, and the 
activation function-2 (AF-2) surface for the recruitment of co-activators. X-
ray crystallography studies showed that this stabilization is obtained mainly 
by a H-bond network between the acidic head of the ligand and three key 
residues of the nuclear receptor: H449, H323 and Y474, the latter belonging 
to the helix 12. HDX and X-ray crystallography also showed that, 
surprisingly, partial agonists cause no direct stabilization of H12 even though 
in some cases have a transactivation output nearly 80% of that of 
rosiglitazione (e.g. BVT.13) [32], suggesting that a non-H12-dependent 
mechanism exists to control co-activator recruitment. Instead, partial agonists 
were shown to preferentially stabilize other regions of the LBD, especially 
the β-sheet region and H3. Helix 3 occupies a central position in the LBD and 
through different ligand binding modes is able to allosterically propagate a 
conformational exchange between different regions that may alter the surface 
of the receptor, eliciting different biological responses. Among these, the 
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inhibition of the phosphorylation of S245 (PPARγ2 residue S273) is very 
desirable as an antidiabetic effect: most of partial agonists bind to the region 
in front of the inner strand of the β-sheet, making H-bonds with S342, 
strongly stabilizing the β-sheet and reducing in this way the flexibility of the 
loop region around the phosphorylatable S245 and making less favorable its 
phosphorylation by Cdk5 [71]. But, while it is easy to assume that ligands 
directly stabilizing the phosphorylation region could affect the 
phosphorylation rate, less clear is the case of other ligands such as LT175 
[52] that, although occupying a region far from the consensus motif, also 
affect the phosphorylation rate. Then we are currently demonstrating, through 
different techniques (NMR, phosphorylation assays, protein-protein docking, 
MD simulation), a new cross-talk mechanism able to allosterically inhibit 
PPARγ phosphorylation. Our future objective is to explore, through HDX 
technology, structural changes remote from the ligand binding site with the 
aim to describe a novel mechanism of ligand inhibition of Cdk5-mediated 
PPARγ phosphorylation and to probe that the protection of the consensus 
region is variably affected by ligands depending on their binding mode. 
 However, so far it is not yet possible to establish a straightforward 
relation between a given ligand binding mode and a specific pharmacological 
profile. Generally, it can be said that compounds strongly stabilizing the H12 
in its active conformation (through direct H-bonds with this helix) are unable 
to uncouple the insulin sensitizing activity from the adipogenic effect. There 
are also partial agonists or antagonists facing the helix 12, but not interacting 
directly with it, that form different H-bond networks compared to TZDs, for 
example making H-bonds with Y327 and S289. These compounds (betulinic 
acid, benzimidazoles, SR1663) showed a reduced adipogenic effect, 
maintaining at the same time the insulin sensitizing action. Partial agonists 
occupying the region between H3 and the β-sheet (caulophyllogenin, 
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halofenic acid, AL29-26) can, in principle, inhibit the phosphorylation of 
S245 and the level of inhibition could be associated to the degree of 
stabilization of the β-sheet induced by the ligand. This question can be better 
addressed by HDX experiments, that measure the degree of exposition to the 
solvent (and to Cdk5) of the β-sheet, rather than X-ray studies.  
 A further research direction under consideration is to explore the 
therapeutic potential of PPAR pan agonists that would combine the agonistic 
activities toward PPARγ, PPARα and PPARβ/δ in a single ligand with a 
balanced activation profile; these compounds may prove to be the ultimate 
combination of PPAR activities for treatment of T2DM and its further 
complications. Indeed, pan agonists would regroup the beneficial effects of 
the three PPAR subtypes by normalizing insulin resistance, plasma lipids and 
adiposity [201]. To this purpose, the ligand AL29-26 has been identified 
using a SBVS approach and it has been shown to be a potent full agonist on 
PPARα, and a partial agonist on PPARγ and β/δ subtypes. To date, the data 
show that an appropriate dual PPARγ/α activation results in improved 
metabolic profile. However, as already hinted, partial agonists of PPARγ are 
more desirable to avoid the serious side-effects caused by full agonists. On 
the contrary, a strong activation of PPARα is also advantageous because 
improves dyslipidemia, lowering plasma triglycerides and increasing HDL 
cholesterol levels. Therefore, the search for the optimal pharmacological 
profile of a ligand plays an important role and for this purpose it is required 
the understanding, at molecular level, of the mechanism by which the ligand 
behaves as full or partial agonist on PPARs. In the paper concerning the 
ligand AL29-26, a rationale for the difference of ligand activity toward α and 
γ subtypes has been provided and a new cavity of PPARα-LBD never 
observed before has been discovered, thus opening new opportunities to 
rational design of more balanced PPAR modulators. 
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 In this thesis, crystal structure of PPARγ mutants were also 
characterized. Particularly, the structure of the human pathological PPARγ 
F360L mutant showed as a simple conservative mutation to leucine leads to 
dramatic conformational changes in the C-terminal region of the receptor 
LBD, revealing the impact of mutations on dynamics and communication 
pathways among PPARγ domains. In particular, F360L mutation is 
responsible of the lack of van der Waals interactions and the weakening of 
two important salt bridges connecting H3 and the loop 11/12, with a 
consequent destabilization and rearrangement of this loop resulting in the 
increased dinamycs of the helix 12 and in a less efficient co-activators 
recruitment. In conclusion, the elucidation of the crystal structure of the 
PPARγ-LBD F360L mutant has provided considerable insight into the 
structural basis of the transactivation deficiency of this mutant, which has 
been associated with familial partial lipodistrophy. The study of other known 
pathological mutants, associated to metabolic disorder and different types of 
cancer, has been continued using spectroscopic techniques (fluorescence and 
CD spectroscopy) to investigate the effects of a single aminoacidic 
substitution on PPARγ thermal, thermodynamic and spectral properties 
(manuscript in preparation). 
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Abstract
New catechol-containing chemical entities have been investigated as matrix metalloproteinase
inhibitors as well as antioxidant molecules. The combination of the two properties could
represent a useful feature due to the potential application in all the pathological processes
characterized by increased proteolytic activity and radical oxygen species (ROS) production,
such as inflammation and photoaging. A series of catechol-based molecules were synthesized
and tested for both proteolytic and oxidative inhibitory activity, and the detailed binding mode
was assessed by crystal structure determination of the complex between a catechol derivative
and the matrix metalloproteinase-8. Surprisingly, X-ray structure reveals that the catechol
oxygens do not coordinates the zinc atom.
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Introduction
Matrix metalloproteinases (MMPs) are a family of zinc-contain-
ing endopeptidases, capable to process all the extracellular matrix
components. They can be classified in collagenases (MMP-1,
MMP-8, MMP-13, MMP-18), gelatinases (MMP-2, MMP-9), and
metalloelastase (MMP-12), based on the substrate that they
process.
Their enzymatic activity is finely regulated in physiological
conditions: MMPs are responsible for tissue regeneration and
remodeling, as well as bioavailability of pro-factors that need
proteolytic cut activation. Endogenous molecules such as tissue
inhibitors of metalloproteinases (TIMPs) are responsible for the
physiological fine regulation of the numerous isoforms1.
However, several external factors (e.g. solar UV irradiation) or
pathological conditions (cancer, metastasis, or chronic inflam-
mation) are able to stimulate an overexpression of specific MMPs.
Therefore, due to their implications in complex pathological
processes, MMPs continue to be considered a pivotal target for
therapeutic intervention2.
The selectivity still represents the main challenge in the MMP
inhibitor design: the importance of selective targeting3,4 has
already been previously proved in MMP inhibition strategy5
especially because in the last decade, a number of inhibitors failed
in clinical trial phases6, mainly due to their broad spectrum
activity.
Photoaging represents another process in which the proteolytic
activity of MMPs has a notorious and critical role; collagenases,
in particular, are responsible for the decomposition of particular
types of collagen and other proteins in the extracellular matrix of
the dermis7–10. The breakdown of dermal collagen and elastin is
purported to be one of the major contributing factors to loss of
skin’s firmness and elasticity. Physiologically, the human skin
expresses a number of MMPs, including MMP-1, -2, -3, -8, -9,
and -13, all of which are capable of attacking native fibrillar
collagen.
Chronic exposure to solar UV radiation is an accelerator factor
for photoaging. UV irradiation is known to provoke oxidative
stress through the generation of reactive oxygen species (ROS),
which are responsible to interfere with physiological pathways
and ultimately activate the overexpression of a number of
proteolytic enzymes such as MMPs in skin cells, capable to
destroy the dermal connective tissue. In addition, ROS can
regulate pro-MMPs activation11–15.
Thus, the antioxidant activity associated with the inhibition of
MMPs could represent a promising strategy to obtain new
chemical entities capable to reduce photoaging and prevent
wrinkles and damage of the skin, and be effective for other
pathological conditions where oxidative stress occurs.
MMP inhibitors (MMPIs) are usually characterized by a
backbone that interacts with the specificity pocket S10, coupled to
a metal chelator portion that binds to the catalytic Zinc ion. To
expand the library of potential MMPIs and to overcome some
limitations of the hydroxamic acid moiety16,17, other zing binding
Address for correspondence: Paolo Tortorella. E-mail:
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groups (ZBGs) as essential portion in MMP inhibitor molecule of
new synthesis have been developed18–22.
Recently, a series of rosmarinic acid derivatives has been
identified as micromolar MMP-1 inhibitors23. In addition, phen-
olic and polyphenolic compounds have already been used as
antioxidants, and their activity seems to impact several different
pathways. In particular, one of the most tested hypothesis is that
they exert protective effects against cancer and other chronic
diseases by reducing ROS levels13. Natural compounds derived
from green tea (EGCG), mainly known for their antioxidant
properties, have shown relevance when applied on wrinkles or
fine lines caused by aging, due to their ability to enhance collagen
levels and to inhibit MMPs24. Many other natural compounds,
such as phytosterol, fucosterol, resveratrol, soy isoflavones, alpha-
tocopherol, and vitamin E and C, are also able to inhibit MMPs
and ROS and reduce the degradation of skin25–28. Some MMPIs
have been studied in topical cosmetic compositions to counteract
the effect of photo and chronological skin aging. For example,
their use has been reported in combination with UV blockers (e.g.
octinoxate and zinc oxide)12, natural estrogen (e.g. 17-beta
estradiol or an estrogen-like steroid)12, or antioxidants (Alpha
Lipoic Acid, ALA)29.
In this study, we present a new class of MMPIs obtained by
combining a catecholic portion with a backbone able to reach the
S10 specific pocket of the enzyme isoforms. All these compounds
were tested toward MMP-2, -8, and -9 whereas their in vitro
antioxidant activity was evaluated by DPPH assay. In order to
better understand the interactions between MMPs and the
chemical inhibitor, the X-ray structure of the complex between
MMP-8 and one compound of the series was resolved.
Results and discussion
Starting from the promising inhibitory activity values obtained
testing catechol on different MMPs30, we decided to further
investigate catecholic derivatives by focusing our attention on the
backbone that, in the classical structure activity relationship
(SAR) of MMPIs, blocks the substrate access to the active site.
Therefore, we report herein the synthesis and biological activity
of three set of analogs (Figure 1) in which the catechol is
connected through an amide (compounds 1–6) or a sulfonamide
(compounds 7–17) group to a series of alkylaryl or aryl moieties
in order to reach the S10 specificity pocket of the different enzyme
isoforms.
Most compounds present a diphenyl or a phenoxyphenyl
residue, based on the results obtained by our previous works in
which these groups were linked to typical ZBGs3,4,19,22,31–34. The
relative position of sulfonamide linking group as well as the
importance of hydroxyl groups were evaluated. To this aim, we
prepared a fourth set of compounds 18–22 (Figure 2) character-
ized by the lack of hydroxyl groups or the presence of a single
hydroxyl group in different position of the aromatic ring.
Compounds 1–6 were obtained via condensation of dibenzy-
loxybenzoic acid or corresponding chloride with the appropriate
aniline or benzylamine and following by debenzylation through
catalytic hydrogenation (Scheme 1). N-(4-diphenylmethyl)-N-
methyl-2,3-dibenzyloxybenzamide (26) was obtained through
methylation of the sulfonamide nitrogen of the dibenzylate
intermediate (25).
Compounds 7–13 and 18–22 were synthesized via condensa-
tion of the suitable aniline or benzyl amine with the appropriate
sulfonyl chloride (Schemes 2 and 3). Subsequent deprotection
under H2 atmosphere in the presence of 10% Pd/C or with BBr3
was needed to obtain the final compounds. N-(2,3-dihydroxy-
phenyl)-N-methyl-4-phenyl sulfonamide (10) and N-(2,3-dihy-
droxy-phenyl)-N-methyl-4-phenoxy-phenyl sulfonamide (11)
were obtained through methylation of the sulfonamide nitrogen
of the dibenzylate intermediate.
Compounds 14–17 were synthesized via condensation of 3,4-
(methylenedioxy)aniline or benzylamine with the appropriate
sulfonyl chloride (Scheme 4). Subsequent deprotection with BBr3
was needed to obtain the final compounds.
All synthesized compounds 1–22 were tested against MMP-2,
-8, and -9 (Tables 1 and 2). Compound 1 shows a very weak
activity against all considered MMPs. As expected, the introduc-
tion of a diphenyl moiety (2) provides more potency and
selectivity on MMP-2. A significant increase of activity toward
all MMPs is obtained by inserting a methylene spacer (3), while
the methylation of the amide nitrogen (4) reduces it. The
introduction of an oxygen atom between the phenyl rings results
in an increase of activity (5 versus 2) or selectivity for MMP-2
(6 versus 3).
As well as for amide derivatives, compounds 7 and 8 still
maintain good activity values toward MMP-2, showing an
increased activity also on MMP-8 and -9. The introduction of
the more flexible phenoxy phenyl structure (9) results in a slight
increase of activity toward all the enzyme isoforms, with IC50
values around 6 mM against all tested MMPs.
The methylation of the sulfonamide nitrogen still confirms its
detrimental effects on MMP-8 and -9 (10 and 11), while no loss in
activity results for these N-methyl derivatives against MMP-2.
Compound 10 stands out for its very interesting selectivity toward
MMP-2. The insertion of a methylene between the sulfonamide
moiety and the catecholic portion (12) allows to obtain inhibition
activity in the low micromolar range toward MMP-2, -8, and -9
and even the substitution of the phenyl ring with a bromine atom
(13) maintains high activity values against all isoforms.
Moving the hydroxyl groups from the 2,3 to the 3,4 positions
of the aromatic ring, it results a slight increase of activity when
the sulfonamide moiety is directly linked to the phenyl residue
(8 versus 14); in this case, the substitution of phenyl with bromine
(15) reduces the activity on MMP-8 and MMP-9. The introduction
Figure 1. Catechol-based MMP inhibitors.
Figure 2. Catechol-based MMP inhibitors.
2 M. Tauro et al. J Enzyme Inhib Med Chem, Early Online: 1–13
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of a methylene spacer into the structure of 14 gives 16 with lower
activity toward all isoforms, whereas the same modification for
15 affords 17 showing reduced activity only against MMP-2.
In order to evaluate whether the presence of hydroxyl
groups was essential for inhibitory activity, we prepared the
mono- (20–22) or non-substituted (18, 19) analogs (Table 2).
However, these compounds show a complete loss of activity
against all isoforms.
The in vitro antioxidant activity of these catecholic derivatives
was also evaluated by DPPH assay (Tables 1 and 2), considered as
Scheme 2. Reagents and conditions: (a) Et3N, CH2Cl2, reflux; (b) dry DMF, NaH, CH3I, 0
!C; (c) THF/MeOH, 10% Pd/C, H2, r.t. or BBr3, CH2Cl2,
0 !C 1 h.
Scheme 3. Reagents and conditions: (a) Et3N, CH2Cl2, reflux.
Scheme 1. Reagents and conditions: (a) anhydrous THF, r.t. or DMAP, DCC, CH2Cl2, r.t.; (b) dry DMF, NaH, CH3I, 0
!C; (c) H2, 10% Pd-C, CH3OH/
THF 2:5, r.t.
Scheme 4. Reagents and conditions: (a) Et3N, CH2Cl2, reflux; (b) BBr3, CH2Cl2, 0
!C 1 h.
DOI: 10.1080/14756366.2016.1217853 Catechol-based MMP inhibitors 3
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one of the standard colorimetric method for the evaluation of
antioxidant properties of pure compounds and is routinely
practiced for assessment of free radical scavenging potential of
an antioxidant molecule. Experiments were performed also with
gallic acid, a naturally occurring plant phenol as the reference
substance.
Several studies suggest that structure–antioxidant activity
relationship for phenolic compounds depends on the position
of hydroxyl groups, the presence of other functional
groups in the whole molecule, and their conjugation to hydroxyl
groups35.
For compounds 1–17, antioxidant activity could be mainly
ascribed to the reducing power of the o-dihydroxy structure;
elimination of the hydroxy groups (18 and 19) or their substitution
with methoxy ones (data not shown) results in a complete loss of
activity. Derivatives with hydroxyl groups in positions 2, 3 show
a better antioxidant activity with respect to the 3, 4 substitutions
(8 versus 14).
The reduction of the o-dihydroxy structure to phenol (20–22)
results in a decrease of the activity strongly dependent from the
substituent position: only the 2-substituted analog (22) maintains
an interesting antioxidant activity, while no or low activity is
observed in the 3- or 4-substituted derivative, respectively (20 and
21). Therefore, it can be argued that the presence of two phenolic
groups is not the only factor determining the antioxidant activity
of our derivatives.
Table 1. MMP activity values expressed as IC50 (mM) and antioxidant activity values expressed as EC50 in DPPH assay and ARP.
Compounds n R R1 MMP-2 MMP-8 MMP-9 EC50
a ARPb
Gallic acid 0.065± 0.012 15.4
1 0 H H 4100 4100 4100 0.130± 0.041 7.7
2 0 C6H5 H 34± 6 4100 4100 0.163± 0.012 6.1
3 1 C6H5 H 4.0± 1.4 25± 4 56± 8 0.099± 0.009 10.1
4 1 C6H5 CH3 4100 4100 4100 0.112± 0.021 8.9
5 0 C6H5O H 6.6± 1.2 26± 5 33± 5 0.104± 0.044 9.6
6 1 C6H5O H 4.2± 0.9 94± 4 95± 5 0.119± 0.009 8.4
7 0 CH3O H 12± 4 16±3 19± 3 0.128± 0.013 7.8
8 0 C6H5 H 12± 3 8.7± 2.0 6.2 ± 0.4 0.101± 0.001 9.9
9 0 C6H5O H 6.3± 2.3 6.2 ± 1.5 6.5 ± 2.0 0.112± 0.012 8.9
10 0 C6H5 CH3 9.5 ± 2.5 4100 4100 0.133± 0.023 7.5
11 0 C6H5O CH3 17.5± 2.1 33.5± 0.7 29± 4 0.138± 0.004 7.2
12 1 C6H5 H 7± 2 2.5± 0.9 2.1 ± 1.0 0.166± 0.011 6.0
13 1 Br H 4.4± 0.5 1.9 ± 0.4 2.0 ± 0.5 0.172± 0.025 5.8
14 0 C6H5 H 7.0± 0.2 3.1 ± 1.1 2.7 ± 0.8 0.143± 0.020 7.0
15 0 Br H 5.6± 1.5 6± 2 5.5± 2.0 0.192± 0.042 5.2
16 1 C6H5 H 12± 2 6±1 7.5± 1.5 0.167± 0.023 6.0
17 1 Br H 10± 1 4.4± 0.3 2.5 ± 0.1 0.188± 0.002 5.3
ammol of antioxidant/mmol of DPPH. bAntiradical power (ARP)¼ 1/EC50.
Table 2. MMP activity values expressed as IC50 (mM) and antioxidant activity values expressed as EC50 in DPPH assay and ARP.
Compounds n R1 R2 R3 MMP-2 MMP-8 MMP-9 EC50
a ARPb
18 0 H H H 4100 4100 4100 41 51
19 1 H H H 4100 4100 4100 41 51
20 0 H H OH 4100 4100 4100 0.37± 0.09 2.7
21 0 H OH H 4100 4100 4100 41 51
22 0 OH H H 4100 4100 4100 0.15± 0.03 6.6
ammole of antioxidant/mmol of DPPH. bAntiradical power (ARP)¼ 1/EC50.
4 M. Tauro et al. J Enzyme Inhib Med Chem, Early Online: 1–13
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Methylation of the nitrogen results in a reduction of activity for
both the amidic (4 versus 3) and sulfonamide analogs (10 versus 8
and 11 versus 9). The presence of a methylene spacer increases
ARP in the amide series (3 versus 2), while a strong reduction is
observed for sulfonamide derivatives (14 versus 16).
Catechol was identified as a promising ZBG30 but the
introduction of aryl moieties aimed to reach the S10 specificity
pocket of MMP enzymes does not lead to the expected potency
improvement. In addition, at a first glance it is not obvious to
derive a structure activity relationship (SAR) for the catechol
analog series. To elucidate the binding mode of the catechol
compounds, the inhibitor 14 was co-crystallized with MMP-8.
Crystals of the complex MMP-8:14 were grown as described in
the Experimental Section. Surprisingly, the analysis of the Fo-Fc
electron density map in the region of binding of 14 shows the
presence of the catechol and its quinone oxidized form, both
competing for the same binding site (S10 site). The refinement of
the occupancy factors of the two forms reveals the predominance
of the catechol with respect to quinone (77% versus 23%). The
binding mode of the two forms in the S10 site is different at the
level of the aromatic ring containing the zinc binding functions.
As evidenced in Figure 3, only the quinone, with one of its oxygen
atoms, bind the zinc ion with a distance of 1.84 A˚ giving rise to a
distorted tetrahedral coordination, while one of the catechol
oxygens makes H-bonds with the catalytic important E198 side-
chain and the NH of A163, belonging to the antiparallel b-strand.
The sulfonamide NH group of both forms is engaged in a
H-bond with a water molecule further bridged to the P217 CO
group. The sulfonamide junction adopts a g-conformation in
both forms (!86" and !102", respectively), with one of the two
oxygens turned toward the upper rim, giving rise to H-bonds with
the A161 and L160 NH groups. Finally, the diphenyl group deeply
protrudes into the S10 pocket, with its terminal part facing the
charged R222 side-chain (closest distance of 3.1 A˚), at the end of
the pocket.
Integrating different computational approaches, we could
identify the ligand features responsible for ligand–protein inter-
action and explain how small modifications in ligand structures
can influence the inhibition potency. Through a pharmacophore-
based analysis, the features that are needed for the MMP
inhibition have been identified (Figure 4): one aromatic ring
(R9), two acceptor H-bond groups (A1 and A3, respectively), and
one donor H-bond group (D6). Compound 15 was automatically
selected as the reference structure, with a Fit-value of 3.00.
The pharmacophore model highlights the importance of both
hydroxyl groups for the MMP-8 inhibition and of their positions
in relation to the aromatic ring. The resulting QSAR model works
well in discriminating actives versus inactives (Figure 5), is robust
and predictive (correlation values for the MMP-8 inhibition
model, R2: 0.8, Q2: 0.8, F: 51.3, P: 3.3e-006, RMSE: 0.4,
Pearson’s R: 0.9).
The activity prediction is well correlated even with MMP-9
and MMP-2 (Figure 5B and C) experimental values; however,
interestingly, the pharmacophore QSAR model underestimates the
potency of compounds 3, 5, and 6 toward MMP-2. To investigate
this difference and to characterize the interactions corresponding
to the identified features, we integrate the pharmacophore-based
analysis with a structure-based study.
Surprisingly, the X-ray structure of 14 in complex with MMP-8
reveals that the catechol oxygens contribute to a dense water
network around the ligand (see Figure 6). Noteworthy, the
quinone oxidized form of the ligand was found in the crystal
complex, but not in the solution used for inhibition assay (see
supporting information); therefore, we have considered activity
values not related to the oxidized forms, which have been
neglected in the computational studies. Apparently, catechol
oxygen atoms prefer to enter in the water network rather than
Figure 3. Hydrogen bond network of the
catechol form (A) and the oxidized quinone
form (B) of 14 (distances in A˚).
Figure 4. Pharmacophore model on the reference structure 15.
DOI: 10.1080/14756366.2016.1217853 Catechol-based MMP inhibitors 5
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coordinate the zinc ion, suggesting a relevant role of water
molecules in the binding and activity of catechol analogs toward
MMP enzymes. It is well-known the role of water molecules in
ligand–protein interaction, and this role becomes fundamental in
the case of weak binders36. To clarify the role of the water
molecules, the X-ray complex MMP-8:14 has been prepared and
minimized with explicit waters with MacroModel Embrace
Minimization37. The minimized complex reveals the interactions
corresponding to the pharmacophore features: the donor feature
(D6) is located on the OH group establishing an H-bond
interaction with E198 side chain; the acceptor group A1 directly
H-bonds with L160 NH and A161 NH; the acceptor group A3 is
connected through two water molecules to H162 side chain; the
aromatic feature (R9) is located above the zinc ion ensuring a
good orientation for D6 and A3 interactions.
In addition, three relevant clusters of water molecules mediate
the interaction between the ligand and MMP-8 (Figure 6A): (i) the
oxygen bound to D6 is connected through seven water molecules
to A163 CO on the top, H201 CO on the side and H207 side chain
on the bottom; (ii) five water molecules connect the sulfonamide
oxygen with P217 CO, N218 side chain and Y219 NH on the
bottom, and G158 CO on the top; (iii) two water molecules
mediate the interaction between the A3 feature oxygen and H162
side chain.
The structure determination of an enzyme bound to a
potentially therapeutic inhibitor is usually aimed to design
optimized leads: starting from the identification of interactions
involved in binding, moving to the analysis of possible additional
or alternative interactions that can improve the potency. However,
the complex described here highlights difficulties of theoretical
prediction of binding energies and optimization process due to the
fact that the binding involves hydrogen bonding through water
molecules whose positions can change.
This observation prompted us to investigate the influence of
the solvent in the binding of compound 14 with MMP-2 and
MMP-9 (Figure 6B and C). We can observe similar interactions in
all three complexes, but a different hydration by the solvent
(Figure 6A–C). In the MMP-2:14 complex, the oxygen bound
to D6 is not connected with the water molecule cluster 1
(Figure 6B). This difference is due to a sequence difference: A206
in MMP-8 is aligned to E210 in MMP-2. E210 side chain takes
the place of the water molecule present in MMP-8:14 complex
and shifts the water cluster 1 far away from the ligand
(Figure 6B). In the case of MMP-9, we found in this position
D410 (Figure 6C); since it is shorter than the glutamate present in
this position in MMP-2, the cluster 1 water network is restored.
The structure-based analyses, taking into account all possible
ligand–protein interactions and water contribution, ensure a more
accurate prediction of the binding. Differently from what
observed with the ligand-based analysis, the predicted binding
energies of MMP-2:3, 5, and 6 (!303 kJ/mol, !362 kJ/mol and
!366 kJ/mol, respectively) are in a good correlation with the
Figure 6. (A) MMP-8:14 X-ray complex (IC50: 3.1 mM, predicted total energy !395 kJ/mol), (B) MMP-2:14 modeled complex (IC50: 7.0mM, predicted
total energy!379 kJ/mol), and (C) MMP-9:14modeled complex (IC50: 2.7 mM, predicted total energy!405 kJ/mol). The ligand is represented as sticks
and the water molecules as spheres. The network of water molecules is depicted with H-bonds reported as dashed lines and water clusters are encircled.
Figure 5. QSAR models for MMP-8 (A), MMP-9 (B), and MMP-2 (C) (test set + training set molecules).
6 M. Tauro et al. J Enzyme Inhib Med Chem, Early Online: 1–13
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experimental pIC50. The ROC curves of all tested compounds
toward MMP-8, MMP-2, and MMP-9 are shown in Figure 7.
Conclusions
A new series of catechol-based compounds has been synthesized
and tested for MMP inhibitory activity as well as antioxidant
properties. Structure–activity relationship studies were imple-
mented by X-ray analysis of the co-crystallization complex
between MMP-8 and one of these new chemical entities
(compound 14). Computational studies have been performed to
identify a pharmacophore model and rationalize the influence of
chemical structure on inhibition potency.
The activity of these molecules on both MMPs and ROS
encloses a potential therapeutic strategy able to reduce the impact
of these two important targets in degradation processes such as
photoaging or inflammation, as well as to provide an additional
treatment for degenerative phenomenon involving pathological
enzymatic overexpression.
Experimental section
Chemistry
Melting points were determined in open capillaries on a
Gallenkamp electrothermal apparatus. Mass spectra were rec-
orded on a HP MS 6890-5973 MSD spectrometer, electron impact
70 eV, equipped with a HP ChemStation or with an Agilent LC–
MS 1100 Series LC–MSD Trap System VL spectrometer,
electrospray ionization (ESI). 1H-NMR spectra were recorded
using the suitable deuterated solvent on a Varian Mercury 300
NMR Spectrometer. Chemical shifts (d) are expressed as parts per
million (ppm) and the coupling constants (J) in Hertz (Hz).
Microanalyses of solid compounds were carried out with a
Eurovector Euro EA 3000 model analyzer; the analytical results
are within ± 0.4% of theoretical values. Flash column chromatog-
raphy was performed using Geduran silica gel 60 A˚ (45–63 mm).
Chemicals were purchased from Aldrich Chemicals (Milan, Italy)
and were used without any further purification.
Preparation of 2,3-dibenzyloxy-N-4-bromophenylbenzamide, 23
and 25
To a solution of 2,3-dibenzyloxybenzoicacid (30) (2.27mmol) in
anhydrous toluene (35mL), thionyl chloride (23.7mmol) was
added dropwise at 0 !C under nitrogen atmosphere. The mixture
was refluxed for 2 h and concentrated under reduced pressure.
The resulting oil was dissolved in dry THF (30mL) and a solution
of aniline or 4-phenylbenzylamine (7.12mmol) in dry THF
(1mL) was added dropwise at 0 !C. After 12 h at room
temperature, the mixture was concentrated under reduced pressure
and diluted with CH2Cl2. The organic layer was washed with HCl
1N, brine, dried over Na2SO4, and concentrated under reduced
pressure. The residue was purified by column chromatography
(n-hexane/ethyl acetate¼ 9:1) to give the title products.
2,3-Dibenzyloxy-N-phenylbenzamide (23)
53% yield; 1H NMR (CDCl3): d¼ 5.16 and 5.20 (2 s, 4H, 2
CH2Ph), 7.03–7.09, 7.20–7.53, and 7.83–7.87 (m, 18H, aro-
matics), 10.01 (s, 1H, NH); MS (ESI) m/z (%): 432
[M+Na]+ (100)
2,3-Dibenzyloxy-N-(4-diphenyl)methylbenzamide (25)
71% yield; 1H NMR (CDCl3): d 4.54 (s, 2H, CH2N), 4.99, and
5.15 (2 s, 4H, 2 CH2Ph), 7.07–7.59 and 7.79–7.83 (m, 22H,
aromatics), 8.38 (t, 1H, NH); MS (ESI): m/z (%): 522
[M+Na]+ (100), 340 (7).
2,3-Dibenzyloxy-N-4-bromophenylbenzamide
99% yield; mp: 122–124 !C 1H NMR (CDCl3): 5.10 and 5.20 (2 s,
4H, 2 CH2Ph), 7.10–7.50, and 7.80–7.86 (d, 17H, aromatics), 10.0
(s, NH); MS (ESI) m/z: 488 [M+2+Na]+ (100), 486
[M+Na]+ (100).
Preparation of 2,3-dibenzyloxy-N-(4-diphenyl)benzamide (24)
A suspension of 2,3-dibenzyloxy-N-4-bromophenylbenzamide
(0.56mmol), benzeneboronic acid (1.6mmol), Cs2CO3
(1.2mmol), and [Pd(PPh3)4] (0.024mmol) in anhydrous toluene
(15mL) was stirred at 95 !C overnight under nitrogen atmosphere.
Then, the mixture was diluted with 1N HCl (1mL) and ethyl
acetate (1.3mL) at room temperature and filtered through a Celite
pad. The resulting solution was washed with a saturated NaHCO3
solution (3# 15mL), brine, dried over Na2SO4, and concentrated
under reduced pressure. The residue was purified by column
chromatography (9.4:0.5:0.1 petroleum ether/ethyl acetate/IPA) to
give the title product.
74% yield; mp: 121–124 !C; 1H NMR (CDCl3): d¼ 5.18 and
5.21 (2 s, 4H, 2 CH2-Ph), 7.20–7.50, 7.70–7.73, 7.83–7.86, and
8.23–8.26 (d, 22H, aromatics), 10.0 (s, NH). MS(ESI) m/z (%):
508 [M+Na]+(100).
Figure 7. ROC curves (A) MMP-8:14 – AUC: 0.855. (B) MMP-2:14 – AUC: 0.790. (C) MMP-9:14 – AUC: 0.829.
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Preparation of compounds 27 and 28
DCC (2.04mmol) was added to a solution of 2,3-dibenzylox-
ybenzoic acid (30) (1.5mmol) in dichloromethane (30mL) at 0 !C
under nitrogen atmosphere. After 15min, a solution of 4-DMAP
(1.35mmol) and 4-phenoxyaniline or 4-phenoxybenzylamine
(1.38mmol) in dichloromethane (4mL) was added dropwise.
The resulting mixture was allowed to warm to room temperature
and stirred for further 22 h. The resulting precipitate was filtered
off, and the organic layer was washed with a saturated NH4Cl
solution (3" 20mL) and twice with brine, then dried over
Na2SO4, filtered and the solvent removed in vacuo to yield a
brown solid. Purification by flash chromatography (8:1.9:0.1
hexane/chloroform/IPA) and crystallization (THF/hexane) yielded
the title compounds as a white powder.
2,3-Dibenzyloxy-N-(4-phenoxyphenyl)benzamide (27)
73% yield; 1H NMR (CDCl3): d¼ 5.18 and 5.21 (2 s, 4H,
2 CH2Ph), 6.89–6.99, 7.05–7.10, 7.21–7.53, and 7.83–7.88
(m, 22H, aromatics), 9.99 (s, 1H, NH).
2,3-Dibenzyloxy-N-(4-phenoxyphenyl)methylbenzamide (28)
69% yield; 1H NMR (CDCl3): d¼ 4.47 (d, 2H, CH2N), 4.99 and
5.15 (2 s, 4H, 2 CH2Ph), 6.88–7.48, and 7.76–7.82 (m, 22H,
aromatics), 8.31 (t, 1H, -OH); MS (ESI) m/z (%): m/z 514 [M-H]$
(100), 408 (9), 315 (9), 223 (9).
General procedure for the preparation of 29–31, 34–39, and
18–22
A solution of the suitable sulfonyl chloride (1.4mmol) in CH2Cl2
(5mL) was added to a solution of the appropriate aniline
(1.5mmol) and Et3N (2.8mmol) in CH2Cl2 (5mL). The mixture
was refluxed for 4 h, cooled, diluted with CH2Cl2 (10mL), washed
with 1N HCl and brine, dried over Na2SO4, and then evaporated in
vacuo. The crude product was purified by flash column chroma-
tography on silica gel using different mixtures as eluent (indicated
in brackets) or was used for the next step without any purification.
N-(2,3-dibenzyloxy)phenyl-4-methoxyphenylsulfonamide (29)
(Petroleum ether/ethyl acetate 9:1, 51% yield); 1H NMR (CDCl3):
d¼ 3.79 (s, 3H, OCH3), 4.78 and 5.07 (2 s, 4H, 2 OCH2Ph), 6.70–
6.97 (m, 4H, aromatics), 7.04 (bb, 1H, NH), 7.15–7.42 (m, 11H,
aromatics), 7.63–7.68 (m, 2H aromatics); MS (ESI) m/z (%): 498
[M+Na]+ (100), 407 (6), 304 (15).
N-(2,3-dibenzyloxy)phenyl-4-diphenylsulfonamide (30)
(Petroleum ether/ethyl acetate/methylene chloride 9:0.5:0.5, 70%
yield); 1H NMR (CDCl3): d¼ 4.79 and 5.07 (2 s, 4H, 2 OCH2Ph),
6.72–6.75, 6.94–7.00 (m, 2H, aromatics), 7.11 (bb, 1H, NH),
7,20–7.62, and 7.76–7.80 (m, 20H, aromatics); MS (ESI) m/z (%):
544 [M+Na]+ (100), 304 (75).
N-(2,3-dibenzyloxy)phenyl-4-phenoxyphenylsulfonamide (31)
(Petroleum ether/chloroform/IPA 9:0.9:0.1, 81% yield); 1H NMR
(CDCl3): d¼ 4.81 and 5.09 (2 s, 4H, 2 OCH2), 6.72–6.75, 6.90–
7.04, 7.16–7.47, 7.63–7.77 (m, 22H, aromatics and 1H, NH); MS
(ESI) m/z (%): 560 [M+Na]+ (100), 469 (5).
N-(2,3-dimethoxyphenyl)methyl-4-diphenylsulfonamide (34)
98% yield; mp: 120–121 !C; 1H NMR (CDCl3): d¼ 3.73 (s, 3H,
OCH3), 3.76 (s, 3H, OCH3), 4.19 (d, J¼ 6.0Hz, 2H, CH2NH),
5.30 (t, J¼ 6.0Hz, 1H, NH), 6.72–6.79, 6.85–6.92, 7.38–7.50,
7.55–7.65, 7.83–7.88 (m, 12H, aromatics); 13C NMR (CDCl3): d
43.6, 56.0, 60.9, 112.6, 121.7, 124.3, 127.5, 127.7, 127.9, 128.7,
129.3, 130.0, 138.8, 139.6, 145.4, 147.1, 152.6.
N-(2,3-dimethoxyphenyl)methyl-4-bromophenylsulfonamide (35)
88%yield;mp:125 !C;1HNMR(CDCl3):d3.72(s,3H,OCH3),3.80
(s, 3H,OCH3), 4.15 (d, J¼ 6.0Hz, 2H,CH2NH), 5.28 (t, J¼ 6.0Hz,
1H, NH), 6.64–6.68, 6.76–6.80, 6.85–6.91, 7.47–7.51, 7.57–7.61
(m, 7H, aromatics); 13C NMR (CDCl3): d 43.8, 56.0, 60.8, 112.7,
121.7, 124.3, 127.4, 128.8, 129.6, 132.2, 139.4, 147.0, 152.6.
N-(1,3-benzodioxol-5-yl)-4-diphenylsulfonamide (36)
(CH2Cl2, 56% yield); mp: 145–146
!C; 1H NMR (CDCl3):
d¼ 5.93 (s, 2H, -CH2), 6.46–6.50, 6.62–6.66, 6.72–6.74 (m, 3H,
aromatic), 6.85 (bb, 1H, NH), 7.37–7.49, 7.55–7.67, 7.79–7.84
(m, 9H, aromatics); 13C NMR (CDCl3): d 101.8, 105.8, 108.5,
117.2, 127.5, 127.8, 128.1, 128.8, 129.3, 130.2, 137.6, 139.4,
146.0, 146.3, 148.3.
N-(1,3-benzodioxol-5-yl)-4-bromophenylsulfonamide (37)
62% yield; mp: 140–141 !C; 1H NMR (CDCl3): d¼ 5.94 (s, 2H,
CH2), 6.41–6.45, 6.61–6.64, 6.67–6.81 (m, 3H, aromatics), 6.97
(bb, 1H, NH), 7.54–7.62 (m, 4H, aromatics); 13C NMR (CDCl3):
d¼ 101.9, 105.8, 108.6, 116.6, 117.3, 128.4, 129.1, 132.6, 137.9,
146.6, 148.4.
N-(1,3-benzodioxol-5-ylmethyl)-4-diphenylsulfonamide (38)
(CH2Cl2, 98% yield); mp: 159–160
!C; 1H NMR (CDCl3):
d¼ 4.08 (d, J¼ 6.0Hz, 2H, CH2NH), 4.86 (t, J¼ 6.0Hz, 1H,
NH), 5.87 (s, 2H, CH2), 6.63–6.70, 7.39–7.52, 7.58–7.63, 7.67–
7.62, 7.88–7.93 (m, 12H, aromatics); 13C NMR (CDCl3):
d¼ 45.7, 101.4, 108.4, 108.7, 121.6, 127.6, 127.9, 127.9, 128.7,
129.3, 130.1, 138.7, 139.5, 145.8, 147.6, 148.1.
N-(1,3-benzodioxol-5-ylmethyl)-4-bromophenylsulfonamide (39)
(CH2Cl2, 97% yield); mp: 148–149
!C; 1H NMR (CDCl3):
d¼ 4.04 (d, J¼ 6.0Hz, 2H, CH2NH), 4.84 (t, J¼ 6.0Hz, 1H,
NH), 5.93 (s, 2H, –CH2–), 6.60–6.70, 7.59–7.71 (m, 7H,
aromatics); 13C NMR (CDCl3): d¼ 45.4, 101.5, 108.5, 108.6,
121.7, 127.9, 128.9, 129.8, 132.6, 139.3, 147.6, 148.2.
N-phenyl-4-diphenylsulfonamide (18)
55% yield; mp: 126–127 !C; 1H NMR (CDCl3): d¼ 6.97 (bb, 1H,
NH), 7.10–7.15, 7.22–7.29, 7.40–7.48, 7.53–7.58, 7.62–7.66,
7.83–7.86 (m, 14H, aromatics); 13C NMR (CDCl3): d¼ 121.8,
125.6, 127.7, 127.09 128.1, 128.0, 128.8, 129.3, 129.6, 136.7,
137.7, 139.3, 146.1. MS (ESI) m/z (%): 308 [M-H]$ (18), 244
(100). HR-MS [(C19H17NO2S-H)]
$, m/z 308.0744 (calc.
308.0751).
N-benzyl-4-diphenylsulfonamide (19)
75% yield; mp: 134–135 !C; 1H NMR (CDCl3): d¼ 4.19 (d,
J¼ 6.0Hz, 2H, CH2NH), 4.74 (t, J¼ 6.0Hz, 1H, NH), 7.20–7.31,
7.41–7.53, 7.59–7.63, 7.69–7.73, 7.91–7.95 (m, 14H, aromatics);
13C NMR (CDCl3): d¼ 47.6, 127.6, 127.9, 128.0, 128.1, 128.2,
128.4, 128.8, 129.0, 129.3, 136.4, 138.6, 139.5, 145.9. MS (ESI)
m/z (%): 322 [M-H]$ (5), 153 (100). HR-MS [(C19H17NO2S-
H)]$, m/z 322.0903 (calc. 322.0907).
N-(4-hydroxyphenyl)-4-diphenylsulfonamide (20)
63% yield; mp: 212–214 !C; 1H NMR ([D6]DMSO): d¼ 6.58–
6.61, 6.84–6.88, 7.40–7.82 (m, 13H, aromatics), 9.30 and 9.78
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(bb, 2H, –OH and –NH); 13C NMR ([D6]DMSO): d¼ 116.0,
124.4, 127.5, 127.6, 127.8, 128.9, 129.0, 129.5, 138.8, 138.9,
144.4, 155.3. MS (ESI) m/z (%): 324 [M-H]" (100). HR-MS
[(C18H15NO3S+Na)]
+, m/z 348.0665 (calc. 348.0665).
N-(3-hydroxyphenyl)-4-diphenylsulfonamide (21)
71% yield; mp: 258–259 #C; 1H NMR ([D6]DMSO): d¼ 5.85–
6.30, 6.58–6.63, 7.31–7.73 (m, 13H, aromatics), 8.51 (bb, 2H,
–OH and –NH); 13C NMR ([D6]DMSO): d¼ 105.6, 107.8, 112.5,
126.6, 126.8, 127.2, 127.3, 127.5, 128.2, 128.8, 129.4, 139.8,
141.7, 157.8. MS (ESI) m/z (%): 324 [M-H]" (100). HR-MS
[(C18H15NO3S-H)]
", m/z 324.0694 (calc. 324.0700).
N-(2-hydroxyphenyl)-4-diphenylsulfonamide (22)
55% yield; mp: 155–157 #C; 1H NMR ([D6]DMSO): d¼ 6.66–
6.73, 6.89–6.94, 7.14–7.17, 7.38–7.50, 7.68–7.80 (m, 13H,
aromatics), 9.43 (bb, 2H, OH and NH); 13C NMR
([D6]DMSO): d¼ 116.0, 119.4, 124.5, 125.0, 126.6, 127.4,
127.5, 127.8, 128.9, 129.5, 138.8, 140.0, 144.3, 150.7. MS
(ESI) m/z (%) 324 [M-H]" (95), 217 (100); m/z (%): 348
[M+Na]+ (100). HR-MS [(C18H15NO3S-H)]
", m/z 324.0695
(calc. 324.0700).
General procedure for the preparation of 26, 32 and 33
3a or 30 or 31 (1mmol) was dissolved in anhydrous DMF (20mL)
under argon atmosphere at 0 #C. Then, NaH (3mmol, 95%
powder) and, after 30min, CH3I (50mL) were carefully added
and the mixture was stirred overnight at room temperature. After
evaporation of volatiles, the residue was dissolved in ethyl acetate
and washed with 1N HCl (3$ 50mL) and brine (3$ 40mL),
dried over Na2SO4, filtered, and concentrated in vacuo giving a
yellow oil, that was used for the next step without any
purification.
N-(4-diphenylmethyl)-N-methyl-2,3-dibenzyloxybenzamide (26)
97% yield; 1H NMR (CDCl3): d¼ 2,76 (s, 3H, CH3N), 3.00 (s,
2H, CH2N), 5.15 and 5.17 (2 s, 4H, 2 CH2Ph), 6.92–7.55 (m, 22H,
aromatics); MS (ESI) m/z (%) 536 [M+Na]+ (100).
N-(2,3-dibenzyloxyphenyl)-N-methyl-4-diphenylsulfonamide (32)
90% yield; 1H NMR ([D6]DMSO): d¼ 3.10 (s, 3H, CH3N), 4.99
and 5.11 (2 s, 4H, 2 OCH2Ph), 6.76–6.82, 6.95–7.02, and 7.20–
7.88 (m, 22H, aromatics); MS (ESI) m/z (%): 558[M+Na]+ (100),
304 (7).
N-(2,3-dibenzyloxyphenyl)-N-methyl-4-phenoxyphenylsulfona-
mide (33)
84% yield; 1H NMR ([D6]DMSO): d¼ 3.11 (s, 3H, CH3N), 4.99,
and 5.10 (2 s, 4H, 2 OCH2Ph), 6.76–6.79, 6.94–7.05, 7.18–7.43,
and 7.71–7.76 (m, 22H, aromatics); MS (ESI) m/z (%): 574
[M-Na]+ (100), 319 (16), 228 (6).
General procedure for the preparation of compounds 1–6
A mixture of the appropriate dibenzyloxybenzamide 23–28
(0.38mmol) and 10% Pd-C (24mg) in CH3OH/THF 2:5 (14mL)
was stirred at room temperature for 20 h under H2 atmosphere at
6 atm. The mixture was filtered through a Celite pad and
concentrated in vacuo to give the title product as a white solid.
2,3-Dihydroxy-N-4-phenylbenzamide (1)
72% yield; mp: 114–117 #C; 1H NMR (CDCl3): d¼ 5.82 (s, 1H,
NH), 6.82–6.87, 7.05–7.12, 7.19–7.25 and 7.38–7.60 (m, 8H,
aromatics), 7.95 (s, 1H, OH), 12.34 (s, 1H, OH); 13C NMR
(CDCl3): d¼ 114.3, 116.1, 118.6, 119.0, 121.3, 125.5, 129.2,
136.4, 146.1, 149.3, 168.4. MS (ESI) m/z (%): 228 [M-H]" (100).
HR-MS [(C13H11NO3-H)]
", m/z 228.0663 (calc. 228.0663).
N-(4-diphenyl)-2,3-dihydroxybenzamide (2)
38% yield; mp: 226–228; 1H NMR (CDCl3): d¼ 5.92 (s, 1H,
NH), 6.81–6.91, 7.09–7.12, 7.25–7.69, 7.76–7.88 7.98—8.01 and
8.07–8.26 (m, 12H, aromatics), 9,53 (s, 1H, OH), 12,32 (s, 1H,
OH); MS (ESI): m/z (%): 304 [M-H]" (100). HR-MS
[(C19H15NO3-H)]
-, m/z 304.0972 (calc. 304.0972).
N-(4-diphenyl)methyl-2,3-dihydroxybenzamide (3)
79% yield; mp: 111–113 #C; 1H NMR (CDCl3): d¼ 4.68 (d, 2H,
CH2N, J¼ 5.49), 5.80 (s, 1H, OH), 6.62 (bb, 1H, NH), 6.73–6.78,
6.89–6.91, 7.05–7.09, 7.34–7.47 and 7.57–7.71 (m, 12H, aro-
matics), 12.68 (s, 1H, OH); 13C NMR (CDCl3): d¼ 43.4, 113.8,
115.9, 118.2, 118.7, 127.1, 127.5, 127.7, 128.3, 128.8, 136.2,
140.5, 141.0, 146.0, 149.2, 169.9. MS (ESI): m/z (%): 318 [M-H]"
(100). HR-MS [(C20H17NO3-H)]
", m/z 318.1127 (calc. 318.1136).
N-(4-diphenyl)methyl-N-methyl-2,3-dihydroxybenzamide (4)
33% yield; mp: 160–163 #C; 1H NMR ([D6]DMSO): d¼ 3.14 (s,
3H, CH3), 4.81 (s, 2H, CH2), 5.80 (bb, 1H, OH), 6.70–6.75, 6.89–
7.01, 7.33–7.66 (m, 12H, aromatics), 10.2 (bb, 1H, OH);
MS (ESI) m/z (%): 356 [M-H+Na+]" (100). HR-MS
[(C21H19NO3+H)]
+, m/z 334.1435 (calc. 334.1438).
2,3-dihydroxy-N-(4-phenoxyphenyl)benzamide (5)
38
84% yield; mp: 164–165 #C; 1H NMR (CDCl3): 5,82 (s, 1H, NH),
6.81–6.87, 7.00–7.15, 7.14–7.39, and 7.51–7.55 (m, 12H, aro-
matics), 7,93 (s, 2H, OH); 13C NMR (CD3OD): d¼ 116.2, 118.1,
118.2, 118.5, 118.5, 118.8, 122.9, 123.1, 129.5, 133.1, 146.0,
148.4, 154.1, 157.5, 168.2. MS (ESI) m/z (%) 320 [M-H]" (100).
HR-MS [(C19H15NO4-H)]
", m/z 320.0923 (calc. 320.0928).
N-(4-phenoxyphenyl)methyl-2,3-dihydroxy-benzamide (6)38
79% yield; mp: 113–114 #C; 1H NMR (CDCl3): d¼ 4.60 (d,
J¼ 5.66, CH2N, 2H), 5.82 (s, 1H, OH), 6.59 (bb, 1H, NH), 6.72–
6.91, 6.97–7.14, and 7.29–7.37 (m, 12H, aromatics), 12.67 (s, 1H,
OH); 13C NMR (CD3OD): d¼ 42.0, 115.3, 117.3, 118.2, 118.3,
118.3, 118.5, 122.9, 128.8, 129.4, 133.6, 145.9, 148.9, 156.4,
157.4, 170.0. MS (ESI) m/z (%): 334 [M-H]" (100). HR-MS
[(C20H17NO4-H)]
", m/z 334.1074 (calc. 334.1085).
General procedure for the preparation of compounds 7–11
To a stirred suspension of the appropriate intermediate (29–33)
(0.41mmol) in THF/MeOH (16mL, 3:1), 10% Pd/C (26mg) was
added. After stirring overnight under hydrogen atmosphere
(6 atm), the reaction mixture was filtered through a pad of
Celite and concentrated under reduced pressure affording the
desired product.
N-(2,3-dihydroxyphenyl)-4-methoxyphenylsulfonamide (7)
82% yield; mp: 147–149 #C; 1H NMR ([D6]DMSO): d¼ 3.78 (s,
3H, CH3), 6.53–6.59, 6.98–7.01, 7.64–7.67 (m, 7H, aromatics),
8.87 (bb, 3H, 2 OH, NH); MS (ESI) m/z (%): 294 [M-H]" (100),
171 (59). 13C NMR ([D6]DMSO): d¼ 56.0, 112.8, 114.5, 114.7,
118.8, 125.6, 129.4, 132.6, 138.7, 146.0, 162.7. HR-MS
[(C13H13NO5S-H)]
", m/z 294.0436 (calc. 294.0442).
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N-(2,3-dihydroxyphenyl)-4-diphenylsulfonamide (8)38
79% yield; mp: 182–183 !C; 1H NMR (DMSO-d6): d 6.45–6.63,
7.38–7.50, 7.69–7.82 (m, 12H, aromatics), 9.00 (bb, 3H, 2- OH,
-NH); 13C NMR ([D6]DMSO): d¼ 113.0, 115.0, 118.8, 125.4,
127.5, 127.9, 128.9, 129.5, 138.9, 138.9, 139.9, 144.3, 146.1. MS
(ESI): m/z 340 [M-H]# (93), 217 (100). HR-MS [(C18H15NO4S-
H)]#, m/z 340.0643 (calc. 340.0649).
N-(2,3-dihydroxyphenyl)-4-phenoxyphenylsulfonamide (9)38
80% yield; mp: 176–178 !C; 1H NMR (CDCl3): d¼ 2.20–2.60
(bb, 3H, 2-OH and -NH), 6.54–6.58, 6.74–6.85, 6.93–6.96, 7.09–
7.14, 7.28–7.33, 7.62–7.65 (m, 12H, aromatics); MS (ESI) m/z
(%): 380 [M+Na]+ (100). 13C NMR (CD3OD): d¼ 112.2, 114.8,
116.8, 118.6, 119.8, 124.5, 124.7, 129.3, 129.8, 133.3, 138.2,
145.3, 155.3, 161.5. HR-MS [(C18H15NO5S-H)]
#, m/z 356.0594
(calc. 356.0598).
N-(2,3-dihydroxyphenyl)-N-methyl-4-diphenylsulfonamide (10)
57% yield; mp: 170–172 !C; 1H NMR (CDCl3): d¼ 3.22 (s, 3H,
NCH3), 5.99–6.02, 6.62–6.67, 6.87–6.89, and 7.43–7.71 (m, 14H,
aromatics and -OH); MS (ESI) m/z (%): 354 [M-H]# (100), 217
(61). 13C NMR (CD3OD): d¼ 37.6, 114.8, 118.4, 119.4, 126.9,
128.0, 128.1, 128.3, 128.7, 138.8, 139.2, 143.3, 145.4, 146.1. HR-
MS [(C19H17NO4S-H)]
#, m/z 354.0799 (calc. 320.0806).
N-(2,3-dihydroxyphenyl)-N-methyl-4-phenoxyphenylsulfonamide
(11)
68% yield; mp: 150–152 !C; 1H NMR (CDCl3): d¼ 3.16 (m, 3H,
NCH3), 4.99 (bb, 2H, OH), 5.99–6.02, 6.65–7.54 (m, 12H,
aromatics); MS (ESI) m/z (%): 370 [M-H]# (100); m/z 340
[M+Na]+ (100), 233 (81). 13C NMR (CD3OD): d¼ 37.5, 114.7,
116.9, 118.3, 119.4, 119.9, 124.6, 128.0, 129.9, 130.0, 131.8,
143.3, 146.1, 155.3, 161.7. HR-MS [(C19H17NO5S-H)]
#, m/z
370.0749 (calc. 370.0755).
General procedure for the preparation of compounds 12–17
To a solution of the appropriate sulfonamide 34–39 (1.36mmol)
in dry CH2Cl2 (20mL) was added a 1M solution of boron
tribromide (3.26mmol) in CH2Cl2, at 0
!C and under nitrogen
atmosphere. After 1 h at room temperature, methanol (5mL) was
added dropwise carefully at 0 !C, and the mixture was stirred for
additional 10min. The crude was diluted with a 1:1 mixture of
AcOEt/H2O, the organic phase was washed with brine, dried, and
purified by flash chromatography on silica gel affording the
desired product.
N-(2,3-dihydroxyphenyl)methyl-4-diphenylsulfonamide (12)
55% yield; mp: 154–155 !C; 1H NMR (CD3OD): d¼ 4.12 (s, 2H,
CH2), 6.47–6.52, 6.58–6.63, 7.32–7.46, 7.57–7.66, 7.81–7.87 (m,
12H, aromatics); 13C NMR (CD3OD): d 42.2, 114.2, 119.1, 120.1,
123.6, 127.1, 127.2, 127.4, 128.2, 128.9, 139.3, 139.6, 143.3,
144.8, 145.2. MS (ESI) m/z (%): 354 [M-H]# (7), 234 (100),
HR-MS [(C19H17NO4S-H)]
#, m/z 354.0811 (calc. 354.0806).
N-(2,3-dihydroxyphenyl)methyl-4-bromophenylsulfonamide (13)
75% yield; mp: 179–180 !C; 1H NMR (CD3OD): d¼ 4.10 (s, 2H,
CH2), 6.47–6.57, 6.61–6.64, 7.54–7.65 (m, 7H, aromatics);
13C
NMR (CD3OD): d¼ 42.2, 114.3, 119.1, 120.2, 123.3, 126.7,
128.6, 131.9, 141.2, 143.3, 144.7. MS (ESI) m/z (%): 356 [M-H]#
(1), 236 (100), HR-MS [(C13H12BrNO4S-H)]
#, m/z 355.9591
(calc. 355.9598).
N-(3,4-dihydroxyphenyl)-4-diphenylsulfonamide (14)
88% yield; mp: 216 !C (dec.); 1H NMR (CD3OD): d¼ 6.37–6.41,
6.58–6.66, 7.31–7.44, 7.54–7.58, 7.62–7.66, 7.72–7.76 (m, 12H,
aromatics); 13C NMR (CD3OD): d¼ 111.2, 114.8, 115.1, 127.0,
127.1, 127.7, 128.3, 128.9, 129.3, 138.4, 139.3, 143.4, 145.4. MS
(ESI) m/z (%): 340 [M-H]# (11), 153 (100), HR-MS
[(C18H15NO4S-H)]
#, m/z 340.0632 (calc. 340.0649).
N-(3,4-dihydroxyphenyl)-4-bromophenylsulfonamide (15)
62% yield; mp: 209 !C (dec.); 1H NMR (CD3OD): d¼ 6.30–6.34,
6.57–6.61, 7.53–7.62 (m, 7H, aromatics); 13C NMR (CD3OD):
d¼ 111.4, 115.0, 115.1, 127.1, 128.9, 128.9, 132.0, 138.9, 143.6,
145.4. MS (ESI) m/z (%): 342 [M-H]# (12), 157 (100). HR-MS
[(C12H10BrNO4S+Na)]
+, m/z 365.9400 (calc. 365.9406).
N-(3,4-dihydroxyphenyl)methyl-4-diphenylsulfonamide (16)
58% yield; mp: 189 !C (dec.); 1H NMR (CD3OD): d 3.92 (s, 2H,
CH2), 6.47–6.51, 6.59–6.66, 7.37–7.50, 7.64–7.88, 7.72–7.76,
7.83–7.87 (m, 12H, aromatics); 13C NMR (CD3OD): d¼ 114.9,
115.2, 119.4, 127.2, 127.3, 127.4, 128.2, 128.7, 128.9, 139.6,
139.6, 144.7, 145.1, 145.3. MS (ESI) m/z (%): 354 [M-H]# (7),
234 (100), HR-MS [(C19H17NO4S-H)]
#, m/z 354.0811 (calc.
320.0806).
N-(3,4-dihydroxyphenyl)methyl-4-bromophenylsulfonamide (17)
47% yield; mp: 124–125 !C; 1H NMR (CD3OD): d¼ 3.90 (s, 2H,
CH2), 6.46–6.49, 6.61–65, 7.62–7.69 (m, 7H, aromatics);
13C
NMR (CD3OD): d¼ 46.6, 115.0, 115.2, 126.8, 128.5, 128.6,
132.1, 140.3, 144.7, 145.1. MS (ESI) m/z (%): 356 [M-H]# (1),
236 (100), HR-MS [(C13H12BrNO4S-H)]
#, m/z 355.9538 (calc.
355.9598).
DPPH assay
The DPPH radical scavenging assay was performed in 96-well
microplates according to the method reported by Blois with some
modifications39,40. Briefly, a freshly prepared solution of DPPH in
methanol (100 mM final concentration) was added to test
compounds methanolic solution. The mixtures were shaken
vigorously and left to stand in the dark for 30min at room
temperature, and then absorbance was read at 520 nm using a
spectrophotometric plate reader (Victor 3 Perkin–Elmer). The
antioxidant activity was determined as the RSA% (radical
scavenging activity), calculated using following equation:
RSA% ¼ 100$ ½ðAo # AiÞ=Ao(
where, Ao and Ai are the DPPH absorbance in the absence or in
presence of antioxidant, respectively. Different sample concen-
trations were used in order to obtain antiradical curves for
calculating the EC50 values. The value of EC50 was expressed in
terms of molar ratio of antioxidant to DPPH. ARP is inverse of
EC50 value, the larger the ARP the more efficient the antioxidant.
The EC50 values and statistical analyses were processed using
GraphPad Prism41 and are expressed as mean±SEM of at least
three independent measurements in triplicate.
MMP inhibition assays
The catalytic domains of MMP-2, -8, and -9 were purchased from
Enzo Life Sciences. The assays were performed in triplicate in 96-
well white microtiter plates (Corning, NBS). For assay measure-
ments, inhibitor stock solutions (DMSO, 25mM) were diluted to
six different concentrations (1 nM–250 mM) in fluorometric assay
buffer (50 mM Tris)HCl pH 7.5, 200 mM NaCl, 1mM CaCl2,
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1mM ZnCl2, 0.05% Brij-35, and 1% DMSO). Enzyme and
inhibitor solutions were incubated in the assay buffer for 15min
at room temperature before the addition of the fluorogenic
substrate solution (OmniMMP¼Mca-Pro-Leu-Gly-Leu-Dpa-Ala-
Arg-NH2, Calbiochem, 2.5mM final concentration). After further
incubation for 2–4 h at 37 "C, fluorescence was measured
(!ex¼ 340 nm, !em¼ 405 nm) using a Perkin–Elmer Victor V3
plate reader.
Control wells lacked inhibitor. The MMP inhibition activity
was expressed in relative fluorescence units (RFU). Percent
inhibition was calculated from control reactions without inhibitor,
IC50 values were determined using GraphPad Prism
41 and are
expressed as mean±SEM of at least three independent measure-
ments in triplicate.
Expression and purification of the protein
The truncated form M80-G242 of the catalytic domain of MMP-8
was expressed in E. coli strain BL21 (DE3). At an OD600 0.5–0.6
expression of the collagenase was induced in a 1 l culture by
adding IPTG to a final concentration of 0.5mM. Inclusion bodies
isolated and purified from harvested E. coli cells were resus-
pended in 20mL of 6M urea, 100mM b-mercaptoethanol and
20 mMTris, pH 8.5, and incubated at room temperature o/n under
shaking to extract the solubilized collagenase. This extract was
centrifuged for 300 at 40 000 rpm, and the supernatant was loaded
onto a Mono Q-Sepharose column (GE Healthcare) previously
equilibrated with the denaturating buffer.
Elution of the collagenase was carried out by applying a
linear gradient of 0–1 M NaCl in the same buffer at a flow rate
of 1mL/min. The truncated form of MMP-8 was eluted at a salt
concentration of 100mM NaCl and could be purified to apparent
homogeneity. A further step of purification was carried out by gel
filtration using a HiLoadSuperdex 75 column (GE Healthcare)
equilibrated with 6M urea, 10mM DTT, and 20mM Tris, pH 8.5
at a flow rate of 0.5mL/min. The collected protein was then
refolded onto a HiLoadSuperdex 75 column in buffer MES-NaOH
3mM, pH 6.0, 100 mM NaCl, 5mM CaCl2, 0.5mM ZnCl2, NaN3
0.02% at a flow rate of 0.5mL/min. The fraction containing the
desalted and refolded protein was eluted after ca. 13mL.
Protein crystallization
The inhibitor (stock solution 50mM in DMSO) was immediately
added to the fraction containing the refolded protein in the ratio
3:1 (final concentration of DMSO 1%) in order to prevent
autoproteolysis during concentration. The MMP-8 protein with
the inhibitor was then concentrated with Amicon-Ultra 15, to a
final concentration of 6mg/mL. Crystallization was performed by
hanging-drop vapor diffusion method at 20 "C. Hanging droplets
were made by mixing 2mL of protein/inhibitor solution with 5mL
of PEG solution (10% (m/v) PEG6000, 0.2 M MES-NaOH, 0.02%
NaN3, pH 6.0). Droplets were concentrated against a reservoir
buffer containing 1.0–2.0 M sodium phosphate, 0.02% NaN3, pH
6.0. Crystals appeared after few days.
Data collection and processing
X-ray data were collected under cryogenic conditions (100 K) at
the ID29 beamline of ESRF, Grenoble, using a wavelength of
0.976 A˚ and a Pilatus 6M_F detector. The crystals were flash-
frozen in the nitrogen stream after transferring them for few
seconds into the mother solution containing 35% PEG400. Data
were integrated and scaled using the programs MOSFLM and
Scala42. The statistics of collection is given in Table 1 of the
supporting Information.
Structure solution and refinement
Structure solution was performed with AMoRe43 using the
coordinates of the complex between MMP-8 and a non-zinc
chelating inhibitor (PDB entry 3DPE)44 as the starting model.
The coordinates were then refined with CNS45. The statistics
of refinement is summarized in Table 1 of the supporting
Information.
Computational studies
Ligand-based studies: ligands reported in Tables 1 and 2 were
manually built using the Built facility in Maestro37. 3D structures,
stereoisomers, tautomers, and protomers at pH 7.0± 0.5 were
generated with LigPrep37. All synthesized analogs were aligned to
the crystallographic coordinates of 14 with Phase Shape
Screening37 and, using the resulting aligned conformation, a
pharmacophore-based QSAR model was built with Phase pro-
gram. The minimum intersite distance between the features was
set to be 1 A˚. Molecules with pIC5054 toward MMP-8 were
grouped as the inactive molecule set, while those with pIC5045
were grouped as the active molecules; all actives were set to be
matched during the screening. The QSAR model was constructed
using molecules 1, 12, 16, 17, 18, and 21 as test set and all the
others as training set. The best model has 15 as reference
molecule, and is made of four features: 1 aromatic ring (R9), 2
acceptor groups (A1 and A3), and 1 donor group (D6). Excluded
volume features were added around the shape of reference
molecule.
Structure-based studies: the hydrogen atoms of the X-ray
complex–MMP-8:14 has been added and optimized with the
Protein Preparation Wizard tool from Schro¨dinger37. Then the
complex with explicit waters was minimized to a derivative
convergence of 0.05 kJ/mol A˚ using the Polak–Ribiere Conjugate
Gradient (PRCG) minimization algorithm, the OPLS2005 force
field, with MacroModel Embrace Minimization37. A shell of 15 A˚
around the catalytic zinc was set to be free to move, another shell
of 5 A˚ minimized applying a force constant of 200 kJ/mol A˚2.
The interaction energy between the receptor and each ligand
was calculated with the Interaction energy mode implemented in
Embrace. The same procedure was applied to calculate the
interaction energies of MMP-2:14 and MMP-9:14. Ligand
coordinates were taken from the MMP-8 bound conformation of
14. Protein and water coordinates were downloaded from the
Protein Data Bank (PDB): 1GKC.pdb46 and 1QIB.pdb47 for
MMP-9 and MMP-2, respectively. Then, interaction energies were
calculated for all compounds reported in Tables 1 and 2
previously aligned to 14. Calculated energies were used to
derive ROC curves (see Figure 7). For the ROC curve calculations
molecules with pIC5044 were considered active and all the others
inactive.
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